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Chapter 1 – Introductory chapter  
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This introductory chapter contains some sections adapted from text contributing to a book chapter 
written by the author.1 
 
1.1 - Cancer as a genetic disease  
The concept of cancer as a clonal expansion of cells that have undergone genomic (and/or 
epigenomic) changes conferring malignant properties is now broadly accepted. The development and 
refinement of this hypothesis has been guided by application of new technologies that have analysed 
cellular genetic material at increasingly higher resolution to produce previously unimagined quantities 
of data.  
 
In the early twentieth century, microscopic analysis led to the observation that chromosome 
aberrations can occur in malignant cells.2 Theodor Boveri made the seminal suggestion that such 
aberrations might be directly implicated in tumourigenesis. Studying abnormal mitoses in sea urchin 
embryos led him to hypothesise that disordered cellular properties, including malignancy, resulted 
from an unbalanced chromosome complement. Boveri proposed the existence of both “inhibiting 
chromosomes,” i.e. those that normally act to suppress cell division and “stimulatory chromosomes,” 
which alter a cell’s relationship with its external environment to encourage a proliferative state. These 
ideas were prophetic of current conceptualisation of the roles of tumour suppressor genes and proto-
oncogenes in the pathogenesis of human cancers.3 Over 50 years later in the 1960’s, a specific 
chromosomal abnormality was associated with a particular tumour when the Philadelphia 
chromosome (resulting from a translocation between chromosomes 9 and 22), was identified in the 
blood of chronic myeloid leukaemia patients.4 Chromosomal gains, losses and rearrangements may 
result from genomic instability in advanced cancers but may also, as with the Philadelphia 
chromosome, be key to tumour initiation. With the development of DNA sequencing techniques, it 
became possible to study such initiating events at the individual gene level and so define causative 
genetic abnormalities not visible by chromosome analysis, i.e. at the nucleotide level.  
 
1.1.1 - Oncogenes, tumour suppressor genes and cancer predisposition 
The development of the concept of the oncogene was a crucial step towards understanding how 
genetic changes can lead to cancer. Oncogenes were initially discovered by analysing cells with 
malignant properties that had been induced by a retrovirus. It was found that tumorigenic potential 
was conferred by one component gene of the virus, which was described as the oncogene.5 Further 
research revealed that orthologues of the viral oncogenes were present in normal cells, which were 
labelled proto-oncogenes.5  Subsequently it was elucidated that genetic changes, unrelated to viral 
infection, that result in enhanced or altered function of proto-oncogenes could directly promote 
tumourigenesis. Proto-oncogenes are involved in a range of cellular processes that are pertinent to cell 
growth/proliferation including cell cycle regulation and growth signalling.  
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The discovery of tumour suppressor genes (TSGs), the other main gene class significant in cancer 
development, has been particularly relevant to the understanding of inherited tumours. Although TSG 
inactivation is frequent in both inherited and sporadic forms of cancers, there are many more TSGs 
where constitutional variants are known to cause cancer predisposition than proto-oncogenes. Under 
normal circumstances, a TSG often functions to inhibit cell proliferation and inherited or acquired 
events that induce a loss of function compromise this role, thereby promoting tumourigenesis. TSG 
inactivation may lead directly to cellular attributes that encourage malignant transformation or be 
indirect in other instances (e.g. inactivation of DNA repair genes with resultant failure to repair 
deleterious mutations in other TSGs or proto-oncogenes).  
 
Whilst some genetic changes appear particularly important in conferring tumour defining properties to 
cells (such events may be referred to as driver mutations), the transition from normal cell to malignant 
is typically a multi-step process (though genome-wide sequencing studies have shown that the number 
of mutations may vary from less than 10 to thousands).  In tumours that contain hundreds or 
thousands of mutations, normal DNA repair mechanisms are typically compromised and most of the 
mutations do not have a role in driving tumourigenesis (referred to as passenger mutations). A source 
of much debate, often based on epidemiological evidence, has been how many changes are essential 
for the process of tumour development. Work by Nordling observed cancer mortality correlating with 
age and estimated that, on average, six mutational events in a given cell were required for a cancer to 
occur.6 The work only studied certain cancer types and observed that many malignancies did not 
conform to this model. More recently, a sequencing investigation of 29 cancer types (7664 samples) 
and observation of gene’s non-synonymous to synonymous variant ratio (this should be high in TSGs 
and oncogenes) suggested around four tumourigenic mutational events are observed on average, 
though the number does vary between cancer types.7 
 
Work by Al Knudson suggested that at in a rare embryonal tumour, retinoblastoma, the age at onset 
distribution was consistent with two critical rate limiting mutational events. By comparing the age at 
onset in familial and sporadic cases, Knudson proposed a model whereby in familial cases only a 
single rate-limiting mutational event (“hit”) was required. These predictions were consistent with the 
hypothesis that in familial cases, the first rate-limiting mutation is inherited from an affected parent 
and that only one further hit (a somatic mutation) is required to initiate tumourigenesis. Sporadic 
cases, in contrast, require two somatic mutations to initiate tumourigenesis8 (Figure 1.1). This model 
explains the very high risk of retinoblastoma and frequent occurrence of bilateral tumours in 
individuals with the familial form while sporadic cases present at an older age and have single 
unilateral tumours.  
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Familial retinoblastoma is caused by germline (constitutional) loss-of-function variants in the RB1 
TSG, which was identified through analysis of retinoblastoma tumours with Knudson’s hypothesis in 
mind. Previous evidence existed that a region of chromosome 13 was the area undergoing the 
hypothesised second hit. Some individuals with retinoblastoma had been reported to harbour a 
constitutional deletion at this region9 and acquired loss or partial deletion of this area of chromosome 
13 had been shown in retinoblastoma tumour cells.10 Identification of the RB1 gene within the target 
region was followed by demonstration that inherited cases had an inactivating constitutional variant 
and a second hit in the tumour cells, whereas tumours from cases that didn’t show inheritance 
exhibited inactivating hits of both RB1 alleles in tumour but not normal cells (implying that both 
events occurred somatically).11 
 
Knudson’s hypothesis and the subsequent identification of the RB1 TSG11 was a seminal event in the 
development of inherited cancer genetics. Apart from highlighting the role of TSGs in cancer 
pathogenesis, it demonstrated that inherited constitutional variants leading to tumour predisposition 
could be identified through study of affected families and that genes affected by them could 
additionally be implicated in the more common sporadic counterparts to inherited tumours.  
 
Figure 1.1 – Knudson’s two hit model conceptual diagram1 
 
 
The identification of RB1 prompted a continuing search for further cancer predisposition genes 
(CPGs) that has yielded findings relevant to both individuals who harbour deleterious variants 
affecting them and those patients diagnosed with tumours occurring outside of the inherited context. 
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CPGs have been discovered that do not conform to a two hit TSG model and a number of 
constitutionally activated proto-oncogenes have been found to cause cancer predisposition (e.g. RET 
in Multiple Endocrine Neoplasia Type 212,13 and MET in hereditary papillary kidney cancer14). The 
search has focused on individuals with specific clinical characteristics of inherited cancer 
predisposition (e.g. young age at diagnosis of a particular cancer type) but advances in genetic 
technology are also providing the means for large scale sequencing in individuals with less specific 
features. 
 
1.2 - The development of DNA sequencing techniques 
Identification of CPGs has relied on the aforementioned development of DNA sequencing techniques 
that have allowed analysis of genomic regions at the nucleotide level. Around the time of, and 
following, the publication of the structure of DNA in 1953,15 methods had been formulated to produce 
libraries of DNA fragments through techniques such as restriction enzymes and polymerase 
reactions.16–19 This area would later be greatly assisted by the development of molecular cloning with 
recombinant DNA vectors20 and polymerase chain reaction (PCR).21 
 
A crucial advance in the analysis of libraries came with the advent of two strategies to infer the 
sequence of DNA by observing varying migration rates of different fragments through a 
polyacrylamide electrophoresis gel. Sanger and Coulson’s “plus minus” technique22 used a 
polymerase to produce DNA fragments of different lengths that started from the same molecular 
location due to the use of a single primer. Four initial reactions were undertaken where one of the four 
nucleotides used for extension (e.g. adenine) was radiolabelled. For each of those reactions, two 
further polymerisations were performed on the population of fragments containing the radiolabelled 
nucleotides. In one of these (the “plus” reaction), only nucleotides corresponding to the radiolabelled 
one (e.g. adenine) were available for polymerisation and in the counterpart reaction (the “minus” 
reaction), the other three were available (e.g. thymine, cytosine, guanine). When run on the 
electrophoresis gel, the positions of fragments (visible due to radioactivity) from the plus reaction 
would reveal the lengths of fragments where extension was not possible due to the fragment ending in 
a given nucleotide (e.g. adenine). The gel positions from the minus reaction would reveal the lengths 
of fragments ending in another nucleotide (e.g. thymine, cytosine or guanine). Consideration of all 
eight reactions could reveal the sequence of the section of DNA in question. Maxam and Gilbert23 
produced a technique with number of similarities but without using a polymerase to produce 
fragments of varying lengths. Instead, chemical cleavage at specific bases of radiolabelled DNA was 
performed and the lengths of resulting fragments from a particular cleavage reaction used to infer the 
positions of that nucleotide in the studied sequence. A further critical step in the advancement of 
sequencing was the incorporation of radiolabelled chain terminating nucleotides into the polymerase 
reactions of Sanger’s technique that did not have a 3’ hydroxyl group necessary for extension of the 
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nucleic acid sequence.24 If four polymerase reactions were performed where a proportion of the 
nucleotide pool is made up of a single type of chain terminating nucleotides (e.g. adenine), a 
population of fragments ending in that base would be produced. The relative positions of fragments 
from the four reactions on an electrophoresis gel would subsequently reveal the template sequence. 
Sanger sequencing was developed further by the substitution of radiolabelling for fluorescent chain 
terminating nucleotides, allowing a single polymerase reaction as they could be visually distinguished 
from each other. The electrophoresis gel was also substituted for capillary electrophoresis where the 
chain terminating nucleotide colour detected by a fixed camera at a given time could be used to infer 
the last base of a particular fragment size.16 
 
Sanger sequencing based techniques formed the basis of most sequencing performed in the latter part 
of the twentieth century, including that contributing to the human genome reference sequence 
published in 2001.25 Although improvements efficiency had taken place, these processes remained 
reliant on separate reactions to sequence each template fragment of interest, which were limited in 
length. The parallelisation of reactions increased the scope of sequencing significantly and brought 
about the techniques widely referred to as next generation sequencing (NGS). An early NGS method 
was developed by 454 Life Sciences,26 which incorporates synthetic adapter sequences to a potentially 
large library of DNA molecules, allowing attachment to beads (optimally one molecule per bead). A 
PCR reaction is then used to amplify the DNA attached to each bead ready for separate sequencing 
reactions. Crucially, each bead is attached to a fixed position on a solid surface from which 
sequencing readout pertaining to that bead will be measured. Rather than utilising chain terminating 
nucleotides, sequencing reactions proceed by pyrosequencing. Pyrosequencing still produces 
sequence readouts through synthesis based on a template but measures the release of pyrophosphate 
that occurs when a nucleotide is incorporated into a growing complementary DNA strand in real time. 
Pyrophosphate can be converted to adenosine triphosphate, which in turn can form the substrate for a 
fluorescent luciferase reaction. The relevant enzymes are introduced to the solid surface along with a 
nucleotide pool of a single type. If the next position in the growing DNA strand is complementary to 
that base it will be incorporated and light emitted. Reactants are subsequently washed away and the 
process repeated for the other three nucleotides.  
 
The NGS platform that would become mostly widely used was developed by Solexa and later 
acquired by Illumina, whose products provided the sequencing data for this project. This technique27 
still utilises adapter sequences and location onto a solid surface (referred to as a flow cell) but 
hybridises adaptors to complementary oligonucleotides rather than beads. Fixed molecules 
subsequently undergo PCR amplifications at their respective locations. Illumina NGS sequencing 
reactions use a pool of all four fluorescent chain terminating nucleotides during polymerisation. 
Incorporation of a particular nucleotide in the growing synthesised DNA molecule and washing away 
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of the other nucleotides allows light emission of a colour corresponding to the incorporated 
nucleotide, which is detected at the relevant position on the flow cell. In contrast to Sanger 
sequencing, the fluorescent and chain terminating portions of the incorporated nucleotide are then 
chemically removed and incorporation of nucleotides can continue along the growing molecule. An 
advantage of this approach is that it avoids inaccuracies associated with pyrosequencing of 
homopolymer tracts as only one nucleotide is incorporated at a time. A limitation is the relatively 
short length of sequence readouts (reads) that can be obtained, which has implications for accuracy of 
alignment to reference sequences. However, the technique produces reads from each end of a DNA 
template (paired end data) that can be used to make inferences such as whether a deletion exists in a 
genomic region (indicated by a longer than expected insert size between two paired reads). 
 
Whilst Illumina products remain the dominant sequencing platforms, other technological 
developments have led to further advances and a group of assays referred to as third generation 
sequencing. These techniques are characterised by the sequencing of single (rather than amplified) 
molecules and the production of long reads that facilitate alignment to (or production of) reference 
genomes. They are particularly relevant to some applications such as identifying structural variants 
due to an increased chance of reads being generated containing a chromosomal breakpoint. Prominent 
platforms include those produced by Pacific Biosystems28,29 and Oxford Nanopore.30 The former 
utilises nano-engineered wells that are small enough to induce rapid decay of light from a laser source 
as it penetrates the well. Consequently, a visualisation area at the base is created where a single DNA 
polymerase is bound. Exposure of wells to template DNA molecules and fluorescently labelled 
nucleotides induces strand synthesis where incorporation of specific nucleotides can be visualised 
through their fluorescent signal with minimal noise due to the small size of the visualisation area. 
Rather than observing nucleotide incorporation by DNA polymerase, Oxford Nanopore technology 
passes single stranded DNA molecules through a nano-pore following denaturation by an enzyme 
located at the pore entrance. The pore is embedded in a polarised membrane, inducing movement of 
the DNA through it and creating ionic flows that are altered in a characteristic manner by the passage 
of particular bases. The sequence of bases can be inferred from measurement of these. One source of 
excitement with this platform is its miniaturisation that makes use at the bedside or in the field 
feasible.  
 
NGS applications produce a series of reads from the sequenced population of molecules with no 
accompanying information regarding genomic location from which they were sequenced or whether 
they show any evidence of variation from a reference sequence. NGS sequencing data can be 
translated into variants as a result of extensive work that has taken place to produce software and 
algorithms for this purpose. A key initial step is the alignment of each read to its corresponding 
position in the chosen reference sequence. This can be performed with a number of tools but this 
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project utilised the widely used Burrows Wheeler Aligner31 and more recently developed Illumina 
Isaac.32 In an ideal situation, each read is confidently aligned to a unique genomic position but 
similarities between different regions can produce multiple alignments for the same read. This begets 
uncertainties as to whether apparent sequence variation in the read results from genuine deviation 
from the reference or an origin from a similar but different location. Alignment can then be followed 
by variant calling whereby the most likely sequence at a given site is calculated on the basis of a 
number of lines of evidence such as quality of the base call in the read (incorporated pre-alignment), 
the number of reads supporting a particular base call and the extent to which base calls in the read 
match those in the reference genomic region it is aligned to. Like alignment, a number of different 
variant calling tools exist with Genome Alignment Toolkit HaplotypeCaller33 (preceded by Unified 
Genotyper) being the most widely used for germline variants and Illumina Isaac also being used in 
this work. 
 
The descriptions of NGS techniques above emphasise commonalities between workflows but there 
are key variables in the processes that influence suitability for the question and resources at hand. A 
key parameter is the genomic regions covered by sequencing reads, which may range from a single 
gene to close to an entire genome (whole genome sequencing). Techniques that selectively produce 
sequencing reads aligning to a number of pre-defined genes are frequently referred to as gene panels, 
whereas incorporation of all coding regions can be designated exome sequencing. The pre-sequencing 
DNA library preparation steps for these outcomes are frequently similar and generally involve the 
hybridisation of oligonucleotide sequences corresponding to regions of interest to molecules in the 
library. The oligonucleotides are designed with modifications (e.g. magnetic beads or biotin) to enable 
their physical extraction along with the library molecules they are attached to, a process referred to as 
capture. Panel or exome sequencing also usually involves a PCR amplification step where primers 
attach to common adaptor sequences introduced to library molecules. This might be prior to capture 
where all fragmented molecules can be amplified, or afterwards when only molecules of interest 
undergo PCR. Whole genome sequencing does not require capture or PCR and libraries prepared for 
it are the result of fragmentation of a sample with subsequent ligation of adapter sequences at random. 
Any genomic region is eligible for coverage by sequencing reads and the lack of a PCR step also 
reduces variation in coverage as regions that are difficult to amplify are less likely to be under-
represented. 
 
A further important distinguishing feature between NGS applications is sequencing depth, which 
refers to the number of reads that align to a given base and is expressed as 1X, 2X and so forth. A 
higher number of reads produces greater confidence of a variant call, particularly if somatic variants 
are sought. However, higher depth may be associated with greater resource expenditure and high 
confidence calls can still be made with lower numbers of reads. The number of generated reads can be 
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influenced by numerous variables in the sequencing process (e.g. starting DNA quantity, number of 
samples per flow cell used) but depth is frequently inversely correlated with extent of genomic 
coverage. Gene panels often provide hundreds to thousands of reads per target base whereas whole 
genome sequencing depth is typically well below 100X.  
 
An additional key variable in NGS sequencing is read length. Much of the recent development in 
genomics has been based on short read sequencing, typically in the region of 100-150bp. However, 
long read techniques such as those mentioned above provide the opportunity to increase this number 
to multiple thousands. Advantages include more specific alignment to reference sequences with 
consequent reduction in reads mapping to multiple sites and spurious base calls. Structural variant 
calling can also be improved due to the greater chance of observing reads crossing chromosomal 
breakpoints and phasing of variants is facilitated by an increased probability of individual reads 
covering areas in which multiple variants lie. 
 
1.3 - Identifying cancer predisposition genes 
A variety of different study designs have been used to identify CPGs, generally using one of the 
sequencing techniques described above in combination with a strategy to narrow down the genomic 
region of interest.  
 
Earlier efforts focused on large families with multiple affected members and used genetic linkage to 
elucidate regions that segregated with cancer incidence. This strategy is greatly assisted by high 
penetrance of variants affecting the CPG that is sought. In some cases (e.g. RB1) the suggested CPG 
location was supported by the identification of deletions/allele loss in tumour material. Having 
defined a region containing the putative CPG that was as small as possible, all genes within the region 
were then sequenced to identify those that were recurrently mutated. Some CPGs (e.g. APC and VHL) 
are frequently somatically mutated in cancer and these observations can assist in proposing regions or 
genes as candidates. Occurrence of multiple constitutional variants in a given gene amongst 
individuals with the cancer in which the somatic mutations were reported can be taken as evidence of 
its status as a CPG. Recently, molecular characterisation of tumours has accelerated and is assisting 
with investigation in this area. cBioPortal, for example, contains data from over 70,000 sampled 
tumours from a variety of cancer genome sequencing projects.34  
 
Previously, technological and resource constraints meant that genes/regions to be sequenced were 
highly targeted. NGS platforms have enabled analysis of whole genomes, coding regions (exomes) or 
a selected series of genes at a cost that is realistic for many research groups. NGS has greatly 
facilitated CPG identification in projects that often start with a less defined hypothesis in terms of a 
candidate gene/region. The challenges presented by the resultant large numbers of rare genetic 
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variants are often significant but combination with other lines of evidence can filter causative 
candidates. Evidence can include gene expression in the tissue of interest or involvement of the 
candidate gene product in a cellular process relevant to cancer (e.g. DNA repair). Segregation of 
variants within families with multiple affected members remains critical in many analyses and it is 
notable that in the study reporting POLE as a CPG described below, an initial search for shared 
coding variants between unrelated probands did not produce any firm candidate genes.35 
 
Recent examples of CPG discovery using NGS techniques include studies of individuals with 
colorectal adenomas and cancer that causally implicated NTHL136 and POLE.35 The former study 
applied exome sequencing to 51 individuals (from 48 families) with multiple colonic adenomas and 
focused on truncating variants shared between unrelated participants. Under a recessive inheritance 
hypothesis, five genes were identified that contained such variants, one of which (NTHL1) was a 
DNA repair gene. Four individuals from three families had a biallelic truncating variant in this gene 
that was not detected in controls. POLE was identified as causing adenomas through whole genome 
sequencing of members of a single family with multiple affected individuals. The analysis took 
advantage of pre-existing linkage analysis in the family to restrict the area of investigation to a small 
number of genomic regions. Six non-synonymous coding variants in those regions were shared 
between all three sequenced cases, one of which was within a gene (POLE) with relevance to DNA 
repair as it encodes a protein product with a polymerase proof reading function. The putative 
causative variant was then identified in 12 out of 3805 additional colorectal cancer cases used as a 
validation set and no controls. 
 
A further approach that has yielded success in CPG identification is that of a case control analysis 
whereby frequency of variants in a given gene is compared with that in a set of controls. If deleterious 
variants in a CPG confer moderate cancer risks, multiple variant carriers in a kindred are likely to be 
unaffected due to incomplete penetrance. Therefore, segregation data to narrow down candidate 
variants may be misleading. Case control studies do not rely on multi-case families but are greatly 
assisted by large numbers of participating individuals. A number of CPGs have been identified by 
undertaking sequencing in breast cancer cohorts, a common tumour type facilitating a high number of 
participants. CHEK2 was proposed as a CPG due to its role in DNA repair and interaction with 
BRCA1. A founder truncating variant was found to be significantly more frequent in breast cancer 
cases vs controls and estimated to lead to a doubling of risk.37 Similarly, PALB2 associates with 
BRCA2, a line of evidence that helped identify it as a breast CPG in a study observing truncating 
variants in 10 out of 923 familial breast cancer probands compared with zero out of 1084 controls.22  
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1.4 - Risks associated with variants in cancer predisposition genes 
NGS technologies have assisted novel CPG discovery but pathogenic variants affecting many of them 
are often estimated to cause lower tumour risks than some earlier discoveries such as APC and TP53. 
Most CPGs that affect large numbers of individuals, and in which high penetrance variants occur may 
have been discovered. 
 
Newly identified high risk CPGs are likely to be rare and consequently account for a very small 
proportion of population cancer burden. Despite this, associated clinical utility will be significant for 
affected individuals and can provide insights into similar tumours that are not due to constitutional 
variants in the CPG in question. Furthermore, any contribution to a greater range of variants known to 
be relevant to a particular cancer phenotype can be incorporated into a more comprehensive 
diagnostic test. Such a test has an enhanced negative predictive value in patients who consult with the 
relevant phenotype but, as is often the case, do not receive a molecular diagnosis explaining their 
tumours.  
 
Case control based analyses can reveal significant association of variant/gene with tumour without 
necessarily reflecting a very high risk of that neoplasm developing. BRIP1 and PALB2, for example, 
were originally reported to confer a relative breast cancer risk of 2 and 2.3 respectively.38,39 
Interestingly, further observations of variant carriers has revised the PALB2 associated risk to a much 
higher level40 and refuted the role of BRIP1 truncating variants in predisposing to breast cancer,41 
illustrating that risks associated with CPG variants are far from static. One factor contributing to this 
flux can be the precise variant composition of studied cohorts. A large multi-centre analysis involving 
42,671 breast cancer cases and an equal number of controls noted variant frequency and estimated 
risks for ten rare variants in PALB2, CHEK2 and ATM. Risks were often comparable to those earlier 
gene level based estimates but varied substantially between variants in the same gene.42 
 
Elucidation of the genetic basis of high to moderate penetrance cancer predisposition phenotypes can 
have a large effect on management of affected families but only impact on a small minority of cancer 
patients or at-risk individuals. Genome wide association studies (GWAS) are case control studies of 
large cohorts of cancer patients that reveal more common genetic variants associated with a small 
increased risk of particular cancers in larger numbers of individuals. Identification of alleles such as 
these can provide insights regarding the molecular pathways significant to particular tumours but 
generally haven’t been translated into preventative clinical settings because the associated increased 
risk is not sufficient to prompt specific interventions such as surveillance imaging. However, clinical 
utility might be provided by identifying individuals with multiple risk alleles that may act in 
combination. One report to assess the potential of this approach analysed risks associated with 
combinations of 77 variants which had been previously associated with breast cancer in GWAS 
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studies. A combined polygenic risk score was formulated, which was used to stratify over 30,000 
breast cancer cases and controls into risk quintiles. In those without a family history, the upper 
quintile had a higher lifetime risk of breast cancer (16.6%) than the lower quintile (5.2%). This 
difference was more pronounced in those with a first degree relative with breast cancer (24.4% vs 
8.6%).43 Risk estimates in the top quintile group, therefore, approach those deemed sufficient for risk 
mitigating intervention in the clinic. A more recent report applied polygenic risk scores based on 18 
breast cancer associated GWAS variants to 9222 women seen in a breast cancer family history clinic 
and observed a twofold difference in risk between the top and bottom score quintiles (in women 
without BRCA1/BRCA2 pathogenic variants).44 
 
1.5 - Cancer predisposition genes and their contribution to cancer burden 
The canon of CPGs has reached three figures in number but defining such a gene is not without 
difficulty. A comprehensive review of CPGs was published in 2014 by Rahman and included genes 
where rare pathogenic variants at least double the relative risk of a given cancer type and lead to at 
least 5% of carriers being affected with cancer.45 For some tumours, it is doubtful whether the lower 
end of these risks would be of benefit for clinical management.  
 
The proportion of cancers attributable to inherited cancer syndromes is not easily arrived at due to the 
lack of a clear definition of a CPG and limited information regarding frequency of pathogenic variants 
in the population or the precise tumour risks conferred by them. The figure is often estimated as 
around 10%46 and has been quoted as 3% if only known CPGs are included in the estimate.45 A recent 
analysis of germline sequencing data from participants in The Cancer Genome Atlas (TCGA) 
database searched for rare protein truncating variants in 114 CPGs and identified them in differing 
proportions between cancer types. Figures ranged from 4% in acute myeloid leukaemia and 
glioblastoma to 19% in ovarian cancer.47 Overall, the proportion of cases with CPG truncations was 
roughly consistent with the 10% estimate previously proposed but other types of variant such as 
missense are known to contribute to cancer predisposition and undiscovered CPGs not on the list of 
114 may also be significant.  
 
An estimate of the contribution of all genetic factors to cancers can be arrived at by assessing 
heritability, which is the estimated proportion of variation of a trait (in this case liability to develop a 
tumour) in a population that is accounted for by genetic factors and not by environmental factors or 
chance. Heritability estimates can be derived from observing the incidence of a given cancer type 
amongst relatives of individuals who develop that malignancy and comparing it with incidence in the 
general population from which they were drawn. Any excess incidence is likely to be due to genetic 
commonalities. Concordance of occurrence of a wide range of common cancer types in monozygotic 
vs dizygotic twins have been examined in Scandinavian population-based registries. An advantage to 
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this approach is the ability to distinguish genetic from shared environmental factors as monozygotic 
twins have greater genetic commonality than dizygotic twins but there is likely to be little difference 
between the two twin types in terms of environmental exposure. Estimated heritability ranged from 
27% (breast) to 42% (prostate).48 A later analysis of twins in the same registry was able to include 
80,309 monozygotic and 123,382 dizygotic twins. The overall heritability of cancer was estimated at 
33% with estimates for breast and prostate remaining similar at 31% and 57% respectively. The 
highest heritability estimate was 58% for melanoma, illustrating that variability in risk largely 
explained by genetic factors does not imply that environmental factors (in this case ultraviolet light 
exposure) are insignificant in the individuals developing a given cancer type.49 Analysis of cancer 
cases in the Swedish Family-Cancer Database estimated genetic contribution through comparison of 
incidence in closer vs more distant relatives and provided estimates of between 1% and 53% 
depending on cancer type with thyroid cancer being the highest.50 The heritability estimates described 
above relied on comprehensive registration of twins, cancer occurrences and familial relationships 
between individuals contained in cancer registries. Such resources are not widespread, hampering 
efforts to include greater numbers of individuals and apply estimates to more population groups. Even 
in comprehensive twin registries, rarer cancers may not be frequent enough to derive accurate 
estimates.  
 
Disparity between estimates of proportion of cancers due to recognised predisposition syndromes and 
total heritability suggests that ongoing efforts to identify individuals with constitutional genetic 
factors leading to neoplasia in research and clinical settings may be rewarding. The architecture of 
such factors is likely to be diverse in terms of number of loci involved in a given individual and in the 
nature of mutational mechanisms. Heritability estimates do not give a strong indication of whether 
increased tumour incidence in more closely related individuals is due to a combination of numerous 
lower penetrance alleles or a single high penetrance CPG variant. Constitutional single nucleotide 
variants and indels in coding regions may account for a proportion of unrecognised predisposition 
syndromes but other less readily detectable mechanisms are also likely to be significant in many 
cases. These include structural variants, somatic mosaicism, epimutation and variation in non-coding 
regions. 
 
1.6 - Mendelian conditions due to variants in cancer predisposition genes 
CPG functions are relevant to a variety of cellular processes where disrupted function can beget 
tumourigenic phenomena such as abnormal cell cycle regulation, genomic instability or proliferation. 
Tumour predisposition conferred by CPG variants can often produce sufficient risks for Mendelian 
inheritance patterns to be observed in affected families but unaffected variant carriers may still exist 
in these kindreds due to incomplete penetrance. Most such conditions that have been described show 
an autosomal dominant inheritance pattern where bi-allelic pathogenic variants may be embryonically 
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lethal (e.g. BRCA1). A smaller number of recessive syndromes are also known including colorectal 
polyps and cancers due to bi-allelic pathogenic MUTYH variants.51 Interestingly, a number of CPGs 
are associated with distinct phenotypic effects depending on whether deleterious alleles are present in 
the mono-allelic or bi-allelic state. Pathogenic SDHB variants are associated with 
phaeochromocytoma and paraganglioma in the heterozygous state52 whereas bi-allelic inheritance 
causes a neurodevelopmental disorder.53 Homozygous or compound heterozygous ATM deleterious 
variants were previously identified as the cause of Ataxia Telangiectasia, a childhood onset condition 
causing a number of features including cerebellar ataxia, immunodeficiency and predisposition to 
haematological malignancies.54 The observation of increased breast cancer incidence in heterozygous 
carriers55 helped to define mono-allelic variants in ATM as causative of a moderate risk of that 
tumour. In situations where there is a contrasting phenotype between mono and bi-allelic CPG variant 
carriers, it is possible that tumour risks associated with the mono-allelic state are still present where 
two deleterious alleles are inherited but that these manifestations are infrequently observed due to the 
recessive condition reducing life expectancy. Indeed, some occurrences of breast cancer have been 
reported in individuals with Ataxia Telangiectasia surviving for a longer period.54  
 
1.6.1 - Tumour spectrum associated with cancer predisposition genes 
Collectively, cancer predisposition syndromes can increase the risk of a large number of topographical 
and morphological tumour subtypes. Some inherited cancer syndromes, such as Li-Fraumeni 
syndrome, are associated with an increased risk of a wide range of cancer types but most conditions 
are currently known to predispose to a smaller number of specific tumours. Even Li-Fraumeni 
syndrome related cancers are among a set of four core malignancy types in 70% of cases.56 The reason 
for this specificity is largely yet to be elucidated. Theoretical explanations include aberrant cellular 
mechanisms rendering cells susceptible to further mutation through organ specific environmental 
exposures (e.g. skin exposure to ultraviolet light in Xeroderma Pigmentosum) and relative functional 
redundancy of the relevant CPG in low risk tissues. One intriguing possible mechanism for the latter 
is compensation through expression of CPG paralogues derived from the same ancestral gene. A 
recent study of disease gene paralogue expression across multiple tissues showed that lower levels of 
expression are observed in tissues that are affected by variants in corresponding disease genes, but the 
report was primarily concerned with non-CPGs.57 
 
Some phenotypic specificity may be explained by ascertainment biases influencing the study of CPGs 
and their associated tumour spectra. Identification of CPGs has generally occurred by preferentially 
studying families where there are multiple occurrences of the same tumour type, restricting other 
possible associations. The identification of novel CPGs in these scenarios is likely to underestimate 
the range of tumours caused by variants in that gene. These effects may be exacerbated by the effect 
of clinical criteria used to guide access to genetic testing which further extend ascertainment bias.  
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Widening of the phenotype associated with a CPG after initial identification based on a single cancer 
type is exhibited by the relatively recently described BAP1. This gene was originally reported as a 
CPG through the study of uveal melanoma (UM) cases. Previous evidence existed for a role of BAP1 
in the tumourigenesis of UM such as the observations that it is somatically mutated in around half of 
UM’s58 and is located on chromosome 3, which is often deleted in UMs.59 Germline sequencing of 53 
UM probands with clinical evidence of inherited predisposition showed a truncating BAP1 variant in 
one individual, whose tumour demonstrated loss of the wild type allele and reduced 
immunohistochemistry staining for the protein product. This pattern was also found in a lung 
adenocarcinoma from the individual as well as a meningioma from a relative who also carried the 
variant.60 Subsequently, constitutional BAP1 variants have been associated with a range of other 
tumours including renal cell carcinoma (RCC) where a segregating splice site variant was found in a 
family with four affected individuals. Further analysis of 60 families with clustering of RCC and other 
BAP1 related tumours showed variants in 11.61 
 
RCC has also been observed as an additional phenotype associated with constitutional SDHB variants, 
which were initially identified as predisposing to phaeochromocytoma and paraganglioma through 
sequencing of the gene in affected kindreds. Study of SDHB was prompted by prior knowledge of a 
gene encoding another succinate dehydrogenase enzyme subunit (SDHD) causing similar 
phentoypes.52 Subsequently, RCC was observed in two families with SDHB related paraganglioma 
with loss of heterozygosity shown in all of the kidney tumours.62 Prompted by this and the rationale 
that FH variants can cause RCC and are within a gene that encodes another Krebs cycle enzyme, 
SDHB was sequenced in 68 individuals with familial and/or early onset RCC with variants identified 
in three.63  
 
Rare cancer predisposition syndromes that become established in clinical practice may accumulate 
novel tumour associations through the development of larger series of affected individuals, often 
contributed to by multiple centres. Pathogenic variants in PTEN cause a range of disorders including 
Cowden syndrome, which is characterised by macrocephaly, cutaneous manifestations and cancer of 
the breast, thyroid and endometrium. However, a study of 368 PTEN variant carriers showed 
increased standardised incidence ratios (comparison of adjusted incidence vs general population) for 
colorectal cancer, renal cell carcinoma and melanoma.64 These newly documented associations were 
arguably made possible by collaborative efforts to collect sufficient numbers of cases with the 
intention of better defining phenotypes caused by PTEN variants. 
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1.6.2 - Penetrance of cancer predisposition gene variants 
Whilst elucidating the full tumour spectrum associated with a CPG is of critical importance, clinical 
utility is also derived from accurate penetrance estimates regarding the tumours affected individuals 
are known to be at risk of developing. Accuracy is assisted by the observation of large numbers of 
cases, making estimates more difficult for rarer cancer predisposition syndromes. Even where 
relatively large numbers of cases are diagnosed, risk estimates can be influenced by a range of factors. 
 
Ascertainment biases can influence estimated penetrance as well as associated tumour spectrum 
because individuals where the phenotype is more severe e.g. earlier age of tumour diagnosis, may be 
prioritised for clinical testing. Studies of known variant carriers may consequently over-estimate risks, 
which appears to have occurred in research surrounding Lynch syndrome. Lynch syndrome increases 
the risk of colorectal cancer and is caused by heterozygous variants in mismatch repair genes 
including MLH1, MSH2 and MSH6. Colorectal cancer has a high population frequency and criteria 
have previously been developed to prioritise clinical testing and/or research for families likely to be 
exhibiting tumours caused by Lynch syndrome rather than another cause. The two primary examples 
are the Amsterdam criteria,65 which require a prominent family history for fulfilment and the 
Bethesda criteria,66 which were developed to guide molecular investigation for suspected Lynch 
syndrome and allow for the inclusion of a greater number of families whilst still requiring reasonably 
strong evidence. Use of such criteria to ration molecular investigation can lead to efficient use of 
resources but may over-estimate the tumour risks conferred by deleterious mismatch repair gene 
variants because families with lower risks (perhaps due to a different pattern of modifying genetic 
variants) are less likely to have been eligible for testing. Risk of colorectal cancer due to Lynch 
syndrome has reduced with more recent studies compared with those conducted at an earlier time 
point when molecular analysis was more restricted. A large registry based analysis of Finnish 
pathogenic mismatch repair gene variant carriers in 1999 reported a cumulative colorectal cancer 
incidence of 82% by age 70.67 However, an assessment ten years later based on carriers identified 
through genetics clinics and corrected for ascertainment bias estimated an equivalent figure of 66%.68 
Ascertainment biases can be reduced by prospective observation of cancer incidence in CPG variant 
carriers and a more recent study recorded this in 1,942 carriers of pathogenic variants in Lynch 
syndrome genes.69 Cumulative incidence of colorectal cancer was lower still and reported as 46% for 
MLH1, 35% for MSH2, 20% for MSH6 and 10% for PMS2. Risk estimates are not uniformly reduced 
to this extent through the application of prospective observations. Hereditary Breast and Ovarian 
Cancer is a further cancer predisposition syndrome where accumulation of large cohorts of pathogenic 
variant carriers has occurred and a retrospective meta-analysis of studies in 2003 incorporating 289 
BRCA1 carriers estimated a cumulative breast cancer risk of 65% by age 70 years.70 A collaborative 
prospective analysis 14 years later included 6,036 carriers and estimated a similar risk of 72% by age 
80 years.71  
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Studies of Hereditary Breast and Ovarian Cancer have highlighted a further influence on risk 
estimates, that of family history. Extent of family history is frequently taken as a proxy measure for 
genetic modifying factors that influence cancer risk in addition to the pathogenic CPG variant in 
question. The aforementioned prospective analysis stratified cumulative cancer risks according to 
family history status. For example, BRCA1 pathogenic variant carriers with no family history of breast 
cancer had a 53% cumulative risk of breast cancer by age 70 years but those with at least one first or 
second degree relative diagnosed with that tumour type had a cumulative risk of 71% by the same 
age.71 
 
Identification of CPG variants through clinical testing prompts assessment of pathogenicity using 
various lines of molecular, clinical and literature-based evidence. If the conclusion from the 
diagnostic service is that the variant is pathogenic, patients are frequently managed according to risk 
estimates that are the same for all or most pathogenic variants affecting the gene in question. 
However, the phenotypic effects of different pathogenic variants in the same gene can be contrasting. 
Multiple Endocrine Neoplasia Type 2 (MEN2) is caused by activating missense variants in the RET 
proto-oncogene and is associated with a range of neoplasms including parathyroid 
hyperplasia/adenoma, medullary thyroid cancer and phaeochromocytoma.72 The chance of developing 
these tumours is known to be influenced by the codon in which the variant occurs and specific 
genotype is incorporated into clinical management guidelines. Codon 634 variants lead to higher risk 
of phaeochromocytoma that prompts biochemical screening from eight years of age as opposed to 20 
years as per many other variants.73 In addition, cutaneous lichen amyloidosis is observed, which is not 
seen in carriers of variants in other codons.74 Met918Thr is only known to cause the MEN2B clinical 
subtype, which is associated with additional manifestations such as gastrointestinal 
ganglioneuromatosis.75 Some variant consequences such as premature stop codons are frequently 
taken as indicating a complete loss of function of the affected allele but there is variability even within 
these variant classes. BRCA2 c.9976A>T has a nonsense consequence but occurs close to the 3' end of 
the gene and is not regarded as significantly increasing the risk of breast or ovarian cancer.76  An 
increase in the number of genotype-phenotype correlations such as this in cancer predisposition 
syndromes will be valuable for clinical management and might be expected as technological advances 
prompt greater numbers of individuals to undergo diagnostic testing.  
 
1.7 - Impact of next generation sequencing on cancer predisposition gene variant identification 
in the clinic 
NGS assays have had widespread implications for CPG variant identification in clinical settings. The 
most frequent group of assays applied by diagnostic services target (through PCR and/or selective 
pull-down) multiple genes potentially relevant to the patient's phenotype and are often referred to as 
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gene panels. Pathogenic variants in genes hitherto thought to be unrelated to the phenotype will not be 
detected through this method. The likelihood of this reduces as the number of tested genes increases 
and some panels aim to comprehensively cover all known CPGs. A yet more agnostic approach is that 
of exome or genome sequencing, where data relating to genes of interest can be selectively and 
flexibly analysed in a “virtual panel” technique and stored for future interrogation if new information 
regarding pertinent genomic regions becomes available.  
 
The broadened scope of genetic analysis in clinical settings made possible by NGS technologies 
provides great opportunity to identify more individuals with previously unidentified cancer 
predisposing variants. Detection of variants in known CPGs in greater numbers of individuals allows 
more accurate characterisation of the phenotype associated with them in terms of tumour spectrum 
and penetrance. This begets the potential to reduce the aforementioned ascertainment biases 
associated with narrower access to testing, particularly when variants are found in patients with 
phenotypes previously considered uncharacteristic for aberrations at the locus in question. 
 
1.8 - Clinical utility of cancer predisposition variant identification 
Identification and characterisation of CPGs through research studies has produced opportunities to 
predict risk based on genetic factors elucidated by testing in clinical settings. Genetic testing may be 
diagnostic for individuals who have an existing cancer diagnosis and where an explanation is sought. 
Alternatively, predictive testing aims to assess risk in an unaffected individual through identification 
of relevant genetic variants. These are generally those that have previously been found in another 
family member but wider application of genetic analysis is likely to lead to more predictive testing 
where a variant has not been seen in a relative (e.g. in cases of adoption or deceased parents). 
 
Even with the possibilities produced by NGS, resource constraints still limit the range of cancer 
patients that can be investigated. This is not only due to sequencing costs but also computational 
capacity, data storage, analytical time and sample availability. Prioritisation strategies are therefore 
often used to attempt to enrich for tumour predisposing variants (notwithstanding the associated 
ascertainment biases). Focus is often on a specific tumour type or clinical features suggestive of a 
specific syndrome but may also incorporate general indicators of cancer predisposition such as early 
age at diagnosis, occurrence of multiple primary tumours in the same individual and family history of 
neoplasia. Where family history is reported, the rationale for undertaking genetic testing may be 
stronger if a clustering of rarer tumours is observed as alternative causes are less likely. More 
ambiguity exists where common tumours cluster as this may be due to inherited predisposition or 
result from higher population incidence of the occurrent neoplasms, perhaps due to environmental 
factors. However, there is not a simple relationship between frequency of a specific cancer type and 
whether it is genetic or environmental in origin. An assessment of what proportion of cancer cases 
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were attributable to 14 preventable environmental exposures in the UK showed relatively low figures 
for many tumours with high population frequency including breast (26.8%) and colorectal cancers 
(54.4%).77 
 
Whichever testing prioritisation strategy is chosen, successful elucidation of constitutional genetic 
factors that cause cancer predisposition can produce clinical utility in a number of ways. 
 
1.8.1 - Information as therapy 
Individuals undergoing genetic testing may value a diagnosis of a cancer predisposition syndrome 
independently of risk management or treatment as they may seek an explanation for frequently 
difficult personal and family histories of cancer. Negative results of diagnostic testing can provide 
reassurance although probands are often left with the possibility of unidentified pathogenic variants. 
A negative predictive test leads to greater confidence that the individual undergoing testing has a 
similar risk to the general population. 
 
Much of the experience from genetic testing has been obtained via sequencing of BRCA1 and BRCA2 
in clinical settings and a systematic review of psychological outcomes in women with a family history 
of breast cancer that underwent testing found a reduction in psychological distress for women 
receiving negative results and little change in those who received positive results.78 A study of 
individuals undergoing predictive testing for BRCA1 or BRCA2 variants reported that 92% would 
recommend the process to others in the same situation.79 One area of concern with predictive testing is 
the situation where some family members are found to carry a causative variant and others are not. An 
analysis of sibling dyads having predictive tests suggested some negative impact on relationship 
where the result was discordant between the two.80 Any assessment of psychological benefits of 
genetic testing should be seen in the context of uptake, which, in the case of predictive testing, has 
been shown to be around half of eligible individuals for the conditions seen most commonly in the 
genetics clinic.81,82 Those not pursuing testing may represent individuals who would not perceive as 
much benefit and future more widespread application of genetic testing could lead to more negative 
psychological sequelae in the absence of well-considered genetic counselling and consent processes.   
 
Individuals consulting clinical services for assessment for a cancer predisposition syndrome may do 
so primarily to provide a genetic diagnosis in the family. This gives the opportunity for risk prediction 
and management in relatives even if prognosis is poor in the proband. An assessment of motivations 
for diagnostic testing in a series of colorectal cancer patients showed greater importance placed on 
information for relatives than desire to increase certainty regarding personal risk.83 
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Lastly, identification of pathogenic CPG variants in potential parents may facilitate reproductive 
decisions and produce the possibility to test for the variant in a foetus (prenatal diagnosis) or pre-
implantation embryos (pre-implantation genetic diagnosis). These techniques are generally applied in 
severe (mainly non-neoplastic) childhood onset disorders and less frequently for cancer predisposition 
syndromes due to their frequently later onset and manifestations that are more amenable to risk 
mitigation strategies. However, a number of adult onset cancer syndromes are present on the list of 
conditions approved for pre-implantation genetic diagnosis by the Human Fertilisation and Embryo 
Authority84 and a reportedly high proportion of individuals at risk of Lynch syndrome who regard 
prenatal diagnosis as ethically acceptable85 suggest that uptake may increase in future.  
  
1.8.2 - Clinical surveillance 
A current mainstay of cancer predisposition syndrome management is regular clinical surveillance of 
at-risk tissue to identify tumours at an earlier and more treatable stage. A number of potential 
modalities exist for this purpose such as imaging, endoscopic examination and biochemical analysis, 
which are applied depending on the tissue or syndrome in question. Age range and frequency of 
surveillance investigations are guided by observational evidence from series of affected cases but the 
quality of this evidence can be compromised by rarity of a condition and/or ascertainment biases 
influencing which patients are included in studied cohorts.  
 
Effectiveness of surveillance programmes is currently uncertain for most cancer predisposition 
syndromes but for conditions that have a higher incidence, larger screened cohorts can be assembled 
to provide greater clarity. A systematic review of Lynch syndrome screening, for example, showed 
reduction in colorectal cancer incidence and related mortality in screened (with regular colonoscopy) 
cases.86 In rarer conditions, inference can be made from indirect information sources. Von Hippel 
Lindau disease leads to increased risk of a number of tumours including central nervous system 
haemangioblastoma, phaeochromocytoma and renal cell carcinoma. Protocols for surveillance are 
widely used but no prospective follow up data comparing screened with unscreened individuals exists. 
However, an increase in mean survival by 16.3 years has been observed among patients diagnosed 
after 1990, a time when systematic screening protocols were introduced.87 
 
Surveillance programmes may be more straightforward where there are relatively few at-risk tissues 
to screen but many cancer predisposition syndromes lead to diverse tumour risks that can make 
execution of surveillance more complex and potentially less acceptable to patients. Li-Fraumeni 
syndrome is associated with a high risk of cancer that may arise from multiple organs and intensive, 
multi-modality screening regimens have been proposed in response to this.88 Uncertainties 
surrounding effectiveness of these strategies has led, in many services, to a focus only on breast 
screening where greater confidence of utility exists. However, evidence is accumulating regarding the 
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benefits of whole body magnetic resonance imaging (MRI) and a 14% cancer detection rate from a 
one-off MRI has been reported in pathogenic TP53 variant carriers.89 A meta-analysis of this 
technique including 578 carriers reported a rate of 7% that was only contributed to by mostly non-
breast cancers.90 Promising figures such as these should be seen in the context of false positives and in 
the former study, 34% of 44 participants underwent further investigation for a lesion eventually 
diagnosed as benign with a corresponding figure of 24% in the meta-analysis.  
 
Screening has more harmful potential (e.g. through unnecessary biopsy or surgery) where the 
penetrance of a CPG is low. In Hereditary Leiomyomatosis and Renal Cell Carcinoma caused by 
deleterious FH variants, only 15-20% of variant carriers develop kidney cancer but of those that do, 
many have reached an advanced stage with associated poor prognosis.91 Difficult clinical situations 
such as this may be assisted by stratification of risk amongst CPG variant carriers, potentially based 
on the particular variant in the causative gene or other factors such as constitutional genetic modifers. 
Alternatively, acceptability, specificity and sensitivity of screening tests might be improved for low 
risk individuals by exploiting the phenomena of circulating tumour cells or DNA. Identification of 
specific markers of tumour development could facilitate potential future surveillance programmes 
based on blood sampling. 
 
1.8.3 - Prophylactic surgery 
In some syndromes where at-risk tissue is safely removable and non-essential, prophylactic surgery 
may be an effective preventative strategy. Influences on whether this is a reasonable option include 
extent of risk reduction, function (and loss thereafter) of the tissue in question and potential for 
complications following surgery. These factors need to be weighed against the efficacy and 
acceptability of surveillance strategies as an alternative.  Prophylactic surgery can produce significant 
reduction in tumour risk and bilateral mastectomy in pathogenic BRCA1 and BRCA2 variant carriers 
is estimated to reduce the risk of breast cancer by around 90%.92 Preventative oophorectomy has been 
reported to reduce ovarian cancer risk to a similar degree93,94 but this procedure results in infertility 
and the requirement for hormone replacement in pre-menopausal women. Mastectomy may intuitively 
be regarded as having fewer negative consequences but negative psychological impact from this 
procedure can ensue.95 In Hereditary Diffuse Gastric Cancer families, total prophylactic gastrectomy 
in pathogenic CDH1 variant carriers is recommended but is associated with significant post-surgical 
morbidity from gastrointestinal symptoms.96 The risk reduction provided by this procedure can be 
assumed to be significant but is difficult to quantify given the rarity of Hereditary Diffuse Gastric 
Cancer and the lower potential to assemble a series of controls (i.e. no surgery performed) with which 
to compare cancer incidence. A similar scenario exists for Familial Adenomatous Polyposis, where 
colorectal cancer risk97 has been estimated to be at a level sufficient to warrant colectomy in all 
diagnosed cases, leaving few cases with an intact colon for further observation.  
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1.8.4 - Pharmacological management 
Pharmacological prevention or treatment based on constitutional genetic status is in its infancy but it 
is hoped that this area will develop as molecular characterisation of syndromes and tumours 
accelerates. 
 
Chemo-preventative strategies are seldom used in cancer predisposition syndromes but are an 
attractive proposition because side effects or economic cost are more likely to be outweighed by the 
high tumour risks involved. One of the more notable advances in this area has been the re-purposing 
of an established drug (aspirin) rather than development of a new agent.  The observation of lower 
colorectal cancer rates in individuals taking aspirin prompted a trial in individuals with Lynch 
syndrome.98 Here, daily aspirin was associated with an approximate 60% reduction in colorectal 
cancer incidence99 and later guidelines indicated that aspirin use should be discussed with individuals 
from Lynch syndrome families.100 
 
Pharmacological interventions in cancer predisposition syndromes may also be based on targeting a 
specific cellular aberration due to the causative constitutional variant. This area has received 
increasing attention in recent years but examples of current use remain infrequent. Vismodegib is an 
inhibitor of the hedgehog signalling pathway that is abnormally upregulated in basal cell carcinomas 
resulting from constitutional PTCH1 variants and a second hit of the wild type allele (Gorlin 
syndrome).101–103 The agent has been demonstrated to reduce basal cell carcinoma occurrence in 
Gorlin syndrome104  but cost has prevented approval for use in the UK in either the hereditary or 
sporadic context.105 A more widely used group of agents are poly ADP ribose polymerase (PARP) 
inhibitors for BRCA1/2 related tumours, which are generally deficient in double stranded DNA repair 
by homologous recombination due to a second hit of the wild type allele. PARP inhibitors disrupt a 
different DNA repair mechanism (base excision repair), thus rendering tumour cells non-viable whilst 
sparing other cells where a second hit has not occurred and homologous recombination persists.106  
 
1.9 - Multiple Primary Tumours  
Multiple primary tumours (MPT) describes the scenario where two or more histologically distinct 
tumours that are not due to metastasis, recurrence or local spread are diagnosed in the same 
individual. These may be synchronous (diagnosed at the same time point) or metachronous 
(diagnosed months to years apart).  
 
1.9.1 - Multiple primary tumours in the general population 
The first description of MPT is attributed to Theodor Billroth in the nineteenth century.107 It has been 
considered a rare phenomenon but has been observed more often as cancer survivorship has 
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lengthened.108 Registry based studies have highlighted MPT as an increasingly frequent problem109 
with a key study observing 253,536 individuals diagnosed with cancer in Connecticut between 1935 
and 1982 and reporting second primary neoplasms in 6.6% of them.110 A more recent review of 
European cancer registries revealed that 6.3% of registered tumours were subsequent primaries111 and 
16% of incident cancers reported to National Cancer Institute (USA) in 2003 were diagnosed in 
patients with a previous cancer.112 
 
MPT due to processes that are non-random can be indicated by a higher than expected incidence of 
second primaries in individuals previously diagnosed with cancer. In the Connecticut study, 
individuals with cancer had 1.3 times the risk of developing a cancer than individuals without a 
malignant diagnosis.110 Relative incidence can be expressed as a standardised incidence ratio (SIR), 
which is a ratio of observed incidence and expected incidence in a corresponding population adjusted 
for risk factors such as age, sex and socioeconomic status. Population based studies have shown raised 
SIRs for a variety of concordant and discordant tumour types following a first primary and in a 
registry containing 633,964 cancer incidences, the SIR for any cancer was 1.3 in men with a previous 
malignancy and 1.6 in women. Some SIRs were below 1, suggesting lower incidence of cancer in 
individuals with certain malignant diagnoses. One explanation for this is that therapy for an initial 
primary may serendipitously treat a nascent cancer, particularly concordant tumours but potentially 
also discordant. Alternatively, poor prognosis associated with particular tumours may lead to less 
extensive surveillance and reduced probability of diagnosis of subsequent cancers before death 
occurs. For example the SIR for gastric cancer in men is 0.6 after 10-38 years.113 
 
1.9.2 - Aetiology of multiple primary tumours 
Multiple factors may contribute to the occurrence of MPT whose relative importance may be 
challenging to assess.  
 
Correlation of number of stem cell divisions and cancer occurrence in different tissues has been 
interpreted as showing that variation in cancer incidence between tissues, and therefore many 
tumours, can be largely explained by mutagenic events that are not due to exogenous exposures or 
inherited factors.114 The lifetime risk of cancer (excluding non-melanoma skin cancer) in the UK is 
estimated at around 1 in 2 for those born in the year 1960115 and under this rationale, many of the 
tumours contributing to that figure would have little exogenous or constitutional genetic contribution. 
These might occur in the same individual if survival following a first diagnosis is of sufficient 
duration.  
 
Follow up for cancer diagnoses can lead to the detection of second primaries that would not otherwise 
have been detected in the patient’s lifetime, referred to as lead time bias. This situation does not 
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explain the aetiology of the neoplasms but influences the rate and spectrum of multiple primaries 
observed in a population. Second cancers may be identified due to systematic examination or imaging 
of tissue at risk of recurrence, for example through skin examinations after diagnosis of cutaneous 
malignant melanoma.116 Surveillance imaging modalities might also include other organs in which 
cancers may be detected incidentally, as has been reported during follow up for pancreatic and 
prostate cancer with positron emission tomography/computed tomography.117–119 Surgical intervention 
for a first primary may reveal a synchronous tumour that may have remained undiagnosed if an 
alternative management strategy had been chosen. Endometrial cancer can be diagnosed after total 
abdominal hysterectomy and bilateral salpingo-oophrectomy for ovarian cancer,120 though it has been 
debated whether this particular pairing represents truly distinct primaries.  
 
Radiotherapy or chemotherapy used to treat a first cancer may beget subsequent primary tumours. 
This can include non-cytotoxic drugs such as tamoxifen, which increases the risk of endometrial 
cancer following treatment for breast cancer.121 Second cancers caused by treatment frequently occur 
many years after initial carcinogenic treatment occurred. Robust causative associations between 
therapies and subsequent neoplasms are difficult to delineate for a number of reasons. Poor survival 
from some initial tumour types means that subsequent primaries are less likely to be observed in 
individuals with that diagnosis because death may occur before they are reported.  In addition, best 
practice treatment regimens often change over time and between centres. Collation of individuals with 
a particular diagnosis who are treated in the same manner may be challenging, especially if the 
tumour type in question is uncommon. Some treatment modalities for particular cancers may have 
only recently been adopted and carcinogenic effects might not have been observed yet. For example, 
renal cell carcinoma has previously been considered to be resistant to radiotherapy but more recent 
evidence suggests utility for this approach,122 potentially increasing rates of radiation-related 
malignancies in renal cell carcinoma patients.   
 
Despite these difficulties, a range of associations with treatment have been demonstrated. Histological 
or molecular examination of neoplasms may not reveal distinguishing features between treatment 
related and sporadic tumours in all cases but is useful in some scenarios. For example, leukaemias 
exhibiting microsatellite instability are more frequent where a tumour is therapy related but rare 
where leukaemia is diagnosed in the absence of a personal history of cancer.123  
 
Patterns of treatment related cancer show differences dependent on whether chemotherapy or 
radiotherapy is used. Radiation related cancers generally occur ten years or more following 
exposure124 and associations have often been reported by studies observing survivors of events such as 
the atomic bomb attacks in Japan in 1945125 and Chernobyl nuclear accident in 1986.126 Solid tumours 
such as those of the thyroid, lung, stomach, skin and connective tissue (sarcoma) are the most 
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frequently associated with radiation exposure127 with sites reflecting tissue sensitivity and area of 
exposure. Haematological tumours such as leukaemias also occur at increased rates and may occur 
sooner after exposure.128 The association of radiotherapy for Hodgkin’s lymphoma and breast cancer 
is well established and has led to alteration in Hodgkin’s lymphoma management with the intention of 
reducing radiation dosage to breast tissue.129–131 
 
Malignancies due to chemotherapeutic agents are more frequently haematological and may occur 
following a relatively short post exposure time period. Alkylating agents (e.g. etoposide) can cause 
acute myeloid leukaemia that usually manifests after five to seven years. Leukaemias due to 
epipodophyllotoxins often have a three year latency period.132 Chemotherapy can also lead to solid 
tumours, one example being dose responsive increased bladder cancer incidence after 
cyclophosphamide administration.133  
 
Carcinogenic effects of treatment can be modified by a range of variables, perhaps most intuitively by 
dosage as higher levels of radiation or cytotoxic agents can produce greater potential for mutational 
events. Higher dosages might also lead to lower risk due to enhanced induction of cell death in clones 
with malignant potential.123 Age at treatment may also be a modifying factor. If this is younger, there 
is likely to be a longer length of time in which further tumours can occur and a number of the known 
therapy-tumour associations have been found through follow up of children with diagnoses such as 
neuroblastoma.134 Rather than simply more time to observe subsequent primaries, there is also 
evidence that second primary incidence at a given time point in follow up is lower in individuals 
where treatment exposure occurred at a later age.124 Theoretical explanations include greater cellular 
proliferation at earlier ages that enhances clonal expansion of cells that have undergone tumourigenic 
genetic changes and increases the probability that further tumourigenic mutations will occur in 
daughter cells. Whilst systemic chemotherapy may affect a large variety of tissues accessible via the 
circulation, the pattern of carcinogenesis due to radiotherapy is modified by the field of treatment. 
Increased incidence of lung and oesophageal cancer, for example, are observed after radiotherapy for 
breast cancer.135 Combination of therapeutic modalities may produce modifying effects. Doxorubicin 
used in Wilms tumour patients increases the risk of breast cancer following radiotherapy136 and higher 
frequency of gastrointestinal malignancies has been reported  following combined chemotherapy and 
radiotherapy for Hodgkin’s lymphoma than would be expected if the risks from each modality were 
summed.137 Constitutional genetic factors may also influence probability of subsequent tumours after 
treatment. Cancer predisposition syndromes can increase sensitivity to chemotherapy or radiotherapy 
as is seen for basal cell carcinomas after radiotherapy for medulloblastoma in Gorlin syndrome138 and 
various radiation induced neoplasms in Li-Fraumeni syndrome.139 Indirect modifying effects due to 
genetic factors are exhibited by cytochrome p450 enzyme gene variants, which increase or decrease 
blood levels of chemotherapeutic drugs through their effect on metabolism of some agents.140  
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Particular environmental exposures may increase the risk of more than one cancer type and can 
consequently account for some MPT cases. Smoking, for example, has a role in the aetiology or both 
aerodigestive tract cancers and lung adenocarcinoma and incidence of the former is increased 
following diagnosis of the latter.141 Distinct environmental exposures may also contribute to MPT and 
some may be common enough to give rise to many individuals who experience multiple exposures. 
Smoking prevalence in adults is estimated at 20% in England142 while obesity affects an estimated 
~25%.143  Multiplication of probabilities would indicate that ~5% of adults have both exposures but 
this assumes random distribution in the population, which is not necessarily true (e.g. smoking and 
alcohol consumption, both carcinogenic factors, are associated with one another144). 
 
A role for constitutional genetic factors in the causation of MPT is indicated by increased incidence of 
second cancers in those with a family history of a corresponding neoplasm as it can be inferred that 
the increase is likely due to a shared heritable component. Studies arising from the Swedish Family 
Cancer Database have reported increased incidence of concordant and discordant second primaries in 
breast cancer cases with an affected parent compared with those without a parent diagnosed with 
breast cancer. As an example, the SIR (based on expected population incidence) for ovarian cancer 
following breast cancer was 2.0 in those with a family history of breast cancer and 1.7 in those 
without. The SIRs for acute lymphoid leukaemia were 12.7 vs 1.9 and 4.6 vs 3.0 for breast cancer.145 
Similarly, greater incidence of a second colorectal cancer has been observed among patients who have 
a first degree relative with that tumour type with a two-fold risk observed compared to non-familial 
cases.146 Such observations suggest that inherited genetic factors contribute to the burden of second 
cancers in the general population, a proportion of which are monogenic.  
 
Cancer predisposition syndromes form the focus of this thesis and can be suggested by clinical 
observations such as diagnosis of neoplasia at a young age or a family history of tumours (but not in 
cases due to de novo variants), particularly if histological concordance is present or if neoplasms are 
associated with a particular syndrome (e.g. colorectal and endometrial cancers in Lynch syndrome). 
Multiple tumours per se are also frequently taken as a clinical indicator and many predisposition 
syndromes are associated with a high frequency of the phenomenon.  A number of syndromes that 
affect cutaneous areas are very frequently associated with multiple primaries. Xeroderma 
Pigmentosum causes multiple squamous cell carcinomas, basal cell carcinomas and melanomas in sun 
exposed areas.147 Gorlin syndrome due to PTCH1 variants also predisposes to basal cell cancers.148 
Neurofibromatosis type 1 and type 2 lead to, amongst other manifestations, multiple cutaneous 
neurofibromas and bilateral vestibular schwannomas respectively.149,150 In practice, diagnosis and 
treatment of each tumour as a separate entity is more likely to occur in syndromes causing internal 
malignancies. Multiple cancers have been observed in 55% of 91 Li-Fraumeni cases with pathogenic 
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variants in TP53151 and in 3% of Peutz-Jeghers syndrome cases with pathogenic variants in STK11.152 
Retinoblastoma is the predominant feature of the syndrome that carries its name but the full tumour 
spectrum includes extra-ocular cancers such as osteosarcoma, soft tissue sarcoma and melanoma. 
Observation of 1,852 bilateral retinoblastoma cases alive at one year following diagnosis showed a 
cumulative incidence of second primaries at 50 years of 47% and 38% with and without family 
history (of retinoblastoma) respectively.153 Subsequent primaries are also a significant feature of 
cancer predisposition syndromes more commonly seen in clinical genetics departments. A study of 
491 breast cancer cases carrying pathogenic BRCA1 or BRCA2 variants demonstrated ovarian cancer 
incidence of 12.7% for BRCA1 and 6.8% for BRCA2.154 In an analysis of 127 endometrial cancer 
patients with pathogenic variants in mismatch repair genes associated with Lynch syndrome, 48% had 
developed colorectal cancer at 20 years following initial diagnosis.155 Given associations such as 
these, many patients with MPT will be referred for clinical evaluation with the intention of elucidating 
the causative CPG variant using genetic testing. 
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Chapter 2 – Methods applicable to multiple 
sections 
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The methods outlined in this chapter are applicable to investigation discussed in multiple chapters in 
this thesis. Methods specific to particular analyses are discussed in the relevant chapters. 
 
2.1 - Study participants 
Study participants were invited for recruitment through identification by clinical genetics services or 
by participation in previous research studies. The criteria for invitation were the development of two 
primary tumours by age 60 years or three primary tumours by age 70 years. Individuals with a single 
primary could also be included if they had a first degree relative who fulfilled these criteria. Most 
participants were eligible for recruitment on the basis of multiple malignant tumours but benign 
neoplasms could also be taken into account. A breakdown of phenotype and how eligibility criteria 
were fulfilled for each analysis can be found in the methods section of the chapter pertaining to that 
analysis. In each family, there was a clinical suspicion of a cancer predisposition syndrome but 
routine genetic assessment/testing had not identified a constitutional molecular genetic diagnosis to 
fully explain the tumour phenotype at the time of recruitment. Tumours in the same tissue type and 
organ were considered separate primaries if, in the case of paired organs, they occurred bilaterally or 
if the medical record clearly denoted them as distinct. International Agency for Research on Cancer 
guidance for defining separate primaries were also used.156  
 
All participants gave written informed consent to participate in the National Institute of Health 
Research (NIHR) BioResource Rare Diseases (BRIDGE), Molecular Pathology of Human Genetic 
Disease (HumGenDis), and/or Investigating Hereditary Cancer Predisposition (IHCAP) studies. The 
NIHR BioResource projects were approved by Research Ethics Committees in the UK and 
appropriate ethics authorities in non-UK enrolment centres. Ethical approval for HumGenDis and 
IHCAP was given by South Birmingham and East of England, Cambridgeshire and Hertfordshire 
Research Ethics Committees respectively. 
 
2.2 - Tumour labelling and classification 
Initially, each tumour reported by recruiters or detected in the medical record was labelled with a 
topographical and morphological code based on the International Classification of Diseases for 
Oncology, Third Edition.157 Selected codes were the most specific possible given the information 
available e.g. the morphological code chosen for breast cancer could have been “Infiltrating duct 
carcinoma” (8500/3) if a histology report was provided or “Neoplasm, malignant” (8000/3) if only the 
descriptor “breast cancer” was provided by the recruiting clinician.  
 
In order to provide phenotypic groups for data analysis and results interpretation, tumours that 
occurred in participants were subsequently binned into categories on the basis of the initial coding. 
Tabulation of occurrent tumours pertaining to each analysis performed is referred to in the section 
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describing that analysis. Bins were generally named on the basis of topographical site. Tumours were 
assigned to such bins if they occurred at the specified sites unless there was evidence of a histological 
subtype that wouldn’t be clinically described by the site-based term (e.g. medullary thyroid cancer 
would not be included in the “thyroid” bin but papillary thyroid cancer or “thyroid cancer” would be 
included). If a tumour type was not well described by a purely site-based label, a bin was created with 
a more specific term (e.g. paraganglioma, gastrointestinal stromal tumour and non-melanoma skin 
cancer). Haematological tumour bins were labelled according to cell lineage (e.g. lymphoid, myeloid).  
 
2.3 - DNA samples 
DNA from lymphocytes was either obtained from DNA stored in diagnostic laboratories attached to 
clinical genetics centres or extracted from newly obtained blood samples. DNA extraction from blood 
was performed by the East Anglian Medical Genetics Laboratory using a Flex Star automated DNA 
extraction instrument (Autogen, Holliston, MA, USA). Some extractions from blood were performed 
by the Cambridge Translational Genomics Laboratory using a guanidine and precipitation-based 
methodology.  
 
2.4 - Sequencing 
Massively parallel sequencing was performed on blood DNA samples using whole genome 
sequencing (WGS) and a gene panel assay of cancer predisposition genes. The key steps in these 
processes are described in Figure 2.1. 
 
Figure 2.1 - Key sequencing steps 
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2.4.1 - Whole genome sequencing and bioinformatic processing of sequencing output 
WGS and bioinformatic processing to produce variant call format (VCF) files was performed on 
samples from study participants as part of, and according to protocols devised by, the BRIDGE study.  
 
DNA samples were checked for adequate concentration (30 ng/μl in 110 μl) with the PicoGreen assay 
(ThermoFisher, Waltham, MA, USA) and DNA degradation with gel electrophoresis. Purity was 
checked (adequate measurement optical density 260/280 1.75-2.04) with a Trinean DropQuant system 
(Trinean, Pleasanton, CA, USA). Samples passing quality control checks were shipped on dry ice to 
the sequencing provider (Illumina Inc., Great Chesterford, UK). Further quality controls were 
performed by the sequencing provider with a further check for adequate DNA concentration (30 
ng/μl) and use of a microarray assay to ensure that samples were able to generate high quality 
genotyping results (Illumina Infinium Human Core Exome microarray). If samples were observed to 
have a repeated array genotyping call rate <0.99 or high levels of cross-contamination they did not go 
forward for WGS. The genotyping data were also used for sample identification before data delivery.  
 
0.5μg of the DNA sample was fragmented using Covaris LE220 (Covaris Inc., Woburn, MA, USA) to 
obtain an average size of 450 base pair (bp) DNA fragments. DNA samples were processed using the 
Illumina TruSeq DNA PCR-Free Sample Preparation kit (Figure 2.2, Illumina Inc., San Diego, CA, 
USA) on the Hamilton Microlab Star (Hamilton Robotics, Inc., Reno, NV, USA). The final libraries 
were checked using the Roche LightCycler 480 II (Roche Diagnostics Corporation, Indianapolis, IN, 
USA) with KAPA Library Quantification Kit (Kapa Biosystems, Inc., Wilmington, MA, USA) for 
concentration.  
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Figure 2.2 - Illumina TruSeq DNA PCR-Free library preparation158 
 
 
 
 
Libraries were sequenced with an Illumina HiSeq 2500 instrument with three different read lengths 
over the course of the project (February 2014 to June 2017). These were 100 bp (377 samples, three 
lanes used), 125 bp (3,154 samples, two lanes used). Some samples were sequenced with 150 bp reads 
(9,656 samples) on a single lane of an Illumina HiSeq X instrument. These numbers relate to all 
samples sequenced for the BRIDGE study and not just those that were in the multiple primary 
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tumours arm. The minimum coverage was 95% bases at 15X per lane and no more the 5% of insert 
sizes could be less than double the read length. The mean coverage achieved for 100, 125 and 150 bp 
read length was 41.4X, 37.9X and 35.3X respectively with a mean percentile of coverage of 31.0X, 
25.7X and 26.2X. 90% of the utilised reference genome was covered at ≥19X in all samples. 
 
Files containing sequencing data were delivered to and stored by the University of Cambridge High 
Performance Computing Service. FASTQ files were generated by HiSeq Analysis Software v2.0 
(Illumina Inc., San Diego, CA, USA). Read alignment to GRCh37 was performed using Illumina 
Isaac aligner version SAAC00776.15.01.27.32 Single nucleotide variants and indels were called from 
resulting binary compressed sequence alignment map (BAM) files using Illumina Starling software 
version 2.1.4.2. Output was in VCF and genome VCF format (gVCF), the latter of which contains 
information regarding coverage, alignment quality and other factors that contribute to a PASS filter at 
non-variant positions. gVCF files allow assessments of quality parameters at sites across samples to 
inform exclusion of problematic loci. 
 
To identify sample duplication, a genotyping array was utilised to estimate kinship between samples. 
This assay incorporated a subset 8,872 single nucleotide polymorphisms (SNPs) randomly selected 
from those included on Roche microarrays for assessing kinship (Roche, Basel, Switzerland). 
Assessments of kinship using resulting data were performed using PLINK159 and an output indicating 
a high degree of kinship prompted investigation as to the reason. Samples demonstrated to be 
duplicates or where the cause could not be determined led to the exclusion of one of the samples with 
inferior WGS data quality. 
 
Measures were also taken to exclude samples on the basis of inadequate variant quality. Samples were 
removed if more than 5% of sites did not pass quality filters in the gVCF or if the ratio of observed 
transitions to transversions (which can be used to assess accuracy of single nucleotide variant calls160) 
fell outside of the interquartile range of values observed in the relevant sequencing batch. 
Additionally, exclusions were made if an inadequate proportion (<99.45%) of variant calls from 
common single nucleotide variant positions passed quality filters. Common variants were defined as 
those with a population specific minor allele frequency of >5% in gnomAD.161 Contamination of 
samples by other DNA samples was also checked using verifyBamID software162 and exclusion made 
if estimated contamination exceeded 3%. Sites associated with consistently poor quality calls across 
retained samples were excluded from all retained samples. Exclusion was based on overall pass rate 
that, for a given site, describes the proportion of samples where a call was possible multiplied by the 
proportion of those calls that passed quality filters. A threshold of overall pass rate of 0.99 was 
utilised.  
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Annotation of variants was performed according to the downstream analysis used in this project (see 
relevant chapters) but frequently utilised UK10K163 allele frequency information that was added to 
variants by BRIDGE annotation pipelines. 
 
Structural variant calling algorithms Canvas version 1.1.0.5164 and Manta version 0.23.1165 were also 
applied to the data. The former detects copy number variation based on sustained increases or 
decreases in sequencing read counts along genomic regions and is best suited for variants that exceed 
10kb in length. The latter predicts inversions, translocations, tandem duplications, insertions and 
deletions based on the presence of split reads and/or evidence from paired reads and is designed to 
detect variants between 50bp and 10kb. Separate files containing calls corresponding to all structural 
variant modalities were provided for analysis.  
 
Ethnicity and relatedness to other sequenced samples was estimated using a further SNP array-based 
strategy incorporating 292,878 variant sites used by the HumanCoreExome-12v1.1, 
HumanCoreExome-24v1.0 and HumanOmni2.5-8v1.1 genotyping arrays. This number was reduced 
to unlinked, high quality SNPs used for analysis following exclusions. SNPs were excluded if there 
was a missing genotype in at least one sequenced individual, if the minor allele frequency was <0.3 
amongst sequenced individuals, if more than two alleles had been observed in sequenced individuals 
or in 1000 Genomes Phase 3 data (to assist with coding of genotypes),166 if the overall pass rate (see 
above) for a site was <0.99, or if assessment with PLINK159 indicated linkage disequilibrium between 
pairs of SNPs (r2 > 0.2). 32,875 SNPs passing these filters were considered in a principal component 
analysis of unrelated individuals (defined using the KING R package167) in the 1000 Genomes Project 
Phase 3 performed using PC-AiR and PC-Relate functions of the GENESIS R package.168 The 
resulting kinship matrix was analysed by PRIMUS software to produce a final set of unrelated 
individuals with pre-designated population of origin as part of 1000 Genomes annotation, forming the 
basis of partition into non-Finnish Europeans, Finns, Africans, South Asians and East Asians. 
Genotypes from individuals sequenced by the BRIDGE project were subsequently projected on to the 
1000 Genomes principal components and the most likely ethnicity calculated on the basis of 
likelihood of the projected data assuming each of the five ethnicities. A numerical assessment of 
degree of familial relatedness was provided by a similar process which merged BRIDGE data with 
1000 Genomes data (to produce greater genetic diversity for principal component analysis) and 
executed PC-Relate on input data. 
 
2.4.2 - Gene panel sequencing and bioinformatic processing of sequencing output 
Gene panel-based sequencing and bioinformatic processing to produce VCF files was performed by 
colleagues in the Department of Medical Genetics, University of Cambridge. 
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The Illumina TruSight Cancer panel (Illumina Inc., San Diego, CA, USA) is the result of 
collaboration between the Institute of Cancer Research and Illumina to produce an assay that 
sequences a comprehensive collection of 94 cancer predisposition genes (Table 2.1). Library 
preparation from DNA samples was performed according to the manufacturer’s protocol (Figure 2.3). 
Assessments of fragment size, quality and quantification were performed using a Bioanalyzer 
instrument (Agilent, Santa Clara, CA, USA). 
 
Table 2.1 - Genes sequenced by Illumina TruSight Cancer panel 
AIP CEBPA FANCA KIT PRF1 SLX4 
ALK CEP57 FANCB MAX PRKAR1A SMAD4 
APC CHEK2 FANCC MEN1 PTCH1 SMARCB1 
ATM CYLD FANCD2 MET PTEN STK11 
BAP1 DDB2 FANCE MLH1 RAD51C SUFU 
BLM DICER1 FANCF MSH2 RAD51D TMEM127 
BMPR1A DIS3L2 FANCG MSH6 RB1 TP53 
BRCA1 EGFR FANCI MUTYH RECQL4 TSC1 
BRCA2 EPCAM FANCL NBN RET TSC2 
BRIP1 ERCC2 FANCM NF1 RHBDF2 VHL 
BUB1B ERCC3 FH NF2 RUNX1 WRN 
CDC73 ERCC4 FLCN NSD1 SBDS WT1 
CDH1 ERCC5 GATA2 PALB2 SDHAF2 XPA 
CDK4 EXT1 GPC3 PHOX2B SDHB XPC 
CDKN1C EXT2 HNF1A PMS1 SDHC  
CDKN2A EZH2 HRAS PMS2 SDHD  
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Figure 2.3 - Illumina TruSight Cancer library preparation (taken from Illumina datasheet169)  
 
 
Libraries were sequenced with an Illumina MiSeq (Illumina Inc., San Diego, CA, USA). BCL files 
resulting from the sequencing were converted in FASTQ files using Illumina’s bcl2fastq (Illumina 
Inc., San Diego, CA, USA). FASTQ files were checked for coverage and other quality control 
parameters using fastqc software. FASTQ files were aligned to the hg19 version of the reference 
genome using BWA-MEM31 with default parameters and samtools170 to produce a BAM file. Variants 
were called from BAM files using the Genome Analysis Tool Kit (GATK) Unified Genotyper 
algorithm.33,171  
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Chapter 3 – Multiple primary tumours in 
referral and registry-based series 
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Sections of this chapter discussing composition of a series of research participants with multiple 
primary tumours are based on corresponding sections of a previously published journal article 
(Whitworth et al).172  
 
3.1 – Introduction 
Research participants forming the basis of the studies presented in this thesis were individuals with 
multiple primary tumours (MPT) that were recruited via clinical genetics centres after referral for 
suspected cancer predisposition syndromes. Referrals to cancer genetics services are influenced by the 
relatively narrow range of cancer predisposition genes (CPGs) and well-defined syndromes that have 
historically prompted assessment. Indeed, previous analyses have recorded that referrals for breast or 
bowel cancer (associated with hereditary breast/ovarian cancer and Lynch syndrome) make up around 
80% of the total.173,174 However, inherited cancer syndromes as a whole can lead to a wide spectrum 
of tumours. Many affected individuals may not be assessed in the clinic but increasing sequencing 
capabilities of National Health Service genetics laboratories offers greater opportunity to do so. 
Although there are numerous epidemiological assessments of MPT in the literature,109,111,175 reports 
often focus on risks following a specific initial cancer rather than a the relative occurrence of 
particular combinations.  
 
To assess the nature of MPT combinations occurring in general populations, data from two cancer 
registries and a large treatment centre were obtained. Additionally, a series of MPT cases was 
ascertained through clinical genetics services that went on to be subject to sequencing analyses 
(herein referred to as the MPT series). This was compared with the registry series considered most 
representative of the population from which the MPT series was drawn to highlight differences that 
might influence the range of cancer predisposing genetic variants observed. 
 
3.2 - Methods 
Scripts used in these analyses are stored as an appendix in the form of a GitHub repository 
(https://github.com/jameswhitworth/Thesis-
Elucidating_the_genetic_basis_of_multiple_primary_tumours-Scripts_appendix 
doi:10.5281/zenodo.1501206). They are denoted with the prefix "RA" (repository appendix) in the 
text and in the repository. Script RA3.1 was used for all collations, calculations and figures in this 
chapter. 
 
3.2.1 - Collection and analysis of registry data 
Data pertaining to individuals diagnosed with two or more cancers before the age of 60 years were 
obtained from three sources. The National Cancer Registration Service – Eastern Office (East Anglia 
(EA) Registry) covers a population in the UK of ~5.5 million176 and provided data covering a period 
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from 2009-2014. Data were also obtained from the Netherlands Cancer Registry (Dutch Registry) 
covering a period from 1989-2014. Additionally, records with no time limit were interrogated from 
the Antoni Van Leeuwenhoek hospital (AVL), a major cancer treatment centre in Amsterdam, 
Netherlands. Data were filtered to only include information relating to tumours diagnosed at age 60 
years or below.  
 
Classification of tumours was based on International Classification of Diseases for Oncology (ICD-O-
3)157 topographical and morphological codes. Topographical codes were available for all tumours but 
some entries in the AVL data lacked a morphological code. In order to maximise the proportion of 
genuinely multiple primaries in the data, International Agency for Research on Cancer criteria156 were 
applied. These criteria group sites and histological diagnoses that are considered to be equivalent in 
order to assist with classification. For a given individual, a maximum of one tumour from each 
topographical code grouping (the earliest to occur) was included unless any tumours at that same site 
were within a distinct morphological grouping. A final descriptive classification for each tumour was 
based on site and cell of origin as outlined in Table A1 (table predominantly describes tumours in 
MPT series but provides classification information for all tumours in registry/treatment centre data). 
Combinations of discordant cancers were then counted with individuals diagnosed with more than two 
tumours having multiple combinations assigned to them. For example, a history of tumours A, B and 
C would result in combinations A-B, A-C and B-C being recorded. 
 
For tumours making up the collated combinations, possible indicators of a higher likelihood of a 
cancer susceptibility syndrome as a significant causative factor (rather than environmental exposures 
or chance) were noted. Although the most frequently diagnosed syndromes are associated with 
common tumour types, rare tumours may indicate a lesser role of chance as a predominant cause and 
it was noted whether the neoplasm was among the UK top five incident cancers (which make up 64% 
of all cancer diagnoses in the UK177). Heritability estimate was also noted for the occurrent tumours as 
a higher heritability estimate should increase the probability of genetic predisposition contributing to 
the tumours observed. Heritability describes the proportion of variance of a given phenotype that is 
attributable to inherited factors although it does not imply the relative role of numerous lower 
penetrance vs individual higher penetrance factors. For various cancer types, heritability has been 
estimated using statistical techniques that control or adjust for non-inherited factors such as 
environmental exposure, most notably through twin studies.49,50 Estimates obtained from two such 
studies (Czene et al. 2002 and Mucci et al. 2016) were applied to tumours in this instance.  
 
3.2.2 - Ascertainment and description of a multiple primary tumour series 
A series of MPT cases was ascertained in order to study the molecular genetic basis of the tumours 
diagnosed in those individuals. 460 participants from 440 families were recruited through clinical 
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genetics services in the UK (442 cases), Greece (nine cases), Hong Kong (three cases), USA (three 
cases), Israel (two cases) and Ireland (one case). In each family there was a clinical suspicion of a 
cancer predisposition syndrome, but routine genetic assessment/testing had not identified a 
constitutional molecular genetic diagnosis at the time of recruitment. 435 individuals had developed 
MPT (defined here as ≥2 primaries by age 60 years or ≥3 by 70 years) while 25 had developed a 
single primary and had a first-degree relative with MPT. Tumour classification and counting of 
combinations was performed in the same manner as for the registry series. 
 
3.2.3 - Comparison of Multiple Primary Tumour series with a population series 
To consider how the tumour combinations in the MPT series differed from a general population, the 
combination frequencies were compared with the EA registry dataset as this was considered to be the 
most similar to the population from which the MPT series was drawn. Registry data recorded 
individuals with two cancers (or central nervous system (CNS) tumours) diagnoses before the age of 
60 and only included tumours diagnosed before that age. Consequently, only combinations in MPT 
data of two malignant (or CNS) tumours occurring under age 60 were considered for this comparison 
(n=430). Two tailed Fishers exact tests were performed using the fish.test function in R version 
3.4.3.178  
 
3.3 - Results 
 
3.3.1 - Registry and treatment centre series 
The AVL, Dutch registry and EA series contained 4004, 1592 and 471 individuals respectively but 
information regarding sex was not included in the original data as obtained.  
 
The most frequent individual tumour types are shown in Table 3.1 (also includes information for MPT 
series only including tumours diagnosed before age 60 described below). 8433 tumours were 
observed in the AVL series, in which breast cancer was the most common (19.2% total). Breast 
cancer was the second most frequent tumour in the Dutch registry (11.4% of 4,111 tumours) and EA 
series (17% of 989 tumours). The most frequent tumour in the Dutch registry series was cancer of the 
aerodigestive tract (14.3%) while the most frequent in the EA series was non-melanoma skin cancer 
(NMSC, 25.3%). Lung cancer did not make up ≥2% of the total in the EA series. 
 
A large diversity of combination types existed in all the datasets (4,725, 3,274 and 560 respectively) 
with only a small number making up more than 2% of the total for each dataset (Table 3.2, also 
includes information for MPT series only including tumours diagnosed before age 60 described 
below). In the EA series, NMSC in combination with breast cancer (13.9% of total) and melanoma 
(11.4% of total) were twice as frequent as the third most frequent combination. Aerodigestive tract 
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cancer in association with lung cancer (6.1% of total) was most frequent in the Dutch registry series 
whilst breast cancer and melanoma made up the largest proportion of total combinations in the AVL 
series (5.1% of total). More frequent combinations are described graphically in Figures 3.1, 3.2 and 
3.3. 
 
Figure 3.1 - AVL series tumour combinations comprising >0.25% total (equivalent to >2 
combinations in MPT series, see below) 
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Figure 3.2 - Dutch registry series tumour combinations comprising >0.25% total (equivalent to 
>2 combinations in MPT series, see below) 
 
Figure 3.3 - EA Registry series tumour combinations comprising >0.25% total (equivalent to >2 
combinations in MPT series, see below) 
 
 
43 
 
Table 3.1 – Most frequent tumour types in 
registry data and MPT (tumours under 60 
only) series 
Tumour type Number 
AVL  
Breast 1622 (19.2%) 
Lung 699 (8.3%) 
Colorectal 678 (8%) 
Haematological lymphoid 647 (7.7%) 
Melanoma 626 (7.4%) 
NMSC 500 (5.9%) 
Aerodigestive Tract 463 (5.5%) 
Ovary 357 (4.2%) 
Cervix 297 (3.5%) 
Bladder 273 (3.2%) 
Soft Tissue Sarcoma 238 (2.8%) 
Endometrium 201 (2.4%) 
Prostate 178 (2.1%) 
Kidney 169 (2%) 
Dutch registry  
Aerodigestive Tract 588 (14.3%) 
Breast 467 (11.4%) 
Lung 358 (8.7%) 
NMSC 314 (7.6%) 
Colorectal 310 (7.5%) 
Haematological lymphoid 272 (6.6%) 
Melanoma 242 (5.9%) 
Endometrium 178 (4.3%) 
Prostate 163 (4%) 
Ovary 147 (3.6%) 
Bladder 135 (3.3%) 
Kidney 123 (3%) 
Oesophagus 96 (2.3%) 
East Anglia registry  
NMSC 250 (25.3%) 
Breast 168 (17%) 
Melanoma 93 (9.4%) 
Haematological lymphoid 73 (7.4%) 
Prostate 59 (6%) 
Colorectal 52 (5.3%) 
Endometrium 42 (4.2%) 
Aerodigestive Tract 34 (3.4%) 
Ovary 29 (2.9%) 
Thyroid 27 (2.7%) 
Bladder 17 (2%) 
Testicular 17 (2%) 
Kidney 16 (2%) 
Lung 16 (2%) 
MPT series (tumours 
under 60 only) 
 
Breast 221 (29.2%) 
Colorectal 78 (10.3%) 
Kidney 59 (7.8%) 
Ovary 45 (5.9%) 
NMSC 43 (5.7%) 
Endometrium 40 (5.3%) 
Thyroid 39 (5.1%) 
Melanoma 38 (5%) 
Haematological lymphoid 25 (3.3%) 
Soft Tissue Sarcoma 13 (1.7%) 
GIST 12 (1.6%) 
 
Table 3.2 – Tumour combination types 
representing ≥2% total in registry data 
and MPT (only tumours diagnosed under 
60) series 
Combination Number 
AVL  
Breast-Melanoma 241 (5.1%) 
Breast-Ovary 181 (3.8%) 
Breast- Haematological lymphoid 179 (3.8%) 
Breast-Colorectal 167 (3.5%) 
Breast-Lung 163 (3.4%) 
Aerodigestive Tract-Lung 149 (3.2%) 
Breast-NMSC 142 (3%) 
Breast-Cervix 108 (2.3%) 
Melanoma-NMSC 100 (2.1%) 
Dutch registry  
Aerodigestive Tract-Lung 201 (6.1%) 
Breast-Lung 99 (3%) 
Aerodigestive Tract-Oesophagus 94 (2.9%) 
Breast-Melanoma 87 (2.7%) 
Breast-Colorectal 83 (2.5%) 
Endometrium-Ovary 70 (2.1%) 
Breast-Endometrium 69 (2.1%) 
East Anglia registry  
Breast-NMSC 78 (13.9%) 
Melanoma-NMSC 64 (11.4%) 
Haem Lymphoid-NMSC 29 (5.2%) 
NMSC-Prostate 26 (4.6%) 
Breast-Endometrium 21 (3.8%) 
Breast-Melanoma 19 (3.4%) 
Breast-Colorectal 15 (2.7%) 
Colorectal-NMSC 14 (2.5%) 
Breast- Haematological lymphoid 13 (2.3%) 
MPT series (tumours under 60 only)  
Breast-Colorectal 29 (6.7%) 
Breast-Ovary 23 (5.3%) 
Breast-Endometrium 20 (4.7%) 
Breast-NMSC 19 (4.4%) 
Breast-Thyroid 19 (4.4%) 
Breast- Haematological lymphoid 18 (4.2%) 
Endometrium-Ovary 17 (4%) 
Breast-Melanoma 14 (3.3%) 
 
GIST – Gastrintestinal stromal tumour, NMSC – Non-
melanoma skin cancer 
44 
 
3.3.2 - Multiple Primary Tumour series 
460 individuals (106 (23%) males and 354 (77%) females) in 440 families had been diagnosed with 
1,143 primary tumours distributed among 87 categories based on site and cell of origin (Table A1). 
The most frequent tumour types and combinations are shown in Table 3.3 and Figure 3.4. Breast 
cancer was the most frequent tumour representing 24.6% of the total with colorectal cancer (9.9%) the 
second. The most frequent combination type was breast and colorectal cancer representing 5.8% of 
the total combinations. 
 
As per registry cases, the occurrence of any two discordant primaries in the same individual was 
considered as a tumour combination with a total of 883 combinations and 327 combination types 
observed (individuals with three or more discordant tumours would have multiple combinations). 206 
(63%) combination types occurred once and 53 (16.2%) occurred twice. The 68 (20.8%) combination 
types occurring three or more times are illustrated in Figure 3.4.  
 
Table 3.3 - Most frequent tumours and combinations in MPT series 
Tumour category making up >5% total (total n=1,143) Number 
Breast 281 (24.6%) 
Colorectal 113 (9.9%) 
Kidney 83 (7.3%) 
NMSC 67 (5.9%) 
Ovary 58 (5.1%) 
Tumour combination making up >1% total (total n=883) Number 
Breast-Colorectal 51 (5.8%) 
Breast-NMSC 35 (4.0%) 
Breast-Ovary 34 (3.9%) 
Breast-Endometrium 33 (3.7%) 
Breast-Haematological lymphoid 26 (2.9%) 
Breast-Melanoma 24 (2.7%) 
Breast-Thyroid 23 (2.6%) 
Endometrium-Ovary 19 (2.2%) 
Breast-Kidney 18 (2.0%) 
Colorectal-NMSC 14 (1.6%) 
Breast-Lung 12 (1.4%) 
Haematological lymphoid-NMSC 11 (1.2%) 
Breast-Soft Tissue Sarcoma 10 (1.1%) 
Colorectal-Endometrium 9 (1.0%) 
Kidney-Pituitary 9 (1.0%) 
Kidney-Thyroid 9 (1.0%) 
Melanoma-NMSC 9 (1.0%) 
 
NMSC – Non-melanoma skin cancer 
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Figure 3.4 - MPT series tumour combinations occurring three or more times 
 
 
Tumour combinations in all the series were assessed for characteristics suggestive of a greater 
likelihood of a significant inherited component (Table 3.4). Combinations where both tumours were 
not in the top five incident cancers and had a heritability estimate >20% made up 12.4% in the AVL 
series, 15.2% in the Dutch registry series and 4.8% in the EA series (Table 3.4). The equivalent figure 
in the MPT series was 11.4%, which reduced to 7.2% if only tumours under 60 were considered (see 
below) 
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Table 3.4– Tumour combination characteristics in registry data and Multiple Primary Tumour 
series 
 MPT series 
MPT series 
(only tumours 
under 60y) 
AVL series 
Dutch 
Registry 
East Anglia 
Registry 
Number of individuals 460 313 4004 1592 471 
Number of discordant tumour 
combinations 
883 430 4725 3274 560 
≥1 tumour not among 5 most common 750 (84.9%) 366 (85.1%) 4067 (86.1%) 2864 (87.5%) 419 (74.8%) 
2 tumours not among 5 most common 295 (33.4%) 120 (27.9%) 1321 (27.9%) 1033 (31.5%) 86 (15.3%) 
One tumour with heritability estimate 
>20% 
611 (69.2%) 274 (63.7%) 3532 (74.7%) 2675 (81.7%) 269 (48%) 
Both tumours with heritability 
estimate >20% 
174 (19.7%) 67 (15.6%) 1233 (26.1%) 1124 (34.3%) 50 (8.9%) 
One tumour not among 5 most 
common and heritability estimate 
>20% 
519 (58.8%) 229 (53.2%) 3030 (64.1%) 2333 (71.2%) 232 (41.4%) 
Both tumours not among 5 most 
common and heritability estimate 
>20% 
101 (11.4%) 31 (7.2%) 588 (12.4%) 499 (15.2%) 27 (4.8%) 
 
 
3.3.3 - Comparison of MPT series (tumours under 60 only) with EA Registry series 
To compare tumour combination distributions in the MPT series with a population-based dataset, the 
MPT series was subset to only include tumours diagnosed under the age of 60 years. This resulted in 
313 MPT series individuals with 430 combinations (Figure 3.5), which were compared to 471 
individuals with 560 combinations in the EA cancer registry data (Table 3.5). There was a significant 
difference (Fishers exact p value < 0.05) in tumour combination frequencies in 7/17 combination 
types that represented at least 1% of the MPT (tumours under 60 only) cohort total. Breast cancer in 
combination with ovarian, thyroid, lymphoid haematological, kidney cancer and meningioma were 
over-represented. Breast cancer in combination with non-melanoma skin was under-represented along 
with various other combinations involving skin cancers. Other less prominently over-represented 
tumour combinations were endometrium-ovary and kidney-thyroid. 
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Figure 3.5 - MPT series (tumours under 60 only) tumour combinations comprising >0.25% total 
(equivalent to >2 combinations in MPT series) 
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Table 3.5 - Comparison of MPT series (tumours under 60 only) with EA series 
Combination 
MPT 
count 
MPT 
proportion 
(%) 
EA count 
EA 
proportion 
(%) 
Difference 
in 
proportion 
MPT vs EA 
Fishers exact p 
value (two 
tailed) 
Breast-Colorectal 29 6.7 15 2.7 4 0.00278 
Breast-Ovary 23 5.3 11 2 3.3 0.00451 
Breast-Endometrium 20 4.7 21 3.8 0.9 0.52165 
Breast-NMSC 19 4.4 78 13.9 -9.5 <0.00001 
Breast-Thyroid 19 4.4 2 0.4 4 0.00001 
Breast-Haem Lymphoid 18 4.2 13 2.3 1.9 0.10084 
Endometrium-Ovary 17 4 10 1.8 2.2 0.04809 
Breast-Melanoma 14 3.3 19 3.4 -0.1 1 
Breast-CNS Meningioma 7 1.6 0 0 1.6 0.00284 
Breast-Kidney 6 1.4 1 0.2 1.2 0.04729 
Melanoma-Thyroid 6 1.4 2 0.4 1 0.08405 
Breast-Lung 6 1.4 3 0.5 0.9 0.18776 
Kidney-Thyroid 5 1.2 0 0 1.2 0.01526 
Bladder-Breast 5 1.2 1 0.2 1 0.091 
Colorectal-Thyroid 5 1.2 1 0.2 1 0.091 
Breast-Soft Tissue Sarcoma 5 1.2 2 0.4 0.8 0.2498 
Breast-Cervix 5 1.2 7 1.3 -0.1 1 
Combinations not representing >1% total in MPT series (tumours Under 60) but comprising >1% total in EA series 
Melanoma-NMSC 4 0.9 64 11.4 -10.5 <0.00001 
Haem Lymphoid-NMSC 4 0.9 29 5.2 -4.3 0.00012 
NMSC-Prostate 0 0 26 4.6 -4.6 <0.00001 
Colorectal-NMSC 4 0.9 14 2.5 -1.6 0.09153 
Aerodigestive Tract-NMSC 3 0.7 11 2 -1.3 0.10941 
Bladder-Prostate 0 0 10 1.8 -1.8 0.00646 
NMSC-Thyroid 2 0.5 9 1.6 -1.1 0.12644 
Haem Lymphoid-Prostate 0 0 9 1.6 -1.6 0.00629 
NMSC-Ovary 3 0.7 6 1.1 -0.4 0.73911 
Colorectal-Haem Lymphoid 2 0.5 6 1.1 -0.6 0.47736 
Endometrium-NMSC 1 0.2 6 1.1 -0.9 0.14633 
 
Haem, Haematological, NMSC – Non-melanoma skin cancer 
 
3.4 - Discussion 
 
3.4.1 - Registry and treatment centre-based data 
To assess the nature of MPT at a population level, data was obtained from two cancer registries and a 
large cancer treatment centre.  
 
The most frequent tumour types in those series broadly reflected established population frequency but 
notable differences were observed. NMSC accounted for over a quarter of tumours in the EA series 
but less than 8% in both the AVL series and Dutch registry. This may, as for other tumour types, 
reflect differences in reporting and recording by registries and in the case of the AVL series, pattern 
of referral to that centre. Lung cancer was infrequent in the EA series (2% total) but common in the 
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AVL and Dutch registry series. Lung cancer might be expected to be under-represented in multiple 
primaries cohorts as prognosis is poorer than for other common cancers where increased survival time 
increases the probability of further primaries. Possible explanations for the differences in lung cancer 
frequency between series include differences in lung cancer prognosis or detection/reporting of new 
primaries in terminally ill patients. Frequencies of all tumour types is likely to be influenced by the 
time period that the obtained data captured. Whereas the EA registry recorded 2009-2014, the Dutch 
registry went back to 1989. Changing incidence rates would therefore have influenced the cancer 
profile observed. 
 
The vast majority of tumour combinations were comprised of combination types making up only a 
small proportion of the total. The more frequent tumour combinations broadly reflect those cancers 
that have a higher population incidence. Some recognised associations are also observed such as 
aerodigestive tract and lung cancer in the Dutch registry series, both associated with tobacco smoking.  
 
A range of criteria proposed as suggestive of tumours being due to a cancer susceptibility syndrome 
were applied to the combinations and fulfilment of them recorded. Although the probability of such a 
syndrome conferred by these factors is not quantified, this suggested that combinations more likely to 
have a genetic aetiology exist in the population at appreciable rates. These figures were relatively 
consistent across the studied datasets. Whilst it is not known how many of these individuals were 
referred for clinical genetic assessment, this proportion may represent a group of individuals who 
would benefit from such assessment as testing capabilities develop.  
 
3.4.2 - Comparison of Multiple Primary Tumour series with a population-based series 
The MPT series was revised to only include tumours diagnosed under the age of 60 in order to make it 
comparable with the EA series. Striking differences were noted in frequencies of individual tumour 
types and combinations, likely reflecting common cancers with a significant hereditary component 
and for which genetic testing has been routinely available for a number of years. For example, breast 
cancer, while common in all series, made up close to a third of tumours in the MPT series. Kidney 
and colorectal cancers were also more frequent whilst NMSC, lung and aerodigestive tract cancers, 
which are generally not characteristic of cancer predisposition syndromes, were less frequent. 
Compared to EA registry cases, combinations such as breast-ovary (5.3% vs 2%) and breast-
colorectal (6.7% vs 2.7%) are over-represented in the MPT (tumours under 60 only) series. Some of 
these cancers are sex specific, likely contributing to the uneven sex distribution in this series 
(although the sex breakdown of EA cases is not known). In some cases, specific tumour combinations 
may raise the possibility of a specific inherited cancer syndrome and prompt referral to genetics 
services (and hence the possibility of recruitment to the study). For example, the difference in breast-
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thyroid frequency (4.4% in MPT series (tumours under 60 only) vs 0.4% in EA series) may be 
accounted for by suspicion of germline PTEN variants.  
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Chapter 4 – Analysis for variants in known 
cancer predisposition genes in a multiple 
primary tumour series 
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Sections of this chapter discussing interrogation of sequencing data from a series of research 
participants with multiple primary tumours for clinically relevant variants are based on a previously 
published journal article (Whitworth et al.).172 The chapter is divided into three parts, the first of 
which (4.1) is concerned with detection of constitutional single nucleotide variants, indels and 
structural variants affecting cancer predisposition genes (CPGs). The second part (4.2) describes the 
formulation of a clinical scoring system to attempt to predict pathogenic variant carriers and the third 
part (4.3) discusses a search for mosaic CPG variants. 
 
4.1 - Comprehensive analysis of known cancer predisposition genes in a multiple primary 
tumour series 
 
4.1.1 – Introduction 
Clinical next generation sequencing (NGS) assays for possible inherited cancer predisposition 
generally target single genes or panels of CPGs but genome-wide analysis through whole exome 
sequencing (WES) or whole genome sequencing (WGS) is also possible. Though more expensive 
than WES, WGS should provide the most comprehensive analysis as it (a) can interrogate effectively 
all coding and non-coding areas of the genome, (b) provides more uniform read coverage compared to 
WES, particularly in areas where target enrichment/capture is difficult,179,180 and (c) is able to detect a 
wide range of structural variations such as deletions, translocations, and inversions.181 However, WGS 
is still in its infancy as a clinical diagnostic tool and few assessments of its application in hereditary 
cancer appear in the literature. Here, WGS has been applied to a large heterogeneous multiple primary 
tumour (MPT) cohort (n=460 incorporating 440 families) to investigate the potential role of 
comprehensive CPG analysis in this group. 
 
4.1.2 - Methods 
Workflow for the analysis is summarised in Figure 4.1. Scripts used in these analyses are stored as an 
appendix in the form of a GitHub repository (https://github.com/jameswhitworth/Thesis-
Elucidating_the_genetic_basis_of_multiple_primary_tumours-Scripts_appendix 
doi:10.5281/zenodo.1501206). They are denoted with the prefix "RA" (repository appendix) in the 
text in and in the repository.  
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Figure 4.1 - Workflow for interrogation of whole genome sequencing data for clinically relevant 
variants 
 
 
4.1.2.1 - Participants 
460 participants from 440 families were recruited through clinical genetics services as described in 
Chapter 3. MPT was defined as ≥2 primaries by age 60 years or ≥3 by 70 years. 
 
4.1.2.2 - Single nucleotide variant and indel identification in whole genome sequencing data and 
assessment (Script RA4.1) 
Variants were extracted from variant call format (VCF) files if they were within a gene specified in a 
comprehensive list of 83 CPGs (gene list in Table 4.1). The gene list used for analysis was initially 
comprised of all genes listed in a 2014 review of CPGs45 (n=114) and/or those sequenced by the 
TruSight Cancer panel (Illumina Inc., San Diego, CA, USA) (n=94, Table A2). Two additional more 
recently described CPGs were also included, namely NTHL1 ([MIM:602656])36 and CDKN2B 
([MIM:600431]).182 Genes were subsequently reviewed and filtered to produce a list that would be 
applicable to referrals to clinical cancer genetic services. Genes were included if deleterious variants 
affecting them are associated with adult onset tumours and if neoplastic lesions are likely to be a 
primary presenting feature. For example, SOS1 was not included as although Noonan syndrome is 
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associated with increased neoplasia risk, other features of the condition are likely to prompt initial 
referral.  
 
Table 4.1 - Gene list used for analysis (n=83) 
AIP  CDKN2A  EXT2  NF1  RAD51D  SMARCE1  
ALKa CDKN2B  FH  NF2  RB1  SRY  
APC  CEBPA  FLCN  NTHL1b  RETa STK11  
ATM  CHEK2  GATA2  PALB2  RHBDF2a SUFU  
AXIN2  CYLD  HFEb PDGFRAa RUNX1  TGFBR1  
BAP1  DDB2  HNF1A  PHOX2B  SDHA  TMEM127  
BMPR1A  DICER1  KITa PMS2  SDHAF2  TP53  
BRCA1  EGFRa MAX  POLD1  SDHB  TSC1  
BRCA2  EPCAM  MEN1  POLE  SDHC  TSC2  
BRIP1  ERCC2b METa POLHb SDHD  VHL  
CDC73  ERCC3b MLH1  PRKAR1A  SERPINA1b  WT1  
CDH1  ERCC4b MSH2  PTCH1  SMAD4  XPAb 
CDK4a ERCC5b MSH6  PTEN  SMARCA4  XPCb 
CDKN1B  EXT1  MUTYHb RAD51C  SMARCB1   
 
a Genes considered as proto-oncogenes 
b Gene considered as associated with tumour predisposition in homozygous or compound heterozygous state only 
 
For each gene on the gene list, the Ensembl canonical transcript identifier was selected by referencing 
gene-canonical transcript pairs provided by the Exome Aggregation Consortium (ExAC).161 
Canonical transcripts are defined according the following hierarchy: 1) longest Consensus Coding 
Sequence (CCDS)183 translation with no stop codons, 2) Longest Ensembl/Havana merged translation 
with no stop codons, 3) longest translation with no stop codons and 4) if no translation, longest non-
protein-coding transcript.184 Lists of transcripts were then used to obtain GRCh37 coordinates for the 
protein coding regions within them with Biomart.185  Coordinates were then used to produce BED 
files +/- 5 base pairs for use in filtering of VCF files. BED files were used in conjunction with 
bcftools (version 1.4) view170 to extract variants in the corresponding regions and with FILTER PASS 
annotation (quality criteria as applied by the National Institute of Health Research BioResource Rare 
Disease (BRIDGE)  project) from merged VCF files containing per chromosome variants called from 
BRIDGE WGS data (all sequenced individuals). Per chromosome files were merged with bcftools 
concat170 and filtered with bcftools filter to remove variants if they failed to satisfy quality the quality 
criteria of GQ≥30 (phred scaled probability of the called genotype being incorrect), DP≥10 (number 
of reads covering the variant base/s 10 or greater) and variant allele fraction (VAF) ≥33%. The 
filtered merged VCF was then annotated with Variant Effect Predictor (VEP) version 90.186 
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In order to identify clinically relevant variants, resulting data were subject to a further range of filters 
(Figure 4.2) using the VEP filter script. Variants were excluded if they had an allele frequency above 
0.01 in either ExAC161 (all populations) or 1000 genomes project166 (all populations). Variants were 
retained if the predicted consequence was among a list of sequence ontology (SO) terms indicating an 
effect on the protein product. 
 
Filtered variants were considered for further review if the predicted consequence was among a list of 
SO terms indicating protein truncation and/or if there was evidence of pathogenicity in ClinVar187 
(≥2* evidence of pathogenic or likely pathogenic (P/LP) effect corresponding to multiple submissions 
with no conflicts as to assertion of clinical significance) or if the variant was assigned a disease 
mutation (DM) status in the Human Gene Mutation Database188 (HGMD). In order to consider a 
subset of non-truncating variants that are predicted to be pathogenic by in-silico tools but do not 
appear in public databases, variants exceeding a phred scaled Combined Annotation Dependent 
Depletion (CADD)189 score threshold of 34 were also retained for further review. CADD was selected 
for this purpose given that it incorporates a range of tools and consequently a number of lines of 
evidence. The threshold was chosen as the median of scores assigned to other variants (affecting any 
gene) deemed pathogenic according to the criteria described below. Identification of variants for 
retention due to CADD score alone was, therefore, done as a second variant filtering process after 
assessment of variants retained for other reasons. 
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Figure 4.2 - Filters applied to whole genome sequencing data – Single nucleotide variants and 
indels 
 
ACMG – American College of Medical Genetics, HGMD- Human Gene Mutation Database, SO – Sequence Ontology, VCF – 
Variant call format  
 
Sequence variants in non-coding regions such as introns that affected genes in the gene list would not 
be extracted from the original VCF files based on the strategy described as their SO consequence 
would not be within the utilised list. Therefore, a list of known pathogenic variants falling outside of 
exons or splice sites/regions was compiled using ClinVar and used to filter VCFs based on their 
genomic positions in a separate interrogation. Variants were incorporated in the list if they occurred in 
or near a gene on the list, were classified as near gene, non-coding RNA or untranslated region, and 
had ≥2* evidence of a pathogenic or likely pathogenic effect. This process produced only three known 
pathogenic variants to search for in the WGS data. Distant non-coding variants affecting gene 
function (e.g. enhancers) were not considered in the analysis described in this chapter.  
 
Retained variants were subsequently excluded if their putative pathogenicity could be refuted by 
fulfilling one of the following criteria: 1) A predicted protein truncating variant where there was ≥2* 
evidence of a benign or uncertain effect in ClinVar, 2) A predicted protein truncating variant in a 
proto-oncogene in a list compiled based on literature review45 (constitutional cancer predisposing 
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variants in proto-oncogenes are associated with gain of function variants so truncation of protein 
product is unlikely to increase tumour risk), 3) A predicted protein truncating variant affecting <5% of 
the canonical transcript (based on the LOFTEE VEP plugin), 4) A variant affecting a gene associated 
with only recessive tumour predisposition (as defined by literature review36,45,190) unless an individual 
appeared to harbour two filtered variants in the same gene, 5) An HGMD DM status variant or variant 
which exceeded the CADD score threshold where there was ≥2* ClinVar evidence of a benign or 
uncertain clinical effect or 1* evidence if there were multiple submissions without any containing a 
likely pathogenic or pathogenic assertion.  
 
Variants passing filters were reviewed with Integrated Genomics Viewer191 (IGV) to check for issues 
such as adjacent variants affecting the predicted consequence or variants being located at the end of 
sequencing reads. Pathogenicity was then assessed according to the American College of Medical 
Genetics (ACMG) criteria (Table 4.2),192 which provides a framework to compile multiple weighted 
lines of evidence. Additionally, for each variant it was noted whether the corresponding individual 
had previously been diagnosed with a tumour typically associated with pathogenic variants in the 
relevant gene (according to Rahman,45 the Familial Cancer Database,190 or the original paper reporting 
the gene as a CPG). Validation of P/LP variants was carried out using data generated from Illumina 
TruSight Cancer panel (TCP) or by the BRIDGE project Sanger sequencing service according to 
standard protocols (if TCP data was unavailable). 
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Table 4.2 - American College of Medical Genetics criteria as applied to single nucleotide variant and indel analysis 
 
Evidence of benign nature 
Stand-alone evidence ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
BA1 Allele frequency is >5% in Exome Sequencing 
Project, 1000 Genomes Project, or Exome 
Aggregation Consortium. 
All variants fulfilling this criterion filtered prior to analysis. Yes 
Strong evidence ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
BS1 Allele frequency is greater than expected for 
disorder. 
Uncertainties around prevalence and penetrance of inherited cancer 
syndromes prevent accurate assessment of this criterion. All variants are 
rare. 
Yes 
BS2 Observed in a healthy adult individual for a 
recessive (homozygous), dominant 
(heterozygous), or X-linked (hemizygous) 
disorder, with full penetrance expected at an 
early age. 
Full penetrance at an early age not expected for inherited cancer syndromes 
caused by variation in genes considered. 
Yes 
BS3 Well-established in vitro or in vivo functional 
studies show no damaging effect on protein 
function or splicing. 
If variant present in HGMD with DM or DM? status, reviewed linked papers 
for functional studies. If variant annotated with PubMed ID by Variant Effect 
Predictor, reviewed listed articles. Loss of heterozygosity in tumour and/or 
evidence of RNA disruption considered. 
No 
BS4 Lack of segregation in affected members of a 
family. 
Criterion not used due to lack of specificity of phenotypes and incomplete 
penetrance of inherited cancer syndromes considered. 
Yes 
Supporting evidence ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
BP1 Missense variant in a gene for which primarily 
truncating variants are known to cause disease. 
Criterion fulfilled if no missense variants in the gene appear in HGMD (with 
DM status) or ClinVar with pathogenic assertion. 
No 
BP2 Observed in trans with a pathogenic variant for a 
fully penetrant dominant gene/disorder or 
observed in cis with a pathogenic variant in any 
inheritance pattern. 
Analysed variants not phased. Yes 
BP3 In-frame deletions/insertions in a repetitive 
region without a known function. 
All filtered inframe deletions/insertions scored as PM4 following review. 
Therefore, none fulfil BP3. 
Yes 
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BP4 Multiple lines of computational evidence suggest 
no impact on gene or gene product 
(conservation, evolutionary, splicing impact, etc.). 
Fulfilled if CADD score (where given) 10 or below (corresponding to variant 
being outside top 10% predicted most deleterious variants). 
No 
BP5 Variant found in a case with an alternate 
molecular basis for disease. 
Fulfilled for all variants due to alternative (non-genetic predisposition 
related) mechanism in all tumours. 
No 
BP6 Reputable source recently reports variant as 
benign, but the evidence is not available to the 
laboratory to perform an independent 
evaluation. 
Fulfilled if any single report in ClinVar with benign/likely benign assertion. No 
BP7 A synonymous (silent) variant for which splicing 
prediction algorithms predict no impact to the 
splice consensus sequence nor the creation of a 
new splice site AND the nucleotide is not highly 
conserved. 
All variants fulfilling this criterion filtered prior to analysis. Yes 
 
Evidence of pathogenic nature 
Very strong 
evidence 
ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
PVS1 Null variant (nonsense, frameshift, canonical ±1 or 2 
splice sites, initiation codon, single or multi-exon 
deletion) in a gene where LOF is a known mechanism of 
disease. 
Fulfilled if variant had Sequence Ontology term (assigned by Variant Effect 
Predictor) consistent with one of these consequences unless within proto-
oncogene.* 
No 
Strong evidence ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
PS1 Same amino acid change as a previously established 
pathogenic variant regardless of nucleotide change. 
Fulfilled if missense variant leads to same amino acid change as a 
pathogenic missense variant as defined by ClinVar pathogenic or likely 
pathogenic with ≥2* evidence status. 
No 
PS2  De novo (both maternity and paternity confirmed) in a 
patient with the disease and no family history. 
Incomplete penetrance may frequently lead to no family history in inherited 
cancer syndromes. Only one trio in this analysis (filtered variant was not de-
novo). 
Yes 
PS3 Well-established in vitro or in vivo functional studies 
supportive of a damaging effect on the gene or gene 
product. 
If variant present in HGMD with DM or DM? status, reviewed linked papers 
for functional studies. If variant annotated with PubMed ID by Variant Effect 
Predictor, reviewed listed articles. Loss of heterozygosity in tumour and/or 
evidence of RNA disruption considered.  
No 
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PS4 The prevalence of the variant in affected individuals is 
significantly increased compared with the prevalence in 
controls. 
Number of variants and phenotypes in the series prevented use of this 
criterion. 
Yes 
Moderate 
evidence 
ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
PM1 Located in a mutational hot spot and/or critical and well-
established functional domain (e.g., active site of an 
enzyme) without benign variation. 
Fulfilled if occurred in Pfam193 domain and relevant domain contains ≥1 
pathogenic/likely pathogenic variants AND 0 benign/likely benign/VUS 
missense variants as defined by ClinVar ≥2* evidence status.  Mutational 
hotspot criterion not used.  
No 
PM2 Absent from controls (or at extremely low frequency if 
recessive) in Exome Sequencing Project, 1000 Genomes 
Project, or Exome Aggregation Consortium. 
Fulfilled if absent in either 1000 Genomes or ExAC based on Variant Effect 
Predictor annotation. 
No 
PM3 For recessive disorders, detected in trans with a 
pathogenic variant. 
Analysed variants not phased. No compound heterozygotes for suspected 
recessive cancer predisposition identified among filtered variants. 
No 
PM4 Protein length changes as a result of in-frame 
deletions/insertions in a non-repeat region or stop-loss 
variants. 
Fulfilled if variant has Sequence Ontology term predicted consequence and 
doesn't occur in repetitive region as defined by UCSC194 repeat masker 
track. 
No 
PM5 Novel missense change at an amino acid residue where a 
different missense change determined to be pathogenic 
has been seen before. 
Fulfilled if missense variant is within the same codon as a pathogenic 
missense variant as defined by ClinVar pathogenic or likely pathogenic with 
≥2* evidence status. 
No 
PM6  Assumed de novo, but without confirmation of paternity 
and maternity. 
Unable to reliably assume de novo due to incomplete penetrance of 
inherited cancer syndromes considered. 
Yes 
Supporting 
evidence 
ACMG description Application to present analysis All variants tagged as not 
fulfilling criteria? 
PP1 Co-segregation with disease in multiple affected family 
members in a gene definitively known to cause the 
disease. 
Incomplete penetrance of considered inherited cancer syndromes and low 
number of participants per family prevented use of criterion.  
Yes 
PP2 Missense variant in a gene that has a low rate of benign 
missense variation and in which missense variants are a 
common mechanism of disease. 
Fulfilled if variant occurs in gene with low rate of benign missense variation 
as defined by ExAC missense constraint metric <-3·09 (equivalent to 
observed vs expected p value 0·01) and ≥1 pathogenic/likely pathogenic 
missense variant in ClinVar with ≥2* evidence status. 
No 
PP3  Multiple lines of computational evidence support a 
deleterious effect on the gene or gene product 
(conservation, evolutionary, splicing impact, etc.). 
Fulfilled if CADD score (where given) 30 or above (corresponding to variant 
being within top 0·1% predicted most deleterious variants). 
No 
PP4 Patient’s phenotype or family history is highly specific 
for a disease with a single genetic aetiology. 
Inherited cancer syndrome phenotypes considered not sufficiently specific 
for fulfilment.  
Yes 
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PP5 Reputable source recently reports variant as pathogenic, 
but the evidence is not available to the laboratory to 
perform an independent evaluation. 
Fulfilled if any single report in ClinVar with pathogenic/likely pathogenic 
assertion or in HGMD with DM status. 
No 
 
ExAC – Exome Aggregation Consortium, HGMD – Human Gene Mutation Database, VUS – Variant of uncertain significance 
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4.1.2.3 - Single nucleotide variant and indel identification in gene panel data and assessment 
(Script RA4.2) 
The variant filtering and assessment process described for WGS data was also applied to per 
individual VCF files containing variant calls made from TCP data. 
 
4.1.2.4 - Structural variant identification and assessment (Script RA4.1) 
Structural variant (SV) calls that were predicted to affect a gene on the gene list (n=83) were filtered 
and assessed according to the quality of the call, rarity of the variant, and biological plausibility of 
tumour predisposition caused by the variant (Figure 4.3).  
 
Variant call files (txt format) provided by the BRIDGE project and containing calls for predicted 
deletions (separate files from Canvas and Manta), copy number gains (Canvas), translocations 
(Manta), duplications (Manta), inversions (Manta) and insertions (Manta) were used. Files were only 
available for 390 out of the 460 individuals included in the analysis of single nucleotide variants and 
indels. Variants were initially filtered by BRIDGE to retain those that were predicted to affect at least 
one exon, occurred at a frequency of less than 1% across all BRIDGE samples (n= 9110) in the data 
release utilised and were not associated with a flag introduced by Manta or Canvas indicating a low-
quality call.  
 
Genomic coordinates for genes of interest were based on gene start and gene end coordinates 
downloaded from Ensembl Biomart184 (GRCh37 build). Manta annotation contains confidence 
intervals describing the range of bases surrounding the predicted SV coordinates that are likely to 
contain the true breakpoints of the variant. These values can be utilised to produce genomic positions 
corresponding to the minimum start, maximum start, minimum end and maximum end of any given 
SV. They were used in the identification Manta called SVs affecting regions of interest. SV calls were 
filtered using an R script according to the criteria outlined in Table 4.3 and minimum quality criteria 
of GQ ≥30 for Manta and QUAL ≥30 for Canvas. 
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Table 4.3 - Conditions used to identify structural variants 
Structural 
variant 
modality 
Conditions for structural variant call to fulfil 
Deletion 
(Manta) 
Max. start < gene start AND min. end > gene end  
OR  
Min. start > gene start AND max. end < gene end  
OR  
Max. start < gene start AND (min. end > gene start AND max. end < gene end)  
OR  
Min. end > gene end AND (max. start < gene end AND min. start > gene start)   
Deletion 
(Canvas) 
Start < gene start AND end > gene end  
OR  
Start > gene start AND end < gene end  
OR  
Start < gene start AND (end > gene start AND end < gene end)  
OR  
End > gene end AND (start < gene end AND start > gene start) 
Copy number 
gain (Canvas) 
Start < gene start AND end > gene end  
OR  
Start < gene start AND (end > gene start AND end < gene end)  
OR  
End > gene end AND (start < gene end AND start > gene start) 
Translocation 
(Manta) 
 
Min. start > gene start AND max. start < gene end 
OR  
Min. end > gene start AND max. end < gene end 
Inversion 
(Manta) 
Min. start > gene start AND max. start < gene end 
OR  
Min. end > gene start AND max. end < gene end 
Insertion 
(Manta) 
Min. start > gene start AND max. start < gene end 
OR  
Min. end > gene start AND max. end < gene end 
Inversion 
(Manta) 
Min. start > gene start AND max. start < gene end 
OR  
Min. end > gene start AND max. end < gene end 
Duplication 
(Manta) 
Max. start < gene start AND min. end > gene end 
OR 
Min. start > gene start AND max. end < gene end  
OR 
Max. start < gene start AND (min. end > gene start AND max. end < gene end)  
OR  
Min. end > gene end AND (max. start < gene end AND min. start > gene start)   
 
Remaining variants were regarded as potentially pathogenic if they were predicted to affect a gene 
associated with tumour predisposition in the heterozygous state (unless there was evidence of 
homozygosity/compound heterozygosity) and fell into either of the following categories. 1) Copy 
number loss of coding regions of a tumour suppressor gene, 2) Predicted breakpoint disrupting a 
tumour suppressor gene. Copy number gain or breakpoints affecting proto-oncogenes was not taken 
as evidence of a clinically relevant SV given that known pathogenic variants in these genes tend to be 
a narrow range of missense variants exerting their effect through specific gain of function 
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mechanisms. It is difficult, therefore, to interpret increased gene dosage as equivalent to one of those 
variants.  
 
Subsequently, these SV calls were reviewed with IGV and excluded if they occurred in the Copy 
Number Variation Map of Human Genome195 (Hg19 stringent). Occurrence of tumours associated 
with disruption of particular genes in individuals harbouring suspected SVs was noted in the same 
manner as for single nucleotide variants and indels. BAM files corresponding to all suspected 
deleterious calls were reviewed in IGV. All SVs considered pertinent following filtering and 
assessment were confirmed with Sanger sequencing according to standard protocols. Inversions, 
translocations and tandem duplications were confirmed by sequencing across breakpoints while 
deletions could be confirmed by fragment size resulting from long range polymerase chain reaction if 
sequencing across the breakpoint was not possible. Validation was performed by colleagues in the 
Cambridge Translational Genomics Laboratory and, in one instance, the University of Cambridge 
Department of Medical Genetics. 
 
Figure 4.3 - Filters applied to whole genome sequencing data – Structural variants 
 
IGV – Integrated Genomics Viewer, NIHR – National Institute of Health Research 
 
4.1.2.5 - Comparison of rate of truncating variants in Multiple Primary Tumour series vs 
gnomAD dataset (Script RA4.3) 
To compare loss of function variant detection rates in the MPT cohort with a large scale WGS dataset 
unselected for neoplastic phenotypes, the gnomAD database161 (downloaded February 2018) was 
65 
 
interrogated for variants occurring in the same set of 83 genes. Only truncating or splice site variants 
were considered for comparison purposes as these are less likely to be false positives and made up 
52/63 (82.5%) (see results section) of the P/LP variants in the MPT cohort. Variants extracted from 
gnomAD were filtered and assessed as per those occurring in the MPT cohort. Given that the sex 
distribution of the MPT cohort was skewed towards females, frequency of variants assessed as P/LP 
was also calculated for males and females in both datasets. For the gnomAD data, the sex distribution 
(55.3% male, 44.6% female) was estimated by taking the sex specific mean allele count incorporating 
all positions in the gnomAD chromosome 1-22 VCF file and comparing the relative counts. In order 
to estimate gnomAD P/LP variant frequency as if sex distribution was equivalent to the MPT series 
(23% male, 77% female), a sex specific frequency based on the estimated sex distribution was applied 
to the estimated total number of gnomAD females (n=6929) and a reduced number of males (n=2064) 
that would achieve the desired proportion. The respective allele frequency estimates were then 
summed to provide a figure to compare with the MPT series. 
 
4.1.2.6 - Calculation of sequencing coverage (Script RA4.4) 
For BAM files from WGS and TCP data, coverage statistics for regions of interest were generated 
with samtools depth.170 A BED file compiled using Ensembl BioMart185 to represent translated exonic 
regions and splice sites of genes in the gene list was utilised.  
 
4.1.2.7 - Statistical analysis 
All statistical tests were performed using R version 3.4.3.178 Pearson’s chi-squared tests and students t 
tests were performed using the chisq.test and t.test functions respectively.  
 
4.1.3 - Results 
 
4.1.3.1 - Clinical characteristics and multiple primary tumour combinations 
The MPT case series used for analysis, containing 460 individuals (106 (23%) males and 354 (77%) 
females) from 440 families is described in Chapter 3. The most frequent tumour types are described in 
Chapter 3 and Table 3.3 with a more comprehensive list in Table A1. Tumour combination 
frequencies are described in Chapter 3, Table 3.3 and Figure 3.4.  
 
Prior genetic testing is described in Table 4.4 with reasons for non-detection of the relevant variant 
illustrated in Figure 4.4. Information regarding previous genetic testing was available for 405/440 
(92%) of probands. No molecular investigations had been performed in 91 (20.7%). 159 (36.1%) had 
undergone BRCA1/BRCA2 testing, 87 (19.8%) had been assessed for Lynch syndrome (where 
microsatellite instability (MSI) and/or immunohistochemistry (IHC) analysis is considered as 
assessment) and 159 (20.7%) had had another germline genetic test. The mean number of genes 
66 
 
analysed (where MSI/IHC is considered as analysing four Lynch syndrome genes) was four. Samples 
from 79 (18%) of probands had undergone sequencing with a multi-gene panel assay with the mean 
number of genes analysed with these assays being 13.8.  
 
4.1.3.2 - Genetic findings – Single nucleotide variants (SNVs) and indels 
Variant filters applied to annotated VCF files produced 89 unique variants in 119 individuals for 
further ACMG guideline-based assessment. Of these, 22 (42 occurrences) could be classified as 
pathogenic, 23 (24 occurrences) as likely pathogenic, 24 (27 occurrences) as a variant of uncertain 
significance (VUS), and 20 (26 occurrences) as likely benign. Six occurrences of P/LP variants 
occurred in two members of the same family and only three of these contributed to the detection rates 
quoted below. No pathogenic non-coding variants were identified. 
 
Overall, 63 variants in 17 genes in 61 (13.9%) probands were assessed as P/LP (Table 4.4). Most 
were nonsense or frameshift variants. Individuals with variants in moderate risk CPGs CHEK2 (n=14) 
and ATM (n=10) were the most frequent with one homozygote for CHEK2 ENST00000328354 
c.1100delC (p.Thr367Metfs) (annotated in these data as ENST00000382580 c.1229delC 
(p.Thr410fs)) detected. Individuals with variants in BRCA2 (n=6), PALB2 (n=6), FH (n=5), NF1 
(n=4), NTHL1 (homozygous, n=3), MAX (n=2), PTEN (n=2), SDHB (n=2), BMPR1A (n=1), BRCA1 
(n=1), CDKN1B (n=1), EXT2 (n=1), MLH1 (n=1), MSH2 (n=1) and PMS2 (n=1) were also noted. 
 
Confirmation of the 63 P/LP SNVs/indels detected by WGS was performed by a second analysis 
(TCP for 52 variants and Sanger sequencing for 11 variants). Pre-testing information was available 
for 57/63 P/LP variants, 41/57 (71.9%) of which occurred in an individual who had at least one 
previous genetic test and 7/57 (12.3%) of which were eventually detected by clinical services. No 
P/LP variants were observed in genes that had previously been tested in the relevant individual by 
diagnostic services (Figure 4.4). The mean number of genes tested in those with a P/LP variant was 
5.3, which was not significantly different to probands without such variants detected (students t-test 
p=0.396). 
 
Of the 61 probands identified with a P/LP variant, 36 (59%, 8.2% of all probands) had previously 
been diagnosed with a tumour typically associated with the relevant CPG. A further eight (1.8%) of 
probands were found to harbour a VUS and had been diagnosed with an associated tumour.  
 
Three probands harboured two P/LP variants in different CPGs. Combinations of variants 
PMS2/BMPR1A, MAX/FH and FLCN/CHEK2 were observed, which are discussed in Chapter 5. 
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Table 4.4 - Filtered single nucleotide variants and indels deemed pathogenic or likely pathogenic by American College of Medical Genetics criteria 
Gene Transcript Coordinate Description Consequence 
Phenotype with age at diagnosis (* indicates 
tumour deemed typically associated with 
deleterious variants in gene) 
Genes tested by clinical 
services 
Consultation 
year 
ATM ENST00000278616 chr11:108099912 c.193C>T (p.Gln65*) Stop gain 
NMSC, 14; PNS Nerve sheath benign, 50; 
Breast, 52a; CNS meningioma, 58 
PTCH1, NF2 (single gene) 2014 
ATM ENST00000278616 chr11:108175528 c.5623C>T (p.Arg1875*) Stop gain Breast, 40a; Breast, 45a 
BRCA1, BRCA2 (excluded in 
other family members) 
2016 
ATM ENST00000278616 chr11:108186841 c.6583+1G>A 
Splice site 
(donor) 
NMSC, <40 PTCH1, SUFU (single gene) 2012 
ATM ENST00000278616 chr11:108196843 
c.6866-6867insT 
(p.Ser2289Serfs) 
Frameshift Thyroid, 39; Paraganglioma, 39 
SDHAF2, SDHB, SDHC, SDHD, 
RET, MAX, TMEM127, VHL 
(panel) 
2015 
ATM ENST00000278616 chr11:108115600 c.748C>T (p.Arg250*) Stop gain Breast, 48a; Colorectal, 60 
MSI (stable) BRCA1, BRCA2, 
MLH1, MSH2 (single gene) 
1999 
ATM ENST00000278616 chr11:108205832 
c.8147T>C 
(p.Val2716Ala) 
Missense Breast, 55a; Colorectal, 56 No testing 2016 
ATM ENST00000278616 chr11:108214084 c.8405delA (p.Gln2802fs) Frameshift Testicular, 21; Thyroid, 35; UKP, 35 No testing 2016 
ATM ENST00000278616 chr11:108180945 
c.5821G>C 
(p.Val1941Leu) 
Missense PNET, 33; Adrenal adenoma, 33 Information unavailable Unknown 
ATM ENST00000278616 chr11:108205807 
c.8122G>A 
(p.Asp2708Asn) 
Missense Lipoma, <13; Bone benign, <13 Information unavailable Unknown 
ATM ENST00000278616 chr11:108202751 
c.7775C>G 
(p.Ser2592Cys) 
Missense Hem lymphoid, 9; Breast, 39a No testing 2014 
BMPR1Ac ENST00000372037 chr10:88676945 c.730C>T (p.Arg244*) Stop gain Colorectal, 50a; Breast, 57 
IHC (PMS2 loss). PMS2 
(single gene) 
2015 
BRCA1 ENST00000471181 chr17:41245586 
c.1961-1962insA 
(p.Lys654fs) 
Frameshift 
Breast, 38a; Haematological lymphoid, 39; 
NMSC, 56; Ovary, 64a 
Information unavailable 2014 
BRCA2 ENST00000544455 chr13:32913017 c.4525C>T (p.Gln1509*) Stop gain Melanoma, 30; Melanoma, 44; Thyroid, 47 No testing 2016 
BRCA2 ENST00000544455 chr13:32914174 c.5682C>G (p.Tyr1894*) Stop gain PNET, 24; Breast, 40a No testing 2014 
BRCA2 ENST00000544455 chr13:32914766 
c.6275-6276delTT 
(p.Leu2092fs) 
Frameshift Thyroid, 38; Colorectal, 57 Information unavailable Unknown 
BRCA2 ENST00000544455 chr13:32914893 
c.6402-6406delTAACT 
(p.Asn2135Leufs) 
Frameshift Testicular, 49; Testicular, 60; Prostate, 68a No testing 2015 
BRCA2 ENST00000544455 chr13:32915027 
c.6535-6536insA 
(p.Val2179fs) 
Frameshift 
Bladder, 53; NMSC, 54; GINET, 55; 
Aerodigestive tract, 59; Colorectal, 63 
No testing 2016 
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BRCA2 ENST00000544455 chr13:32907420 
c.1805-1806insA 
(p.Gly602fs) 
Frameshift 
Hem lymphoid, 42; Breast, 43a; 
Endometrium, 49 
BRCA2 (not known if single 
gene or panel) 
2016 
CDKN1B ENST00000228872 chr12:12870920 
c.148-149delAG 
(p.Arg50fs) 
Frameshift Paraganglioma, 33; Breast, 34 
Illumina TruSight Cancer 
panel (CDKN1B not included) 
Unknown 
CHEK2 ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift Kidney, 56; Kidney, 56; Kidney, 56 FLCN, VHL (single gene) Unknown 
CHEK2 ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift 
Thymus, 53; Breast, 54a; Haematological 
lymphoid, 63; Haematological lymphoid, 67 
Information unavailable 2015 
CHEK2 ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift Kidney, 56; Kidney, 60 Information unavailable 2010 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Thyroid, 45; Pancreas, 48 No testing Unknown 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Fibrofolliculoma (multiple), 18; Kidney, 53 
FH, FLCN, MET, SDHB, VHL 
(panel) 
2015 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 52a; Melanoma, 54 Information unavailable Unknown 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Breast, 50a; Kidney, 62; GI NET, 63; 
Haematological myeloid, 65 
MEN1 (single gene). SDHA, 
SDHAF2, SDHB, SDHC, SDHD, 
RET, MAX, TMEM127, VHL 
(panel) 
2013 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Endometrium, 54; Breast, 57a 
IHC (normal), MLH1, MSH2, 
MSH6 (single gene) 
2016 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Kidney, 70; Haematological lymphoid, 70; 
Colorectal, 72 
No testing 2014 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 31a; Gastric, 49 
BRCA1, BRCA2 (single gene) 
APC, BMPR1A, CDH1, MLH1, 
MSH2, MSH6, MUTYH, 
PMS2, SMAD4, STK11, TP53 
(panel) 
2015 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 45a; Breast, 54a; Breast, 55a No testing 2001 
CHEK2 ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Colorectal, 27; Endometrium, 53; Colorectal, 
56; NMSC (multiple), <64 
IHC (normal) and MSI (high). 
MLH1, MSH2, MSH6, PMS2 
2016 
CHEK2 ENST00000382580 chr22:29105993 c.1051+1C>T 
Splice site 
(donor) 
Breast, 46a; Ovary, 49; Ovary, 49; 
Endometrium, 49 
BRCA1, BRCA2 (single gene) 2012 
CHEK2 ENST00000382580 chr22:29115410 c.784delG (p.Glu262fs) Frameshift 
Colorectal polyps, 46; Parathyroid, 48; 
Parathyroid, 55; Parathyroid, 59 
APC, BMPR1A, CDC73, 
CDKN1B, MEN1, PKD2, SDHB, 
SDHC, SDHD, SMAD4, VHL 
(single gene) 
2010 
CHEK2 ENST00000382580 chr22:29121242 c.562C>T (p.Arg188Trp) Missense Colorectal, 46; Breast, 54a; Endometrium, 67 
BRCA1, BRCA2, MLH1, MSH2 
(single gene) 
2007 
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CHEK2b ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 40a; Pancreas benign, 41 
BRCA1, BRCA2, CDH1, CDK4, 
CDKN2A, MEN1, PTEN, SDHB, 
STK11, TP53, VHL (panel) 
2014 
EXT2 ENST00000395673 chr11:44129776 c.613C>T (p.Gln205*) Stop gain Breast, 40; Colorectal, 48 BRCA1, BRCA2 (single gene) 2013 
FH ENST00000366560 chr1:241661227 
c.1433-1434insAAA 
(p.Lys477_Asn478insLys) 
Inframe 
insertion 
NMSC, 36; Thyroid, 37; NMSC (multiple), 47 
Hereditary cancer panel. 24 
genes (not specified) 
2016 
FH ENST00000366560 chr1:241661227 
c.1433-1434insAAA 
(p.Lys477_Asn478insLys) 
Inframe 
insertion 
Small bowel, 53; Colorectal, 56 MSI (stable) 2016 
FH ENST00000366560 chr1:241661227 
c.1433-1434insAAA 
(p.Lys477_Asn478insLys) 
Inframe 
insertion 
Breast, 49; Colorectal, 65; NMSC, 65 No testing 2016 
FH ENST00000366560 chr1:241676961 c.320A>C (p.Asn107Thr) Missense 
Cutaneous leiomyoma, 36a; Uterine 
leiomyoma (multiple), 36a; Breast, 40 
FH (single gene) 2016 
FHd ENST00000366560 chr1:241675301 c.521C>G (p.Pro174Arg) Missense 
Phaeochromocytoma, 16; 
Phaeochromocytoma, 35 
SDHB, SDHC, SDHC, RET, VHL 
(single gene) 
2008 
MAX ENST00000358664 chr14:65544637 c.289C>T (p.Gln97*) Stop gain 
Phaeochromocytoma, 31a; 
Phaeochromocytoma, 35a 
SDHB, SDHC, SDHD, VHL 
(single gene) 
2008 
MAXd ENST00000358664 chr14:65569057 c.1A>G (p.Met1Val) Start loss 
Phaeochromocytoma, 16a; 
Phaeochromocytoma, 35a 
SDHB, SDHC, SDHC, RET, VHL 
(single gene) 
2008 
MLH1 ENST00000231790 chr3:37083758 c.1884-1G>A 
Splice site 
(acceptor) 
Soft tissue sarcoma, 27; Colorectal, 47a 
APC, BMPR1A, MLH1, MSH2, 
MSH6, MUTYH, SMAD4, 
STK11, TP53 (panel) 
2015 
MSH2 ENST00000233146 chr2:47690234 
c.1452-1455insAATG 
(p.Leu484-Met485fs) 
Frameshift Breast, 40; NMSC, 40; UKP, 42 
BRCA1, BRCA2, TP53, PTEN 
(panel) 
Unknown 
NF1 ENST00000358273 chr17:29546035 
c.1541-1542delAG 
(p.Gln514fs) 
Frameshift 
Nerve sheath benign, <30a; GIST, 46a; CNS 
Nerve sheath, 51a 
No testing 2015 
NF1 ENST00000358273 chr17:29588770 c.4620delA (p.Ala1540fs) Frameshift Lipoma, 29; GIST, 44a No testing 2015 
NF1 ENST00000358273 chr17:29661873 c.5831delT (p.Leu1944fs) Frameshift GIST (multiple), 36a No testing 2015 
NF1 ENST00000358273 chr17:29684007 
c.7768-7769insA 
(p.His2590fs) 
Frameshift PNS Nerve sheath, 20a; GIST, 41a 
KIT, MAX, PDGFRA, SDHA, 
SDHB, SDHC, SDHD, 
TMEM127 (panel) 
2016 
NTHL1b ENST00000219066 chr16:2096239 c.268C>T (p.Gln90*) Stop gain Colorectal, 51a; Breast, 57 No testing Unknown 
NTHL1b ENST00000219066 chr16:2096239 c.268C>T (p.Gln90*) Stop gain 
CNS meningioma, 42; CNS meningioma, 42; 
Colorectal, 44a 
IHC (normal), MSI (stable) 2015 
NTHL1b ENST00000219066 chr16:2096239 c.268C>T (p.Gln90*) Stop gain Colorectal, 48a; Aerodigestive tract, 50 Information unavailable 2012 
PALB2 ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Melanoma, 38; Breast, 47a BRCA1, BRCA2 (single gene) 2011 
PALB2 ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Prostate, 71 No testing Unknown 
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PALB2 ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Melanoma, 31; Breast, 40a BRCA1, BRCA2 (single gene) 2012 
PALB2 ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Anus, 37; Breast, 42a BRCA1, BRCA2 (single gene) 2004 
PALB2 ENST00000261584 chr16:23625409 
c.3116delA 
(p.Asn1039fs) 
Frameshift 
Breast, 35a; Skin sarcoma, 37; Aerodigestive 
tract, 43 
BRCA1, BRCA2 (single gene) 2006 
PALB2 ENST00000261584 chr16:23649437 c.62T>G (p.Leu21*) Stop gain Colorectal, 51; Breast, 54a 
BRCA1, BRCA2, MUTYH 
(single gene) 
2005 
PMS2c ENST00000265849 chr7:6037018 
c.741-742insTGAAG 
(p.Pro247_S248fs) 
Frameshift Colorectal, 50a; Breast, 57 
IHC (PMS2 loss). PMS2 
(single gene) 
2015 
PTEN ENST00000371953 chr10:89720852 c.1003C>T (p.Arg335*) Stop gain Breast, 35a; Ovary, 47; Breast, 49a BRCA1, BRCA2 (single gene) 2010 
PTEN ENST00000371953 chr10:89717672 c.697C>T (p.Arg233*) Stop gain 
Endometrium, 36a; Thyroid, 50a; CNS 
meningioma, 59; Kidney, 62 
PTEN (single gene) 2016 
SDHB ENST00000375499 chr1:17380442 c.223+1C>A 
Splice site 
(donor) 
Paraganglioma, 45a; Pancreas, 51 
BRCA1, BRCA2, CDH1, CDK4, 
CDKN2A, CTRC, MAX, NF1, 
PALB2, PRKAR1A, PTEN, RET, 
SDHA, SDHAF2, SDHB, SDHC, 
SDHD, SPINK1, STK11, 
TMEM127, TP53, VHL (Panel) 
2015 
SDHB ENST00000375499 chr1:17349179 c.689G>A (p.Arg230His) Missense 
Paraganglioma, 40a; Paraganglioma, 40a; 
Paraganglioma, 40a 
SDHAF2, SDHB, SDHC, SDHD, 
RET, MAX, TMEM127, VHL 
(panel) 
2014 
 
List incorporates one individual per family. a - Indicates tumour characteristically associated with pathogenic variant in the relevant gene. b - Homozygous, c - Occurring in same individual. d - Occurring 
in same individual. All structural variants heterozygous. All coordinates are provided for GRCh37. 
UKP - Unknown primary, CNS – Central nervous system, PNS – Peripheral nervous system, NMSC - Non-melanoma skin cancer (includes basal cell carcinoma and squamous cell carcinoma), GI NET - 
Gastrointestinal neuroendocrine tumour, PNET - Pancreatic neuroendocrine tumour, IHC – Immunohistochemistry, MSI – Microsatellite instability.  
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Figure 4.4 - Prior genetic testing and reasons for non-detection of pathogenic/likely pathogenic 
single nucleotide variant or indel 
 
 
4.1.3.3 - Coverage and comparison with panel 
Mean depth in WGS data corresponding to coding bases in the 83 genes analysed was 35X (SD = 7.5) 
with 100% covered at ≥10X. Coverage was also considered for 68 of these genes that are also 
sequenced by the TCP assay (Table 4.5). In WGS data 100% of target bases were covered at ≥10X 
with a mean depth of 35.3X (SD = 7.4). Coverage analysis pertaining to those 68 genes from the 411 
(89.3%) participants also undergoing sequencing with the TCP showed 99.1% target bases at ≥10X 
and a mean depth of 807.3X (SD = 793.2). 
 
72 
 
Table 4.5 - Genes sequenced by Illumina TruSight Cancer panel that appear on list of 83 
analysed genes 
AIP CDKN2A EXT1 MSH6 RB1 TMEM127 
ALK CEBPA EXT2 MUTYH RET TP53 
APC CHEK2 FH NF1 RHBDF2 TSC1 
ATM CYLD FLCN NF2 RUNX1 TSC2 
BAP1 DDB2 GATA2 PALB2 SDHAF2 VHL 
BMPR1A DICER1 HNF1A PHOX2B SDHB WT1 
BRCA1 EGFR KIT PMS2 SDHC XPA 
BRCA2 EPCAM MAX PRKAR1A SDHD XPC 
BRIP1 ERCC2 MEN1 PTCH1 SMAD4  
CDC73 ERCC3 MET PTEN SMARCB1  
CDH1 ERCC4 MLH1 RAD51C STK11  
CDK4 ERCC5 MSH2 RAD51D SUFU  
 
A comparison of the variant detection rate was performed based on the 105 ACMG assessed 
SNVs/indels that were detected by WGS and were within a gene sequenced by the TCP. 99/105 
variants were called from TCP data with quality indicators sufficient to pass filters used for the WGS 
data. Five undetected variants were indels where review with IGV showed a VAF below the threshold 
for filtering, including one P/LP variant in PMS2 (ENST00000265849 c.741-742insTGAAG 
(p.Pro247_Ser248fs)) where 58/202 (20.6%) reads contained the insertion. One undetected variant in 
TMEM127 (ENST00000258439 c.665C>T (p.Ala222Val)) was covered by only two reads, hence 
non-detection.  
 
The filtering and assessment process applied to WGS data was also used for variants called from TCP 
data generated from the same 411 individuals. 108/110 variants from TCP data that passed filters and 
went forward for ACMG assessment were also called from WGS data, meaning that two variants 
(assessed as pathogenic) were not detected by WGS. This was due to VAF being marginally below 
the filtering threshold of 33% for ATM ENST00000278616 c.2426C>A (p.Ser809*) (7/22 (32%) 
reads) and MAX ENST00000358664 c.97C>T (p.Arg33*) (9/29 (31%) reads). 
 
4.1.3.4 - Comparison of loss of function variant detection rate in Multiple Primary Tumour 
WGS data and gnomAD dataset 
In the MPT dataset, 52 truncating or splice site variants were observed in 440 MPT probands 
compared with 298 in 8992 gnomAD genomes based on observed variant frequency estimates 
adjusted to reflect sex distribution of the MPT series (13.6% vs 3.3%, χ2=84.903 p=<0.0001). 41 
truncating or splice site CPG variants occurred in a proband with at least one tumour type 
uncharacteristic of the relevant CPG and the frequency of such variants in these cases was also 
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compared to that in gnomAD. This was significantly higher in the MPT probands with 
truncating/splice site variants and uncharacteristic tumours (41/440 (9.3%) vs 298/8992 (3.3%), 
χ2=43.642 P=<0.0001). 
 
4.1.3.5 - Genetic findings – Structural variants 
Structural variant analysis revealed seven potentially pathogenic variants in 7/440 (1.6%) probands 
(Table 4.6), although SV calls were not available for all individuals. Further details of validation of 
these SVs with Sanger sequencing and IGV plots showing supporting reads (for Manta calls) can be 
found in Appendix 5 (variants 1-7). Three of these probands had previously been diagnosed with 
tumours typically associated with variants in the relevant gene with an additional two having a family 
history of such tumours in a first degree relative (colorectal cancer at age 56 for the case with a 
SMAD4 translocation and renal cell carcinoma at age 69 for the case with the TSC1 duplication). One 
individual with an inversion of PTEN exon 7 had been diagnosed with breast cancer at age 45 and had 
a strong family history of this tumour, which had occurred in her sister (age 57), mother (age 57), and 
maternal cousin (age 49). The proband’s sister had also been diagnosed with a borderline ovarian 
mucinous tumour and nasal basal cell carcinoma at ages 46 and 57 respectively but WGS did not 
detect the PTEN inversion in her sample. A further individual had previously been investigated with 
germline FH sequencing following the diagnosis of multiple cutaneous leiomyomas and a family 
history of a first degree relative undergoing a hysterectomy for uterine leiomyomas. SV analysis 
revealed whole gene deletion of FH. A chromosome 17:10 translocation where the breakpoint was 
within intron 9-10 of FLCN was identified in an individual with fibrofolliculomas and renal cell 
carcinoma who also carried a truncating CHEK2 variant (see SNVs and indels results above). 
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Table 4.6 –Structural variants passing filtering steps 
Gene Chromosome Predicted start Predicted end Algorithm 
Predicted 
consequence 
following IGV 
review 
Phenotype with age at 
diagnosis (* indicates tumour 
deemed typically associated 
with deleterious variants in 
gene) 
Genes tested by clinical 
services 
Year 
consulted 
FLCN 17 
17134310 
(Manta), 
17134474 
(Canvas) 
17136696 
(Manta), 
17137867 
(Canvas) 
Canvas + 
Manta 
Deletion of exon 
2 
Breast, 46; Pulmonary 
lymphangioleiomyomatosis, 
47     Information unavailable 
Unknown 
PTEN 10 89713996 89719837 Manta 
Inversion of exon 
7 
Breast, 45a BRCA1, BRCA2 (single gene) Unknown 
SMAD4 18:9 chr18:48556624.  chr9:127732713 Manta 
Translocation 
with breakpoint 
within 
untranslated 
part of exon 1 
CNS, 42 (Colorectal, 56 in 
mother) 
PMS2, TP53, MLH1 (single 
gene) 
2011 
TSC1 9 135803187 135807261 Manta 
Duplication of 
exon 3 
Testicular, 47; Prostate, 64; 
Lung, 70     
BRCA1, BRCA2 (single gene 
Ashkenazi common 
pathogenic variants) 
2016 
TSC2 16 1566500 2119769 Manta 
Inversion with 
breakpoint in 
intron 16-17 
Small bowel, 42; Colorectal, 43      
IHC (MSH6 loss). MSH6 
(single gene) 
2012 
FH 1 237244834 242310908 Canvas 
Full gene 
deletion 
Multiple cutaneous 
leiomyomata, <55a 
FH (single gene) 2014 
FLCN 17:10 17:17121531 10:43731507 Manta 
Translocation 
with breakpoint 
in intron 9-10 
Multiple fibrofolliculomas, 18; 
Kidney, 53.  
FH, FLCN, MET, SDHB, VHL 
(panel) 
2015 
 
List incorporates one individual per family. a - Indicates tumour characteristically associated with pathogenic variant in the relevant gene. CNS – Central nervous system. All structural variants 
heterozygous. 
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4.1.3.6 - Combined variant detection rate 
If SVs passing filters and ACMG assessed P/LP SNV/indels are combined, a detection rate of 15.2% 
(67 probands tested) is observed. 39 probands (8.9% of total) had such a variant and a typically 
associated tumour. There was no significant difference in P/LP detection rate between probands who 
had been diagnosed with a rare tumour and those who hadn’t (24/136 (17.6%) vs 40/304 (13.1%) 
χ2=1.5235 p=0.2171). Of the 55/67 probands where family history information was available, there 
was no cancer diagnosis in a first degree relative under 60 years in 23 cases (41.8%) and under 50 
years in 34 cases (61.8%). 
 
Limited numbers of family members participated in the study, preventing large scale segregation 
analysis. Of the 70 P/LP variants (including SVs) of interest detected in probands, the relevant locus 
was sequenced in a family member on seven occasions. The relevant variant was detected in 4/7 
family members, two of whom had been diagnosed with a typically associated tumour (breast cancer 
in PALB2 and BRCA1 variants).  
 
4.1.4 - Discussion 
 
4.1.4.1 - Variant detection rates in a multiple primary tumour series 
A previous retrospective analysis of MPT cases (defined as two primaries under age 60 years) 
referred to a UK clinical genetics service without prior genetic testing observed that 20.7% (44/212) 
were found to have a molecular diagnosis upon routine targeted molecular genetic testing including 
BRCA1/BRCA2, mismatch repair gene analysis or other single gene testing (APC, MUTYH, PTEN, 
TP53 and RB1).196  
 
In the current study it was considered whether comprehensive genetic analysis in pre-assessed 
individuals with MPT might increase the diagnostic yield over routine targeted testing. Thus, 460 
individuals with MPT were analysed that had previously undergone routine genetic 
assessment/molecular testing but with no molecular diagnosis made. Interrogation of WGS data for 
variants in 83 CPGs identified a P/LP variant in 67/440 (15.2%) of probands (incorporating 
SNVs/indels and SVs), including those affecting moderate and high-risk CPGs.  
 
As the MPT cohort reported here was mostly ascertained from UK genetics centres (and was similar 
to the cases that were in the previous retrospective cohort that did not have a known genetic cause), it 
is estimated that (assuming that WGS would detect variants identified by routine targeted sequencing 
approaches) that comprehensive genetic analysis in a referred series of individuals with MPT with no 
prior genetic testing would detect a P/LP variant in around a third of cases (20.7% + 12.1% (estimated 
assuming a diagnostic yield of 15.2% in the 79.3% without a variant on routine testing) = 32.8%). The 
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estimated proportion of cases with a P/LP variant and a typical tumour would be ~27.5% (20.7% (all 
of those with detected tested by targeted analysis had a typical tumour) + (79.3% x 8.9% = 7%)).  
Therefore, in individuals seen in a genetic clinic, the presence of MPT (two tumours below 60 years 
or three below 70 years) could be taken as an indication for considering genetic testing. These 
estimates for diagnostic yield are approximate and would be influenced by ascertainment processes 
but do suggest that comprehensive testing for CPG variants significantly increases the detection of 
P/LP variants over the targeted testing that has been routinely employed in most genetics centres. 
 
Most MPT cases with a P/LP variant (39/67 (58.2%), 39/440 (8.9%) of all pre-assessed probands 
tested in the current study) had been diagnosed with a tumour type characteristically associated with 
variants in the relevant CPG, findings which arguably have greater clinical utility then where no 
associated neoplasm is seen. In, addition, a further 8/440 (1.8%) had a VUS and a previous diagnosis 
of a characteristic tumour. Such VUSs might eventually be reclassified as LP variants with further 
investigations (e.g. tumour studies) or additional clinical information (e.g. segregation analysis). 
However, interpretation of segregation data should be cautious in cancer predisposition syndromes 
due to incomplete penetrance and high probability of phenocopies. Tumour studies for loss of 
heterozygosity do not provide absolute confirmation or exclusion of pathogenicity and together, these 
considerations reinforce the importance of data sharing initiatives such as ClinVar.187  
 
A major influence on the number and pattern of variants detected in a study such as this is the tumour 
phenotypes occurring in the cohort, which in this case reflect both population incidence and patterns 
of referral for genetic assessment/investigation (see Chapter 3). Breast cancer accounted for almost a 
quarter of tumours in the MPT series and most genes in which deleterious variants were detected are 
breast CPGs, many of which have not been routinely tested in the UK. Pathogenic variants in ATM 
and CHEK2 are associated with moderate risks197,198 and these genes had not been tested by the 
referring centre in any of the cases with P/LP variants. Six probands had pathogenic variants in 
PALB2, a gene initially thought to confer moderate risk39 but subsequently reported to have a 
penetrance somewhere between moderate and high risk genes such as BRCA1 and BRCA2.40  
 
Genes may remain un-investigated by clinicians not only due to uncertainty surrounding risks but also 
recency of discovery. A number of CPGs in which variants were identified, such as MAX and FH, 
have been relatively recently described. The appearance of these variants in this analysis is likely to 
reflect lack of availability of testing at the time of consultation and subsequent referral for inclusion in 
the study. Molecular genetic testing has been available for other genes, such as MLH1 and PTEN, for 
a greater period of time but some individuals appeared not to have fulfilled the clinical testing criteria 
applied in the referring centre. For example, an individual with breast and ovarian cancer was 
identified with a PTEN nonsense variant but testing for this gene had not been undertaken by clinical 
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services. This is presumably either because there was an absence of other manifestations of PTEN 
variants such as macrocephaly, or that they had not been elucidated due to lack of suspicion for that 
group of disorders. Four individuals were identified with NF1 P/LP variants and exhibited largely 
typical neoplastic phenotypes including neurofibromas, malignant peripheral nerve sheath tumour and 
gastrointestinal stromal tumour. Rather than clinicians not considering the diagnosis, the appearance 
of these participants amongst the positive results likely indicates that neurofibromatosis type 1 is 
frequently regarded as a clinical diagnosis where NF1 sequencing is not required due to reported full 
penetrance. If practice were to change to a more liberal sequencing approach then it may lead to 
revision of the natural history of the disease and more data with which to define genotype-phenotype 
correlations. 
 
 TP53 is a further well-established CPG that is associated with diverse and multiple cancers and has 
clear clinical criteria for testing that are often not fulfilled. Despite this, no pathogenic variants were 
detected. Germline TP53 variant related phenotypes (often with rare and/or early onset cancers) are 
more clearly identifiable clinically and less likely to appear in cohorts such as this without specifically 
ascertaining for them. Consistent with this are pathogenic variant detection rates of ~4% in earlier 
onset (≤30 years) breast cancer cases199 and ~17% in MPT individuals referred for germline TP53  
testing who generally fulfilled criteria for that investigation, had tumours characteristic of Li 
Fraumeni syndrome and an average age at diagnosis (of a first primary) under 30.151 
 
Although this study is, to the author’s knowledge, the first report of the application of WGS to an 
adult MPT series, other studies have used agnostic NGS strategies in single site cancer cohorts. 
Pathogenic variant detection rate in these analyses may be influenced by the assay used, the variant 
filtering/assessment applied and the nature of the series in terms of both phenotype and ascertainment. 
Application of a 76 gene panel to ~1000 adult cancer cases referred for germline genetic testing and 
ACMG guideline based assessment of resulting variants showed a 17.5% rate,200 while a similar sized 
series from the same centre using tumour-normal sequencing in advanced cancer (regardless of 
genetic testing referral) reported an equivalent figure of 12.6%.201 The genes containing the most 
frequent pathogenic variants in both studies are similar to the current study (BRCA1, BRCA2, CHEK2, 
and ATM) but the detection rates are lower than the estimate of around a third of newly referred MPT 
cases, likely reflecting greater likelihood of a germline pathogenic variant in both genetics referrals 
and in MPT individuals. Studies of WGS and/or WES applied to unselected paediatric cancer series 
have also shown pathogenic variant detection rates close to 10% but a contrasting range of affected 
genes with TP53 and genes associated with embryonal tumours playing a far greater role.202–204  
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4.1.4.2 - Atypical tumour-variant associations in multiple primary tumour cases 
In this study multi-gene testing was applied in all cases irrespective of the tumour types diagnosed. 
Strikingly, this resulted in the identification of a large number of probands (29/67, 43.2%) who 
harboured a P/LP CPG variant but whose tumour phenotypes were not entirely typical for the relevant 
CPG.  This situation has been reported at high frequency in other reports of extensive NGS testing of 
cancer cohorts200,203,205 and represents a challenge  for clinicians because the relevance of the variant 
to cancer risk in the consultand and their family is less clear. Specific atypical associations observed 
in this analysis are heterogeneous and numbers are small but some patterns are noted including 5/16 
(31.2%) of CHEK2 variant carriers being previously diagnosed with renal cell carcinoma (RCC) 
(breast cancer occurred in 8/16 (50%)). An odds ratio of 2.1 for RCC has previously been observed in 
CHEK2 variant carriers but only associated with the Ile157Thr founder mutation in a Polish 
population.206 2/6 (33.3%) of PALB2 variant carriers had cutaneous melanoma under the age of 40 
years and 2/10 (20%) individuals with ATM variants had thyroid cancer before that age. However, an 
analysis of 182 melanoma families only demonstrated one pathogenic PALB2 variant207 and thyroid 
malignancies have not been reported at increased frequency in homozygous or heterozygous ATM 
variant carriers.45,55  
 
One potential interpretation of atypical tumour phenotypes is that the tumour spectrum associated 
with some CPGs is wider than currently recognised, in part because to date, testing of particular genes 
has been limited to specific phenotypes. For example, although FH variants were demonstrated to 
predispose to RCC in 2002, they were only shown to predispose to phaeochromocytoma and 
paraganglioma 12 years later.208–210 Therefore, it is suggested that further “agnostic” testing of a 
comprehensive panel of CPGs in MPT cases could lead to the identification of novel gene-tumour 
phenotype associations. The observation of a significantly higher rate of loss of function variants 
associated with non-characteristic tumours in the MPT cohort vs the gnomAD dataset suggests that at 
least some variants identified in individuals with atypical phenotypes are relevant. However, caution 
is necessary in automatically linking a pathogenic CPG variant to the observed tumour phenotype 
without further evidence such as larger studies of variant carriers or tumour studies that demonstrate a 
causative effect of a variant. 
  
Another possibility is that tumours may occur coincidentally in the presence of a pathogenic 
constitutional CPG. Variants might be considered causative in some contexts or tissues (therefore 
likely to pass filtering and assessment) but not in others. For example, an inframe insertion in FH 
(ENST00000366560 c.1433-1434insAAA (p.Lys477_Asn478insLys)) was identified in three cases, 
none of whom had been diagnosed with typical Hereditary Leiomyoma and Renal Cell Carcinoma 
tumours. This variant causes recessively inherited fumarate hydratase deficiency and has been 
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demonstrated to disrupt enzyme activity.211 However, its significance to cancer predisposition in the 
heterozygous state is less well defined.  
 
Unusual MPT-CPG associations can occur when an individual harbours variants in multiple CPGs, 
either due to (at least) one of the variants remaining unidentified through diagnostic testing or because 
of an interactive effect between them. WGS identified three examples in this cohort. The phenomenon 
is discussed in Chapter 5 and termed Multiple Inherited Neoplasia Alleles Syndrome (MINAS).212 
 
4.1.4.3 - Value of germline WGS in the analysis of multiple primary tumour cases 
Although WGS could arguably offer the most sensitive and comprehensive strategy for detecting 
germline CPG variants, it is resource intensive in terms of sequencing, data storage, and analytical 
capacity. In this study, conservative variant filtering/assessment and the small number of non-coding 
variants used for data interrogation reduced the post sequencing burden of variants but small changes 
to these processes would lead to significant increases with uncertain clinical utility. The approximate 
WGS cost per sample as part of the BRIDGE project was £1000, consistent with figures collated by 
the National Human Genome Research Institute in 2016 and higher than the £770 per exome derived 
from that survey.213 The TCP assay in the Stratified Medicine Core Laboratory (Department of 
Medical Genetics, University of Cambridge) is currently charged at around £350 per sample. 
Justification of the extra costs compared to other NGS assays such as panel tests or WES requires the 
demonstration that WGS can increase the diagnostic rate over other approaches through enhanced 
coding SNV/indel detection, SV identification or analysis of non-coding regions.  
 
In this analysis, TCP produced a higher mean depth but slightly lower percentage of target bases 
covered at ≥10X compared to the equivalent regions in WGS data (99.1% vs 100%). WGS identified 
one TMEM127 SNV (assessed as VUS) that wasn’t detected by TCP due to the relevant nucleotide 
being covered by only two reads. There were five additional filtered variants in WGS data that 
weren’t called from panel data, one of which was assessed as likely pathogenic. This was due to the 
VAF being marginally below the chosen threshold, an issue that also accounted for two pathogenic 
variants being called from TCP data but not from WGS. Non-detection of lower VAF variants could 
be resolved through more sensitive bioinformatic filtering of data from either assay. 15 genes on the 
list of 83 were not targeted by the panel and three pathogenic variants were identified in one of them 
(NTHL1) by WGS. This illustrates the broader scope of WGS but the current results do not suggest 
that WGS offers greatly enhanced CPG SNV/indel detection at present. 
 
Copy number variation can be detected through read counts in exome or panel data and there are a 
number of algorithms designed for this task.38 However, non-uniform coverage can compromise 
analysis of relative read depth for this purpose and focus on coding regions reduces the chance of 
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reads covering SV breakpoints. The latter point is particularly pertinent for inversions and 
translocations. WGS addresses some these issues and identified seven SVs predicted to affect a gene 
of interest, two of which occurred in an individual with tumours in their personal and family history 
consistent with variants in that gene. There was no evidence in the medical record of the individual 
with the PTEN inversion exhibiting other clinical features of constitutional variants in this gene but 
also no record of an examination in a consultation where only BRCA1/BRCA2 testing was anticipated. 
Whilst the numbers of potentially pertinent SVs are small, these aberrations would unlikely be 
detected by panel or exome sequencing alone. Copy number variation can be identified from analysis 
of read counts in WES or panel data214 but most diagnostic laboratories rely on techniques such as 
multiplex ligation probe assays (MLPA) to test individual genes. If MLPA is applied to many genes 
then the cost may make WGS more economical than WES/panel-based testing (with concurrent 
MLPA) but a detailed cost benefit analysis would be required to investigate this. Furthermore, WGS 
can detect inversions and translocations that are not characterized by MLPA. A note of caution 
however, arises from a deletion involving exons 14 to 16 of BRCA2 that was highlighted by the 
referring clinician but was not detected through the WGS analysis performed in this study. 
  
Given the current limited benefits of WGS over WES/panel analysis demonstrated in this study, a key 
advantage of the former approach is the ability to prospectively or retrospectively interrogate regions 
that are not yet known to be clinically relevant. This includes novel CPGs and it is noted that many of 
the P/LP variants in this analysis were detected due to the gene/region not being available for testing 
at the time of consultation. Costs of WGS should therefore be considered in the context of possible 
future demand for re-investigation and the consequent resource burden required for this if the region 
of interest (including non-coding) has not been sequenced in the first instance. Adequate systems to 
prioritise and assess the multitude of non-coding variants generated by WGS for clinical use are not 
yet in existence.215 Consequently, few clinically relevant non-coding variants are currently known and 
none were identified in this analysis. However, evidence of regulatory elements that influence 
expression of any given gene is accumulating216 and high throughput functional assays to study them 
provide the opportunity to define diagnostically significant variants influencing risk of neoplasia.217 If 
these processes are successful, the case for WGS as a first line investigative tool would become more 
compelling.  
 
In summary, this work has demonstrated that the application of comprehensive CPG testing to a 
cohort of previously investigated MPT cases resulted in the detection of multiple pathogenic variants 
with relevance to the management of those individuals and their relatives. The finding that 
comprehensive genetic analysis of MPT cases can frequently result in the identification of pathogenic 
CPG variants that cannot readily be attributed as causative for the observed MPT clinical phenotype 
has important implications both for clinical practice and for future research into the phenotypic 
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consequences of germline CPG variants. Summing together variant detection rates from a previous 
series of MPT cases ascertained in a similar manner and the present analysis suggests that first-line 
application of WGS (or other strategies for comprehensive CPG variant detection) to a clinical 
genetics referral-based cohort of MPT cases would detect a deleterious variant in about a third of 
cases, a large proportion of which would not have a family history of cancer in a first degree relative.  
 
4.2 Investigation of a clinical scoring system to predict the presence of pathogenic cancer 
predisposition gene variants in multiple primary tumour cases 
 
4.2.1 - Introduction 
Clinical prioritisation strategies guiding genetic testing can be seen as lying along a spectrum where at 
one end lies the most sensitive approach of testing all individuals who develop a malignancy. At the 
other more focused end, a more traditional approach of targeting testing to highly suggestive 
phenotypes exists. Application of germline genetic testing to all cancer patients would produce greater 
numbers of results with uncertain or limited clinical utility at significant cost and highly targeted 
testing may produce missed diagnoses while compounding ascertainment biases that influence the 
phenotypes associated with CPG variants.  
 
An intermediate strategy might be to utilise general indicators of cancer predisposition to prompt 
agnostic genetic testing and the analysis of MPT cases described in this chapter is illustrative of such 
an approach. Here, all MPT cases fulfilling the inclusion criteria received WGS but it was postulated 
that further factors such as total number of tumours occurring in an individual, extent of family 
history and rarity or estimated heritability of tumours could be incorporated into a scoring system to 
predict those with P/LP variants within the series. If a scoring system could add specificity and be 
easily applied in clinical settings, it may inform the diagnostic process undertaken by genetics 
services.  
 
Therefore, to investigate whether MPT individuals harbouring pathogenic CPG variants could be 
predicted by clinical indicators, a scoring system was devised, herein referred to as a “multiple 
tumour score” (MTS). The MTS was based on assigning integer values to each tumour occurring in a 
single family lineage (including the proband) and taking the sum to produce a single value. A similar, 
albeit more targeted, system has previously been successfully applied to Hereditary Breast and 
Ovarian Cancer in the form of the Manchester score.218 An earlier version of an MTS incorporating 
age at diagnosis and tumour rarity (Table 4.7) was previously published using data generated from 
MPT cases referred to clinical genetics services, some of which contributed to the present study. It 
was shown that around a fifth of individuals who didn’t have a molecular diagnosis identified had an 
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MTS equal to or higher than the median in the diagnosed group, but the predictive capacity wasn’t 
investigated.196 
 
Table 4.7 - Previous multiple tumour score196 
Malignant tumour Age at 
diagnosis 
Score 
Breast, lung, colorectal, prostate, non-melanoma 
skin, cervical 
<30 5 
  30–39 4 
  40–49 3 
  50–59 2 
  >59 1 
Any other malignant tumour <50 5 
  50–59 3 
 
The original MTS was simple to apply clinically but the grouping of tumour histology/morphology 
into only two groups led to some high scores awarded to tumours which were unlikely to have had a 
significant constitutional genetic contribution to their aetiology. For example, cervical cancer has a 
strong association with human papilloma virus infection and has an incidence peak at a relatively 
young age. Its grouping with common cancers with generally later onset led to high scores being 
assigned to earlier onset cervical cancers that were unlikely to reflect higher probability of a cancer 
predisposition syndrome. Additionally, the chosen integer values to assign to each category in the 
scoring system were chosen arbitrarily but only one set of values were proposed. In the context of 
trialling predictive capacity of the MTS, a number of options may reveal a set of preferable values in 
comparison to others.  
 
In this study therefore, it was aimed to improve the MTS to reflect more factors indicating increased 
likelihood of tumour predisposition and provide greater differentiation between scores assigned to 
tumours on the basis of those parameters. The considered variables included age at diagnosis, 
incidence rate of the tumour and estimated heritability. To assist with constructing a scoring system, 
an attempt was made to estimate the relative value of scores that should be assigned on the basis of 
these variables but this did not suggest that it could be estimated with any accuracy. Consequently, a 
number of different systems were proposed and their ability to predict the presence of a P/LP variant 
in the MPT series tested through logistic regression analysis. The series was divided into training and 
test sets with the best performing system from the training set being applied to the test set to assess 
potential clinical utility.  
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4.2.2 - Methods 
 
4.2.2.1 - Defining tumours on which to assign scores 
Analysis was based on the same 440 MPT probands incorporated in the analysis described in section 
4.1. The dependent variable used for logistic regression was the presence or absence of a variant 
assessed as pathogenic or likely pathogenic by that process (including structural variants), herein 
referred to as P/LP Var +ve. 
 
Family history was available for 400 probands. Pedigrees and/or other medical records were reviewed 
in these cases and tumours occurring in a single lineage were recorded in terms of age at diagnosis 
and tumour type. If two lineages contained tumours to record then the one that would be assigned the 
highest score according to the original MTS system196 was used. One intervening relative was 
permitted between any two members of a lineage. 
 
4.2.2.2 - Individual variables analysis (Script RA4.5) 
It was intended that values assigned to tumours in the trialled scoring systems would be weighted to 
produce higher scores for neoplasms deemed more likely to be due to constitutional genetic 
predisposition. Whilst age at diagnosis, incidence and heritability are known to be broadly relevant to 
the probability of a CPG variant being present, a numerical measure of this across cancer types and 
the relative importance of each factor is not easily arrived at. To attempt to assess this for the 
purposes of devising scoring systems to apply to a training set, logistic regression analysis was 
initially performed that separately considered these three factors as independent variables.  
 
In the event of an acceptable fit of the logistic regression models/predictive capacity arising from this 
process, it was anticipated that the regression coefficients (change in natural log of odds of dependent 
variable conferred by a unit increase in the explanatory variable) could guide the relative scoring of 
tumours in the final system/s. For example, if a ten-year decrease in age at diagnosis was associated 
with the same increase in probability of a pathogenic variant as a 30 percent increase in estimated 
heritability, the final score increases conferred by both these changes would be equal.  
 
In these initial logistic regressions, values assigned to participants were directly informed by figures 
relating to these three variables rather than a pre-determined score. Where it was not possible to apply 
a figure (e.g. no heritability estimate available), these tumours were excluded and participants 
excluded if this process led to them no longer fulfilling the original recruitment criteria (two primaries 
before age 60 or three before age 70). This left 370 probands for analysis where 45 individuals were 
designated as P/LP Var +ve. In this and all further analyses, individual scores where family history 
wasn’t considered were also formulated as availability of family history information was not uniform 
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and reliability of tumour reporting may vary between cancer type, recruiting centre and family make-
up. This allowed the inclusion of 407 probands with 56 P/LP Var +ve individuals. 
 
Designation of independent variable values for probands was undertaken as follows. For age, the 
mean of age at diagnosis of all tumours counted in a lineage was taken. For incidence, the incidence 
per 100,000 person-years relevant to each tumour type in a lineage was taken based on Cancer 
Research UK (CRUK) data219 and the mean taken. Where incidence figures were not available in 
CRUK data, the literature was reviewed to obtain them. Estimates are frequently different for males 
and females and these were considered separately according to the sex of the participant. Many 
tumours occurring in the series are known to be rare and incidence estimates may be less reliable than 
for common cancers. Rare cancers can be defined as those with an incidence less than 6 per 100,000 
person years.220 For the purposes of this analysis, any cancer known to be rare and without a reliable 
incidence estimate was assigned a figure given by the mean incidence of all those in the series with a 
known incidence lower than 6 per 100,000 person years (1.56 per 100,000 person years for males and 
1.91 per 100,000 person years for females). Heritability describes the proportion of variance of a 
given phenotype attributable to inherited factors. For various cancer types, it has been estimated using 
statistical techniques that control or adjust for non-inherited factors such as environmental exposure, 
most notably through twin studies.49,50 A higher heritability estimate should increase the probability of 
genetic predisposition contributing to the tumours observed (though this does not imply the relative 
role of lower vs higher penetrance factors). Therefore, participants were assigned independent 
variable values based on the mean of percentage heritability estimates of the diagnosed tumours in a 
lineage. Heritability estimates are not available for a comprehensive range of cancers but a key study 
of heritability estimates contains a pan-cancer estimate of 33%.50 This figure was applied to cancers 
without an estimate unless the population attributable fraction (PAF) of the relevant cancer indicated a 
lower number. In these cases, a heritability estimate was obtained by 100 – PAF. PAF describes the 
proportion of variance in the incidence of a cancer attributable to environmental factors. Whilst it is 
limited by which environmental exposures are measured, high estimates might indicate a more limited 
role for heritable factors. PAF estimates used here were obtained from CRUK data.77,221  
 
Logistic regressions for each variable were performed with the R glm function and goodness of fit 
assessed with Chi square tests (anova function) where the null hypothesis was an improved model fit 
with fewer (i.e. zero) independent variables. The pROC package222 was used to generate receiver 
operator characteristic (ROC) curves and assess the area under curve for each model.  
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4.2.2.3 – Assessment of models based on individual variables to inform scoring system (Script 
RA4.3) 
Results from the logistic regressions based on age, heritability and incidence are described in Table 
4.8. Outputs with and without consideration of family history are shown. No model was assessed as 
having a satisfactory goodness of fit as assessed by Chi square tests. 
 
Table 4.8 – Logistic regression outputs based on individual variables  
Variable Family history included Chi square p value AUC 
Age at diagnosis Yes 0.1258 0.575 
Heredity Yes 0.1515 0.575 
Incidence Yes 0.3081 0.575 
Age at diagnosis No 0.1575 0.5693 
Heredity No 0.1391 0.5814* 
Incidence No 0.7731 0.5038 
 
*Direction of correlation indicated more heritable tumours reduced probability of pathogenic variant 
AUC – Area under curve 
 
4.2.2.4 - Devising a scoring system – Scoring options 
Given that there was insufficient evidence to guide relative importance of variables in a scoring 
system, a range of MTS systems were produced (Table 4.9) to apply to a training set. In order to 
maximise ease of use in potential clinical settings, the score was integer based and arranged values of 
the independent variables (age, incidence and heritability) into weighted bands. The incidence bands 
were designed to reflect the definition of rare tumours then equal gradations up to an incidence level 
at which the UK top 5 incident cancers are observed (>50 per 100,000 person years). Any tumour 
falling into a particular band would be scored with the same integer value and the sum of these for the 
different parameters summed for each tumour. The range of MTS systems proposed were designed to 
provide different levels of weighting between bands and the previously published system was also 
applied.196 
 
86 
 
Table 4.9 – Multiple tumour scoring system options 
Age band (years) Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 
>59 1 1 1 2 2 1 
45-59 2 2 3 4 6 10 
30-44 3 4 9 8 18 20 
<30 4 8 27 16 54 30 
Heritability band (%) Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 
0-25 1 1 1 2 2 1 
26-50 2 2 3 4 6 10 
51-75 3 4 9 8 18 20 
76-100 4 8 27 16 54 30 
Incidence band (per 100K 
person years) 
Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 
>50 1 1 1 2 2 1 
29>50 2 2 3 4 6 10 
6.1-28 3 4 9 8 18 20 
0-6 4 8 27 16 54 30 
 
4.2.2.5 - Assigning scores – Scoring systems (Script RA4.3) 
Occurrent tumours in probands and their relatives in a single lineage were each assigned scores 
according to the proposed systems. Tumours occurring at distant locations or in the same organ pair 
(in the same individual) received separate scores. If it was evident that distinct multiple tumours had 
occurred in the same organ (e.g. skin) then scoring was applied as for two tumours. For cancers of 
unknown primary site, the lowest score possible for a tumour diagnosed at the relevant age was 
assigned. If age at diagnosis was unknown the oldest age band was assumed. 
 
Applications of the scoring systems were undertaken that both incorporated and ignored the incidence 
component due to the fact that the most frequently diagnosed cancer predisposition syndromes cause 
common tumour types and many common tumours have a high estimated heritability.50 As previously, 
analysis was also performed with and without consideration of family history. Where family history 
was considered, 400 probands were included of which 54 were P/LP Var +ve. Where family history 
was not considered, 440 probands were included incorporating 66 P/LP Var +ve individuals. 
 
The data (with and without family history) were split into training and test sets of equal size based on 
random designation of P/LP Var +ve cases to each group and a separate randomisation of cases 
without pathogenic variants (R sample function). Logistic regression for each scoring system was then 
performed as above. If a score within the system could not be assigned to a tumour (e.g. no 
heritability band for benign tumours due to no available estimate) then that tumour was not added to 
the lineage score. This did not result in any exclusion of probands due to insufficient qualifying 
tumours to fulfil the original recruitment criteria. Assessment of models and their predictive capacity 
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incorporated area under ROC curve, chi square goodness of fit tests and consideration of whether a 
higher score led to an increase or decrease in the probability of an individual being labelled as P/LP 
Var +ve. 
 
4.2.3 - Results 
Performance of the models on the training set are shown in Table 4.10. All but one model had a 
goodness of fit insufficient to produce a Chi square p-value below 0.05 or an area under curve (AUC) 
suggestive of good predictive capacity. The best performing score where family history was 
incorporated was system 3 without the incidence component (Chi square p=0.1118, AUC 0.6158). 
System 3 (with incidence component) performed best in those assessments where family history was 
not incorporated (Chi square p=0.03451, AUC 0.5954). 
 
Table 4.10 - Training set model outputs ordered by area under curve 
Scoring system 
Family history 
incorporated 
Incidence 
component 
incorporated 
Chi square p 
value 
Area 
under 
curve 
3 Yes Yes 0.190 0.619 
3 Yes No 0.112 0.616 
3 No Yes 0.035 0.595 
5 No No 0.103 0.589 
2 Yes Yes 0.345 0.581 
2 Yes No 0.244 0.575 
5 Yes No 0.231 0.572 
2 No Yes 0.113 0.569 
6 No No 0.163 0.567 
4 Yes No 0.387 0.554 
Original MTS No Yes 0.300 0.554 
1 Yes No 0.384 0.545 
5 No Yes 0.945 0.544 
6 Yes No 0.521 0.543 
1 Yes Yes 0.536 0.540 
Original MTS Yes Yes 0.706 0.539 
1 No Yes 0.387 0.538 
5 Yes Yes 0.503 0.529 
4 Yes Yes 0.629 0.523 
2 No No 0.339 0.523 
1 No No 0.521 0.517 
4 No Yes 0.803 0.513 
6 Yes Yes 0.724 0.511 
6 No Yes 0.838 0.499 
3 No No 0.250 0.459 
4 No No 0.133 0.427 
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These two models were then applied to the test set (Table 4.11) with family history incorporated 
(system 3 without incidence component applied, Figure 4.5) and without family history incorporated 
(system 3 applied). Goodness of fit was poor in both cases and predictive capacities showed little 
evidence of clinical utility with AUCs of 0.6301 and 0.5309 for system 3 without incidence 
component and system 3 respectively. It was considered what these sensitivities and specificities 
might mean if applied in clinical settings. Scores and P/LP Var +ve status were manually reviewed in 
the test sets to locate a hypothetical optimum score cut-off that would guide whether to perform 
genetic testing or not. For the test set incorporating family history, a cut-off of 28 would save 
performing 75/177 (42.4%) tests but miss 4/25 (16%) pathogenic or likely pathogenic variants. For 
the test set without family history a cut-off of 24 would save performing 54/198 (27.2%) tests but 
miss 8/28 (28.6%) molecular diagnoses. 
 
The best performing model was also applied to a further test set comprised of 212 individuals (44 
P/LP Var +ve) from the series described in the publication where the original MTS system was 
devised.196 Unlike the current MPT cohort, these cases were not ascertained to have no identified 
causative CPG variants despite clinical assessment. No family history was recorded in this series so 
only scoring system 3 was applied.  
 
The goodness of fit assessment produced a Chi square p-value (0.06002) that was not significant at a 
threshold of 0.05 but lower than for other logistic regressions applied. The AUC was 0.6216, which 
was the highest observed value in these analyses. At a hypothetical MTS cut-off of 20 (considered to 
be the optimum from manual inspection of the results), application of this system to this series to 
guide clinical genetic testing would result in 61/212 (28.8%) of individuals not undergoing testing 
with an associated cost of 4/44 (9%) missed P/LP variants. 
 
Table 4.11 - Application of best performing models to test sets 
Test set 
Scoring 
system 
Family 
history 
incorporated 
Incidence 
component 
incorporated 
Chi 
square 
p value 
AUC 
MPT individuals from present analysis 3 No Yes 0.483 0.531 
MPT individuals from present analysis 3 Yes No 0.229 0.630 
212 MPT individuals from previous 
study 
3 No Yes 0.060 0.622 
 
AUC – Area under curve 
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Figure 4.5 - Receiver operator characteristic curve for scoring system 3 without incidence 
component (on test set incorporating family history). Plot shows result from later 
randomisation of training and test sets with area under curve of 0.62. 
 
4.2.4 - Discussion 
To attempt to produce a scoring system that could predict the presence of a pathogenic variant in an 
MPT case series, MTS systems were devised and applied to individuals included in the 
comprehensive CPG analysis described in section 4.1. High penetrance cancer predisposition 
syndromes are rare disorders conferring significant risk to affected individuals. Therefore, sensitivity 
is paramount in diagnostic assays designed to detect them. Although a degree of predictive capability 
for some of the MTS systems was suggested, none performed sufficiently well to suggest an adequate 
balance of sensitivity and specificity.  
 
Of note is the fact that the MPT WGS series to which the scoring systems were applied was pre-
assessed before recruitment to the study and any individuals identified with pathogenic CPG variants 
by clinical services would not have been invited. MPT individuals diagnosed in the clinic could 
potentially have phenotypes and family histories that are more obviously indicative of cancer 
predisposition, leading to higher scores following application of MTS. This non-ascertainment of 
clinically diagnosed individuals may have led to the P/LP Var +ve group not being adequately 
representative of unselected cases or sufficiently differentiated from the P/LP Var -ve group to beget 
good performance of models when applied to the training set. A potential way to address this issue 
would be to include the 44 P/LP Var +ve individuals from the previously published unselected series 
in the training set but this would only be applicable to scoring systems that didn’t incorporate family 
history as information regarding tumours in relatives was not recorded for those individuals. 
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Adaptations to the scoring system may also yield a better correlation between score and pathogenic 
variant status. One difficulty with the age at diagnosis component is that although cancer becomes 
more common with age, incidence of individual cancer types does not have a uniform distribution. 
For example, testicular cancer has a peak incidence between the ages of 30 and 34 and cervical cancer 
has a bimodal incidence peak.177 Even cancer types conforming to typical age distribution patterns 
have varying proportions of cases diagnosed at particular ages. A standard age weighting for all 
tumours may therefore not reflect likelihood of an inherited cancer syndrome. Age scores more 
specific to each tumour type may be of benefit but this would add significant complexity and 
compromise ease of use in the clinic.  
 
Ultimately the central issue in attempting to produce a scoring system to predict the presence of any 
pathogenic CPG variant may be that cancer predisposition syndromes behave differently. Attempting 
to identify them all based on a simple scoring system may fail to allow for this complexity and will 
inevitably predict variants in some genes better than others. For example, in these models a syndrome 
strongly predisposing to tumours in middle age is likely to produce lower scores than an equally 
penetrant condition causing susceptibility in younger age groups. Success in predictive models in 
cancer genetics has tended to centre on using syndrome specific indicators to predict presence of a 
deleterious variant. Such indicators have been based on relatively well characterised cohorts where 
extensive details such as histological subtype can be elucidated. The phenotype of cancer 
predisposition syndromes as an entity per se may not be sufficiently well defined at present for this 
kind of scoring system to be effective.  
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4.3 Interrogation of cancer panel data for possible clinically relevant mosaic variants 
 
4.3.1 - Introduction 
Mosaicism refers to the situation where an individual is composed of two or more genetically distinct 
cell lines due to early postzygotic genetic changes.223 This appears to be a frequent phenomenon, 
potentially affecting a wide variety of loci.224 Cancer susceptibility may result from mosaicism for a 
variant in a CPG and this phenomenon is well recognised as a cause of tumour predisposition that 
may evade detection by conventional genetic testing. Neurofibromatosis type 2 is a condition 
associated with various central nervous system tumours, particularly vestibular schwannomas. It is 
caused by pathogenic variants in the NF2 gene and mosaicism for a cell population containing them is 
estimated to account for around a third of cases.225 A recent study of 108 individuals with phenotypes 
suggestive of Li Fraumeni syndrome identified six mosaic TP53 pathogenic variants using high depth 
sequencing226 and a case of bilateral breast cancer due to a mosaic BRCA1 exon deletion has been 
reported.227 
 
Mosaicism has significant implications aside from influencing variant detection in the laboratory. It 
can lead to attenuated phenotypes or be associated with a lack of family history that may prevent 
further investigation for the condition in question. When detected, it is of reassurance to other family 
members as mosaic variants are not inherited (notwithstanding the possibility of germline mosaicism 
where the cell population with the variant is present in ovaries or testes).  
 
Cell populations containing deleterious variants in CPGs may not be represented in blood and present 
obvious difficulties with detection, even with NGS techniques. More examples of this situation are 
emerging such as the finding of identical HIF2A variants in a patient’s paraganglioma and 
somatostatinoma that explained both tumour’s formation. The variant was not detected, however, in 
blood or other samples including urine, buccal cells and nails.228 In the not uncommon scenario where 
multiple tumours occur in the same patient,111 it may be advantageous to perform genetic analysis on 
both tumours. Such analysis may become more widespread as NGS technologies are applied in 
surgical and oncological settings more frequently.    
 
The detection of mosaicism by blood sampling depends on variant carrying cells making up at least a 
proportion of circulating nucleated cells. If this is the case, the probability of detecting them will be 
enhanced by a greater number of distinguishable molecular enquiries in the analysed DNA sample for 
a given genomic coordinate of interest. Chromatogram peaks from Sanger sequencing visually 
represent the relative proportions of bases at a particular position. They may reveal mosaicism but do 
not give a quantified measurement of read depth or VAF and suggestive chromatogram profiles may 
be easily interpreted as artefact. NGS techniques are also imperfect for detection of mosacism but are 
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often more sensitive for this purpose due to their ability to quantify a particular base call in hundreds 
or thousands of individual reads, revealing variants that are present in only a small proportion of cells 
from which DNA was extracted. As per Sanger sequencing however, these reads may be interpreted 
as artefact and bioinformatic processes are more likely to detect true mosaic variants if optimised for 
that purpose. 
 
4.3.2 - Methods 
To investigate whether mosaic variants in CPGs (detectable in blood) could explain some MPT cases, 
sequence data from TCP was analysed. This assay is more suited to this purpose than WGS due to the 
higher read depth (see section 4.1).  
 
4.3.2.1 - Selection of genes and participants 
CPGs selected to investigate (n=61, Table 4.12) were those appearing in the gene list for WGS-based 
comprehensive CPG analysis that are also sequenced by the TCP. CPGs only associated with 
recessive cancer predisposition were excluded as mosaicism for homozygous/compound heterozygous 
pathogenic variants in the same gene due to post zygotic mutation is a highly unlikely scenario. 
Furthermore, mosaicism for monoallelic variants would not be readily distinguishable from biallelic 
with the sequencing technique utilised. 
 
Table 4.12 - Genes investigated for possible mosaic variants 
AIP CDK4 FH NF1 RET TMEM127 
ALK CDKN2A FLCN NF2 RHBDF2 TP53 
APC CEBPA GATA2 PALB2 RUNX1 TSC1 
ATM CHEK2 HNF1A PHOX2B SDHAF2 TSC2 
BAP1 CYLD KIT PMS2 SDHB VHL 
BMPR1A DDB2 MAX PRKAR1A SDHC WT1 
BRCA1 DICER1 MEN1 PTCH1 SDHD  
BRCA2 EGFR MET PTEN SMAD4  
BRIP1 EPCAM MLH1 RAD51C SMARCB1  
CDC73 EXT1 MSH2 RAD51D STK11  
CDH1 EXT2 MSH6 RB1 SUFU  
 
The considered MPT cases (n=549) comprised those probands appearing in the WGS-based 
comprehensive CPG analysis who also had TCP performed on their sample (n=410). 129 other 
probands were also included who fulfilled eligibility criteria to be included in that analysis but where 
WGS had not been carried out. An additional 10 individuals were added whose eligibility was 
dependent on considering multiple (≥10) colorectal polyps as a qualifying tumour. 
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4.3.2.2 - Bioinformatic processing and filtering (Script RA4.6) 
BAM files generated from TCP sequencing output were subject to variant calling as described 
previously but aligned to hg38. Resulting VCF files were annotated with Annovar.229 Output files 
included a measure of VAF. Variant calling was set up to allow heterozygous calls even with a low 
VAF. 
 
Variants were filtered according to the following criteria: 1) Occurring within a region corresponding 
to a list of canonical transcripts generated from the gene list (Ensembl transcript identifier converted 
to RefSeq230 with Biomart185), 2) Read depth ≥200, 3) VAF between 0.05 and 0.3, 4) Allele frequency 
in 1000 Genomes data (all populations) < 0.01, 5) no indication of a variant call due to multi-mapped 
reads. Multi-mapping describes a situation where sequencing reads align to more than one region of a 
reference genome due to sequence similarity between those regions. A read sequenced from a part of 
the genome with similarity to a region of interest (e.g. a pseudogene) may contribute to variant calls 
pertaining to the region of interest as it is likely that the two locations will not have identical 
sequence. This is particularly relevant to variants with low VAFs and the variant calling/annotation 
pipeline used here included an assessment of the proportion of reads used for that variant call that also 
aligned to another genomic location. No variants with a proportion above 10% appeared in the 
annotation output files and only variants with a proportion of 0% were used in this analysis. 
 
Filtered variants were considered for further assessment if the predicted consequence indicated 
protein truncation (“stop_gain” was the only such annotation in the filtered variants), if there was 
evidence of pathogenicity in ClinVar187 (≥2* evidence of pathogenic or likely pathogenic effect 
corresponding to multiple submissions with no conflicts as to assertion of clinical significance), or if 
the variant was assigned a DM status in HGMD.188 An in-house tool to provide a numerical 
assessment of likelihood of functional alteration using an amalgamation of various in silico tool 
outputs (unpublished) was also applied to variants. Variants could also be considered further by the 
designation of a score suggesting a high probability of a deleterious effect (threshold 0.75 on a scale 
of 0 to 1 where 0 indicates low probability).  
 
Highlighted variants were subsequently reviewed with IGV to check for sequencing artefact. In the 
majority of cases, all bases contributing to the variant call were in an identical position within read 
ends. Variants exhibiting this pattern were excluded.  
 
4.3.2.3 - Calculation of coverage (Script RA4.6) 
For BAM files from panel data, coverage statistics for regions of interest were generated with 
samtools depth.170 A BED file compiled using Ensembl BioMart185 to represent coding bases of the 61 
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genes considered was utilised. Mean depth, standard deviation and percentage of target bases covered 
at a specified depth were calculated using R version 3.4.3.178 
 
4.3.3 - Results 
The mean sequencing depth across considered coding bases was 796.6X (SD 795.3). 84.4% of bases 
were covered at sufficient depth to pass the depth filter. 
 
Two variants passed filters (Table 4.13) and were assessed with ACMG criteria in the same manner as 
those resulting from the WGS analysis described in section 4.1.  
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Table 4.13 - Variants passing filters to elucidate mosaic variants 
Gene Consequence Transcript Variant 
Variant 
allele 
fraction 
Sequencing 
depth 
Phenotype Family history 
ATM 
Inframe 
deletion 
ENST00000278616 
c.7638_7646delTAGAATTTC 
(p.Arg2547_Ser2549del) 
0.27 3354 AML, 12; Breast, 28 
Father - Prostate, 56; Paternal uncle, UKP, 69; Paternal 
grandfather, Prostate, 50-59 
CHEK2 Missense ENST00000382580 c.1166G>A (p.Arg389His) 0.10 436 
Hodgkin lymphoma, 17; 
Breast, 52; Papillary thyroid 
carcinoma, 52; 
Haemangioma (pelvic bone), 
<54 
Paternal grandmother - Oral cancer, 65; Paternal great 
uncle - Throat cancer, 53; Paternal great uncle - Lung, 
67; Paternal great aunt - Breast, 50-59; Paternal great 
aunt - Breast, ? age; Paternal great aunt - UKP, 20-29; 
Paternal great uncle - UKP, ? age 
 
AML – Acute myeloid leukaemia, UKP – Unknown primary 
 
Figure 4.6 - A) ATM c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del). Variant allele fraction 0.27. B) CHEK2 c.1166G>A (p.Arg389His). Variant allele 
fraction 0.1 
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ATM ENST00000278616 c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del) was identified at a 
variant allele fraction of 0.27 (Figure 4.6) in an individual with childhood acute myeloid leukaemia 
and subsequent breast cancer at the age of 28, the latter of which is consistent with constitutional 
pathogenic variants in ATM. There was some family history of prostate cancer but no breast cancer 
was reported in relatives. The variant was assessed as likely pathogenic due to its nature as an inframe 
deletion, multiple reports of pathogenicity in ClinVar (nine pathogenic and one VUS reports) and 
published functional evidence of absent kinase activity following transfection into an ATM null cell 
line.231  
 
A further CHEK2 missense variant c.1166G>A (p.Arg389His) at VAF 0.1 (Figure 4.6) passed filters 
due to predicted high probability of pathogenicity by an in-house in silico prediction tool. The variant 
was identified in an individual whose various diagnosed tumours included breast cancer but 
assessment designated it as a VUS. Six reports exist in ClinVar, all with VUS assertion. 
 
4.3.4 - Discussion 
Interrogation of CPG variants called from panel data for possible mosaicism resulted in only one 
variant that was assessed as pathogenic or likely pathogenic. The low number may, in part, be due to 
inadequate sequencing coverage in some areas. Although the mean depth across considered coding 
bases was 796.6X (SD 795.3), 15.6% of bases were represented by fewer than 200 reads, the selected 
threshold for filtering. 
 
The likely pathogenic inframe deletion in ATM was identified in a sample from an individual who had 
previously been diagnosed with early onset breast cancer, suggesting a possible role in causing the 
tumour phenotype. Tumour material was not available for further investigation in the form of loss of 
heterozygosity analysis. In theory, mosaic pathogenic CPG variants due to postzygotic mutation 
shouldn’t be associated with a significant family history of neoplasia. In this case, prostate cancers 
occurring in the father and grandfather at the relatively early age of 50-59 might suggest some 
constitutional genetic cancer predisposition in that lineage but prostate cancer is not associated with 
ATM variants. Conclusions, therefore, can’t be drawn as to the significance of the family history. 
 
Of note is that this individual was diagnosed with acute myeloid leukaemia (AML) at age 12 years, 
which is generally treated with chemotherapy regimens. They were treated at a time before bone 
marrow transplant was widely practiced so the variant is unlikely to be derived from a bone marrow 
donor. Cancer risks are reported to be increased in survivors of childhood cancer survivors232 and a 
study of 501 childhood AML cases demonstrated a standardised incidence ratio for any cancer of 
10.64, although no breast cancers were noted amongst only five reported second malignancies.233 
Clear associations between treatment and later tumours are difficult to firmly establish (see Chapter 1) 
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but a role for chemotherapy in causing the breast cancer appears a strong possibility. Chemotherapy 
may have acted in conjunction with the ATM variant as it may have led to a compromised response to 
DNA damage caused by the drug regimen and an increased rate of tumourigenic events in cells. 
Alternatively, chemotherapeutic agents may have caused the inframe deletion in a clone of cells. Low 
VAF variants have been demonstrated in relapsed AML patients, the pattern of which is influenced by 
the drugs that are used for the initial therapy.234 However, non-blood cells (such as those in ductal 
breast tissue) were not considered by the study.  
 
The VAF in this case was relatively high (0.27), increasing the probability that this individual is, in 
fact, germline heterozygous for the variant. Analysis of WGS data for clinically relevant variants 
described in section 4.1 demonstrated a number of variants where one assay produced a VAF leading 
to confident heterozygous designation but another gave a value that fell below the threshold for this 
assertion. A further sequencing assay was not performed for the individual with the ATM variant but 
this may have shown a higher VAF. When sampling blood DNA, uncertainty as to whether a low 
VAF for a variant indicates mosaicism in other tissues makes alternative sampling strategies more 
compelling. A more direct measurement of mosaicism for CPG variants causing multiple primaries is 
the demonstration of a particular variant in more than one tumour sample but absence in other non-
tumour samples (e.g. blood), a phenomenon that has been observed previously.228 A mosaic variant 
might also be revealed by absence in blood but presence in a single tumour in which evidence of a 
second “hit” exists (e.g. two deleterious single nucleotide variants or a single variant with no 
heterozygosity observed at that locus) because the presence of two mutational events at the same 
locus can imply that one of them occurred at an early embryological juncture. This rationale has been 
used in the diagnosis of mosaic NF2235 but sequencing of a second tumour may be required to identify 
which of the “hits” is mosaic and which has occurred only in the tumour at hand. The extensive 
acquisition and sequencing of tumour samples from MPT individuals may yield more positive results 
than the present analysis but present challenges if formalin fixed paraffin embedded (FFPE) tissue is 
used due to degradation of DNA stored in that form. Fresh frozen tissue is better suited to sequencing 
studies but requires prospective organisation of acquisition and changes in routine pathology 
laboratory practice. 
 
The paucity of possible pathogenic mosaic variants proposed by this analysis may be simply due to 
the fact that it is a rare phenomenon that has not been widely reported outside of the context of a few 
conditions. The high rate of mosaic TP53 variants in phenotypes suggestive of Li-Fraumeni syndrome 
may be due to the fact that a more specific phenotype was considered where variants in a particular 
gene are more likely. Some multiple primary tumours caused by the same mosaic CPG variant might 
be explained by variants that are incompatible with life in the heterozygous state. Genes containing 
such variants would not be readily identifiable as CPGs in research studies due to lack of surviving 
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affected individuals and would not have been considered here. The sequencing depth of WGS 
generated as part of this project would be inadequate to confidently call mosaic variants in putative 
“mosaic only” CPGs but future studies involving broad coverage of genomic regions with higher 
sequencing depth might be rewarding in this regard. 
99 
 
Chapter 5 – Multiple Inherited Neoplasia 
Alleles syndrome (MINAS) – The occurrence of 
more than one pathogenic cancer predisposition 
gene variant in the same individual 
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This chapter is based on, and expanded from, a previously published journal article (Whitworth et 
al).212 
 
5.1 - Introduction 
In clinical practice the maxim of Occum’s razor is often adopted236 in the sense that whenever 
possible, a single diagnosis is favoured over multiple diagnoses. Rare diseases have a frequency of 
less than one in 2000237 and statistically, the chances of an individual being affected by two or more of 
them would appear to be remote. However, with more than 6,000 rare diseases and up to 6-8% of the 
European population estimated to have such a condition at some point in their lifetime,237 there is 
clearly potential for two or more rare disorders to occur by chance. This scenario has been reported in 
various constitutional genetic disorders with both distinct and overlapping phenotypes, including high 
penetrance cancer predisposition syndromes and/or patients with multiple primary tumours. If 
Occum’s razor is applied then the detection of a pathogenic variant in a specific cancer predisposition 
gene (CPG) might lead the clinician to attribute any tumours that are not typical features of the 
relevant inherited cancer syndrome to variable phenotypic expression or coincidence. In such 
circumstances, the patient may receive suboptimal management and the estimated cancer risks to 
relatives could be erroneous. In addition, studies of patients harbouring multiple deleterious variants 
in different CPGs could provide insights into how the function of the relevant gene products may be 
related e.g. if a particular combination resulted in a more pronounced or novel phenotype (analogous 
to the differences in phenotype between patients with monoallelic and biallelic mismatch repair 
(MMR) gene variants238).The best known examples of patients with multiple CPG aberrations are 
reports of patients with pathogenic variants in both BRCA1 and BRCA2.239–257 Interestingly, the 
phenotype in these patients has generally not been shown to be more severe than when a single variant 
is present.  
 
Through studies undertaken in the author’s laboratory to elucidate the constitutional genetic basis of 
suspected cancer predisposition, ten further individuals (from nine families) have been identified with 
multiple pathogenic CPG variants that would in themselves be considered to confer sufficient risk to 
prompt mitigation strategies. Three of these were detected as part of the whole genome sequencing 
(WGS) based comprehensive CPG analysis in multiple primary tumour (MPT) cases described in 
Chapter 4 and involved combinations of variants in BMPR1A/PMS2, FH/MAX and CHEK2/FLCN 
(translocation). Other studies showed combinations of variants in FLCN/NF1, FLCN/TP53, 
TP53/MSH2, MLH1/XPA, NF1/BRCA2 and SDHA/PALB2 in individuals with various neoplastic 
phenotypes.  
 
To provide a summary of the nature and frequency of similar cases reported to date, the published 
literature was reviewed in systematic fashion. The term “Multilocus Inherited Neoplasia Alleles 
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Syndrome” (MINAS) is proposed to describe this phenomenon in order to assist with sharing of 
information regarding the phenotypic effects of particular variant combinations.212 
 
5.2 - Methods 
 
5.2.1 - Identification of cases in the literature 
In order to review published cases with MINAS, a systematic review of the published literature was 
undertaken. Initially, a list of CPGs (Table 5.1, n=109) was constructed comprising all genes 
sequenced by the Illumina TruSight Cancer panel (Illumina Inc., San Diego, CA, USA) and those 
used for the comprehensive CPG analysis (Chapter 4) that are not targeted by that assay. 
 
The list was then used to perform a Medline database search (1946 to present). Firstly, each gene was 
entered as a search term (if in existence in the database) and a keyword to produce a list of articles 
pertinent to that gene. Secondly, the entries were combined with the OR operator to produce 109 lists, 
each of which contained the articles pertinent to all the genes except one. Thirdly, each of the original 
individual gene entries was combined via the AND operator with the combination entry that lacked 
that particular gene. Therefore, articles referring to a given gene name in combination with any other 
CPG from the list would be captured. Finally, the resulting lists were combined to produce a single 
entry, which was further combined via the AND operator with the linked terms/keywords “germline 
mutation” OR “germline” OR “germ-line” OR “double heterozygosity” OR “double heterozygote” 
OR “genetic predisposition to disease” OR “inherited mutation”. An additional PubMed search was 
also performed using the search term “double heterozygote + cancer.”  
 
Titles or abstracts from resulting articles were read to assess whether they reported a case of MINAS 
and variants described were subsequently reviewed to assess pathogenicity. Variants (and 
consequently cases harbouring them) were included if it was asserted by the publication that they 
were pathogenic and there was a predicted truncating consequence (unless benign status in ClinVar), 
there was pathogenic/likely pathogenic status in ClinVar (2* or 3* evidence unless otherwise stated 
below) or if they are used in current clinical guidelines to predict increased risk. Variants could also 
be designated as pathogenic if the article included studies (e.g. reverse transcriptase polymerase chain 
reaction) that demonstrated abnormal splicing resulting from the variant. It has been speculated that 
lower penetrance variants may confer increased phenotypic severity when in combination with 
pathogenic changes in another gene but these cases were not considered. 
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Table 5.1: Genes used for literature search (n=109) 
AIP CEP57 FANCF NBN RECQL4 TMEM127 
ALK CHEK2 FANCG NF1 RET TP53 
APC CYLD FANCI NF2 RHBDF2 TSC1 
ATM DDB2 FANCL NSD1 RUNX1 TSC2 
AXIN2 DICER1 FANCM NTHL1 SBDS VHL 
BAP1 DIS3L2 FH PALB2 SDHA WRN 
BLM EGFR FLCN PDGFRA SDHAF2 WT1 
BMPR1A EPCAM GATA2 PHOX2B SDHB XPA 
BRCA1 ERCC2 GPC3 PMS1 SDHC XPC 
BRCA2 ERCC3 HFE PMS2 SDHD  
BRIP1 ERCC4 HNF1A POLD1 SERPINA1  
BUB1B ERCC5 HRAS POLE SLX4  
CDC73 EXT1 KIT POLH SMAD4  
CDH1 EXT2 MAX PRF1 SMARCA4  
CDK4 EZH2 MEN1 PRKAR1A SMARCB1  
CDKN1B FANCA MET PTCH1 SMARCE1  
CDKN1C FANCB MLH1 PTEN SRY  
CDKN2A FANCC MSH2 RAD51C STK11  
CDKN2B FANCD2 MSH6 RAD51D SUFU  
CEBPA FANCE MUTYH RB1 TGFBR1  
 
 
5.2.2 - Tumour studies (for PALB2/SDHA variants) 
Demonstration of loss of the wild type allele in DNA samples obtained from tumours can indicate that 
a “second hit” occurred at the locus containing a constitutional variant, providing evidence that the 
constitutional variant was significant in the development of that tumour. For two cases (a mother and 
son diad), loss of heterozygosity (LOH) analysis was performed for SDHA (panel-based sequencing) 
and PALB2 (Sanger sequencing). 
 
5.2.2.1 - DNA extraction from formalin fixed paraffin embedded tumour blocks 
Slides were prepared from formalin fixed paraffin embedded (FFPE) tumour blocks by the Human 
Research Tissue Bank, Cambridge University Hospitals. De-paraffinisation was performed by soaking 
in 100% xylene, 100% ethanol and air drying. In order to optimise the amount of tumour material 
contributing to sequencing results, slides were reviewed by a pathologist to mark selected tissue and 
tumour dissection was performed by colleagues in the Department of Haematology and Oncology 
diagnostic services, Cambridge University Hospitals. Resulting tissue was placed in ATL tissue lysis 
buffer (Qiagen, Hilden, Germany) with proteinase K added before incubation. DNA was purified 
from the resulting lysate with a QiaAmp MinElute Column (Qiagen, Hilden, Germany). 
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5.2.2.2 - Ampliseq panel sequencing 
Library preparation was undertaken by the colleagues in the Stratified Medicine Core Laboratory 
using a custom Ampliseq panel (Thermo Fisher Scientific, Waltham, MA, USA) that included the 
SDHA region of interest. The protocol was adapted from a NEBNext Ultra II protocol for Illumina 
sequencing (New England Biolabs Inc., Ipswich, MA, USA). DNA samples were made up 10ng in 
5µl and transferred to a 96 well plate with two primer pools (to avoid competition for hybridisation 
between adjacent primer pairs). Consequently, two wells were used per sample. Polymerase chain 
reactions (PCR) were performed by adding Q5 mastermix (New England Biolabs Inc., Ipswich, MA, 
USA) (Table 5.2) to each well and thermal cycling under the protocol described in Table 5.3. 
Following completion of PCR reactions, adaptor sequences were removed from amplicons by the 
addition of NEB USER Enzyme (New England Biolabs, Ipswich, MA, USA), which cleaves nucleic 
acids at uracil bases, and incubation with a thermal cycler. Wells corresponding to each sample for 
both primer pools were combined and transferred to wells of a MIDI plate containing 1.8X Agencourt 
AMpure XP magnetic beads (Beckman Coulter, Pasadena, CA, USA) to bind to amplicons. Two 
rounds of pull down and re-suspension were undertaken. To ligate specific barcode sequences to 
amplicons from specific samples, NEB End Repair reaction buffer then NEB End Repair enzyme mix 
(New England Biolabs Inc., Ipswich, MA, USA) was added to each well. 30µl NEB ligation master 
mix, 1µl of ligation enhancer and 2µl barcode sequence solution was added to each well before 
mixing and incubation. Further clean up using AMpure beads with ethanol washes were carried out. 
Quality of prepared libraries was measured by subjecting a 1/1000 dilution of each sample to 
quantitative PCR according to a KAPA protocol (Illumina Inc., San Diego, CA, USA). A 5µl aliquot 
of each sample was then transferred to an Illumina MiSeq instrument for sequencing. 
 
Table 5.2 - PCR reaction components for Ampliseq panel 
Reaction component Volume (µl) 
Q5 Master Mix 25 
Primer Mix                  10 
DNA 5 
Water 10 
Total volume 50 
 
Table 5.3 - PCR thermal cycling protocol for Ampliseq panel – 30 cycles 
Step Temperature (°C) Duration (secs) 
Initial denaturation 98 30 
Denature 98                  10 
Anneal 60 30 
Extend 65 120 
Final extension 65 300 
Hold 4 Hold 
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5.2.2.3 - Sanger sequencing  
DNA extracted from tumours was also subject to Sanger sequencing for a PALB2 variant identified in 
the corresponding blood DNA, performed by colleagues in the Department of Medical Genetics, 
University of Cambridge. PCR reactions for the region of interest were undertaken according to the 
advised protocol for AmpliTaq Gold DNA polymerase 50µl reaction (Thermo Fisher Scientific, 
Waltham, MA, USA). Primers are shown in Table 5.4 and reaction constituents are described in Table 
5.5. Thermal cycling was performed on a Tetrad PTC-225 (MJ research, Waltham, MA, USA) 
according to the protocol described in Table 5.6. PCR products were subject to gel electrophoresis in 
1% agarose gel (90v/40mins) and photographed under ultraviolet light to check for an observable 
band of predicted length. Following PCR, excess primers and deoxynucleotides were removed by 
adding a mixture of Exonuclease I (New England Biolabs, Ipswich, MA, USA) and Shrimp Alkaline 
Phosphatase (GE Healthcare, Chicago, IL, USA) to each PCR product well and incubating. 
Bidirectional Sanger sequencing of resulting products was performed with BigDye Terminator 
Version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the 
reaction constituents described in Table 5.7 and thermal cycling protocol (with a Tetrad PTC-225) 
outlined in Table 5.8. To remove unincorporated dye, 40µl of 75% isopropanol was added to each 
well after the sequencing reaction. The plate containing the wells was then centrifuged and inverted 
onto absorbent paper to remove supernatant. It was left to air dry in dark conditions before adding 
10µl of Hi-Di™ Formamide (Applied Biosystems, Foster City, CA, USA) to each well. The plate was 
then placed on an ABI 3131xl sequence analyser (Applied Biosystems, Foster City, CA, USA). 
Resulting chromatogram files were analysed with Sequencher 5.3 software (Gene Codes Corporation, 
Ann Arbor, MI, USA). 
 
Table 5.4 - Primers used for amplifying region containing PALB2 variant 
Forward primer CAACAGCAACACAAAACCACA 
Reverse primer AACTTTTGCTGAGGTCCAAGG 
 
Table 5.5 - PCR reaction components for Sanger sequencing 
Reaction component Volume (µl) 
AmpliTaq Gold DNA polymerase (5U/µl) 0.25 
10µm Primer Mix     2 
DNA 5 
Water 33.75 
10nM dNTP mix 1 
25nM MgCl2 3 
10X PCR buffer 5 
Total volume 50 
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Table 5.6 - PCR thermal cycling protocol for Sanger sequencing – 32 cycles 
Step Temperature (°C) Duration  
Initial denaturation 95 10 mins 
Denature 95          15 secs 
Anneal 59 30 secs 
Extend 72 1 minute per kb 
Final extension 72 5 mins 
Hold 4 Indefinite 
 
Table 5.7 - Sanger sequencing reaction components 
Reaction component Volume (µl) 
BigDye Terminator Version 3.1 0.75 
Primer solution (10pmol) 1 
5x BigDye sequencing buffer 2 
Water 4.25 
 
Table 5.8 - Thermal cycling protocol for Sanger sequencing reaction – 20 cycles 
Step Temperature (°C) Duration (secs) 
Denature 96 10 
Anneal 50 5 
Extend 60 210 
 
5.3 - Case reports  
 
5.3.1 - Cases identified through sequencing studies 
The following cases were identified through clinical practice of collaborators and/or sequencing 
studies undertaken in the Department of Medical Genetics, University of Cambridge. 
 
FLCN/NF1 
A 39 year old man presented with testicular seminoma and a routine abdominal scan four years later 
revealed a phaeochromocytoma. Following his seminoma diagnosis, he also developed a 
pneumothorax and went on to have six further occurrences. At age 55 years he complained of 
abdominal/ back pain and a computerised topography (CT) scan revealed bilateral renal masses that 
were demonstrated to be renal cell carcinomas (RCCs) following removal. Reinvestigation following 
further episodes of abdominal pain identified two gastrointestinal stromal tumours (GIST). At age 56 
years, a CT lung scan (to investigate a pneumothorax) revealed a malignant peripheral nerve sheath 
tumour (MPNST). Skin examination revealed multiple skin neurofibromas, two café au lait patches 
and axillary freckling but no fibrofolliculomas. A clinical diagnosis of Neurofibromatosis type 1 was 
made and though this was considered to be the cause of his MPNST and possibly 
phaeochromocytoma and GIST, the history of renal cancers and recurrent pneumothorax were 
considered unrelated.  
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Next generation sequencing (NGS) of 94 CPGs was performed using the Illumina TruSight cancer 
panel.169 A previously reported splice site variant in FLCN (ENST00000285071 c.1062+2T>G)258,259 
and a nonsense variant in NF1 (ENST00000356175 c.1381C>T p.(Arg461*)) were detected and 
confirmed by Sanger sequencing. Deleterious FLCN variants cause Birt-Hogg-Dube syndrome 
(BHD), a rare condition where affected individuals are predisposed to RCC, pulmonary cysts, 
pneumothoraces and fibrofolliculomas. The patient’s brother had also been diagnosed with bilateral 
chromophobe RCCs at age 45 years and was found to have facial fibrofolliculomas. Testing of a sister 
and her daughter demonstrated the presence of the FLCN variant but both were asymptomatic with 
normal renal scans. A paternal cousin with numerous fibrofolliculomas and a history of recurrent 
pneumothorax was confirmed to harbour the FLCN variant. The proband's deceased father had 
pancreatic adenocarcinoma but was not known to have features of BHD syndrome during life, 
although he was an obligate carrier of the FLCN variant and autopsy revealed bilateral renal 
oncocytomas. There was no known family history of Neurofibromatosis type 1. 
 
Neurofibromatosis type 1 has a population frequency of 23/100.000260 and might be expected to exist 
in combination with another inherited cancer syndrome relatively rarely, though phenotypic 
variability and use of clinical diagnostic criteria (rather than genetic testing) may underestimate this. It 
is associated with predisposition to a variety of neoplasms including phaeochromocytoma, GIST, 
carcinoid tumour, cutaneous/plexiform neurofibromas and MPNST. Thus, in this case associated with 
two pathogenic CPG variants, the occurrence of the MPNST, phaeochromocytoma, GIST and RCC 
can be explained but testicular seminoma has not been associated with variants in either gene.149,261 
This suggests that the seminoma might be a consequence of the combination of FLCN and NF1 
variants (seminoma has been linked to aberrations in the c-kit, RAS/MAPK and 
PI3K/AKTpathways262,263 and the NF1 and FLCN gene products regulate RAS/MAPK and 
mTOR/PI3K/Akt signalling respectively264,265) or be coincidental, testicular being the most common 
male solid tumour in the 15-34 age group.266 
 
FLCN/TP53 
A 32 year old man presented with dysphagia. There was a previous history of ulcerative colitis for 
which he had undergone a pan-protocolectomy at age 27 years and pathological examination of the 
colectomy specimen had revealed an incidental rectal adenocarcinoma. Endoscopy revealed a 
gastroesophageal junction adenocarcinoma and staging imaging demonstrated a 6cm left kidney 
tumour. Biopsy of the latter suggested a primary renal neoplasm, prompting nephrectomy. Histology 
of the resected kidney confirmed a chromophobe RCC. Examination of the skin showed facial 
fibrofolliculomas. There was no history of cancer in first degree relatives (both parents unaffected at 
age 60) but the maternal grandfather developed oesophageal squamous cell carcinoma at age 54. The 
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paternal grandmother and grandfather developed a brain tumour of uncertain histology and an 
oropharyngeal carcinoma at ages 50 and 49 years respectively.  
 
Genetic investigations revealed two pertinent variants in FLCN (ENST00000285071 c.715C>T 
p.(Arg239Cys))267 and TP53 (ENST00000269305 c.526T>C p.(Cys176Arg)). The latter has been 
reported as a somatic mutational event on multiple occasions,34,268 including in colorectal 
adenocarcinoma34 but not previously in germline samples.268 It is rare and does not appear in the 
Exome Aggregation Consortium (ExAC) dataset.161 In silico tools predict a damaging or function 
altering effect.269–271 No other family members were available for genetic testing. 
 
Kidney tumours, typically with a hybrid chromophobe/oncocytic RCC histopathology, are a major 
feature of BHD syndrome. RCC has been reported in TP53 pathogenic variant carriers though no firm 
association has been made.56 It is noted that the median age at diagnosis of renal tumours in carriers of 
pathogenic FLCN variants (48 years)259 is older than the age at onset of these tumours in this case, 
which might suggest a role for the TP53 variant but rarity of BHD prevents accurate assessment of 
expected age of diagnosis. The relationship between colorectal cancer and BHD syndrome is 
controversial258,272 but an increased risk of colorectal cancer has been reported with ulcerative colitis 
(though typically in those with disease for >10 years273) and also in carriers of pathogenic TP53 
variants.274 To the author’s knowledge, oesophageal cancers have not been reported in carriers of 
pathogenic FLCN variants but have occurred in Li-Fraumeni syndrome (LFS) families, though again 
the association with this condition is not clear.56,190  
 
FLCN/MSH2 
A 53 year old woman presented with rectal adenocarcinoma and had a history of spontaneous 
pneumothorax at age 46 years. Her father had developed colon cancer at 67 years and had several 
pneumothoraces (first at age 41 years). Immunohistochemistry performed on the proband’s rectal 
tumour showed no abnormality but her father’s colon cancer demonstrated loss of staining for MSH2 
and MSH6 proteins. Constitutional genetic testing in the proband did not detect a pathogenic 
mismatch repair gene variant but a truncating FLCN variant (ENST00000285071 c.1285delC 
p.(His429Thrfs*39)) was identified. Three siblings had phenotypic similarities to the proband. A 
sister developed a pneumothorax at age 37 and had facial fibrofolliculomas. She also developed 
endometrial cancer at 52 years. Genetic testing demonstrated the familial FLCN variant and a 
truncating MSH2 variant (ENST00000233146 c.892C>T p.(Gln298*)). The twin sister of this 
individual had pneumothoraces, RCC and colorectal polyps. She also carried both variants, as did a 
brother with facial fibrofolliculomas. 
 
Colorectal and endometrial cancers are characteristic of Lynch syndrome (frequently caused by MSH2 
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variants) and the ages of diagnosis seen in this family are typical.68 However, the proband did not 
carry the pathogenic MSH2 variant detected in her siblings and may represent a phenocopy. Also, a 
role of the FLCN variant in the development of colorectal tumours in the family cannot be 
excluded.258,272 Fibrofolliculomas, RCC and pneumothoraces are not associated with Lynch 
syndrome.275 
 
XPA/MLH1 
A male proband presented with a mucinous caecal cancer at age 65 years and a metachronous sigmoid 
colon cancer in his remaining large bowel at 67 years.  He was one of eight siblings whose father had 
developed colon cancer at age 42 years, but there was no other family history of Lynch syndrome-
related tumours.  His parents were not knowingly consanguineous but were both from the same small 
community in India. The proband had been clinically diagnosed in early childhood with Xeroderma 
Pigmentosum (XP).  His sister had a similar pattern of skin tumours but no internal malignancies.  
Neither of his parents had any reported skin abnormalities.  On examination his sun-exposed skin 
showed considerable signs of ultraviolet damage (e.g. severe freckling and loss of pigment) but no 
other features of XP such as neurological or intellectual deficits.  His skin tumours over the previous 
20 years had included a squamous carcinoma in an actinic keratosis, several seborrheic keratoses, two 
keratoacanthomata/squamous carcinomas, junctional nevi, a squamous carcinoma and two lentigo 
malignae (premalignant melanoma).  Immunohistochemistry demonstrated loss of MLH1 and PMS2 
expression in both colon cancers.  Constitutional genetic testing revealed MLH1 ENST00000231790 
c.306G>T p.(Glu102Asp) (classed as likely pathogenic276).  Fibroblasts from a skin biopsy were 
tested for XP, which showed reduced levels of nucleotide excision repair. He therefore did not have 
mild XP variant (XP-V) as might be expected, but rather had mild variant XP-A, consistent with 
survival into his 60s.  Constitutional genetic analysis revealed a homozygous XPA intron 4 splice 
variant (ENST00000375128 c.620+8A>G). Molecular analysis of his various tumours is summarised 
in Table 5.9. 
 
Table 5.9 - Molecular analysis of tumours from XPA/MLH1 case 
Tumour 
MLH1 
IHC 
PMS2 
IHC 
MSI 
assessment 
Mucinous caecal adenocarcinoma Loss Loss High 
Sigmoid colon adenocarcinoma Loss Loss High 
Squamous carcinoma (#1) Present Present Stable 
Squamous carcinoma (#2) Present Present Stable 
Lentigo maligna Present Present High 
Actinic keratosis Present Present High 
Squamous carcinoma in actinic keratosis  Present Present High 
 
MSI - Microsatellite instability. IHC - Immunohistochemistry  
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The prevalence of microsatellite instability (MSI) in skin tumours associated with XP is unknown. A 
contribution of the MLH1 variant to the dermatological phenotype may be suggested by the MSI in 
some of the skin tumours but the presence of normal MLH1 and PMS2 expression goes against this.  
Skin tumours are associated with Lynch syndrome but these are characteristically sebaceous in origin, 
which were not observed in this case. 
 
NF1/BRCA2 
A female patient with Neurofibromatosis type 1, having one café au lait patch, numerous cutaneous 
neurofibromas, possible Lisch nodules and a MPNST, was diagnosed with ductal breast carcinoma at 
age 48 years and subsequently went on to develop a cutaneous melanoma at age 57 years.  
Constitutional genetic testing revealed both NF1 ENST00000356175 c.6792C>G p.(Tyr2264*) and 
BRCA2 ENST00000544455 c.5213_5216del p.(Thr1738Ilefs*2).277 Pathogenic variants in both genes 
can be associated with breast cancer278 but the risk is much higher for those affecting BRCA2. The 
breast cancer could be consistent with either syndrome and no tumour analysis was reported that 
could help determine which gene was more significant in its initiation. 
 
SDHA/PALB2 
A mother and son presented with GIST at age 66 and 34 respectively with the mother also developing 
breast cancer at age 70 years. Histology and immunohistochemistry of both GISTs showed a mixed 
epithelioid picture (expected in succinate dehydrogenase deficient GIST) and loss of SDHB staining, 
indicating inactivation of a component of the succinate dehydrogenase (SDH) complex (Figure 5.1). 
Constitutional genetic testing of SDHX genes showed a nonsense variant in SDHA 
(ENST00000264932 c.1532C>T (p.R512*)) in both individuals. These variants were confirmed by 
WGS undertaken on a research basis, which also identified PALB2 ENST00000261584 c.3113G>A 
(p.Trp1038*) in both participants.  
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Figure 5.1 - Histology and SDHB immunohistochemistry on SDHA/PALB2 diad. A and C show 
haematoxylin and eosin staining from son and mother respectively. B and D show loss of SDHB 
immunostaining in son and mother respectively. 
 
 
 
 
 
Most GIST occurrences are sporadic and familial forms (known to have causes including 
constitutional variants in KIT, PDGFRA, NF1 and SDHX genes) are rare.279,280 This diad represents a 
further reported case of SDH deficient familial GIST. LOH analysis was performed on DNA from 
both tumours to confirm this and also investigate whether there was any evidence for the PALB2 
variant contributing to tumourigenesis. Loss of the SDHA wild type allele was confirmed with a 
panel-based sequencing assay where variant allele fraction (VAF) was 0.42 in the blood sample from 
the mother and 0.92 in her tumour sample. The son’s samples showed VAF’s of 0.57 in blood and 
0.85 in tumour (Figure 5.2). Loss of the wild type PALB2 allele, which may have indicated a 
contribution to increased penetrance of the SDHA variant and occurrence in two family members, was 
not observed (Figure 5.3). The PALB2 variant is likely to have contributed to the breast cancer 
occurring in the mother but be incidental to the GIST occurrences. However, absence of LOH does 
not necessarily imply absent contribution (see below) and further tumour studies could potentially be 
revealing. Mutational signatures are derived from analysis of somatic single nucleotide variants and 
can provide insights into mutagenic processes leading to cancer in various tumour types.281 One 
signature is associated with biallelic inactivation of BRCA1 and BRCA2 but has also has been 
demonstrated in breast282 and pancreatic283 cancers from individuals with constitutional PALB2 
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truncating variants. Analysis of signatures from these GISTs may show a similar signature but this 
appears unlikely given that the PALB2 variants are not somatically biallelic and that GIST is not 
known to be associated with PALB2 variants. Intriguingly however, succinate accumulation (which 
results from loss of succinate dehydrogenase function) has been reported to suppress DNA repair by 
homologous recombination.284 This process is normally contributed to by functional PALB2 protein 
product and loss of function variants in that gene lead to deficient repair. Feasibly, a concurrent SDHA 
variant could exacerbate that deficiency and promote tumourigenesis synergistically. 
 
Figure 5.2 - Loss of SDHA wild type allele in familial GISTs 
 
 
Figure 5.3 - Retention of PALB2 wild type allele in familial GISTs 
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5.3.2 – Cases identified through whole genome sequencing-based comprehensive cancer 
predisposition gene analysis in multiple primary tumours series 
Subsequently described cases were identified through analysis of WGS data from MPT individuals as 
described in Chapter 4. 
 
PMS2/BMPR1A 
An individual with colorectal adenocarcinoma at age 50 years and breast cancer at 57 years carried 
PMS2 frameshift (ENST00000265849 c.741-742insTGAAG (p.Pro247_Ser248fs)) and BMPR1A 
nonsense (ENST00000372037 c.730C>T (p.Arg244*)) variants. Immunohistochemistry of the bowel 
tumour showed loss of PMS2 expression and microsatellite instability was demonstrated, leading to 
diagnostic sequencing of PMS2. There was no family history of neoplasia other than an ovarian 
cancer in a second degree relative after age 70 years. They had previously undergone surveillance 
colonoscopy for inflammatory bowel disease resulting in identification of a number of polyps but 
there was no evidence from histology reports that these were juvenile polyps. Given the results of the 
tumour studies and a polyp phenotype that is not highly characteristic of Juvenile Polyposis, the 
PMS2 variant would appear likely to be causative of the colorectal adenocarcinoma but the role of 
either variant in development of the breast cancer is not clear. 
 
MAX/FH 
An MPT case with bilateral phaeochromocytoma at age 16 and 35 years with no reported family 
history of neoplasia was identified with FH (ENST00000366560 c.521C>G (p.Pro174Arg)) and MAX 
(ENST00000358664 c.1A>G (p.Met1Val)) variants.285 The latter variant is predicted to abolish the 
MAX initiation codon and analysis of tumour tissue from an individual carrying it has previously 
demonstrated loss of the wild type allele and lack of full length MAX protein.286 It is easier to 
attribute the diagnosed phaeochromocytoma to the truncating MAX variant but evidence for the role of 
FH in this tumour type is accumulating209,210 and this variant may have contributed to tumourigenesis 
in either or both neoplasms. 
 
FLCN/CHEK2 
A further individual had the CHEK2 ENST00000328354 c.1100delC (p.Thr367Metfs) variant 
(annotated in these data as ENST00000382580 c.1229delC (p.Thr410fs)) as well as a chromosome 
17:10 translocation with a breakpoint within intron 9-10 of FLCN. Their phenotype included multiple 
cutaneous fibrofolliculomas and clear cell renal carcinoma at age 53 years. They had previously 
received a clinical diagnosis of BHD syndrome but sequencing of FLCN had not revealed any 
significant variants. The translocation appears to have been the causative factor for the 
fibrofolliculomas and renal cell carcinoma diagnosed in in this individual and the role of the CHEK2 
variant is unlikely to be significant in the development of the diagnosed tumours. 
113 
 
 
5.4 - Combination with cases from literature review 
Combining the cases described above with those identified through literature review, 124 MINAS 
cases involving 29 CPGs were identified200,239–252,254,256,257,287–319 (see Figure 5.4 and Table 5.10). 46 
gene combination types were noted but only nine (BRCA1/BRCA2, BRCA1/MLH1, BRCA1/CHEK2, 
BRCA2/CHEK2, FLCN/MSH2, APC/MSH2, ATM/BRCA1, BMPR1A/MSH2 and APC/MLH1) 
occurred in more than one family. This may reflect ascertainment bias (certain genes are commonly 
screened for simultaneously), common founder mutations present in specific populations and 
hereditary breast cancer, followed by colorectal cancer, being the most common indication for cancer 
genetic assessment.173 Indeed, 13 individuals had a combination of two of the three Ashkenazi 
founder mutations in BRCA1 and BRCA2.  
 
Figure 5.4 - Combinations of pathogenic gene variants in MINAS cases from present report and 
literature review 
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Table 5.10 - Multilocus Inherited Neoplasia Alleles Syndrome – details of published cases incorporating those in this report 
Reference 
Kindred 
within 
report 
Sex Gene 1 Gene 1 variant  Gene 2 Gene 2 variant Clinical features with age in years at which noted (if known) 
Goehringer et al. 
2017 
1 M APC 
ENST00000257430 c.3103dupC 
(p.Gln1035Profs*13) 
BRCA2 
ENST00000544455 
c.516_516+1delGGinsT 
(p.Lys172Asnfs) 
Intestinal polyposis, 35y†; Desmoid tumour (multiple), 36y†; 
Pancreatic adenocarcinoma, 54y‡ 
Kashiwada et al. 
2012 
1 F APC 
ENST00000257430 c.637C>T 
p.(Arg213*) 
FLCN 
ENST00000285071 
c.1285dup 
p.(His429Profs*27) 
Facial papules <28y‡; Colon carcinoma and multiple colon 
polyps 28y†; Recurrent pneumothoraces x4. Pulmonary cysts 
28y (first one)‡ 
Lindor et al. 2012 1 M APC 
ENST00000257430 c.694C>T 
p.(Arg232*) 
MLH1 Deletion exons 16-19 
Rectal carcinoma and multiple colon polyps 14y*; Jejunal 
adenocarcinoma x6 28y x3, 34y, 44y, 52y (Loss of MLH1 and 
PMS2 on IHC)∆; Duodenal adenocarcinoma 54y*; Congenital 
hypertrophy of retinal pigment epithelium 54y†; Squamous 
cell carcinoma. Multiple facial∆; Pilomatricoma. Scalp 54y†; 
Sebaceous adenoma 54y (Loss of MLH1 and PMS2 on IHC)‡ 
Scheenstra et al. 
2003 
1 M APC 
ENST00000257430 c.3927_3931del 
p.(1309Aspfs*4) 
MLH1 
ENST00000231790 
c.677G>A 
p.(Arg226Gln). Affects 
splicing. 
Multiple colon polyps (100's) 10†; Tubular adenomas with 
dysplasia 10y (Loss of MLH1 on IHC)* 
Soravia et al. 
2005 
1 M APC 
ENST00000257430 c.3471-
3474delGAGA p.(Glu1157Aspfs*7) 
MSH2 
ENST00000233146 
c.1192dupG 
p.(Ala398Glyfs*19) 
Colon polyps x5. 4 adenomas 24y (1 dysplastic MSI high. Loss 
of MSH2 and MSH6 on IHC)†; Colon adenocarcinoma. Right 
colon 25y*; Gastric/duodenal adenoma x30 25y*; Desmoid 
tumour. Mesenteric 26y† 
Uhrhammer and 
Bignon. 2008 
1 M APC 
ENST00000257430 
c.3183_3187delACAAA p.(Gln1062*) 
MSH2 
ENST00000233146 
c.255_256del 
p.(Phe85Leufs*14) 
Colon cancer 16y* 
Kilmartin et al. 
1996 
1 M APC 
ENST00000257430 c.3340 C>T 
p.(Arg1114*) 
VHL 
Gene deletion (in 
offspring)  
Retinal haemangioma x2 21y‡; Cerebellar 
haemangioblastoma 41y‡ Rectal carcinoma and multiple 
colonic polyps 41y† 
Sokolenko et al. 
2014 
3 F ATM 
ENST00000278616 c.5932G>T 
(p.Glu1978*) 
BRCA1 
ENST00000357654 
c.181T>G (p.Cys61Gly) 
Breast cancer, 40y* 
Sokolenko et al. 
2014 
4 F ATM 
ENST00000278616 c.5932G>T 
(p.Glu1978*) 
BRCA1 
ENST00000357654 
c.181T>G (p.Cys61Gly) 
Breast cancer, 42y* 
Schrader et al. 
2016 
1 F ATM 
ENST00000278616 c.8793T>A 
(p.C2931*) 
CDH1 
ENST00000261769 
c.1999delC (p.L667fs*12 
Breast carcinoma 70-79y* (LOH ATM, CDH1 variant lost in 
tumour) 
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Sokolenko et al. 
2014 
5 F ATM 
ENST00000278616 c.5932G>T 
(p.Glu1978*) 
CHEK2 del5395 (large deletion) Breast cancer, 67y* 
Crawford et al. 
2017 
1 F ATM ENST00000278616 c.901+1G >A PALB2 
ENST00000261584 
c.2167_2168delAT 
(p.Met723Valfs) 
Ovarian cancer∆ 
Schrader et al. 
2016 
1 M ATM 
ENST00000278616 c.9139C>T 
(p.R3047*) 
RAD51D 
ENST00000345365 
c.803G>A (p.W268*) 
Non-small cell lung cancer 50-59y∆ (No LOH either variant) 
This report 1 F BMPR1A 
ENST00000372037 c.730C>T 
(p.Arg244*) 
PMS2 
ENST00000265849 
c.741-742insTGAAG 
(p.Pro247_S248fs) 
Colorectal carcinoma, 50y*; Breast, 57y∆ 
Silva-Smith et al. 
2018 
1 M BMPR1A ENST00000372037 c.25A > T (p.Arg9*) PMS2 
ENST00000265849 
c.1882C>T (p.Arg628*) 
Colorectal adenocarcinoma, 39y* (Loss of PMS2 
immunostaining); Bladder transitional cell carcinoma, 39y‡ 
Augustyn et al. 
2011 
1 F BRCA1 
ENST00000357654 c.1961delA 
p.(Lys654Serfs*47) 
BRCA2 
ENST00000544455 
c.1672delC 
p,(Ile558Leufs*15) 
Ovarian serous carcinoma with papillary features. Bilateral 
50y* 
Augustyn et al. 
2011 
2 F BRCA1 
ENST00000357654 c.5266dupC 
p.(Gln1756Profs*74) 
BRCA2 
ENST00000544455 
c.4829_4830del 
p.(Val1610Glyfs*4) 
Breast cancer 40y (Triple negative histology)* 
Bell et al. 2002 1 F BRCA1 
ENST00000357654 c.5266dupC 
p.(Gln1756Profs*74) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 33y (LOH BRCA2. No LOH BRCA1)‡; Breast 
cancer 44y (LOH BRCA2. No LOH BRCA1)‡; Breast cancer 47y 
(LOH BRCA1. No LOH BRCA2)† 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
No features 
Caldes 2002 2 M BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
Prostate cancer 66y* 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
Breast cancer 70y* 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
Breast cancer 66y* 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
Breast cancer 28y (No LOH BRCA1 or BRCA2)* 
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Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
No features 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
No features 
Caldes 2002 1 F BRCA1 
ENST00000357654 c.5123C>A 
p.(Ala1708Glu) 
BRCA2 
ENST00000544455 
c.6275_6276del 
p.(Leu2092Profs*7) 
No features 
Choi et al. 2006 1 F BRCA1 
ENST00000357654 
c.1504_1508delTTAAA 
p.(Leu502Alafs*2) 
BRCA2 
ENST00000544455 
c.2798_2799delCA 
p.(Thr933Argfs*2) 
Breast infiltrating duct carcinoma 26y* 
Choi et al. 2006 2 F BRCA1 
ENST00000357654 c.4981G>T 
p.(Glu1661*) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast infiltrating duct carcinoma 33y* 
Heidemann et al. 
2012 
1 F BRCA1 
ENST00000357654 c.5266dup 
p.(Gln1756Profs*74) 
BRCA2 
ENST00000544455 
c.5645C>G p.(Ser1882*) 
Breast cancer 37y*; Breast cancer 39y*; Ovarian cancer 63y* 
Heidemann et al. 
2012 
2 M BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5718_5719delCT 
(p.Ser1907Leufs*4) 
No features 
Heidemann et al. 
2012 
2 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5718_5719delCT 
(p.Ser1907Leufs*4) 
Breast cancer 32y* 
Heidemann et al. 
2012 
3 F BRCA1 
ENST00000357654 c.962G>A 
p.(Trp321*) 
BRCA2 
ENST00000544455 c. 
2231C>G p.(Ser744*) 
Breast cancer 31y*; Breast cancer (contralateral) 35y* 
Heidemann et al. 
2012 
4 F BRCA1 
ENST00000357654 c.3910delG 
p.(Glu1304Lysfs*3) 
BRCA2 
ENST00000544455 
c.2830A>T p.(Lys944*) 
Breast cancer 39y* 
Heidemann et al. 
2012 
5 F BRCA1 ENST00000357654 c.5277+1delG BRCA2 
ENST00000544455 
c.658_659delGT 
p.(Val220Ilefs*4) 
Colorectal cancer. Caecal 58y∆; Ovarian cancer 61y* 
Heidemann et al. 
2012 
5 M BRCA1 ENST00000357654 c.5277+1delG BRCA2 
ENST00000544455 
c.658_659delGT 
p.(Val220Ilefs*4) 
No features 
Heidemann et al. 
2012 
6 F BRCA1 
ENST00000357654 
c.3700_3704delGTAAA 
p.(Val1234Glnfs*8) 
BRCA2 
ENST00000544455 
c.1813_1814insA 
p.(Ile605Asnfs*11) 
Cervical cancer 26y∆; Breast cancer 40y* 
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Leegte et al. 
2005 
1 F BRCA1 
ENST00000357654 c.2685_2686delAA 
p.(Pro897fs*5) 
BRCA2 
ENST00000544455 
c.3487delG p. 
(Asp1163Ilefs*5) 
Ovarian papillary serous cystadenocarcinoma 40y (LOH 
BRCA2)*; Breast infiltrative ductal carcinoma 45y (LOH 
BRCA1)* 
Leegte et al. 
2005 
2 F BRCA1 
ENST00000357654 c.2685_2686delAA 
p.(Pro897fs*5) 
BRCA2 
ENST00000544455 
c.4449delA 
p.(Asp1484Thrfs*2) 
Breast cancer. Ductal 28y* 
Leegte et al. 
2005 
3 F BRCA1 
ENST00000357654 c.66_67delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
No features 
Leegte et al. 
2005 
4 F BRCA1 
ENST00000357654 c.5263_5264insC 
p.(Ser1756Profs*74) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast invasive lobular carcinoma 51y* 
Liede et al. 1998 1 F BRCA1 
ENST00000357654 c.2389G>T 
p.(Glu797*) 
BRCA2 
ENST00000544455 
c.3067_3068insA 
p.(Asn1023Lysfs*3) 
Breast adenocarcinoma 35y* 
Loubser et al. 
2012 
1 M BRCA1 
ENST00000357654 c.2641G>T 
p.(Glu881*) 
BRCA2 
ENST00000544455 
c.7934delG 
p.(Arg2645Asnfs*3) 
No features 49y 
Loubser et al. 
2012 
1 F BRCA1 
ENST00000357654 c.2641G>T 
p.(Glu881*) 
BRCA2 
ENST00000544455 
c.7934delG 
p.(Arg2645Asnfs*3) 
Breast ductal carcinoma 42y 
Moslehi et al. 
2000 
1 F BRCA1 
ENST00000357654 c.66_67delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
No features 36y 
Musolino et al. 
2005 
1 F BRCA1 
ENST00000357654 c.4285_4286insG 
p.(Tyr1429*) 
BRCA2 
ENST00000544455 
c.7738C>T p.(Gln2580*) 
Breast infiltrating duct carcinoma 37y (Triple negative 
histology)* 
Noh et al. 2011 1 F BRCA1 
ENST00000357654 c.3746_3747insA 
p.(Glu1250Argfs*5) 
BRCA2 
ENST00000544455 
c.6952_6953del 
p.(Arg2318Lysfs*21) 
Breast infiltrating duct carcinoma 26y* 
Noh et al. 2011 2 F BRCA1 
ENST00000357654 c.390C>A 
p.(Tyr130*) 
BRCA2 
ENST00000544455 
c.3018delA 
p.(Gly1007Valfs*36) 
Breast infiltrating duct carcinoma 45y* 
Noh et al. 2011 3 F BRCA1 
ENST00000357654 
c.5030_5033delCTAA 
p.(Thr1677Ilefs*2) 
BRCA2 
ENST00000544455 
c.1399A>T p.(Lys467*) 
Breast infiltrating duct carcinoma 35y* 
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Pilato et al. 2010 1 F BRCA1 
ENST00000357654 c.5266dup 
p.(Gln1756Profs*10) 
BRCA2 
ENST00000544455 
c.5796_5797delTA 
p.(His1932Glnfs*12) 
Breast intraductal carcinoma 38y (Triple negative histology)*; 
Ovarian papillary adenocarcinoma. Bilateral 42y* 
Zuradelli et al. 
2010 
2 F BRCA1 
ENST00000357654 c.3916_3917delTT 
p.(Leu1306Aspfs*23) 
BRCA2 
ENST00000544455 
c.5380delG 
p.(Val1794*) 
Breast ductal cancer. Medullary type 30y (ERPR-ve)*; Ovarian 
serous papillary carcinoma 36y* 
Zuradelli et al. 
2010 
3 F BRCA1 
ENST00000357654 c.1687C>T 
p.(Gln563*) 
BRCA2 
ENST00000544455 
c.6469C>T p.(Gln2157*) 
Breast infiltrating duct carcinoma 2x foci 46y (1 lymph node 
ERPR -ve. 1 lymph node ERPR+ve)* 
Zuradelli et al. 
2010 
4 F BRCA1 
ENST00000357654 c.2405_2406delTG 
p.(Val802Glufs*7) 
BRCA2 
ENST00000544455 
c.4285C>T p.(Gln1429*) 
Breast ductal carcinoma 52y (Triple negative histology)*; 
Ovarian serous adenocarcinoma. Bilateral 52y* 
Friedman et al. 
1998 
1 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 38y* 
Friedman et al. 
1998 
2 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Ovarian cancer 57y* 
Friedman et al. 
1998 
3 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
No features 
Friedman et al. 
1998 
4 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 45y* 
Ramus et al. 
1997 
1 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 48y*; Ovarian cancer 50y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 39y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 41y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer. Bilateral 34y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 55y*; Breast cancer (contralateral) 56y* 
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Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
No features 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 40y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer 33y*; Breast cancer (contralateral) 49y* 
Leegte et al. 
2005/Frank et al. 
2002 
Unknown F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
No features 61y 
Randall et al. 
1998 
1 F BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer. Multifocal lobular carcinoma 30y (LOH 
BRCA1)*; Ovarian cancer 41y (LOH BRCA1 and BRCA2)* 
Meynard et al. 
2017 
1 F BRCA1 
ENST00000357654 c.1016dupA 
(p.V340Glyfs*6) 
BRCA2 
ENST00000544455 
c.6814delA 
(p.Arg2272Glufs) 
Bilateral breast carcinoma, 46y* 
Nomizu et al. 
2015 
1 F BRCA1 
ENST00000357654 c.188T>A 
(p.Leu63*) 
BRCA2 
ENST00000544455 
c.5576delTTAA 
(p.Ile1861fs) 
Breast carcinoma, 55y* (Negative immunostaining for BRCA1 
and BRCA2) 
Nomizu et al. 
2015 
1 F BRCA1 
ENST00000357654 c.188T>A 
(p.Leu63*) 
BRCA2 
ENST00000544455 
c.5576delTTAA 
(p.Ile1861fs) 
Breast cancer, 41y*; Endometrial cancer, 46y∆ 
Vietri et al. 2013 1 F BRCA1 ENST00000357654 c.547+2T>A BRCA2 
ENST00000544455 
c.2830A>T (p.Lys944*) 
Bilateral breast cancer, 43y* 
Vietri et al. 2013 1 M BRCA1 ENST00000357654 c.547+2T>A BRCA2 
ENST00000544455 
c.2830A>T (p.Lys944*) 
No tumours, 72y 
Vietri et al. 2013 1 F BRCA1 ENST00000357654 c.547+2T>A BRCA2 
ENST00000544455 
c.2830A>T (p.Lys944*) 
Breast cancer,39y* 
Schrader et al. 
2016 
1 M BRCA1 
ENST00000357654 c.68_69delAG 
p.(Glu23Valfs*17) 
BRIP1 
ENST00000259008 
c.1315C>T (p.R439*) 
Testicular seminoma 20-29y∆ (No LOH either variant) 
Sokolenko et al. 
2014 
1 F BRCA1 
ENST00000357654 c.5266dupC 
p.(Gln1756Profs*74) 
CHEK2 del5395 (large deletion) Breast cancer, 52y (LOH CHEK2, No LOH BRCA1)* 
Sokolenko et al. 
2014 
2 F BRCA1 
ENST00000357654 
c.3247_3251delATGCT (p.Met1083fs) 
CHEK2 del5395 (large deletion) Breast cancer, 42y* 
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Sokolenko et al. 
2014 
6 F BRCA1 
ENST00000357654 c.181T>G 
(p.Cys61Gly) 
CHEK2 
ENST00000382580 
c.1229delC (p.Thr410fs) 
Breast cancer, 58y* 
Sokolenko et al. 
2014 
7 F BRCA1 
ENST00000357654 c.5266dupC 
p.(Gln1756Profs*74) 
CHEK2 
ENST00000382580 
c.396+1G>T 
Breast cancer, 54y* 
Pedroni et al. 
2013 
1 F BRCA1 
ENST00000357654 c. 181T>G 
p.(Cys61Gly) 
MLH1 
ENST00000231790 
c.1489dupC 
p.(Arg497Profs*6) 
Breast cancer 35y (Loss of MLH1 on IHC. LOH MLH1 and 
BRCA1)†; Endometrial carcinoma (Loss of MLH1 on IHC. LOH 
MLH1)‡; Ovarian carcinoma 39y (Loss of MLH1 on IHC. LOH 
MLH1)*; Renal clear cell carcinoma 39y∆; Breast cancer 
(contralateral) 46y (Loss of MLH1 on IHC. LOH and BRCA1)‡ 
Kast et al. 2012 1 F BRCA1 
ENST00000357654 c.213-12A>G, 
p.(Arg71Serfs*21). Cryptic splice site 
MSH6 
ENST00000234420 
c.515dup 
p.(Leu173Thrfs*9) 
Endometrial endometrioid adenocarcinoma 46y (Loss of 
MSH6 on IHC)‡ 
Campos et al. 
2013 
1 F BRCA1 
ENST00000357654 c.4107_4110dup 
p.(Gly1371Ilefs*4) 
NF1 
ENST00000356175 
c.4120C>T p.(Gln1374*) 
Café au lait patches multiple cutaneous neurofibromas and 
Axillary/inguinal freckling in childhood‡; Breast infiltrating 
duct carcinoma 35y‡ 
Pern et al. 2012 1 F BRCA1 
ENST00000357654 c.927delA 
p.(Lys309Asnfs*5) 
PALB2 
ENST00000261584 
c.756dup 
p.(Leu253Serfs*4) 
Uterine myomas <65y∆; Meningioma <65y∆; Breast invasive 
ductal carcinoma. Multifocal 65y (Triple negative histology)* 
Eliade et al. 2017 1 F BRCA1 
ENST00000357654 c.1480C>T 
(p.Gln494*) 
PMS2 
ENST00000265849 
c.251-2A>T 
Breast cancer, 65y†; Ovarian cancer, 72y† 
Bell et al. 2014 1 F BRCA1 
ENST00000357654 c.81-?_134 + ? del 
(p.Cys27*) (exon 3 deletion) 
TP53 
ENST00000269305 
c.375 + 2T > C 
Breast carcinoma, 20y* 
Smith et al. 2008 1 F BRCA1  
ENST00000357654 
c.3331_3334delCAAG 
p.(Gln1111Asnfs*5) 
BRCA2 
ENST00000544455 
c.631+2T>G 
Breast cancer 34y*; Colorectal carcinoma. Transverse. (No 
loss of MMR proteins on IHC. No microsatellite instability) 
35y∆; Breast cancer 53y* 
Smith et al. 2008 1 F BRCA1  
ENST00000357654 
c.3331_3334delCAAG 
p.(Gln1111Asnfs*5) 
BRCA2 
ENST00000544455 
c.631+2T>G 
No features 65y 
Tesoriero et al. 
1999 
1 F BRCA1  
ENST00000357654 c.3769_3770delGA 
p.(Glu1257Glyfs*9) 
BRCA2 
ENST00000544455 
c.5946delT 
p.(Ser1982Argfs*22) 
Breast cancer <40y (LOH BRCA2)* 
Zuradelli et al. 
2010 
1 F BRCA1  
ENST00000357654 c.835delC 
p.(His279Metfs*19) 
BRCA2 
ENST00000544455 
c.8195T>G p.(Leu2732*) 
Breast carcinoma. Metaplastic 43y (Triple negative histology)* 
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Borg et al. 2000 1 F BRCA1  
ENST00000357654 
c.3047_3048insTGAGA 
p.(Asn1018Metfs*8) 
MLH1 
ENST00000231790 
c.131C>T p.(Ser44Phe). 
Additional non-
pathogenic variant 
c.1321G>A 
p.(Ala441Thr) 
Breast invasive ductal carcinoma 35y (MSI low. ERPR -ve)† 
Eliade et al. 2017 3 F BRCA2 
ENST00000544455 c.6952C>T 
(p.Arg2318*) 
CHEK2 
ENST00000328354 
c.1427C>T 
(p.Thr476Met). 7 
ClinVar reports LP 
(more recent), 7 reports 
VUS 
No tumours 
Francies et al. 
2015 
1 F BRCA2 
ENST00000544455 
c.5213_5216delCTTA (p.Thr1738Ilefs) 
CHEK2 
ENST00000382580 
c.1229delC (p.Thr410fs) 
Breast cancer, <50y* 
Schrader et al. 
2016 
1 F BRCA2 
ENST00000544455 c.3846_3847delTG 
(p.V1283fs*2) 
CHEK2 
ENST00000328354 
c.793-1G>A 
Breast carcinoma 50-59y* (No LOH either variant) 
Ghataorhe et al. 
2007 
1 F BRCA2 
ENST00000544455 
c.2808_2811delACAA 
p.(Ala938Profs*21) 
MEN1 
ENST00000312049 c. 
1159+1delGT  
 Abnormal secretory parathyroid gland 34y‡; Pancreatic mass. 
Unknown histology. Non-functional 35y* 
Ghataorhe et al. 
2007 
1 F BRCA2 
ENST00000544455 
c.2808_2811delACAA 
p.(Ala938Profs*21) 
MEN1 
ENST00000312049 c. 
1159+1delGT  
Cushing syndrome (implied pituitary origin) 10y‡; 
Hypercalcaemia (implied hyperparathyroidism) 31y‡ 
Ghataorhe et al. 
2007 
1 M BRCA2 
ENST00000544455 
c.2808_2811delACAA 
p.(Ala938Profs*21) 
MEN1 
ENST00000312049 c. 
1159+1delGT  
Parathyroid hyperplasia 56y‡; Breast cancer 60y† 
Thiffault et al. 
2004 
1 F BRCA2 
ENST00000544455 c.314T>G 
p.(Leu105*) 
MSH2 
ENST00000233146 
c.1277_1386del (Exon 8 
deletion) 
Lobular and ductal carcinoma in situ 32y (ERPR +ve)†; 
Endometrioid adenocarcinoma 40y (No MMR deficiency on 
IHC. MSI low)∆; Colon villotubular adenoma. 40 (Loss of MSH2 
on IHC. MSI high)‡ 
This report 1 F BRCA2 
ENST00000544455 c.5213_5216del 
p.(Thr1738Ilefs*2) 
NF1 
ENST00000356175 
c.6792C>G p.(Tyr2264*) 
Breast ductal carcinoma 48y*; Cutaneous melanoma 57y†; 
Multiple cutaneous neurofibromas‡; Malignant peripheral 
nerve sheath tumour‡; Café au lait patch‡; Possible Lisch 
nodules‡. 
Ahlborn et al. 
2015 
1 F BRCA2 
ENST00000544455 c.9648G>A 
(p.Leu3216=) (abnormal splicing) 
RAD51C 
ENST00000337432 
c.773G>A (p.Arg258His) 
No tumours, 38y 
Monnerat et al. 
2007 
1 F BRCA2 
ENST00000544455 c.4889C>G 
p.(Ser1630*) 
TP53 
ENST00000269305 
c.329G>T p.(Arg110Leu) 
Cutaneous malignant melanoma 65y‡; Breast cancer 69y*; 
Ovarian cancer 69y*; Colon cancer 74y‡ 
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Schrader et al. 
2016 
1 F BRIP1 
ENST00000259008 c.2392C>T 
(p.R798*) 
PMS2 
ENST00000265849 
c.137G>T (p.Ser46Ile) 
Breast carcinoma 80-89y∆ (No LOH PMS2, BRIP1 variant lost 
in tumour) 
Schrader et al. 
2016 
1 F CDH1 
ENST00000261769 
c.1090_1105dupACAGTCACTGACACCA 
(p.D370fs*3) 
CHEK2 
ENST00000382580 
c.1229delC (p.Thr410fs) 
Oesophageal adenocarcinoma 50-59y∆ (No LOH CHEK2, CDH1 
variant lost in tumour) 
Njoroge et al. 
2017 
1 F CDH1 
ENST00000261769 c.2287G>T 
(p.Glu763*) 
PMS2 
ENST00000265849 
c.2445+1G>T 
Breast carcinoma (lobular), 51y† (loss of e-cadherin 
immunostaining); Thyroid papillary carcinoma, 52y∆ 
This report 1 M CHEK2 
ENST00000382580 c.1229delC 
(p.Thr410fs) 
FLCN (SV) 
ENST00000285071 
17:10 translocation with 
a breakpoint within 
intron 9-10 
Fibrofolliculoma (multiple), 18y‡; Renal cell carcinoma, 53y‡ 
Crawford et al. 
2017 
2 F CHEK2 
ENST00000382580 c.1229delC 
(p.Thr410fs) 
RAD51C 
ENST00000337432 
c.397C>T (p.Gln133*) 
Ovarian cancer‡ 
Schrader et al. 
2016 
1 F CHEK2 
ENST00000328354 c.470T>C 
(p.Iel157Thr). 12 ClinVar reports P/LP, 
3 reports VUS 
TP53 
ENST00000269305 
c.505_506delAT 
(p.M169fs*11) 
Soft tissue sarcoma 50-59y‡ (CHEK2 variant lost in tumour) 
This report 1 F FH 
ENST00000366560 c.521C>G 
(p.Pro174Arg) 
MAX 
ENST00000358664 
c.1A>G (p.Met1Val) 
Phaeochromocytoma, 16y*; Phaeochromocytoma, 35y* 
This report 1 F FLCN 
ENST00000285071 c.1285delC 
p.(His429Thrfs*39) 
MSH2 
ENST00000233146 
c.892C>T p.(Gln298*) 
Pneumothorax 37y†; Endometrial cancer 52y‡.  
This report 1 F FLCN 
ENST00000285071 c.1285delC 
p.(His429Thrfs*39) 
MSH2 
ENST00000233146 
c.892C>T p.(Gln298*) 
Renal cell carcinoma†; Colorectal polyps‡; Multiple 
pneumothoraces†. 
This report 1 M FLCN 
ENST00000285071 c.1285delC 
p.(His429Thrfs*39) 
MSH2 
ENST00000233146 
c.892C>T p.(Gln298*) 
Facial fibrofolliculomas† 
This report 1 M FLCN ENST00000285071 c.1062+2T>G NF1 
ENST00000356175 
c.1381C>T p.(Arg461*) 
Testicular seminoma 39y∆; Renal cell carcinoma. 
Chromophobe 55y†; Phaeochromocytoma 43y‡; 
Gastrointestinal stromal tumour x2 55y‡; Malignant 
peripheral nerve sheath tumour 56y‡; Multiple cutaneous 
neurofibromas‡; Cafe au lait patches‡; Recurrent 
pneumothoraces.  
This report 1 M FLCN 
ENST00000285071 c.715C>T 
p.(Arg239Cys) 
TP53 
ENST00000269305 
c.526T>C p.(Cys176Arg) 
Rectal carcinoma 27y∆; Gastroesophageal adenocarcinoma 
32y∆; Renal cell carcinoma. Chromophobe 32y†; Facial 
fibrofolliculomas†. 
123 
 
This report 1 M MLH1 
ENST00000231790 c.306G>T 
p.(Glu102Asp) 
XPA 
ENST00000375128 
c.620+8A>G 
Caecal cancer. Mucinous 65y†; Sigmoid cancer 67y†; Previous 
skin tumours including squamous carcinoma in an actinic 
keratosis, multiple seborrhoeic keratoses, 
keratoacanthomata/squamous carcinomas x2, junctional 
naevi, squamous carcinoma and lentigo malignae x2‡ 
Puijenbroek et al. 
2007 
1 F MSH6 
ENST00000234420 c.1784delT 
p.(Leu595fs*15) 
MUTYH 
(compound 
heterozygote) 
ENST00000450313 
c.536A>G p.(Tyr179Cys) 
and c.1187G>A 
p.(Gly396Asp) 
Colon adenomas x5 48y (All MSI stable. Retained MSH6 
expression)‡ 
Ercolino et al. 
2014 
1 M NF1 ENST00000356175 c.1185+1G>A RET 
ENST00000355710 
c.2410G>A 
p.(Val804Met) 
Macrocephaly, café au lait patches and axillary freckling 57y†; 
Kyphoscoliosis 57y†; Multiple cutaneous neurofibromas 57y†; 
Thyroid C-cell hyperplasia 57y‡; Parathyroid hyperplasia 57y‡ 
This report 1 M PALB2 
ENST00000261584 c.3113G>A 
(p.Trp1038*) 
SDHA 
ENST00000264932 
c.91C>T (p.R31*) 
GIST (gastric), 66y‡ (Loss of SDHB immunostaining and LOH 
SDHA); Breast DCIS, 70y† 
This report 1 F PALB2 
ENST00000261584 c.3113G>A 
(p.Trp1038*) 
SDHA 
ENST00000264932 
c.91C>T (p.R31*) 
GIST (gastric), 34y‡ (Loss of SDHB immunostaining and LOH 
SDHA) 
Eliade et al. 2017 2 F PALB2 
ENST00000261584 c.1135A>T 
(p.Lys379*) 
TP53 
ENST00000269305 
c.743G>A (p.Arg248Gln) 
and c.473C>T 
(p.Arg158His) 
Ovarian cancer, 41y∆; Breast cancer, 61y*; Pancreatic cancer, 
63y† 
Valle et al. 2004 1 F PTEN ENST00000371953 c.634+5G>A APC 
ENST00000257430 
c.541insA 
p.(Gln181Thrfs*12) 
Multiple colonic polyps 10y‡; Subcutaneous nodules‡; 
Multinodular goitre 26y†; Papillary thyroid cancer, multiple 
nodular hyperplasia and follicular adenomas 26y†; Diffuse 
lymphocytic chronic thyroiditis†; Ovarian Morgani hydatid 
15y∆; Cerebellar dysplastic gangliocytoma 26y†; Palmar 
keratosis 26y†; Head fibroma 26y†; Lipomas 26y†; 
Melanocytic naevi x2 28y†; Facial papules 28y†; Oral 
papillomatosis 28y† 
Zbuk et al. 2007 1 F PTEN ENST00000371953 c.47dup p.(Tyr16*) SDHC 
ENST00000367975 
c.397C>T p.(Arg133*) 
Macrocephaly†; Papillomatous papules†; Paraganglioma. Left 
common carotid 18y‡; Fibrocystic breast disease 20's†; 
Papillary thyroid cancer 37y†; Paraganglioma. Right carotid 
body 39y‡; Uterine leiomyomas 30's† 
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Plon et al. 2008 1 F PTEN 
ENST00000371953 c.334C>G 
p.(Leu112Val). Cryptic splice site 
TP53 
ENST00000269305 
c.844C>T p.(Arg282Trp) 
Neuroblastoma 0y‡; Lipoma. Abdominal wall 0y†; 
Haemangiomas 1y†; Macrocephaly†; Ovarian granulosa cell 
tumour 1y (No somatic PTEN or TP53 variants. LOH PTEN. No 
LOH TP53)∆; Xanthoastrocytoma. Temporal lobe 3y (No 
somatic PTEN or TP53 variants. No LOH PTEN or TP53)∆; 
Pelvic liposarcoma 4y (No somatic PTEN or TP53 variants. LOH 
PTEN. No LOH TP53)∆ 
Foppiani et al. 
2008 
1 M RET 
ENST00000355710 c.2410G>A 
p.(Val804Met) 
CDKN2A 
ENST00000304494 
c.142C>A p.(Pro48Thr). 
ClinVar single submitter 
Cutaneous malignant melanoma <55y‡; Parathyroid chief cell 
adenoma 55y†; Thyroid sclerotic papillary carcinoma 55y†; 
Thyroid C cell hyperplasia 55y† 
Mastroianno et 
al. 2011 
1 M RET 
ENST00000355710 c.1997A>T 
p.(Lys666Met) 
MEN1 
ENST00000312049 
c.893+1G>T 
Pituitary tumour 38y‡; Primary hyperparathyroidism 45y*; 
Papillary thyroid cancer 46y∆; Medullary thyroid cancer 46y†; 
Gastric carcinoid tumour 47y‡; Gastrinoma‡ 
Mastroianno et 
al. 2011 
1 M RET 
ENST00000355710 c.1997A>T 
p.(Lys666Met) 
MEN1 
ENST00000312049 
c.893+1G>T 
Primary hyperparathyroidism 40y*; Cushing syndrome 
(implied pituitary origin) 40y‡; Carcinoid tumour 40y‡; 
Lipoma 40y‡; Angiofibroma 40y‡; Papillary thyroid cancer∆; 
Medullary thyroid cancer 40y†; Gastrinoma 41y‡ 
Mastroianno et 
al. 2011 
1 M RET 
ENST00000355710 c.1997A>T 
p.(Lys666Met) 
MEN1 
ENST00000312049 
c.893+1G>T 
No features 6y 
Mastroianno et 
al. 2011 
1 F RET 
ENST00000355710 c.1997A>T 
p.(Lys666Met) 
MEN1 
ENST00000312049 
c.893+1G>T 
Primary hyperparathyroidism 13y*; Pituitary tumour 15y* 
 
†Tumour type associated with pathogenic variants in gene 1 
‡Tumour type associated with pathogenic variants in gene 2 
*Tumour type associated with gene 1 and gene 2 
∆ Tumour type associated with pathogenic variants in neither gene 1 or gene 2 
 
LOH - Loss of heterozygosity i.e. loss of normal allele for quoted gene in tumour, IHC - Immunohistochemistry, ER - Oestrogen receptor, PR - Progesterone receptor, VUS – Variant of uncertain significance, 
MMR – Mismatch repair
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5.5 - Discussion 
 
5.5.1 - Delineating the relative significance of variants through molecular investigation 
In theory, insights into the role of individual CPG variants in the pathogenesis of tumour types rarely 
associated with either of the relevant genes might be derived from LOH studies, assuming the relevant 
inherited cancer genes are tumour suppressor genes. Examples presented here however, show positive 
results in tumours that are characteristic of variants affecting the studied locus.  
 
When performed on DNA from GISTs diagnosed in the mother-son diad with SDHA and PALB2 
variants, results were suggestive of a causative effect of the former but not the latter. A number of 
reports in the literature performed LOH analysis, often indicating a predominant role for one of the 
variants such as the other BMPR1A/PMS2 case316 and, perhaps surprisingly, in the breast cancer from 
an individual with BRCA1 and CHEK2 variants where loss of the wild type CHEK2 allele was 
shown.317 Predominance of one variant was suggested in some cases of BRCA1/BRCA2 MINAS. For 
example, analysis of three primary breast cancers from one individual demonstrated LOH at BRCA1 
in one tumour and at BRCA2 in the other two,255 suggesting that there was no direct interaction 
between the two loci in the tumours. However, a seemingly conflicting result was obtained in another 
case report where LOH at both loci was demonstrated in an ovarian cancer from the same patient.254 
 
Caution should be exercised in the interpretation of results from LOH analysis as they can be 
uninformative if the somatic mutational event (“second hit”) is a single nucleotide variant, indel or 
promoter methylation of the wild-type allele (i.e. no LOH). Where LOH is seen, extensive 
chromosome aberrations occurring later in tumour development may theoretically lead to loss of the 
wild type allele without that event being significant in initiation.  
 
Immunohistochemistry (IHC) studies may also be useful in tumours from MINAS cases as lack of 
staining for the protein product of the variant containing gene/s implies causality. IHC analysis in two 
breast cancers and one ovarian cancer from three individuals reported in the literature with 
BRCA1/BRCA2 MINAS showed loss of both BRCA1 and BRCA2 immunostaining,254,255,315 
suggesting significance of both variants. Loss of staining for SDHB (indicating disruption of the 
succinate dehydrogenase complex) was shown in the SDHA/PALB2 GIST cases and the colorectal 
carcinoma from the BMPR1A/PMS2 case exhibited loss of PMS2 expression. One drawback of IHC is 
that it requires the development of a specific assay per protein or protein complex as opposed to LOH 
analysis that is applicable to any locus with the same sequencing technique. Furthermore, positive 
staining indicates the presence of a protein but not normal function. The use of mutational signatures 
to analyse tumours is in its infancy but represents a further potentially valuable method to delineate 
the relative contribution of multiple CPG variants if their mutagenic effects are distinct. 
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5.5.2 - Phenotypic manifestations combinations of genes containing variants 
An interesting aspect of patients with MINAS is whether pathogenic variants in particular 
combinations of genes are associated with a more severe phenotype (e.g. earlier onset of cancer or 
cancer types that would be unexpected with one of the variants in isolation). A less severe phenotype 
is also feasible. The wide variety of combinations of individual pathogenic constitutional variants 
means that, with the exception of BRCA1/BRCA2 combinations, information regarding observed 
phenotypic effects is limited.   
 
Leegte et al243 described 12 cases of combined BRCA1/BRCA2 pathogenic variant cases and suggested 
that there was no evidence of increased severity whereas Heidemann et al242 reported eight cases and 
suggested that a more severe phenotype was observed in two. Other reports have been on a smaller 
scale but cumulatively, 61 cases were identified in the literature, 56 of whom were female. 54 breast 
cancers were diagnosed in 43 of these individuals with a mean age at diagnosis for a first tumour at 
40.3 years and for all breast cancer 41.3 years. 13 ovarian cancers were diagnosed in 10 individuals 
(all multiple tumours were synchronous bilateral) with a mean age at diagnosis of 49.2. The peak 
incidence age of breast cancer in BRCA1 pathogenic variant carriers is 41-50 years with an equivalent 
figure of 51-60 years for BRCA2. Peak incidence of ovarian cancer for both genes is 61-70 years.71 
The ages at diagnosis noted in the BRCA1/BRCA2 MINAS cases are therefore at the lower end of the 
peak for breast cancer and somewhat lower than that for ovarian cancer. This might suggest a 
synergistic effect of concurrent variants but the numbers of individuals remain small and the series as 
collated is subject to publication and ascertainment biases (e.g. over-representation of founder 
variants, which may be more penetrant). Only four cancers occurred in these cases that are not typical 
of variants in BRCA1 or BRCA2 but one of these was a colorectal cancer occurring at age 35 where 
microsatellite instability studies were normal and no loss of MLH1, MSH2 or MSH6 was 
demonstrated on IHC. This malignancy may therefore have been contributed to by the identified 
constitutional variants (bowel cancer had been diagnosed in the proband’s father) but no further 
tumour studies were performed. 
 
Other combinations of breast CPG variants have been described including BRCA1/CHEK2 (n=4), 
BRCA2/CHEK2 (n=3),  BRCA1/ATM (n=2),  BRCA1/PALB2 (n=1),  ATM/CHEK2 (n=1) and 
ATM/PALB2 (n=1). No atypical tumours or particularly early ages at diagnosis were noted in these 
individuals except for a patient with a combination of pathogenic variants in BRCA1 and PALB2 
where multifocal breast cancer (Table 5.10), uterine leiomyomas and a meningioma were also 
diagnosed.304  
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TP53 variants can cause LFS, which leads to predisposition to various cancer types and is strongly 
associated with early onset breast cancer. They were noted in combination with variants in CHEK2, 
PALB2 and BRCA1 (1 occurrence each). The TP53/CHEK2 case (see above) had a phenotype 
consistent with LFS. The TP53/PALB2 individual had been diagnosed with early onset ovarian 
cancer, which is not typical for variants in either gene but LFS is associated with a wide variety of 
malignancies. The age of onset for the breast cancer (20 years) in the TP53/BRCA1 case is low but 
cannot be interpreted as evidence of synergy between the two variants because LFS characteristically 
causes pre-menopausal breast cancer with breast screening recommended from a woman’s early 
twenties. One report of constitutional deleterious BRCA2 and TP53 variants was identified in the 
literature where the individual concerned had been diagnosed with cutaneous malignant melanoma, 
breast cancer, ovarian cancer and colon cancer between the ages of 65 and 74 years.292 In a mouse 
model where the orthologues of both of these genes are conditionally knocked out in epithelial tissues 
(to avoid embryonic lethality), a greater incidence and earlier onset of mammary and skin carcinomas 
was observed in comparison to mice where only Trp53 or Brca2 was conditionally knocked out, 
suggesting a synergistic effect in these tissues.321 Though the mouse model is not directly comparable 
to the human status, four cancers had occurred in the case of BRCA2/TP53 MINAS but all at 
relatively advanced age.  
 
In addition to the case of BRCA2/NF1 MINAS case reported here, a further combination of variants in 
a hereditary breast and ovarian cancer gene (BRCA1) and NF1 was identified in a patient with 
cutaneous features of Neurofibromatosis type 1 and early onset (age 35) breast cancer.306 The 
exhibited phenotype is consistent with independent expression of each variant but of note is the fact 
that NF1 and BRCA1 are both located on the long arm of chromosome 17. The presence of early onset 
breast cancer and Neurofibromatosis type 1 in the patient’s mother along with both variants being 
found in the proband may suggest that the two altered genes were in cis. Such information has 
significant implications for genetic counselling of families where multiple pathogenic variants are 
identified though interestingly, the proband’s brother who also had Neurofibromatosis type 1, did not 
carry the BRCA1 variant suggesting a recombination event in the mother.  
 
The second most frequently reported examples of specific MINAS were combinations of variants in 
genes predisposing to colorectal cancers.299–303,316 Interestingly, severe phenotypes were noted in two 
patients with APC/MLH1 pathogenic variant combinations with jejunal cancer seen in one case299 and 
accelerated polyp progression in the other.302 In the BMPR1A/PMS2 case identified in the literature, a 
colorectal adenocarcinoma with loss of PMS2 staining on IHC was diagnosed in the apparent absence 
of colorectal polyps, suggesting a lack of BMPR1A variant penetrance. However, there was a strong 
family history of polyps (including in two children) and the level of investigation for polyps in the 
proband is not evident from the article.316  
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The phenotypic consequences of MINAS may be easier to interpret when the two genes involved are 
associated with dissimilar and narrow phenotypes. Most of the newly reported cases here fall into this 
category with phenotypes generally indicating an independent mechanism of action, that is, a 
phenotypic effect consistent with the presence of each variant in isolation. There was some suggestion 
of increased penetrance in the SDHA/PALB2 cases and a possible atypical tumour (colorectal cancer) 
in the FLCN/TP53 case but this cannot be confidently asserted.  
 
In the literature, there are various reports of BRCA1/BRCA2 pathogenic variants in combination with 
those in a mismatch repair gene (Table 5.10). In general, these have not demonstrated clear evidence 
of a synergistic effect on the severity or nature of the phenotype, although one reported case with 
deleterious BRCA1 and MLH1 variants had severe manifestations including endometrial, ovarian, 
clear cell renal and bilateral breast cancers diagnosed at age 39 years. Both breast tumours showed 
loss of the wild-type BRCA1 allele but also showed absent staining of MLH1 on IHC and loss of the 
wild-type MLH1 allele. This suggests that both constitutional variants were significant to breast 
tumorigenesis in this patient. The high number of tumours and the development of early onset RCC 
(not usually associated with BRCA1 or MLH1 variants) suggests a possible synergistic effect.288   
 
Reports of MINAS cases with other specific gene combinations only involve a single proband, 
although four individuals with MEN1/RET MINAS were reported in a single family with the authors 
concluding that more aggressive disease was not exhibited despite evidence for penetrance of both 
variants.296 Pathogenic PTEN variants, which affect the PI3K/Akt signalling pathway322,323 are 
reported in combination with those in TP53,297 APC319 and SDHC298 with tumours characteristic of 
each variant observed in all three cases. A number of the tumours in the PTEN/TP53 case were not 
typical of a variant in either gene and early onset of colonic polyps and paraganglioma were noted in 
the PTEN/APC and PTEN/SDHC individuals respectively. PTEN normally acts via Akt to down 
regulate MDM2 (and therefore increase p53 levels) in addition to its other roles322,323 so this 
interaction may lead to a more severe phenotype. A case of MINAS involving pathogenic FLCN and 
APC variants has also been reported.294 Typical colonic polyps and a colorectal cancer at age 28 
occurred, as well as recurrent pneumothoraces and facial papules. The features are consistent with an 
independent mechanism, though the authors suggested that the FLCN variant might have enhanced 
the tumorigenic process given the observation that somatic mutational events affecting FLCN occur 
frequently in (microsatellite unstable) colorectal cancers.272  
 
There are inherent ascertainment biases influencing which MINAS cases are present in the literature 
(and amongst the newly reported cases here) including more frequent analysis of combinations of 
particular genes, the range of phenotypes referred for testing and the restriction of analysed genes to 
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only those most strongly suggested by the tumour history or examination findings (e.g. cutaneous 
manifestations of cancer predisposition syndromes). Availability, or lack thereof, of sequencing of 
certain genes in some centres may also be a factor and is likely to have led to recognition of four 
FLCN MINAS probands in the centres contributing to the current analyses where this gene is tested 
frequently and is the subject of research studies. The appearance of certain CPG variant combinations 
may not simply be related to the population frequency of individual CPG variants and in utero death 
resulting from certain combinations might lead to a paucity of them being detected clinically. These 
biases are, in part, likely to be reduced by a more comprehensive genetic testing strategy made 
possible by cancer gene panels or whole exome/genome sequencing, which is likely to result in 
increased recognition of MINAS. 
 
Increasing detection will inevitably lead to increased demand for accurate information on the likely 
phenotypic effect of particular variant combinations, in particular whether a more severe (i.e. a 
synergistic interaction) or even attenuated phenotype is to be anticipated rather than the variants 
having an independent effect. The MINAS cases described here are broadly indicative of an 
independent expression of both variants whereby the chance of necessary further tumourigenic events 
(e.g. second hits) is not greatly influenced by the other variant. In such a scenario, the probability of 
developing a cancer (due to either CPG variant) might be increased to a degree due to a greater 
variety of possible tumour initiating events but this might not be observable clinically. 
 
Despite the general picture of independent effects, some individuals appear to show earlier age at 
diagnosis or unusual/more numerous tumours and in certain circumstances it may be prudent to 
expect that particular combinations of aberrant genes might result in a more severe phenotype. In 
practice, it is difficult to distinguish between these effects and incidental unrelated tumours but 
tumour studies can be helpful. There are a number of feasible mechanisms whereby a synergistic 
effect may ensue such as increased genomic instability leading a greater chance of necessary further 
tumourigenic mutation. Tumour development might be encouraged by compromised function of 
components of two tumour suppressive pathways (e.g. DNA repair and cell cycle regulation) or the 
loss of two components in a single pathway may lead to enhanced downstream aberrant signal. Two 
gain-of-function variants in proto-oncogenes might predict a more severe phenotype (though no 
reports of such cases were found) because, in contrast to tumour suppressor genes, the further event of 
somatic inactivation of a wild-type allele is not required to initiate tumorigenesis. An intriguing 
potential way in which MINAS might influence phenotype is the situation where an individual has 
pathogenic variants in two tumour suppressor genes that map to the same chromosome region. Loss of 
part of a chromosome harbouring both wild type alleles will result in a tumour that is homozygous 
null for both. This may have occurred in the FLCN/TP53 case as these genes map to 17p11.2 and 
17p13.1 respectively.  
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It is also feasible that in some situations, MINAS might lead to an attenuated tumour phenotype that is 
milder than if one of the pathogenic CPG variants was present in isolation. Clinically, these cases 
would be difficult to recognise because individuals would be less likely to present to clinical services. 
Where MINAS has been identified in an individual, it may not be possible to distinguish between 
attenuation conferred by MINAS and non-penetrance as cancer predisposition syndromes are usually 
not fully penetrant. If numerous further cases are uncovered by routine multigene testing strategies in 
future however, opportunities may arise to compare MINAS individuals with single CPG variant 
carriers to observe for differences in phenotypic severity. The most obvious mechanism by which 
MINAS might be protective against neoplasia is synthetic lethality. This phenomenon has been 
demonstrated through the efficacy of poly ADP ribose polymerase (PARP) inhibitors in cancers 
arising in carriers of pathogenic variants in BRCA1 or BRCA2, which have often undergone a second 
hit affecting the wild type allele. Resulting dysfunction of double stranded break repair is 
compounded by inhibition of base excision repair by PARP inhibition and tumour cells are unable to 
tolerate the compromise of both processes.106 In tumours from MINAS cases that have undergone a 
second hit at one of the variant containing genes therefore, it might be anticipated that haplo-
insufficiency or a second hit at the other loci may render the clone untenable in some cases. 
 
5.5.3 - Data sharing 
There are myriad possible combinations of high penetrance CPG variants but conclusions as to their 
effect, as with many genetic conditions, are limited by small numbers. A useful resource with which 
to discern the effects of individually rare combinations and improve future management of patients 
with MINAS would be a reference database containing clinical, genetic and tumour information. Such 
information could guide the clinician as to what the effect of each combination of aberrant genes 
might be and prompt collation of individuals for further study. To facilitate sharing of such 
information, the author has established an online registry where cases can be uploaded via the Leiden 
Open Variant Database and identified by the phenotypic tag “MINAS” 
(http://databases.lovd.nl/shared/diseases/04296).  
 
At present, clinical cancer genetics services remain predominantly focused on identifying a small 
range of CPG variants leading to risk that is amenable to mitigation strategies. Conceptualising 
MINAS, and indeed variants, in this manner may therefore be useful in the short to medium term but 
risks emphasising a false dichotomy between disease and non-disease-causing variants when a 
spectrum of risk may be a more accurate view. In an era of genomics and effective personalised 
medicine, the role of moderate to low penetrance variants and polygenic risk scores is likely to 
become more prominent. In the fullness of time, case sharing platforms might include a collection of 
risk conferring variants per individual in most cases although this may compound the issue of small 
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numbers of genetically similar individuals from which to draw conclusions regarding phenotypic 
effects. 
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Chapter 6 - Analysis for variants in putative 
novel loci associated with cancer predisposition 
genes in a multiple primary tumour series 
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Scripts used in these analyses are stored as an appendix in the form of a GitHub repository 
(https://github.com/jameswhitworth/Thesis-
Elucidating_the_genetic_basis_of_multiple_primary_tumours-Scripts_appendix 
doi:10.5281/zenodo.1501206). They are denoted with the prefix "RA" (repository appendix) in the 
text in and in the repository.  
 
6.1 - Introduction 
An aim of this project was to determine if studying individuals with multiple primary tumours (MPT) 
might lead to the identification of novel candidate loci relevant to cancer predisposition. To this end, 
data resulting from whole genome sequencing (WGS) of samples from MPT cases were used to 
perform case-control based analyses where the exposure of interest was the presence of a variant 
affecting loci of interest. A number of sets of genomic regions were proposed based on various lines 
of evidence suggesting a potential role in tumour susceptibility. The MPT series used for this purpose 
was that defined in Chapter 3 with some additional exclusions based on ancestry. A range of separate 
case control based studies were executed with the different loci of interest and phenotypic 
subdivisions of cases as described below.  
 
Analyses were performed utilising counts of individuals with truncating variants affecting genes in 
lists that were compiled to include those that are recurrently mutated in somatic cancer studies, 
involved in DNA repair or functionally related to known cancer predisposition genes (CPGs) (section 
6.2). Missense variants in known or putative proto-oncogenes causing tumour predisposition were 
also considered (section 6.3), as were coding variants affecting telomere related genes in individuals 
with estimated telomere length at the higher and lower end of that observed in the series (section 6.4). 
Frequency of variants in various non-coding regions was also analysed in cases vs controls (section 
6.5). Regions of interest included enhancers and promoters of known CPGs (section 6.5.2.1) and 
ultra-conserved regions (section 6.5.2.2). Variants affecting expression quantitative trait loci (eQTL) 
reported to influence expression of CPGs in normal tissues (section 6.5.2.3) and cancer samples 
(section 6.5.2.3) were also counted and analysed. Many of the workflows used were common between 
the separate case-control based analyses. These are described in greater detail in the first section 
concerning the truncating variant analysis and subsequently referred to if used in other analyses. A 
summary of the study design is depicted in Figure 6.1 for coding variants and Figure 6.2 for non-
coding variants.  
 
Additionally, a segregation-based analysis was performed on a family suspected to be manifesting a 
recessive cancer predisposition syndrome. 
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Figure 6.1 - Study design – Coding variants
 
MAF – Minor allele frequency, SNV – Single nucleotide variant, SV – Structural variant, VEP – Variant Effect Predictor 
 
135 
 
Figure 6.2 - Study design – Non-coding variants 
 
CPG – Cancer predisposition gene, eQTL – Expression quantitative trait locus/loci, GTEx - Genotype Tissue Expression Project, MAF – Minor allele frequency, SNV – Single nucleotide variant, 
SV – Structural variant
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6.2 Analysis of predicted truncating variants in known or suspected cancer predisposition genes 
 
6.2.1 - Introduction 
Sequencing studies to elucidate disease causing genetic factors often generate large numbers of 
potentially causative variants, particularly if massively parallel techniques such as WGS are used. The 
majority of these will not make a significant contribution to the disease phenotype in question and the 
classification of variants based on various lines of evidence is a large and active area of research. 
Assertions as to the pathogenicity of a variant are frequently made on the basis of predicted molecular 
consequence on the protein product and truncating consequences are generally regarded as strong 
evidence of a deleterious effect on function. Truncating variants include those inducing frameshifts, 
premature stop codons and aberrant splicing due to disruption of canonical splice sites. Such variants 
may lead to reduced protein function through absence of a functional portion of amino acid sequence 
or through nonsense mediated decay whereby premature stop codons within transcripts lead to 
detection and degradation by intracellular mechanisms following transcription.324 
 
A degree of caution is necessary when assigning pathogenic status to a truncating variant as they have 
been shown to be frequent in individuals where no disease phenotype is evident. Previously, 
interrogation and variant assessment of data from 185 individuals in the 1000 Genomes project 
demonstrated around 100 truncating variants (including large deletions) per individual, around a fifth 
of which were homozygous, indicating complete inactivation.325 A study of over 10,000 individuals 
from a society where consanguineous unions are common (Pakistan) and who were enrolled in a 
cardiovascular risk study demonstrated at least one gene with homozygous putative loss of function 
variants in 17.5% individuals.326 Such occurrences are frequently termed “human knockouts.” Given 
findings such as these, it follows that mechanisms must exist whereby the presence of a constitutional 
truncating variant in an individual does not necessarily lead to disease. This may be the case even 
when the variant occurs in a gene known to be associated with medical conditions. BRCA2 
ENST00000544455 c.9976A>T (p.K3326*) is a nonsense variant that leads to truncation of the final 
93 amino acids of the protein product. BRCA2 protein resulting from this transcript contains 3418 
amino acids so this variant leads to a loss of less than 3% of the protein and BRCA2 function appears 
to be retained. The variant is generally regarded as benign and although there is some evidence to 
suggest an increased breast cancer risk associated with it, this is not at the level observed for other 
BRCA2 truncations.327 Truncating variants may not lead to the loss of large part of a protein product 
even if they occur at more 5’ locations within the gene. TP53 ENST00000617185 c.387C>G 
(p.Y126*) occurs 215 amino acids before the end of the transcript but has been demonstrated to 
produce a full length protein with retained function through the generation of an alternative splice 
site.328 A nonsense variant ENST00000357033 c.4250T>A (p.Leu1417X) in DMD, a gene associated 
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with Duchenne and Becker muscular dystrophy, has been observed in an individual with a phenotype 
intermediate between the two disease subdivisions. Reverse transcriptase polymerase chain reaction 
studies demonstrated that the variant led to alternative splicing and skipping of a single exon,329 a 
phenomenon that has been synthetically emulated with therapeutic intent.330 Many diseases with a 
constitutional genetic basis and which can be caused by truncating variants manifest in specific 
tissues, implying that there may be a compensatory mechanism in unaffected tissues. A study of 
expression of disease gene paralogues across multiple tissues recently showed that lower levels of 
paralogue expression are observed in tissues generally affected by variants in the gene corresponding 
to that paralogue.57 If such a putative compensatory situation occurred across a broad range of tissues 
then it may account for non-penetrance of truncating variants. Additionally, extensive aberration of 
protein function due to a truncating variant may be protective against disease, as evidenced by 
truncating variants in PCSK9 leading to reduced cardiovascular risk due to reduced binding to low 
density lipoprotein (LDL) receptors and consequent reduced circulating LDL levels.331 
 
Despite these potential mechanisms of reduced or absent disease-causing effect of truncations, the 
majority of known pathogenic variants in CPGs are truncating in nature. Indeed, a search of ClinVar 
with the 83 gene names used for the WGS-based comprehensive CPG analysis described in Chapter 4 
showed 8,784 variants classified as pathogenic or likely pathogenic with 2* evidence or higher, 7,659 
(87%) of which were classified as frameshift, nonsense or splice site. Analyses to consider the 
frequency of these variant classes in MPT cases vs controls were therefore undertaken. 
 
Studies associating genetic variants with disease are assisted by focusing on proposed loci at which 
causative variants may reside. Benefits include reduced use of analytical resources, a lower chance of 
false negatives resulting from application of correction for multiple hypothesis testing, and, in the 
presence of a possible significant result, the provision of further lines of evidence of causality other 
than the association itself. Proposition of candidate loci may be through various means including 
linkage analysis and identification of genes more likely to be relevant to the disease in question. 
According to the latter strategy, a number of gene lists were curated based on possible relevance to 
cancer predisposition and the frequency of truncating variants within these genes was recorded. Given 
that there is significant overlap between CPGs and genes observed to be recurrently mutated in 
somatic cancer sequencing studies,45 a list was formulated based on top results from The Cancer 
Genome Atlas (TCGA) studies. Additionally, gene lists were produced based on the ratio of non-
synonymous to synonymous variants in cancer tissues, evidence of a role in DNA repair and 
functional relatedness to known CPGs. Variant counts at these loci were then used to perform case-
control analyses on various phenotypic sub-groups within the MPT series. Given that structural 
variants such as chromosomal deletions and translocations affecting genes of interest may also lead to 
absent or non-functional protein products, their frequency was also considered. 
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6.2.2 - Methods 
 
6.2.2.1 - Gene lists 
Five gene lists were compiled that contained known CPGs or genes hypothesised to be CPGs. The 
methods used for compilation are described below. 
 
6.2.2.1.1 - Genes somatically mutated in cancer sequencing studies and known cancer 
predisposition genes 
In order to identify genes in which variants are significantly over-represented in malignant tumours, 
study summaries from all available TCGA studies were downloaded from the cBioPortal data portal.34 
TCGA is a collaborative project to perform somatic sequencing on a wide variety of tumour types on 
a large scale. One study each from the Broad Institute, Michigan Centre for Translational Pathology, 
Memorial Sloane Kettering Centre were also downloaded. Study summaries each contain a list of 
genes that were noted to contain variants in the cancer type studied, along with the frequency at which 
variants were recorded. A number of factors may influence the frequency at which a given gene is 
mutated in a sample of sequenced tumour tissue including gene size, expression level (due to 
transcription coupled repair),332 background mutation rate of the specific tumour type and the time 
point at which replication occurs during the cell cycle.333 The MutSig tool is designed to highlight 
significantly mutated genes while taking account of these processes and has been applied to many of 
the TCGA studies appearing in cBioPortal. Output is expressed as a p-value where the null hypothesis 
is no difference in mutation frequency in a given gene between tumour and control tissue. 
Downloaded study summaries (n=41, Table 6.1) that included this measure were selected and any 
gene with MutSig p <0.01 (n=902) used for the gene list.  
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Table 6.1 - Cancer sequencing datasets with MutSig assessment downloaded from cBioPortal 
Name of study 
Research 
group 
Published 
dataset (if TCGA) 
Samples 
Adenoid cystic carcinoma MSK  60 
Adrenocortical carcinoma TCGA   90 
Bladder urothelial carcinoma TCGA   130 
Bladder urothelial carcinoma TCGA Yes 130 
Brain lower grade glioma TCGA   286 
Breast invasive carcinoma TCGA Yes 993 
Breast invasive carcinoma TCGA   982 
Breast invasive carcinoma TCGA Yes 507 
Cervical squamous cell carcinoma and endocervical 
adenocarcinoma 
TCGA   194 
Cholangiocarcinoma TCGA   35 
Cutaneous melanoma TCGA   345 
Diffuse large B cell lymphoma TCGA   48 
Gastric adenocarcinoma TCGA   289 
Gastric adenocarcinoma TCGA Yes 289 
Glioblastoma TCGA Yes 91 
Glioblastoma multiformae TCGA   290 
Head and neck squamous cell carcinoma TCGA   279 
Head and neck squamous cell carcinoma TCGA Yes 279 
Kidney chromophobe TCGA Yes 65 
Kidney chromophobe TCGA   66 
Liver hepatocellular carcinoma TCGA   198 
Lung adenocarcinoma TCGA   230 
Lung adenocarcinoma TCGA Yes 230 
Lung squamous cell carcinoma TCGA   178 
Pancreatic adenocarcinoma TCGA   146 
Phaeochromocytoma and paraganglioma TCGA   183 
Prostate adenocarcinoma TCGA   332 
Prostate adenocarcinoma TCGA Yes 333 
Prostate adenocarcinoma Broad  112 
Prostate adenocarcinoma metastatic MCTP  61 
Renal cell carcinoma - clear cell TCGA   417 
Renal cell carcinoma - clear cell TCGA Yes 424 
Renal cell carcinoma – papillary TCGA   161 
Sarcoma TCGA   247 
Testicular germ cell cancer TCGA   155 
Thyroid carcinoma TCGA   405 
Thyroid papillary carcinoma TCGA Yes 248 
Uterine carcinosarcoma TCGA   57 
Uterine corpus endometrial carcinoma TCGA Yes 248 
Uterine corpus endometrial carcinoma TCGA   248 
Uveal melanoma TCGA   80 
 
TCGA – The Cancer Genome Atlas, Broad – Broad Institute, MCTP – Michigan Centre for Translational Pathology, MSK – 
Memorial Sloane Kettering 
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Five of the top twenty UK incident cancers177 did not have a corresponding TCGA study summary 
with the MutSig tool applied (acute myeloid leukaemia, colorectal, oesophageal, ovarian, myeloma). 
In these instances, the publication linked to the cBioPortal study of the relevant tumour type334–340 
(n=7) was retrieved and interrogated to find genes that the authors reported as significantly mutated 
(n=94). MutSig had been applied in six out of seven of the publications whilst one publication had 
used the Mutational Significance in Cancer suite of tools for a similar purpose. The same p-value 
threshold was used (where quoted) as for the cBioPortal study summaries.341 
 
To incorporate known CPGs into the gene list and potentially demonstrate novel phenotypic 
manifestations, all genes appearing in a comprehensive review of CPGs45 (n=114) or sequenced by 
the Illumina TruSight Cancer gene panel assay (Illumina Inc., San Diego, CA, USA) (n=94) were 
added. Additionally, published CPGs NTHL136 and CDKN2B182 that didn’t appear in either of the two 
lists were included. 
 
Compilation of the sources above produced a list of 1,060 gene names, which were converted to 
Ensembl gene identifiers with Ensembl BioMart.185 Where multiple identifiers existed for a single 
gene name, the identifier linked to the gene name on the Ensembl browser184 was used (also used to 
select gene identifiers for all gene lists described below). This process resulted in a final gene list of 
1,055 unique gene identifiers, referred to in results tables as the “Full” gene list (Table A3). 
 
6.2.2.1.2 - Refinement of gene list 
The utilisation of techniques to correct for multiple hypothesis testing used in these analyses (see 
below) may lead to an increased probability of false negative results with a higher number of tests 
performed. Consequently, an attempt was made to identify genes on the list that were most likely to 
be significant in tumour predisposition with the intention of producing a refined list where there was 
less chance of type two error. Two techniques were used to produce two separate refined lists for 
further analysis.  
 
Predicted nonsense, frameshift or splice (loss of function) variants may be tolerated due to lack of 
haploinsufficiency for a given gene. Loss of function variants in genes that don’t exhibit 
haploinsufficiency are consequently likely to be more frequent in populations. LoFtool342 is a method 
that considers the per gene ratio of loss of function to synonymous variants in Exome Aggregation 
Consortium (ExAC) data161 to produce a ranking of genes according to predicted tolerance to 
functional loss of one allele. Ensembl variant effect predictor186 was used to annotate the original gene 
list and the quartile of scores predicting greatest intolerance were selected to produce a refined 
LoFtool-based list of 469 genes. This is referred to in results tables as the “Loftool” gene list (Table 
A4).  
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Despite tools such as MutSig to identify somatically mutated genes that contribute to the cancers in 
which they are found, many genes highlighted by cancer sequencing studies may not be functionally 
relevant to tumourigenesis. To identify genes on the original list which were most likely to be 
functionally relevant, the WebGestalt tool343 was used to identify gene ontology (GO) terms344,345 
enriched among those assigned to those genes. WebGestalt was run twice for biological process GO 
terms and molecular function GO terms and the significantly over-represented terms from each 
enquiry (false discovery rate <0.05) noted. Any gene with at least one assigned GO term among these 
outputs was retained to produce a refined list of 617 genes (Table A5), which is referred to in results 
tables as the “Webgestalt” gene list. 
 
6.2.2.1.3 - Other gene lists utilised 
Genes that frequently contain somatic cancer driver variants may be identified through methods other 
than counting the number of variants per gene in a given cancer type. A recent study analysed 29 
cancer types (7,664 samples) and observed the ratio of non-synonymous variants to synonymous 
variants per gene. On the basis that genes which tend to accumulate positively selected (at the somatic 
level) variants in tumours are likely to have an increased ratio, a set of 179 genes under  positive 
selection (false discovery rate <0.05) was generated7 (Table A6). This list was utilised directly for 
downstream analysis and is referred to as the “CGP” list in results tables after the Cancer Genome 
Project that produced the original publication. 
 
Many CPGs are involved in DNA repair, including those that are most frequently tested clinically 
(BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2). Consequently, a further gene list (Table A7) was 
utilised comprising all genes assigned with the DNA repair GO term (GO:0006281) (n=446) and is 
labelled as the “Repair” gene list in results tables.  
 
Novel CPGs may also be uncovered through their interaction with existing ones. A final gene list was 
compiled by identifying interacting partners of known CPGs (n=133, comprised of all those appearing 
in a comprehensive review of CPGs45 (n=114), sequenced by Illumina TruSight Cancer gene panel 
assay (Illumina Inc., San Diego, CA, USA) (n=94), NTHL136 and CDKN2B182). Interactions were 
found using the GeneMania platform346 and a list of 142 genes produced (Table A8), which is referred 
to as the “Mania” gene list in results tables.  
 
6.2.2.2 - Variant filtering – Single nucleotide variants (SNVs) and indels (Script RA6.1) 
For all gene lists, the Ensembl canonical transcript identifier was selected for each Ensembl gene 
identifier by referencing gene-canonical transcript pairs provided by ExAC.161 Canonical transcripts 
are defined according the following hierarchy: 1) Longest Consensus Coding Sequence (CCDS)183 
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translation with no stop codons, 2) Longest Ensembl/Havana merged translation with no stop codons, 
3) Longest translation with no stop codons and 4) If no translation, longest non-protein-coding 
transcript.184 Lists of transcripts were then used to obtain GRCh37 coordinates for the protein coding 
regions within them with Biomart.185 Regions that were designated as within a patch region were 
excluded. Coordinates were then used to produce BED files +/- 5 base pairs for use in filtering of 
variant call format (VCF) files. 
 
BED files were used in conjunction with bcftools view (version 1.4)170 to extract variants in the 
corresponding regions that had FILTER PASS annotation from merged VCF files (one file per 
chromosome) containing variants called from NIHR BioResource Rare Diseases project (BRIDGE) 
WGS data (all sequenced individuals) and/or 1958 birth cohort exome sequencing data (see below). 
Variants from the latter dataset are subject to differences in frequency from BRIDGE data due to 
differences in sequencing coverage, variant calling or quality filtering and they were not used for 
downstream hypothesis testing. Filtered per chromosome files were then merged using bcftools concat 
and filtered with bcftools filter to exclude genotypes where read depth (DP) was less than 10, 
genotype quality (GQ) was less than 30 (corresponding to an estimated probability of the genotype 
call being incorrect of 1/1000) and variant allele fraction was less than 0.3. 
 
The filtered merged VCF was then annotated with Variant Effect Predictor (VEP) version 90,186 
including the LOFTEE plugin347 to specifically annotate predicted loss of function variants (nonsense, 
frameshift and splice site) with flags to indicate low confidence of functional loss of an allele as a 
result of the variant.  Annotated variants were then filtered with the VEP filter script to include 
variants where impact was assigned as HIGH and where LOFTEE did not indicate that a variant 
occurred in the last 5% of the transcript. Further filtering was performed to remove variants with an 
allele frequency of  >0.01 in the 1000 Genomes European166 or UK10K163 whole genome datasets. 
Variants were also excluded if they had an allele frequency of  >0.05 across all samples in the 
BRIDGE project (n=9,424). The final merged VCF, containing genotype information for all BRIDGE 
samples pertaining to each filtered variant was read into R178 (version 3.4.4) for further analysis. 
 
6.2.2.3 - Identification of structural variant calls affecting genes of interest (Script RA6.2) 
Selective filtering for truncating variants affecting genes of interest is based on the rationale that such 
variants are more likely to lead to an absent or non-functional protein product than other types of 
variant. However, structural variants (SVs) such as chromosomal deletions and translocations may 
also have this effect and are not identified by variant calling algorithms designed for SNVs and indels. 
WGS data gives the potential to identify SVs and the frequency of these aberrations predicted to 
affect the genes of interest were also recorded. 
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Files containing SV calls by Canvas or Manta (txt format) were initially filtered by the BRIDGE 
project to retain those that occurred at a frequency of less than 1% across all BRIDGE samples (n= 
9,110) and were not associated with a flag introduced by Manta or Canvas indicating a low-quality 
call. Those files were subsequently filtered again with an R script to only retain variants fulfilling 
minimum quality criteria (GQ ≥30 for Manta, QUAL ≥30 for Canvas). 
 
SV modalities that are most likely to disrupt protein function were considered and files containing 
calls for predicted deletions (separate files from Canvas and Manta), translocations (Manta), 
inversions (Manta) and insertions (Manta) were used. Interrogation of variants to elucidate those that 
affected genes of interest (each gene list described above was considered separately) was based on 
identifying variants where the predicted breakpoints contained or occurred within exon or gene 
start/end coordinates downloaded from Ensembl Biomart184 (GRCh37 build). Translocations, 
inversions and insertions may exert deleterious effects due to breakpoints in non-coding regions of 
genes and for these SV modalities, coordinate files corresponding to the length of the gene were used. 
To avoid including purely intronic deletions amongst potentially pertinent SV calls, coordinate files 
corresponding to coding exons of genes of interest were used for analysis of deletions called by 
Canvas or Manta. 
 
The conditions that a variant call was required to fulfil in order to be considered as affecting a region 
of interest are outlined in Table 6.2 and were executed using an R script. Manta annotation contained 
confidence intervals describing the range of bases surrounding the predicted breakpoint that are likely 
to contain the true breakpoint. These values can be utilised to produce genomic positions 
corresponding to the minimum start, maximum start, minimum end and maximum end of a given SV. 
These values were used in the identification of Manta called SVs affecting regions of interest.  
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Table 6.2 - Conditions used to identify structural variants 
Structural 
variant 
modality 
Coordinate 
file used 
Conditions for structural variant call to fulfil 
Deletion 
(Manta) 
Exon 
Max. start < exon start AND min. end > exon end  
OR  
Min. start > exon start AND max. end < exon end  
OR  
Max. start < exon start AND (min. end > exon start and max. 
end < exon end)  
OR  
Min. end > exon end AND (max. start < exon end AND min. 
start > exon start)   
Deletion 
(Canvas) 
Exon 
Start < exon start AND end > exon end  
OR  
Start > exon start AND end < exon end  
OR  
Start < exon start AND (end > exon start AND end < exon end)  
OR  
End > exon end AND (start < exon end AND start > exon start) 
Translocation 
(Manta) 
 
Gene 
Min. start > gene start and max. start < gene end 
OR  
Min. end > gene start and max. end < gene end 
Inversion 
(Manta) 
Gene 
Min. start > gene start and max. start < gene end 
OR  
Min. end > gene start and max. end < gene end 
Insertion 
(Manta) 
Gene 
Min. start > gene start and max. start < gene end 
OR  
Min. end > gene start and max. end < gene end 
 
6.2.2.4 - Defining phenotypic groups 
The multiple primary tumour cases participating in this study were phenotypically heterogeneous. 
Whilst some CPGs are associated with a diverse range of tumour types, variants in many of them are 
implicated in a narrower selection of neoplasms. For such CPGs, causative variants may be more 
readily detectable in a case-control study design where homogeneity of cases is enhanced. This is on 
the basis that in a situation where a particular set of variants cause a phenotype, signal is less likely to 
be diluted by an increase in N due to cases that don’t conform to that phenotype. To this end, MPT 
probands were subdivided into 107 groups based on phenotype. Any proband being assigned to a 
subgroup had to first fulfil the general eligibility criteria of being diagnosed with two primary tumours 
under the age of 60 years or three under the age of 70 years. Additionally, only those assessed as 
European ethnicity were included to prevent misinterpretation of allele frequencies solely due to 
ancestral differences (individuals assessed as European ethnicity accounted for 424/452 MPT cases 
fulfilling general eligibility criteria).  
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The analysed subgroups, along with the number of individuals with each one, are outlined in Table 
6.3 and included an analysis including all eligible participants. Single tumour subgroups contained all 
individuals diagnosed with a given tumour type before the age of 70 years. Combination subgroups 
(referred to as “2 from 2” in tables) were proposed by the presence of any discordant tumour 
combination (both before age 70 years) in an MPT individual. Subgroups which contained any 
individual diagnosed with ≥1 (or ≥2) of a selection of tumours (e.g. 1 from 2, 2 from 4 etc.) were also 
proposed and were intended to represent the tumour spectrum associated with existing cancer 
predisposition syndromes from literature review. This was based on the rationale that novel CPGs are 
often functionally related to existing ones. Two further subgroups were put forward due to 
identification of commonality of genomic aberrations (incorporating single nucleotide and copy 
number variants) across multiple tumour types in a large pan-cancer analysis based on TCGA data.348  
An R script was utilised to extract the sample identifiers for all individuals fulfilling the conditions 
required be included in a subgroup. To provide greater confidence in any forthcoming statistically 
significant results, phenotypic subgroups were only analysed if they contained at least three 
individuals in the case of single tumour groups or five individuals in any other group. A lower 
threshold was chosen in the single tumour groups given the suspected reduction in phenotypic 
heterogeneity vs other groups. For structural variant analysis, Canvas and Manta calls were only 
available for 360/424 individuals. Consequently, the sizes of phenotypic subgroups were reduced for 
any variant frequency comparison involving SVs and are outlined in Table 6.3.  
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Table 6.3 - Phenotypic subgroups used in analysis 
No. 
individuals 
No. individuals for 
counts incorporating 
structural variants 
Syndrome, gene or 
phenotypic grouping 
forming basis of subgroup 
No. tumours 
required to be 
included 
Tumours 
424 360 Nil 
N/A - All MPT 
individuals 
All 
273 231 STK11 1 From 4 Colorectal, Breast, Gastric, Ovary sex cord-gonadal stromal 
260 219 PTEN 1 From 3 Breast, Thyroid, Endometrium 
253 216 Genomic commonality41 1 From 4 Breast, Aerodigestive tract, Lung, Ovary 
241 206 BRCA1, BRCA2 1 From 2 Breast, Ovary 
241 210 TP53 1 From 8 
Breast, ACC, CNS, Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
219 188 PALB2 1 From 2 Breast, Pancreas 
215 186 CDH1 1 From 2 Breast, Gastric 
215 186 Nil 1 From 1 Breast 
173 143 Lynch syndrome 1 From 4 Colorectal, Endometrium, Ovary, Sebaceous 
141 117 Genomic commonality41 1 From 2 Colorectal, Endometrium 
115   BAP1 1 From 6 Uveal melanoma, Kidney, Melanoma, Lung, Mesothelioma, CNS meningioma 
99 82 BMPR1A 1 From 2 Colorectal, Gastric 
99 80 WRN 1 From 7 
Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma, Thyroid 
98 81 Nil 1 From 1 Colorectal 
77 68 Xeroderma Pigmentosum 1 From 2 NMSC, Melanoma 
77 68 VHL 1 From 4 Kidney, Phaeochromocytoma, Paraganglioma, CNS haemangioblastoma 
74 64 RMRP 1 From 2 NMSC, Haematological lymphoid 
74 64 DOCK8 1 From 2 NMSC, Haematological lymphoid 
67 59 RB1 1 From 7 
Retinoblastoma, Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, Uterine 
sarcoma, Melanoma 
64 56 TSC1, TSC2 1 From 3 Kidney, Kidney angiomyolipoma, CNS 
58 52 FLCN 1 From 4 Kidney, Adrenal oncocytoma, Kidney oncocytoma, Fibrofolliculoma 
58 52 FH 1 From 4 Kidney, Uterine leiomyoma, Uterine sarcoma, Cutaneous leiomyoma 
56 50 Nil 1 From 1 Kidney 
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53 46 NBN 1 From 3 Haematological lymphoid, CNS, Soft tissue sarcoma 
52 45 TERT 1 From 4 Haematological myeloid, Aerodigestive tract, Anus, Melanoma 
51 42 Nil 1 From 1 Endometrium 
50 36 CDKN1B 1 From 2 Thyroid, Pituitary 
50 41 CDKN2A 1 From 3 Melanoma, Pancreas, CNS 
50 42 Nil 1 From 1 Ovary 
47 39 RECQL4 1 From 2 NMSC, Bone sarcoma 
45 38 Nil 1 From 1 NMSC 
44 32 PRKAR1A 1 From 3 Cardiac myxoma, Thyroid, Ovary sex cord-gonadal stromal 
44 36 MEN1 1 From 8 
Pituitary, Parathyroid, ACC, GINET, Lung carcinoid, Ovary neuroendocrine, 
Paraganglioma, Phaeochromocytoma 
44 39 STK11 2 From 4 Colorectal, Breast, Gastric, Ovary sex cord-gonadal stromal 
43 35 PTEN 2 From 3 Breast, Thyroid, Endometrium 
42 37 Nil 2 From 2 Breast, Colorectal 
38 33 GBA 1 From 2 Haematological lymphoid, Haematological myeloid 
38 34 Genomic commonality41 2 From 4 Breast, Aerodigestive tract, Lung, Ovary 
38 27 Nil 1 From 1 Thyroid 
37 30 Neuroendocrine tumours 1 From 6 
GINET, Lung carcinoid, Ovary neuroendocrine, Paraganglioma, 
Phaeochromocytoma, PNET 
36 32 Nil 1 From 1 Melanoma 
33 30 Nil 1 From 1 Haematological lymphoid 
32 29 SDHA 1 From 3 Phaeochromocytoma, Paraganglioma, GIST 
31 27 Sarcomas 1 From 5 Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, Uterine sarcoma 
28 24 Lynch syndrome 2 From 4 Colorectal, Endometrium, Ovary, Sebaceous 
27 22 CNS tumour 1 From 4 CNS, CNS haemangioblastoma, CNS meningioma, CNS nerve sheath 
27 21 Fanconi anaemia 1 From 5 Haematological myeloid, Aerodigestive tract, Oesophagus, Cervix, Penis 
27 24 Nil 2 From 2 Breast, Endometrium 
24 22 Nil 2 From 2 Breast, Ovary 
23 21 HRAS 1 From 2 Soft tissue sarcoma, Bladder 
23 19 NF2 1 From 3 CNS meningioma, CNS, CNS nerve sheath 
21 19 Nil 2 From 2 Breast, NMSC 
20 17 Nil 2 From 2 Breast, Haematological lymphoid 
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18 14 BUB1B 1 From 3 Wilms, Soft tissue sarcoma, Haematological myeloid 
18 18 Nil 2 From 2 Breast, Melanoma 
17 13 DKC1 1 From 3 Haematological myeloid, Aerodigestive tract, Anus 
17 13 TP53 2 From 8 
Breast, ACC, CNS, Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
17 16 Nil 2 From 2 Endometrium, Ovary 
17 14 Nil 1 From 1 Lung 
17 15 Nil 1 From 1 Prostate 
15 11 Nil 2 From 2 Breast, Thyroid 
15 14 Nil 1 From 1 GIST 
14 13 Nil 2 From 2 Breast, Kidney 
13 11 NF1 1 From 3 CNS, PNS nerve sheath, PNS nerve sheath benign 
13 11 Nil 1 From 1 Soft tissue sarcoma 
12 10 Nil 1 From 1 CNS meningioma 
12 11 Nil 1 From 1 Colorectal polyps 
12 9 Nil 1 From 1 Pituitary 
11 9 BAP1 2 From 6 Uveal melanoma, Kidney, Melanoma, Lung, Mesothelioma, CNS meningioma 
11 9 Nil 1 From 1 Aerodigestive tract 
11 10 Nil 1 From 1 Paraganglioma 
10 8 Nil 2 From 2 Breast, Lung 
10 9 Nil 2 From 2 Colorectal, NMSC 
10 10 Nil 1 From 1 Bladder 
9 7 Nil 2 From 2 Breast, Soft tissue sarcoma 
8 7 RET 1 From 2 Thyroid medullary, Phaeochromocytoma 
8 6 Nil 2 From 2 Colorectal, Endometrium 
8 3 Nil 2 From 2 Kidney, Thyroid 
8 6 Nil 1 From 1 CNS 
8 7 Nil 1 From 1 PNET 
7 6 CDC73 1 From 2 Parathyroid, Bone benign 
7 7 WRN 2 From 7 
Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma, Thyroid 
7 6 Nil 1 From 1 Cervix 
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7 5 Nil 1 From 1 GINET 
7 4 Nil 1 From 1 Pancreas 
7 6 Nil 1 From 1 Phaeochromocytoma 
6 5 Nil 2 From 2 Colorectal, Prostate 
6 4 Nil 2 From 2 Colorectal, Thyroid 
6 6 Nil 1 From 1 CNS nerve sheath 
6 5 Nil 1 From 1 Testicular 
5 5 Nil 2 From 2 Breast, Cervix 
5 5 Nil 2 From 2 Breast, CNS meningioma 
5 4 Nil 2 From 2 Kidney, Lung 
5 3 Nil 1 From 1 Haematological myeloid 
5 3 Nil 1 From 1 Lung carcinoid 
5 4 Nil 1 From 1 Uveal melanoma 
4 3 Nil 1 From 1 Bone benign 
4 3 Nil 1 From 1 CNS haemangioblastoma 
4 3 Nil 1 From 1 Ovary sex cord-gonadal stromal 
4 4 Nil 1 From 1 PNS nerve sheath benign 
4 4 Nil 1 From 1 Salivary gland 
4 4 Nil 1 From 1 Small bowel 
3 3 Nil 1 From 1 ACC 
3 3 Nil 1 From 1 Kidney oncocytoma 
3 2 Nil 1 From 1 Oesophagus 
3 3 Nil 1 From 1 Parathyroid 
 
ACC – Adrenocortical carcinoma, CNS – Central nervous system, GINET – Gastrointestinal neuroendocrine tumour, GIST – Gastrointestinal stromal tumour, NMSC – Non-melanoma skin cancer, PNET – 
Pancreatic neuroendocrine tumour, PNS – Peripheral nervous system 
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6.2.2.5 - Control group 
In order to compare variant frequency in cases vs controls, a control group (n=4,053) was used that 
was made up of participants (assessed as European ethnicity) in other non-MPT arms of the BRIDGE 
project. Genotype data from these individuals was included in the merged VCF used for analysis of 
cases. This control dataset offered the advantage of having been sequenced and bioinformatically 
processed in an identical manner to cases, minimising the probability of observing differences in 
variant frequencies due to discrepancies in those processes between datasets. A disadvantage is that 
BRIDGE participants predominantly exhibit rare disease phenotypes, which may be caused by genetic 
variation that could also contribute to tumourigenic processes. To counter this, the recruitment criteria 
for different arms of the project were reviewed and samples excluded if they belonged to an arm 
where there was considered to be a higher probability of neoplastic processes occurring. Individual 
phenotypic information was not available to perform exclusions on a case by case basis. A summary 
of the constituent samples of the control set can be found in Table 6.4. 
 
Table 6.4 - Control group derived from non-MPT arms of BRIDGE project 
Acronym Full name 
No. 
samples 
No. 
samples 
(European) 
Rationale for exclusion 
SPEED 
Specialist pathology evaluating 
exomes in diagnostics 
1389 869 N/A 
PAH Pulmonary arterial hypertension 1157 966 
Variants in BMPR2 can be 
causative. Bone morphogenetic 
protein signalling downregulated in 
some cancers.  
PID Primary immune disorders 1371 1078 N/A 
BPD  
Bleeding, thrombotic and platelet 
diseases 
1170 984 N/A 
GEL Genomics England pilot 2000 1694 
May include suspected inherited 
cancers. Unknown if case or 
control. 
PMG 
Primary membranous 
glomerulonephritis 
193 167 N/A 
SRNS 
Steroid resistant nephrotic 
syndrome 
252 166 N/A 
ICP 
Intrahepatic cholestasis of 
pregnancy 
270 190 N/A 
HCM Hypertrophic cardiomyopathy 253 227 N/A 
SMD Stem cell and myeloid disorders 257 130 Fanconi anaemia phenotypes 
CSVD Cerebral small vessel disease 250 233 N/A 
NPD Neuropathic pain disorders 195 139 N/A 
 
For structural variant analysis, Canvas and Manta calls were only available for 3,889/4,053 
individuals and this was the size of the control group used for any comparisons involving structural 
variant frequency. 
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VCF files from the 1958 birth cohort exome sequencing data349 were also interrogated for variants in 
the regions of interest though allele frequencies would only be used as a further line of evidence in the 
event of potentially significant results highlighted by other comparisons (rather than hypothesis 
testing). This is due to the high number of apparently spurious results generated due to differences in 
sequencing coverage and pre-VCF variant filtering.  
 
6.2.2.6 - Variant counting and hypothesis testing – Single nucleotide variants and indels (Script 
RA6.1) 
Counting of variants and hypothesis testing was performed in R. For each of the gene lists, the variant 
table read into the R environment was subset to only include variants within a gene on that list. 
Subsequently, for every phenotypic subgroup, frequency of each variant in cases and controls was 
recorded with separate counts generated for heterozygous and homozygous genotypes. To test for 
statistically significant differences in frequency of variants detected in cases vs controls, a 
contingency table was constructed for each variant to denote cases and controls with or without the 
variant. Separate tables were produced for heterozygous, homozygous and summed heterozygous and 
homozygous genotypes. A Fishers exact test350 was then performed on contingency tables to test the 
null hypothesis of no difference in variant frequency in cases vs controls. This test was considered 
appropriate given that analysis was based on rare truncating variants and, for each test, it was 
expected that one of the values in the contingency table would be less than five. To allow for multiple 
hypothesis testing, Benjamani-Hochberg correction351 was applied to the p-values generated from all 
hypothesis tests where the number of tests was taken as the number of variant sites present in the 
analysed variant table (including all BRIDGE individuals and 1958 birth cohort individuals). Rather 
than simply increase p-values as a direct function of the number of tests (as in more conservative 
methods such as Bonferroni correction), this technique takes into account the distribution of p-values 
generated by all the tests in the experiment to produce a false discovery rate expressed as a q-value. A 
q-value of 0.05 implies that amongst all p-values in the experiment with a q-value <0.05, 5% will be 
false positives.  
 
Pathogenic truncating variants in a given CPG are often diverse and analysis of individual variants 
may not detect genes in which variants are over-represented in cases vs controls. Consequently, 
counts of individuals harbouring ≥1 variant in a given gene were also analysed. For each phenotypic 
subgroup, contingency tables were produced for every gene on the analysed gene list comprising 
counts of cases and controls with or without a variant in that gene. Individuals with heterozygous, 
homozygous and heterozygous or homozygous variants were considered separately. Fishers exact 
tests were again applied to the contingency tables with Benjamani-Hochberg correction where the 
152 
 
number of tests was taken as the number of genes on the analysed list. The process was repeated for 
each of the gene lists. 
 
6.2.2.7 - Variant counting and hypothesis testing - Structural variants (Script RA6.2) 
The “per gene” analysis was also undertaken using counts of structural variants. For each gene on the 
gene lists (as used for analysis of single nucleotide variants and indels), the number of individuals 
with a variant fulfilling one of the qualifying criteria (Table 6.2) was noted to produce counts for case 
and control groups. As individual structural variants are unlikely to be shared between unrelated 
individuals and given the margin of error in precise predicted breakpoints, counts of individual 
variants were not considered. Rather, comparisons were made of the frequency of individuals with a 
structural variant affecting a given gene in cases vs controls. The same phenotypic subgroups were 
used as for single nucleotide variant and indel analysis although the number of included individuals 
within these subgroups was frequently reduced due to variant calls pertaining to a number of 
individuals being unavailable. 
 
6.2.2.8 - Variant counting and hypothesis testing – Single nucleotide variants and indels 
combined with structural variants (Script RA6.3) 
Under the rationale that structural variants and single nucleotide variants/indels affecting a given gene 
may both lead to loss of a functional protein product, counts of variants were combined amongst cases 
and controls. For each gene on an analysed list therefore, the total number of individuals with a 
qualifying variant of any type could be compared with that observed in controls. As per structural 
variant analysis in isolation, the numbers of cases and controls included in these analyses were 
smaller due to structural variant calls for some individuals being unavailable. 
 
6.3 Analysis of variants in known or putative proto-oncogenes 
 
6.3.1 - Introduction 
Whilst most described CPGs are tumour suppressor genes, a number of cancer predisposition 
syndromes are due to deleterious variants in proto-oncogenes. Such variants lead to tumourigenesis 
through a gain of function mechanism and are typically non-truncating. Examples include Multiple 
Endocrine Neoplasia Type 2, which is associated with susceptibility to medullary thyroid cancer, 
phaeochromocytoma and parathyroid tumours. Causative variants are missense and affect a relatively 
narrow range of codons of the RET gene, leading to dimerisation of the receptor tyrosine kinase gene 
product and/or persistent signalling.13 MET encodes a further receptor tyrosine kinase where missense 
variants (in the tyrosine kinase domain) can cause Hereditary Papillary Renal Cell Carcinoma.14 
Studies to identify novel CPGs frequently (as above) prioritise frameshift, nonsense and splice site 
variants but this strategy will not detect potentially causative gain of function variants in proto-
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oncogenes. Consequently, data resulting from MPT cases were also interrogated for missense variants 
and inframe insertions/deletions in genes with functional similarity to existing proto-oncogene CPGs. 
Counts of variants were used for further comparisons of cases and controls. Structural variant calls 
were also interrogated to identify SVs predicted to lead to increased copy number of these genes with 
subsequent use in a separate analysis as well as one combined with single nucleotide variants and 
indels.  
 
6.3.2 – Methods 
 
6.3.2.1 – Gene list composition 
In order to compile a list of known and putative gain of function CPGs proposed by functional 
relatedness, a comprehensive review of CPGs45 was interrogated to elicit any CPG annotated with  a 
gain of function mechanism of action (ALK, CDK4, EGFR, HRAS, KIT, MET, PDGFRA, PTPN11, 
RET, RHBDF2, SOS1). Resulting genes were annotated with HUGO Gene Nomenclature Committee 
(HGNC) gene family identifiers and all terms pertaining to known gain of function CPGs were 
compiled and reviewed. All of these terms considered consistent with tumourigenic processes were 
used to search the HGNC Gene Families Index352 (Table 6.5) and all gene names assigned with these 
terms downloaded for use in analysis (Table A9). Gene names included in the downloaded table 
(n=184) were used to obtain a list of canonical transcripts and coding region genomic coordinates as 
described for truncating variants.  
 
Table 6.5 - HUGO Gene Nomenclature Committee gene families used to search for possible 
proto-oncogene CPGs 
Identifier Description 
321 Receptor Tyrosine Kinases 
496 Cyclin dependent kinases 
1096 Erb-b2 receptor tyrosine kinases 
389 RAS type GTPase family 
812 Protein tyrosine phosphatases, non-receptor type 
722 Rho guanine nucleotide exchange factors 
 
6.3.2.2 – Variant filtering and case control comparison (Scripts RA6.4 , RA.6.5 and RA6.6) 
Coordinates were used to extract variants from WGS VCFs as per truncating variant analysis. 
Following annotation of the resulting merged VCF with VEP, variants were filtered based on allele 
frequency as previously described and on consequence, with only variants annotated with the 
consequences “missense_variant”, “inframe_deletion” or “inframe_insertion” being retained. To 
identify predicted SVs causing increased dosage of the genes on the gene list, copy number gain 
variant calls called by the Canvas algorithm were interrogated. Only this modality of SV call was 
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considered as other variant types such as deletions and translocations (notwithstanding the possibility 
of fusion genes and displacement to more transcriptionally active sites) are less likely to be consistent 
with a gain of function mechanism. Files containing calls were searched as per truncating variant 
analysis but would only pass filters if the start of the variant call was at a genomic coordinate before 
the start of the gene and the end of the variant call was after the end of the gene as defined by 
coordinates downloaded from Ensembl Biomart.184   
 
Variant counting and hypothesis testing were executed in the same manner as for the truncating 
variant analysis. Phenotypic subgroups used were restricted to the group containing all MPT cases 
(n=424) and another comprised of all individuals diagnosed with at least one tumour amongst a list of 
neoplasms known to be associated45 with existing gain of function CPGs (Melanoma, Lung, Bladder, 
Gastrointestinal stromal tumour, Kidney, Thyroid medullary, Phaeochromocytoma, Paraganglioma, 
Soft tissue sarcoma, Haematological myeloid, n=152). The number of tests for Benjamani-Hochberg 
adjustment in analysis of individual variant frequency was taken as the number of unique variants 
detected in cases or controls. For counts of individuals with variants per gene, the number of tests was 
taken as the number of genes on the gene list (n=184). 
 
For each gene on the gene list, the number of individuals with a copy number gain SV (Table 6.2) was 
recorded in case and control groups and hypothesis testing performed with those counts. SV counts 
were also combined with SNV/indel counts for each individual each gene and compared. The same 
two subgroups were analysed but the number of individuals in each was reduced due to non-
availability of SV calls for some participants (All MPT cases n=360, 1 from 10 of Melanoma, Lung, 
Bladder, Gastrointestinal stromal tumour, Kidney, Thyroid medullary, Phaeochromocytoma, 
Paraganglioma, Soft tissue sarcoma, Haematological myeloid n=133). The control group was reduced 
to 3,889 individuals. The number of tests for multiple hypothesis correction was again the number of 
genes on the gene list (n=184). 
 
6.4 Analysis of estimated telomere length and counts of variants in genes related to telomere 
function in individuals with multiple primary tumours 
 
6.4.1 -Introduction 
Telomeres are repetitive sequences located at the ends of chromosomes that have a role in avoidance 
of genomic instability that may ensue through recognition of chromosome ends as areas of DNA 
damage. The process of cell division leads to a shortening of telomeres due to incomplete synthesis of 
the lagging strand by polymerases and further processing of chromosome ends to maintain telomere 
structure.353 It follows that ageing should be associated with shortening and this has been observed in 
a number of studies. A systematic review of length measurement studies estimated the rate to be 
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around 20 base pairs per year.354 Regulation and maintenance of telomeres is executed by two primary 
complexes. Telomerase lengthens them by adding repeats through a reverse transcriptase mechanism 
but has reduced activity in human tissues after embryonic development. Shelterin binds to telomeres 
and has a role in regulating telomerase activity as well as inhibiting DNA damage responses such as 
ATM activation and non-homologous end joining.353 
 
Telomere maintenance is known to be relevant to the development of cancer but observations relating 
to telomere length in tumour and germline samples from individuals with neoplasia have led to a 
complex picture. As telomeres become shorter, they may become more vulnerable to DNA repair 
mechanisms that lead to chromosome aberrations. Resulting genome instability can potentially lead to 
somatic changes necessary for tumour development and both shortened telomeres and chromosome 
abnormalities indicative of unprotected telomeres have been observed in studies of cancer.355–357 
Furthermore, constitutional pathogenic variants in the telomerase reverse transcriptase component 
gene TERT are associated with predisposition to particular cancers and affected individuals have been 
demonstrated to exhibit shorter telomere length.358,359 Familial pulmonary fibrosis is associated with 
an increased risk of lung cancer whereas Dyskeratosis Congenita, also associated with TERT variants, 
causes nail dysplasia, oral leukoplakia and cutaneous pigmentation abnormalities as well as 
predisposition to acute myeloid leukaemia and aerodigestive tract cancers. Shorter telomeres have 
also been observed in BRCA1 and BRCA2 pathogenic variant carriers vs controls.360 
 
Despite observations such as these indicating an association with shorter telomere length and 
neoplasia, most human cancers show upregulated telomerase activity.361 A constitutional variant in the 
TERT promoter that causes upregulation of telomerase has been identified in a family with multiple 
occurrences of melanoma and subsequently observed recurrently in melanoma cell lines from 
sporadic cases.362 Constitutional loss of function variants in POT1, part of the shelterin complex, have 
also been seen in familial melanoma cases and shown to reduce binding to telomeres.363 Affected 
individuals had longer telomere length, seemingly related to the normal role of POT1 in inhibiting 
telomerase activity.353 Additionally, a large study of around 95,000 individuals demonstrated an 
association between genetic determinants of longer telomere length (three single nucleotide 
polymorphisms in telomerase component genes) and increased cancer risk. Increased risk of lung 
cancer and melanoma was also shown to be associated with longer telomere length.364 
 
To regard association of cancer with both shorter and longer telomere length/increased telomerase 
activity as contradictory would be to over-simplify interpretation of these phenomena. Telomere 
shortening can be regarded as a tumour suppressive mechanism as it is associated with activation of 
DNA damage responses, reduced proliferation and apoptosis. However, it may also increase the 
chance of chromosomal instability and tumourigenic aberrations. Subsequently, acquisition of 
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telomerase activity in cells that had sufficiently short telomeres to provoke these events could lead to 
developing tumour cells continued viability. Hypotheses to explain why longer telomeres can prompt 
cancer include avoidance of the tumour suppressive effects of telomere shortening and a dysregulated 
telomere phenotype with longer, unprotected telomeres.353 Under the former model, tumourigenic 
mutational processes would predominantly be through means unrelated to shortened telomeres. In the 
latter model, oncogenic abnormalities would include telomere related structural variants such as 
telomere containing chromosome fusions, as have been observed in chronic lymphocytic leukaemias 
associated with somatic POT1 variants.365 
 
WGS provides an opportunity to gain insight into telomere biology through the estimation of their 
length in a DNA sample. This is due to the fact that, in contrast to targeted sequencing approaches, 
reads from telomeric regions are generated in sufficient numbers. Given that telomere length has 
relevance to tumourigenic processes, telomere length was estimated in MPT cases as well as controls. 
A regression model was fitted to estimated length vs age at sampling to assess deviation from the 
model. Both longer and shorter telomeres have been noted in individuals with cancer predisposition 
syndromes and within the MPT cases, two groups were identified who had length estimates within the 
top and bottom quartiles of residuals. Two case-control based analyses were then performed using the 
two groups as cases and regarding counts of variants in telomere related genes as the exposure of 
interest. 
 
6.4.2 -Methods 
 
6.4.2.1 - Analysing telomere length in BRIDGE BAM files (Script RA6.7) 
To estimate leukocyte telomere length in individuals using WGS data, the Telomerecat package 
(version 3.2)366 was used. This tool isolates sequencing read pairs from BAM files that are consistent 
with telomeric origin (contain ≥2 CCCTAA or TTAGGG sequences) to produce a “telbam” file. 
Telomere length is then estimated from the ratio of entirely telomeric read pairs to read pairs arising 
from telomeric and non-telomeric regions (as longer telomeres are more likely to produce read pairs 
entirely sequenced from telomeric areas). Telbams were produced for WGS BAM files with the 
telomerecat bam2telbam function and length estimates from telbams were generated with the 
telbm2length command. Prior to categorising telbam reads, telbam2length considers sequencing 
errors which involves generating a distribution of genotype quality scores from random loci and 
comparing it with a distribution from loci that are apparent mismatches to telomeric sequence. 
Consequently, non-identical outputs are generated from each run of telbam2length. To allow for this, 
ten outputs were generated for each telbam and the mean taken as the telomere length estimate for that 
sample.  
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6.4.2.2 - Estimated age at sampling 
Telomere length reduces with cell division and is inversely correlated with age.354 Measurement of it 
in this context should take into account the age at sampling. Documentation of this was provided by 
BRIDGE. For samples in the MPT arm (labelled MPMT in the BRIDGE project), the medical record 
was further reviewed to provide a date (or year if date not available) that the sample was taken. 
Samples were excluded from further analysis if an age was unavailable. A table was then compiled 
that linked per sample estimated telomere length with age at sampling. There is some evidence that 
telomere length is associated with ancestry367,368 and non-European samples were excluded given that 
this would produce a minor reduction in the number of MPT cases and also that only European 
ethnicity samples would be used for variant frequency analysis downstream. It has previously been 
suggested that sex also influences telomere length but a meta-analysis to investigate this was not 
conclusive369 and samples from male and female study participants were considered together. 
 
6.4.2.3 - Fitting a linear model to estimated telomere length vs age at sampling and calculating 
residuals (Script RA6.7) 
In order to assess the degree of deviance from expected telomere length given the age at sampling, the 
R lm function was used to fit a linear model (Figure 6.3) to the relationship between mean estimated 
telomere length and age at sampling across all 3,557 samples (Table 6.6, MPT, n=417 and non-MPT, 
n=3140). Significance testing of the model (F-statistic p-value < 2.2e-16) indicated rejecting the null 
hypothesis of no relationship between the variables. 
 
Next, residuals based on the linear model were taken to provide a measure of how far the mean 
estimated telomere length deviated from the expected value for each individual given the age at 
sampling (Figure 6.4). Residuals of MPT cases were compared with non-MPT controls (Figure 6.5) 
with a Welch t-test (as Bartlett test indicated unequal variance between the groups, p = 3.371e-12), 
which showed significantly lower (i.e. shorter telomere length) residuals in the MPT group (p = 
0.001105).  
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Table 6.6 - BRIDGE samples used in telomere length analysis 
BRIDGE sub-project Mean age at sampling Number of samples 
BPD 42.59351 481 
PID 43.21670 1003 
SPEED 34.54710 672 
PMG 39.33607 150 
MPMT 56.41230 417 
ICP 35.94946 147 
HCM 59.22851 188 
CSVD 59.28183 197 
NPD 51.53243 136 
SRNS 33.58158 166 
 
Figure 6.3 - Plot of linear model. MPMT individuals indicated by red points 
 
Red points indicate MPT samples. Green points indicate non-MPMT samples 
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Figure 6.4 - Plot of residuals by project 
 
NIHR (National Institute of Health Research) BioResource also referred to as BRIDGE  
 
Figure 6.5 - Plot of residuals MPMT vs non-MPMT 
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6.4.2.4 – Results of comparison of residuals between BRIDGE projects with discussion 
Residuals as a function of telomere length were significantly lower (i.e. suggesting shorter telomeres) 
in the MPMT arm cases although the difference was not large. Extent of deviation from the linear 
model is susceptible to inaccuracies surrounding the documented date of sampling and this was not 
uniformly clear due to the fact that a large number of DNA samples were not from blood freshly taken 
for the purposes of the study. Furthermore, dates for non-MPMT BRIDGE arms could not be 
reviewed as part of the present analysis and may have been subject to biases. A large contributor to 
the difference in residuals between non-MPMT and MPMT appears to be the Specialist Pathology: 
Evaluating Exomes in Diagnostics (SPEED) study, which recruits paediatric cases with suspected 
monogenic neurological disorders. Any over-estimate in the age at sampling in that study could have 
led to the higher residuals. Alternatively, a poorer fit of the linear model at lower age at sampling is 
suggested by the scatter plot and could have contributed to greater deviations. A further possible 
explanation for comparatively shorter telomeres in the MPMT arm includes the effect of 
chemotherapeutic agents, which many participants would have been exposed to prior to blood 
sampling for DNA extraction. A study of 260 sporadic breast cancer patients treated with first line 
chemotherapy showed shorter telomere length than in controls, an effect that was also observed in 236 
familial breast cancer cases. In both series, recovery of telomere length was also observed.370 In a 
review of studies regarding the effect of a wide variety of chemotherapy drugs on telomere length in 
cell lines, a large majority of reports observed shortening.371 
 
6.4.2.5 – Analysis of variants in telomere related genes amongst multiple primary tumour cases 
with shortest and longest residuals 
To investigate the hypothesis that MPT cases with shorter or longer telomeres may have been 
predisposed to developing tumours due to a constitutional genetic variant in a telomere related gene 
(according to a list defined below), two case control analyses were performed where cases were 
identified by telomere length. To this end, the bottom and top quartile of residuals from the linear 
model in MPT cases were taken and corresponding individuals used to form a case group (n=107 for 
low residual group, n=105 for high residual group). The control group was made up of the same 4,053 
European individuals used in the truncating variant analysis.  
 
6.4.2.6 – Collating a list of telomere related genes 
The variants of interest for analysis were those within genes documented as being related to telomere 
function. To formulate a gene list, the Gene Ontology database annotation file (version 2.1)344 was 
downloaded and any line containing the character string “telomer” extracted. All GO terms within 
these lines were reviewed and a list of relevant terms compiled. Additionally, terms on this list were 
entered into the European Bioinformatics Institute QuickGo tool for GO term searches372 to generate 
161 
 
an ontology term map. Any additional telomere related terms connected to the existing ones were then 
added to the list of terms of interest (Table 6.7). This amalgamated list of 19 GO terms was used to 
search the Gene Ontology annotation file to extract all gene names annotated with at least one of the 
terms (n=137) (Table A10). 
 
Table 6.7 - Gene ontology terms relating to telomere function 
Identifier Description 
GO:0003720 telomerase activity 
GO:0010833 telomere maintenance via telomere lengthening 
GO:0032204 regulation of telomere maintenance 
GO:0032205 negative regulation of telomere maintenance 
GO:0032206 positive regulation of telomere maintenance 
GO:0032210 regulation of telomere maintenance via telomerase 
GO:0051972 regulation of telomerase activity 
GO:1904356 regulation of telomere maintenance via telomere lengthening 
GO:1904357 negative regulation of telomere maintenance via telomere lengthening 
GO:1904358 positive regulation of telomere maintenance via telomere lengthening 
GO:0032211 negative regulation of telomere maintenance via telomerase 
GO:0051973 positive regulation of telomerase activity 
GO:0032212 positive regulation of telomere maintenance via telomerase 
GO:0005697 telomerase holoenzyme complex 
GO:0070034 telomerase RNA binding 
GO:0000723 telomere maintenance 
GO:0032201 telomere maintenance via semi-conservative replication 
GO:0007004 telomere maintenance via telomerase 
GO:0042162 telomeric DNA binding 
 
6.4.2.7 – Variant filtering and case control comparison (Scripts RA6.8, RA6.9 and RA6.10) 
As previously described for truncating variant analysis, gene names were used to identify canonical 
transcripts, Ensembl gene IDs and coding region genomic coordinates. A BED file based on these 
coordinates was used to extract variants in the regions of interest from WGS VCFs. The resulting 
merged VCF was annotated and filtered based on allele frequency as previously but all of the 
following consequence annotations could be included: “splice_acceptor_variant”, 
“splice_donor_variant”, “stop_gained”, “frameshift_variant”, “stop_lost”, “start_lost”, 
“initiator_codon_variant”, “inframe_insertion”, “inframe_deletion”, “missense_variant” or 
“protein_altering_variant.” Files containing SV calls were interrogated in the same manner as for 
truncating variants and any call fulfilling the filtering criteria was used to inform the counts of 
individuals with an SV predicted to affect each gene on the gene list.  
 
Counting of variants and individuals with variants per gene with hypothesis testing was performed as 
per truncating variant analysis. The number of tests for Benjamani-Hochberg adjustment in analysis 
of individual variant frequency was taken as the number of unique variants detected in cases or 
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controls. For counts of individuals with variants per gene, the number of tests was taken as the 
number of genes on the telomere related gene list (n=137). 
 
Counts of individuals with SVs per gene and SVs combined with SNVs/indels per gene were also 
considered as per truncating variant analysis. For these purposes the number of individuals in each 
group was reduced due to SV calls for some participants being unavailable (low residual group n=80, 
high residual group n=81). The size of the control group was reduced to 3,889. The number of tests 
for multiple hypothesis correction was again the number of genes on the gene list (n=137). 
 
6.5 Analysis of non-coding variants potentially relevant to cancer predisposition 
 
6.5.1 - Introduction 
A key potential advantage of WGS in identifying constitutional variants predisposing to neoplasia is 
the ability to sequence non-coding regions. Although coding regions make up a small minority of the 
human genome, the majority of disease associated variants are within them.373 Potential contributing 
factors to this observation are lower functional redundancy in coding regions and a hitherto restricted 
ability to sequence non-coding areas with assays commonly used in research studies.  
 
The use of WGS in genetic research is increasing but the identification of individual non-coding 
variants that can cause Mendelian disorders has been infrequent. This is partly due to the difficulty in 
annotating non-coding variants with information that guides whether it is relevant for disease or not. 
Non-coding variants impacting on CPG function are consequently few in number but have been 
described. One example is CDKN2A ENST00000304494 c.-34G>T, which is within the 5’ UTR, has 
been reported to disrupt splicing,374 and has pathogenic status in ClinVar. Efforts to combine germline 
DNA sequencing and RNA sequencing in tissues have produced association of non-coding variants 
with gene expression375 and may contribute to the elucidation of disease-causing variants. 
 
Although the number of specific non-coding variants associated with cancer predisposition syndromes 
are low in number, a large body of evidence has accumulated that indicates which regions are more 
likely to be significant in disease causation. The ENCODE project is a notable accumulation of such 
evidence, which compiles the findings of a large number of experiments performed using a wide 
variety of assays.216 An example is co-immunoprecipitation sequencing (ChIP-seq), which identifies 
regions of the genome bound to defined proteins of interest (e.g. proteins known to bind to DNA) 
through antibody binding to those proteins, pull down and subsequent massively parallel 
sequencing.376 A further assay type utilised by the project identifies less condensed areas of chromatin  
(i.e. more likely to be transcribed) by their sensitivity to cleavage by DNAse enzymes.377 Efforts such 
as ENCODE have resulted in a canon of non-coding regions where transcription or binding influence 
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gene expression including promoters and long range regulatory elements such as enhancers. 
Additionally, functional relevance of non-coding regions can be indicated by conservation across 
species and lists of these regions have been curated.378 
 
Given that WGS data generated as part of the present study gave the opportunity to search for non-
coding variants in regions potentially relevant to tumour development, frequency of variants affecting 
a range of such regions were recorded and compared with controls in a similar manner to the case-
control based analyses described earlier in this chapter. 
 
6.5.2 - Methods 
Study design relating to non-coding variants is summarised in Figure 6.2. 
 
6.5.2.1 - Enhancers and promoters (Scripts RA6.11, RA6.12 and RA6.13) 
Non-coding regions of the genome may exert a phenotypic effect by affecting gene expression. Two 
recognised mechanisms involve promoters, which lie close to the genes whose transcription they 
influence, and enhancers, which are more distant.379  
 
In order to identify promoters and enhancers which may affect CPGs, the GeneCards380 database was 
searched with the gene names (n=133) corresponding to all genes appearing in a comprehensive 
review of CPGs45 (n=114) or sequenced by the Illumina TruSight Cancer gene panel assay (Illumina 
Inc., San Diego, CA, USA) (n=94). Additionally, published CPGs NTHL136 and CDKN2B182 that 
didn’t appear in either of the two lists were included. For each page corresponding to an individual 
gene name (searched 07/09/2017), available information regarding relevant enhancers and promoters 
was extracted and reviewed to produce a list of regions of interest. 
 
Reported promoters for a gene in GeneCards are based on the Ensembl database and expressed as 
Ensembl regulatory region identifiers.184 All such identifiers (n=73) on the interrogated gene pages 
were taken and converted to GRCh37 coordinates with BioMart.185 Enhancers associated with a gene 
in GeneCards (collated by the GeneHancer database381) are taken from a number of sources including 
the Encyclopaedia of DNA elements (ENCODE),216 Ensembl, Functional Annotation of the 
Mammalian Genome (FANTOM5)382 and VISTA,383 a browser containing experimentally validated 
non-coding elements with enhancer activity. Putative enhancers are given “Elite GeneHancer” status 
if they are supported by ≥2 of these evidence sources and only these (n=1050) were taken for further 
use. Genomic coordinates for enhancers were obtained via download from the GeneCards website. 
 
Coordinates corresponding to all elements of interest (n=1,123) were compiled and used to produce a 
BED file. This was in turn used to interrogate BRIDGE WGS data and produce a variant table with 
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filtering for quality and allele frequency as described for analysis of truncating variants. No filter was 
imposed for molecular consequence. 
 
Files containing structural variant calls were also interrogated to identify variants predicted to disrupt 
any of the elements of interest using the same genomic coordinates as used in the BED file and the 
same quality and variant frequency filtering criteria used for truncating variant analysis. 
Consequences of SVs in non-protein coding regions are less readily predictable than for coding 
regions and only deletions (Canvas or Manta calls) or translocations (Manta calls) were considered 
further as they were considered to be more likely to cause functional disruption. 
 
To assess for significant differences in frequency of variants within the non-coding regions of interest, 
variant counts and hypothesis testing (Fishers exact tests with Benjamani-Hochberg correction) was 
also performed as per the analysis of truncating variants. Frequency of each observed variant was 
considered where the number of tests (for correction purposes) was equal to the number of unique 
variants observed in cases or controls. Counts of individuals with variants in each of the non-coding 
elements were also analysed where the number of tests was the number of elements considered 
(n=1,123). The phenotypic subgroups used were the same as for truncating variant analysis. Counts of 
individuals with SVs and SVs combined with SNVs/indels in each element were also compared in 
cases vs controls. Reduction in the size of case and control groups due to SV call availability was as 
per truncating variant analysis. 
 
6.5.2.2 - Ultra-conserved elements (Scripts RA6.14, RA6.15 and RA6.16) 
Functional activity of non-coding regions can also be suggested by evolutionary conservation and 
further regions to analyse in MPT cases were identified in this way. The Database of Ultra-conserved 
Non-coding Elements (UCNE)378 has curated 4,351 non-coding regions that exceed 200 base pairs in 
length and have ≥95% sequence homology between human and chicken based on data downloaded 
from the University of California Santa Cruz (UCSC) browser. Most are predicted to regulate 
transcription and are categorised as intergenic (n=2,139), intronic (n=1,713) or untranslated regions 
(n=499). Human hg19 UCNE data (downloaded 21/9/2018) was used to provide genomic coordinates 
for all reported elements. Using these coordinates, analysis of frequency of variants (SNVs/indels, 
SVs, SNVs/indels combined with SVs) in cases vs controls was performed in the same way as for 
enhancers and promoters. 
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6.5.2.3 - Expression quantitative trait loci (Scripts RA6.17, RA6.18 and RA6.19 for expression 
quantitative trait loci from Genotype Tissue Expression Project. Scripts RA6.20, RA6.21 and 
RA6.22 for expression quantitative trait loci from cancer tissue studies) 
Association of non-coding variants with gene expression levels across multiple tissue types has 
recently been reported in two major publications.375,384 Such variants have been termed expression 
quantitative trait loci (eQTL) and given that they may affect expression of CPGs, their role in the 
MPT series was also investigated. 
 
The first set of eQTL considered were those identified by the Genotype Tissue Expression Project 
(GTEx) that were reported to affect expression of 83 CPGs appearing in the gene list used for the 
WGS-based comprehensive CPG analysis described in Chapter 4 and listed in Table 4.1. Genes on 
this smaller list of CPGs were considered to have more robust evidence for a role in predisposition to 
adult onset tumours. Variant-gene pairs reported by GTEx have been relatively recently described in a 
single analysis and the smaller list was utilised to provide greater confidence of phenotypic relevance 
in any potentially significant results observed. GTEx recently reported 12,546 unique variant gene-
pairs (observation of the same pairs in multiple tissues meant that 48,452 variant-gene-tissue 
combinations were reported) from the analysis of 10,294 samples from post-mortem donors between 
the ages of 21 and 70 years.375 Donors had never been diagnosed with metastatic cancer and had not 
been treated with chemotherapy or radiotherapy in the two years prior to death. All variant gene pairs 
containing observations from all 48 tissue types (Table 6.8) were downloaded from the GTEx portal 
(version 7). Those quoted as significant by GTEx (q value <0.05) and reported to affect the expression 
of a gene on the gene list were selected but excluded if the data indicated that an eQTL had a positive 
effect on tumour suppressor gene expression or negative effect on proto-oncogene expression.  
 
Table 6.8 - GTEx tissue types 
GTEx tissue 
Tumour in participant prompting interrogation for variant-
gene pairs observed in GTEx tissue 
Adipose_Subcutaneous Lipoma 
Adipose_Visceral_Omentum N/A (no tumours in series in this tissue) 
Adrenal_Gland Phaeochromocytoma, ACC 
Artery_Aorta N/A (no tumours in series in this tissue) 
Artery_Coronary N/A (no tumours in series in this tissue) 
Artery_Tibial N/A (no tumours in series in this tissue) 
Brain_Amygdala CNS, CNS nerve sheath 
Brain_Anterior_cingulate_cortex_BA24 CNS, CNS nerve sheath 
Brain_Caudate_basal_ganglia CNS, CNS nerve sheath 
Brain_Cerebellar_Hemisphere CNS, CNS nerve sheath 
Brain_Cerebellum CNS, CNS nerve sheath 
Brain_Cortex CNS, CNS nerve sheath 
Brain_Frontal_Cortex_BA9 CNS, CNS nerve sheath 
Brain_Hippocampus CNS, CNS nerve sheath 
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Brain_Hypothalamus CNS, CNS nerve sheath 
Brain_Nucleus_accumbens_basal_ganglia CNS, CNS nerve sheath 
Brain_Putamen_basal_ganglia CNS, CNS nerve sheath 
Brain_Spinal_cord_cervical_c-1 CNS, CNS nerve sheath 
Brain_Substantia_nigra CNS, CNS nerve sheath 
Breast_Mammary_Tissue Breast 
Cells_EBV-transformed_lymphocytes Haematological lymphoid 
Cells_Transformed_fibroblasts N/A (not site specific) 
Colon_Sigmoid Colorectal 
Colon_Transverse Colorectal 
Esophagus_Gastroesophageal_Junction Oesophagus 
Esophagus_Mucosa Oesophagus 
Esophagus_Muscularis Oesophagus 
Heart_Atrial_Appendage Cardiac myxoma 
Heart_Left_Ventricle N/A (no tumours in series in this tissue) 
Liver N/A (no tumours in series in this tissue) 
Lung Lung 
Minor_Salivary_Gland Salivary gland 
Muscle_Skeletal Soft tissue sarcoma 
Nerve_Tibial 
PNS nerve sheath benign, PNS nerves heath, Nerve sheath 
benign 
Ovary Ovary 
Pancreas Pancreas 
Pituitary Pituitary 
Prostate Prostate 
Skin_Not_Sun_Exposed_Suprapubic NMSC, Melanoma, Skin benign 
Skin_Sun_Exposed_Lower_leg NMSC, Melanoma, Skin benign 
Small_Intestine_Terminal_Ileum Small bowel, GINET 
Spleen N/A (no tumours in series in this tissue) 
Stomach Gastric 
Testis Testicular 
Thyroid Thyroid 
Uterus Endometrial, Uterine leiomyoma, Uterine sarcoma 
Vagina N/A (no tumours in series in this tissue) 
Whole_Blood 
Haematological lymphoid, Haematological myeloid, 
Haematological polycythaemia, Haematological 
thrombocythaemia 
 
ACC – Adrenocortical carcinoma, CNS – Central Nervous system, EBV – Epstein Barr Virus, GINET – Gastrointestinal 
neuroendocrine tumour, NMSC – Non-melanoma skin cancer, PNS – Peripheral nervous system. 
 
The second set of eQTL were reported by a study analysing tumour tissues as opposed to assumed 
normal tissues from donors.384 Paired tumour-normal WGS with matched transcriptome was obtained 
for 930 samples and associations identified between somatic SNVs and expression of target genes 
proposed by the variant being within a putative regulatory region (as defined by GeneHancer or 
within 1kb of a transcription start site). eQTL are frequently expressed as regions because SNVs 
occurring within 50bp of each other are grouped together. Supplementary tables from the publication 
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resulting from the study were downloaded and higher confidence eQTL (10% false discovery rate cut-
off incorporating 102 at 5% cut-off and 67 at 5-10% cut-off) from 22 cancer types were retained for 
further consideration. Most eQTL were duplicated across cancer types, meaning that 27 unique eQTL 
were used for downstream analysis (Table 6.9). Given that these variants were identified in cancer 
tissues, no further selection for eQTL affecting particular genes was performed. 
 
Table 6.9 - Expression quantitative trait loci identified through analysis of cancer tissues 
Gene affected 
eQTL 
chromosome 
eQTL start eQTL end 
Distance to gene transcription 
start site (bp) 
HYI 1 43824528 43824563 95115 
RCSD1 1 167427918 167427936 -171547 
LIMS2 2 128439680 128439729 -345 
C2orf27A 2 133024749 133024808 544715 
C3orf18 3 49823985 49824038 781212 
GLYCTK 3 52322011 52322052 196 
HERC3 4 88637542 88637550 -876028 
TERT 5 1295161 1295253 -45 
TIGD6 5 149312169 149312257 67958 
C6orf136 6 30704977 30705039 90192 
TAS2R5 7 141437957 141437957 -52060 
NCALD 8 103118690 103118718 17858 
ENPP2 8 120718851 120719000 -67820 
PARD3 10 34955724 34955748 148517 
TSPAN32 11 2017704 2017713 -305535 
TMEM138 11 61735191 61735192 605719 
KCNJ5 11 128761332 128761340 23 
ACOT1 14 74231057 74231077 227139 
EDC3 15 74626537 74626587 361824 
HMG20A 15 77965491 77965558 252532 
ZNF44 19 13128329 13128457 -722679 
ZNF284 19 43772478 43772537 -803790 
DHX34 19 47901366 47901512 48901 
CA11 19 49660338 49660421 -510929 
ZNF551_ZNF544 19 58322231 58322339 128948 
SIRPB1 20 1598197 1598223 2479 
CTNNBL1 20 36794104 36794104 471747 
 
 
The resulting genomic coordinates corresponding to both sets of eQTL were used to produce two 
BED files with which to extract variants from VCFs generated from WGS data as per the truncation 
variant analysis, although no filter was imposed relating to predicted consequence of the variant. 
 
For eQTL generated by GTEx, a number of phenotypic subgroups of cases (drawn from the same pool 
as for truncating variant analysis) were subject to case-control analysis according to the tissues in 
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which eQTL were reported to have an effect. For example, in breast cancer cases, only eQTL altering 
gene expression in breast tissue would be considered. Initially, all GTEx tissues were designated with 
tumour labels corresponding to neoplasms occurring in the MPT series that could arise from that 
tissue (Table A11). For example, adrenal gland tissue was attached to the terms phaeochromocytoma 
and adrenal cortical carcinoma. 23 phenotypic subgroups of cases were formulated to incorporate all 
cases with a tumour arising from a GTEx tissue. A group containing all cases was also used (Table 
6.10). 
 
Table 6.10 - Phenotypic subgroups used for GTEx expression quantitative trait loci analysis 
No. tumours required 
to be included 
Tumours 
No. 
individuals 
No. individuals for 
counts incorporating 
structural variants 
N/A - All MPT 
individuals 
All 424 360 
1 From 1 Breast 215 186 
1 From 1 Colorectal 98 81 
1 From 3 NMSC, Melanoma, Skin benign 78 68 
1 From 3 
Endometrium, Uterine leiomyoma, 
Uterine sarcoma 
53 44 
1 From 1 Ovary 50 42 
1 From 4 
Haematological lymphoid, 
Haematological myeloid, Haematological 
polycythaemia, Haematological 
thrombocythaemia 
40 35 
1 From 1 Thyroid 38 27 
1 From 1 Haematological lymphoid 33 30 
1 From 1 Lung 17 14 
1 From 1 Prostate 17 15 
1 From 2 CNS, CNS nerve sheath 14 12 
1 From 1 Soft tissue sarcoma 13 11 
1 From 1 Pituitary 12 9 
1 From 2 Small bowel, GINET 11 9 
1 From 2 Phaeochromocytoma, ACC 10 9 
1 From 1 Pancreas 7 4 
1 From 3 
PNS nerve sheath benign, PNS nerve 
sheath, Nerve sheath benign 
6 6 
1 From 1 Testicular 6 5 
1 From 1 Salivary gland 4 4 
1 From 1 Oesophagus 3 2 
1 From 1 Cardiac myxoma 2 2 
1 From 1 Gastric 2 2 
 
ACC – Adrenocortical carcinoma, CNS – Central nervous system, GINET – Gastrointestinal neuroendocrine tumour, GIST – 
Gastrointestinal stromal tumour, NMSC – Non-melanoma skin cancer, PNS – Peripheral nervous system 
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Each variant in the variant table produced by filtering was annotated with the corresponding GTEx 
eQTL identifier, the gene whose expression is affected by it, and the tissue where the association is 
noted. This annotation was used, for each phenotypic subgroup, to reduce the variant table down to 
only those eQTL which influence expression in a tissue relevant to that subgroup. Counting of 
individuals with variants amongst cases vs controls with hypothesis testing was performed as per 
truncating variant analysis. For counts of individuals with particular variants, the number of tests for 
correction purposes was taken as the number of unique tissue specific variants in the variant table in 
cases or controls. For the counts of individuals with variants at eQTL reported to affect the expression 
of each gene, the number of tests was taken as 83 (number of genes considered that are affected by 
GTEx eQTL).  
 
As per other analyses described in this chapter, structural variant call data were also interrogated for 
SVs that affected the considered eQTL. This was performed as per truncating variant analysis but 
only filtered for deletions of the eQTL (Canvas or Manta calls) because GTEx eQTL are expressed as 
single nucleotide coordinates and breakpoints are less likely to be relevant. eQTL reported to enhance 
expression of proto-oncogenes were filtered out because deletion of an eQTL in which variants are 
associated with downregulation of a tumour suppressor gene is more likely to emulate the effect of an 
eQTL SNV at that loci than an SV (of any type) is to emulate an eQTL SNV that upregulates 
expression of a proto-oncogene. Counts of individuals with SVs affecting eQTLs reported to 
influence expression of each gene were compared between cases and controls using the same 
phenotypic subgroups, albeit with reduction in numbers due to SV call availability (Table 6.10). 
Counts of individuals with SVs combined with SNVs/indels were also considered. Subsetting of 
eQTL according to tissue type was used as for SNVs/indels. The number of tests for Benjamani-
Hochberg multiple hypothesis adjustment was again 83.  
 
For the eQTL reported from cancer tissue studies, the broader phenotypic subgroupings used for 
truncating variant analysis were employed as differences in gene expression contributing to 
tumourigenesis in one cancer type may be relevant to others. Variant counting within these groups 
and hypothesis testing was performed as per GTEx based analysis but without any variant sub-setting 
based on the tissue in which the eQTL was reported. 27 (the number of eQTL considered, each with a 
unique associated gene) was taken as the number of tests when considering counts of individuals with 
a variant in an eQTL reported to affect the expression of each gene. SV counts and counts of SVs and 
SNVs indels affecting these eQTL was also considered in the same way but given that eQTL reported 
from cancer tissue studies are expressed as regions, deletions (Canvas or Manta) and translocations 
(Manta) were included as these SV types may be more likely to emulate the effect of variants in those 
regions than inversions, gains, insertions or duplications.  
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6.6 - Analysis for causative variants in a family with suspected recessive tumour predisposition 
 
6.6.1 - Introduction 
Whilst case control based analyses have identified numerous variants and genes contributing to 
disease, the basis of multiple genetic conditions has been elucidated by analysing families where 
multiple members have a phenotype that is considered to be due to the same genetic factor under a 
hypothesised mode of inheritance. Consideration of the segregation of variants in affected and 
unaffected family members can reduce the number of putative causative variants, particularly under a 
recessive hypothesis or in a presumed dominant inheritance pattern where more than one family is 
available for analysis. The MPT series contained few family members of probands but a single family 
with a possible autosomal recessive tumour predisposition syndrome was investigated.  
 
Autosomal recessive conditions can be suggested by the occurrence of multiple siblings affected with 
a similar phenotype that are born to unaffected parents, particularly if both males and females are 
affected. In the investigated family, a brother and sister had been affected with osteomas and/or 
lipoma. The female sibling had bilateral mandibular osteomas at age 11 whilst the male sibling had 
osteoma in an unspecified site (not histologically confirmed) and a 5.5cm (largest dimension) lipoma 
in the left deltoid region, both before the age of 13 years. There was a further unaffected male sibling 
aged 9 years and both parents had no history of tumours. There was no family history of neoplasms 
except for two diagnoses of breast (age 74 years) and prostate (age ~60 years) cancer in the paternal 
grandmother and a paternal uncle respectively. No consanguinity was reported in the medical record.   
 
The female sibling had had APC genetic testing with no deleterious variants identified. The male 
sibling was identified as harbouring an ATM variant that was assessed as likely pathogenic in the 
WGS-based comprehensive CPG analysis described in Chapter 4. This variant was not present in the 
sister, however. 
 
WGS had been performed on blood samples from both affected siblings and both parents. Variants 
resulting from this were analysed according to both a homozygous and compound heterozygous 
hypothesised mechanism of causation. 
 
6.6.2 - Methods 
 
6.6.2.1 - Variant filtering (Script RA6.23) 
Initially, all exonic variants from the four samples were extracted from per chromosome BRIDGE 
merged VCFs using a pre-prepared hg19 based BED file associated with the Nextera Rapid Capture 
kit version 1.2 (Illumina Inc., San Diego, CA, USA) and merged into a single VCF. Exonic variants 
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were chosen because using all variants from WGS would result in a high number of putative causative 
variants, about which information regarding possible pathogenicity would likely be inadequate for 
exclusion. The merged VCF was filtered with bcftools filter based on quality parameters (as per 
truncating variant analysis) to exclude genotypes that didn’t meet the specified criteria.  
 
Subsequently, the file was split into per individual VCFs and bcftools view used to output six new per 
individual files containing variants where the genotype conformed to a specified zygosity. For the 
affected siblings, files containing only sites with homozygous variants were created as well as files 
containing only sites with heterozygous variants. Files containing only sites with heterozygous 
variants were output for both parents. 
 
To check for possible causative variants according to a homozygous hypothesis, bcftools isec was 
used to output sites that were present in both offspring homozygous VCFs and both parental 
heterozygous VCFs. The coordinates of any variants fulfilling these criteria where then used to extract 
variants at those positions from the original merged VCF containing genotype information for all four 
individuals. The newly subset merged VCF was then annotated with Ensembl VEP and filtered to 
retain variants with a consequence annotation suggestive of an effect on protein function 
(“splice_acceptor_variant”, “splice_donor_variant”, “stop_gained”, “frameshift_variant”, “stop_lost”, 
“start_lost”, “initiator_codon_variant”, “inframe_insertion”, “inframe_deletion”, “missense_variant”, 
“protein_altering_variant”) and with an allele frequency in 1000 Genomes European data of <0.05.  
 
Potentially causative variants according to a compound heterozygote hypothesis were generated in a 
similar manner but bcftools isec was this time used to output separate files containing variant sites 
present in the heterozygous VCFs from both offspring and one parent, with the process repeated for 
the other parent. Coordinates generated from both these enquiries were collated and used for a further 
extraction of variants from the merged VCF. 
 
6.6.2.2 - Review of filtered variants 
Variants identified by the above process according to a homozygous hypothesis (n=2) were reviewed 
further, taking into consideration allele frequencies in publically available datasets161,166,349 and in the 
European non-MPT BRIDGE control group as previously utilised in case control analyses. Presence 
in other MPT cases was also considered. In addition, the GeneCards380 entry for the relevant genes 
was reviewed for disease associations and functional descriptions. GeneMania346 was used to check 
for interactions between genes containing variants and known CPGs. There are no osteoma studies 
contained in the cBioportal34 platform but gene names were entered into it to check for recurrent 
mutation or expression abnormalities across tumour types. 
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Variant pairs that were identified by the workflow designed to search for causative compound 
heterozygous variants were only considered further if they were in the same gene, each parent 
harboured one of them and both offspring were heterozygous for both variants. Resulting variants 
were then reviewed in a similar way to those proposed as part the homozygous hypothesis. If either 
variant in a variant pair had a maximum allele frequency in any 1000 Genomes or gnomAD 
population above 0.05 then the corresponding variant pair was not considered further. 
 
6.7 - Results 
Outputs from the various analyses to detect novel loci potentially involved in cancer predisposition 
are presented and discussed together in this section. These include case control analysis of truncating 
variants, variants in putative proto-oncogenes and variants in genes associated with telomere 
function/maintenance. Also incorporated are analyses of non-coding variants, namely variants within 
ultra-conserved regions/enhancers/promoters or those within loci associated with altered expression of 
CPGs reported by either the GTEx project (in normal tissues) or Zhang et al (in cancer tissues).384 
 
6.7.1 - Truncating variants in known or suspected cancer predisposition genes (see 6.2) 
Counts of individuals harbouring variants in each gene on a gene list were considered and compared 
with that in a group of controls. Frequency of individual variants was also considered. Analyses were 
performed utilising multiple gene lists, phenotypic subgroups and zygosity statuses with multiple 
hypothesis correction applied within each analysis. 
 
Gene level comparisons where the q-value was below a 0.05 significance threshold (n=53) are shown 
in Table 6.11 whilst comparisons at variant level are described in Table 6.12. These are considered to 
be the genes/variants most likely to represent causative association with the considered phenotype. 
Most of the genes/variants have multiple highlighted results, indicating that the result reaches the 
significance threshold in multiple comparisons using a number of different gene lists, phenotypic 
subgroups or zygosity states. 
 
Top gene level results were CHEK2, MAX, NF1 or PALB2, all of which are known CPGs. Significant 
results involving CHEK2 were noted in eight phenotypic subgroups, seven of which specifically 
incorporated breast cancer cases. Individuals with CHEK2 variants are summarised, along with the 
variant they harboured, in Table 6.13. Nine participants with c.1229delC (p.Thr410fs) (also referred 
to as c.1100delC) were recorded as well as five individuals with other variants. Although non-breast 
tumours were included in most of the subgroups producing significant results, most of the individuals 
contributing to them (10/11 females) had previously been diagnosed with breast cancer. CHEK2 
truncating variants were also over-represented across all MPT cases (Figure 6.4) due to fourteen 
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heterozygotes and one homozygote. 8/14 heterozygotes (57.1%, all female) were breast cancer cases 
whilst 6/14 (42.8%, 5 females and 1 male) had not been diagnosed with that tumour. 
 
Figure 6.4 - Hypothesis tests (individuals with variants per gene) from analysis of all MPT cases 
(n= 424) - Full gene list (n=1055), heterozygous individuals 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
 
The spectrum of non-breast tumours in variant carriers is heterogeneous but the most frequent is renal 
cell carcinoma (RCC), which occurred in 4/14 (28.6%) heterozygous individuals, three of whom were 
males who had not developed breast cancer. One individual with RCC was also identified with a 
translocation affecting FLCN. When compared with the 409 MPT individuals without a heterozygous 
CHEK2 truncating variant (homozygote for c.1229delC (p.Thr410fs) excluded), the frequency of 
RCC was not significantly increased at a p-value threshold of <0.05 (4/14 cases in variant carriers vs 
52/409 in non-variant carriers, Fishers exact test p = 0.09975). Furthermore, CHEK2 was not 
highlighted in the analysis of the RCC phenotypic subgroup (56 individuals). At variant level, eight 
individuals (1 male and 7 females) with CHEK2 c.1229delC (p.Thr410fs) led to over-representation 
(heterozygous or homozygous) in the subgroup diagnosed with breast, thyroid or endometrial cancer 
(Figure 6.5). Six carriers (all female) had breast cancer, 2 had endometrial cancer and 1 (male) had 
thyroid malignancy. 
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Figure 6.5 - Hypothesis tests (individual variants) from analysis of cases with ≥1 tumour from 
Breast, thyroid and endometrium (n=260) - Repair gene list (n=445), heterozygous or 
homozygous individuals. 22:29091856:AG>A corresponds to CHEK2 c.1229delC (p.Thr410fs) 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
 
Truncating variants in NF1 were over-represented in a number of phenotypic subgroups involving 
gastrointestinal stromal tumour (GIST) (Figure 6.6), accounted for by four individuals diagnosed with 
that tumour (Table 6.14). All of these individuals had typical features of Neurofibromatosis type 1 and 
had previously been diagnosed clinically. 
 
Figure 6.6 - Hypothesis tests (individuals with variants per gene) from analysis of GIST cases 
(n= 15) - Full gene list (n=1055), heterozygous individuals 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
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PALB2 truncating variants were observed in five breast cancer cases (Table 6.15), leading to 
individuals with variants in that gene being over-represented in six phenotypic subgroups. These 
included the group of any individual with breast cancer (n=215, heterozygotes or homozygotes) 
(Figure 6.7) and other groupings involving breast cancer. There was also over-representation in the 
subgroup diagnosed with at least one tumour from haematological myeloid, aerodigestive tract, anus 
or melanoma (tumours associated with TERT variants) but all four individuals contributing to this 
result had also been diagnosed with breast cancer. Three heterozygotes from this subgroup harboured 
the c.3113G>A (p.Trp1038*) variant, leading to a significantly elevated frequency of this particular 
variant vs controls (Table 6.15, Figure 6.8) 
 
Figure 6.7 - Hypothesis tests (individuals with variants per gene) from analysis of breast cancer 
cases (n= 215) - Mania gene list (n=142), heterozygous or homozygous individuals 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
 
176 
 
Figure 6.8 - Hypothesis tests (individual variants) from analysis of cases with ≥1 tumour from 
Haematological myeloid, aerodigestive tract, anus and melanoma (n=52) - Repair gene list 
(n=445), heterozygous individuals. 16:23632683:C>T corresponds to PALB2 c.3113G>A 
(p.Trp1038*) 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
 
 
Two individuals with phaeochromocytoma (Table 6.16) harboured heterozygous truncating variants in 
MAX, leading to q-values below 0.05 when comparing their frequency between controls and 
individuals with at least one tumour from kidney, phaeochromocytoma, paraganglioma and 
haemangioblastoma (tumours associated with VHL variants) (Figure 6.9).  
 
Figure 6.9 - Hypothesis tests (individuals with variants per gene) from analysis of cases with ≥1 
tumour from kidney, phaeochromocytoma, paraganglioma and central nervous system 
haemangioblastoma (n= 77) - Mania gene list (n=142), heterozygous individuals 
 
Plot shows data points corresponding to gene variants that were present in any BRIDGE or 1958BC sample 
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Table 6.11 – Genes in which truncating variants over-represented in cases vs controls 
Gene Phenotypic subgroup 
Gene 
list/s 
Het 
cases 
Proportion 
cases het 
(%) 
Het 
controls 
Proportio
n controls 
het (%) 
q value 
for hets 
Hom 
cases 
Het or 
hom 
cases 
Proportion 
cases het 
or hom (%) 
Het or 
hom 
controls 
Proportion 
controls het 
or hom (%) 
q value 
for het 
or hom 
CHEK2 1 From 2 - Breast, Gastric Mania 7 3 26 0.6 0.074 1 8 4 26 0.6 0.03 
CHEK2 1 From 2 - Breast, Ovary Mania 7 3 26 0.6 0.139 1 8 3 26 0.6 0.05 
CHEK2 1 From 2 - Breast, Pancreas Full 8 4 26 0.6 0.244 1 9 4 26 0.6 0.048 
CHEK2 1 From 2 - Breast, Pancreas Mania 8 4 26 0.6 0.033 1 9 4 26 0.6 0.006 
CHEK2 1 From 2 - Breast, Pancreas Repair 8 4 26 0.6 0.103 1 9 4 26 0.6 0.02 
CHEK2 1 From 2 - Breast, Pancreas 
Webgesta
lt 
8 4 26 0.6 0.143 1 9 4 26 0.6 0.028 
CHEK2 1 From 3 - Breast, Thyroid, Endometrium Full 9 3 26 0.6 0.17 1 10 4 26 0.6 0.035 
CHEK2 1 From 3 - Breast, Thyroid, Endometrium Mania 9 3 26 0.6 0.023 1 10 4 26 0.6 0.005 
CHEK2 1 From 3 - Breast, Thyroid, Endometrium Repair 9 3 26 0.6 0.072 1 10 4 26 0.6 0.015 
CHEK2 1 From 3 - Breast, Thyroid, Endometrium 
Webgesta
lt 
9 3 26 0.6 0.099 1 10 4 26 0.6 0.021 
CHEK2 
1 From 4 - Colorectal, Breast, Gastric, Ovary 
sex cord-gonadal stromal 
Mania 8 3 26 0.6 0.085 1 9 3 26 0.6 0.032 
CHEK2 
1 From 8 - Breast, ACC, CNS, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma 
Mania 7 3 26 0.6 0.092 1 8 3 26 0.6 0.031 
CHEK2 All Full 13 3 26 0.6 0.035 1 14 3 26 0.6 0.009 
CHEK2 All Mania 13 3 26 0.6 0.005 1 14 3 26 0.6 0.001 
CHEK2 All Repair 13 3 26 0.6 0.015 1 14 3 26 0.6 0.004 
CHEK2 All 
Webgesta
lt 
13 3 26 0.6 0.021 1 14 3 26 0.6 0.005 
CHEK2 1 From 1 – Breast Mania 7 3 26 0.6 0.074 1 8 4 26 0.6 0.03 
MAX 
1 From 4 - Kidney, Phaeochromocytoma, 
Paraganglioma, CNS haemangioblastoma 
Mania 2 3 0 0 0.049 0 2 3 0 0 0.049 
NF1 
1 From 3 - Phaeochromocytoma, 
Paraganglioma, GIST 
CGP 4 13 3 0.07 0.00002 0 4 13 3 0.07 0.00002 
NF1 
1 From 3 - Phaeochromocytoma, 
Paraganglioma, GIST 
Full 4 13 3 0.07 0.0001 0 4 13 3 0.07 0.0001 
NF1 
1 From 3 - Phaeochromocytoma, 
Paraganglioma, GIST 
Loftool 4 13 3 0.07 0.00005 0 4 13 3 0.07 0.00005 
NF1 
1 From 3 - Phaeochromocytoma, 
Paraganglioma, GIST 
Mania 4 13 3 0.07 0.00002 0 4 13 3 0.07 0.00002 
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NF1 
1 From 3 - Phaeochromocytoma, 
Paraganglioma, GIST 
Webgesta
lt 
4 13 3 0.07 0.00007 0 4 13 3 0.07 0.00007 
NF1 
1 From 5 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
CGP 4 13 3 0.07 0.00002 0 4 13 3 0.07 0.00002 
NF1 
1 From 5 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
Full 4 13 3 0.07 0.0001 0 4 13 3 0.07 0.0001 
NF1 
1 From 5 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
Loftool 4 13 3 0.07 0.00004 0 4 13 3 0.07 0.00004 
NF1 
1 From 5 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
Mania 4 13 3 0.07 0.00001 0 4 13 3 0.07 0.00001 
NF1 
1 From 5 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma 
Webgesta
lt 
4 13 3 0.07 0.00006 0 4 13 3 0.07 0.00006 
NF1 
1 From 7 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma, Melanoma, Thyroid 
CGP 4 4 3 0.07 0.002 0 4 4 3 0.07 0.002 
NF1 
1 From 7 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma, Melanoma, Thyroid 
Full 4 4 3 0.07 0.011 0 4 4 3 0.07 0.011 
NF1 
1 From 7 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma, Melanoma, Thyroid 
Loftool 4 4 3 0.07 0.005 0 4 4 3 0.07 0.005 
NF1 
1 From 7 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma, Melanoma, Thyroid 
Mania 4 4 3 0.07 0.001 0 4 4 3 0.07 0.001 
NF1 
1 From 7 - Connective tissue soft tissue 
sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma, Melanoma, Thyroid 
Webgesta
lt 
4 4 3 0.07 0.006 0 4 4 3 0.07 0.006 
NF1 
1 From 7 - Retinoblastoma, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma 
CGP 4 6 3 0.07 0.0005 0 4 6 3 0.07 0.0005 
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NF1 
1 From 7 - Retinoblastoma, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma 
Full 4 6 3 0.07 0.002 0 4 6 3 0.07 0.002 
NF1 
1 From 7 - Retinoblastoma, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma 
Loftool 4 6 3 0.07 0.001 0 4 6 3 0.07 0.001 
NF1 
1 From 7 - Retinoblastoma, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma 
Mania 4 6 3 0.07 0.0003 0 4 6 3 0.07 0.0003 
NF1 
1 From 7 - Retinoblastoma, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma, 
Melanoma 
Webgesta
lt 
4 6 3 0.07 0.001 0 4 6 3 0.07 0.001 
NF1 
1 From 8 - Breast, ACC, CNS, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma 
Mania 4 2 3 0.07 0.042 0 4 2 3 0.07 0.031 
NF1 1 From 1 – GIST CGP 4 27 3 0.07 
0.00000
1 
0 4 27 3 0.07 
0.00000
1 
NF1 1 From 1 – GIST Full 4 27 3 0.07 
0.00000
4 
0 4 27 3 0.07 
0.00000
4 
NF1 1 From 1 – GIST Loftool 4 27 3 0.07 
0.00000
2 
0 4 27 3 0.07 
0.00000
2 
NF1 1 From 1 – GIST Mania 4 27 3 0.07 
0.00000
3 
0 4 27 3 0.07 
0.00000
3 
NF1 1 From 1 – GIST 
Webgesta
lt 
4 27 3 0.07 
0.00000
1 
0 4 27 3 0.07 
0.00000
1 
PALB2 1 From 2 - Breast, Gastric Mania 5 2 9 0.2 0.061 0 5 2 9 0.2 0.030 
PALB2 1 From 2 - Breast, Ovary Mania 5 2 9 0.2 0.01 0 5 2 9 0.2 0.05 
PALB2 1 From 2 - Breast, Pancreas Mania 5 2 9 0.2 0.033 0 5 2 9 0.2 0.033 
PALB2 
1 From 4 – Haematological myeloid, 
Aerodigestive tract, Anus, Melanoma 
Full 4 8 9 0.2 0.016 0 4 8 9 0.2 0.016 
PALB2 
1 From 4 – Haematological myeloid, 
Aerodigestive tract, Anus, Melanoma 
Mania 4 8 9 0.2 0.002 0 4 8 9 0.2 0.002 
PALB2 
1 From 4 – Haematological myeloid, 
Aerodigestive tract, Anus, Melanoma 
Repair 4 8 9 0.2 0.007 0 4 8 9 0.2 0.007 
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PALB2 
1 From 4 – Haematological myeloid, 
Aerodigestive tract, Anus, Melanoma 
Webgesta
lt 
4 8 9 0.2 0.009 0 4 8 9 0.2 0.009 
PALB2 
1 From 8 - Breast, ACC, CNS, Connective 
tissue soft tissue sarcoma, Bone sarcoma, 
GIST, Skin sarcoma, Uterine sarcoma 
Mania 5 2 9 0.2 0.05 0 5 2 9 0.2 0.033 
PALB2 1 From 1 – Breast Mania 5 2 9 0.2 0.06 0 5 2 9 0.2 0.03 
 
ACC – Adrenocortical carcinoma, CNS – Central nervous system, GIST – Gastrointestinal stromal tumour, Het – Heterozygous, Hom - Homozygous 
 
Table 6.12 – Truncating variants over-represented in cases vs controls 
Gene Transcript Coordinate Description Gene list Phenotypic subgroup 
Het 
cases 
Het 
controls 
q value 
for hets 
Hom 
cases 
Hom 
controls 
Het or 
hom 
cases 
Het or 
hom 
controls 
q value 
for hets 
or homs 
PALB2 ENST00000261584 chr16:23632683 
c.3113G>A 
(p.Trp1038*) 
Repair 
1 From 4 – Haematological 
myeloid, Aerodigestive tract, 
Anus, Melanoma 
3 3 0.019 0 0 3 3 0.019 
PALB2 ENST00000261584 chr16:23632683 
c.3113G>A 
(p.Trp1038*) 
Mania 
1 From 4 – Haematological 
myeloid, Aerodigestive tract, 
Anus, Melanoma 
3 3 0.024 0 0 3 3 0.024 
CHEK2 ENST00000382580 chr22:29091856 
c.1229delC 
(p.Thr410fs) 
Repair 
1 From 3 – Breast, Thyroid, 
Endometrium 
7 17 0.19 1 0 8 17 0.034 
CHEK2 ENST00000382580 chr22:29091856 
c.1229delC 
(p.Thr410fs) 
Mania 
1 From 3 – Breast, Thyroid, 
Endometrium 
7 17 0.25 1 0 8 17 0.045 
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Table 6.13 – Truncating variants in CHEK2 (heterozygous) 
Transcript Coordinate Description Consequence Phenotype with age at diagnosis Family history of neoplasia reported 
ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift Kidney, 56; Kidney, 56; Kidney, 56 Unavailable 
ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift Kidney, 56; Kidney, 60 Mother - Breast, 47 
ENST00000382580 chr22:29091226 c.1392delT (p.Leu464fs) Frameshift 
Thymus, 53; Breast, 54; Haematological 
lymphoid, 63; Haematological lymphoid, 67 
Daughter - Ovary, 41, Colorectal, 41; Paternal uncle 
- Lung, 76; Paternal uncle - Lung, 78 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs)* Frameshift 
Fibrofolliculoma (multiple), 18; Kidney (clear cell 
carcinoma), 53 
Unavailable 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 52; Melanoma, 54 
Mother - Breast, <45; Sister - NMSC, <58; Maternal 
aunt - Ovary, >59 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Endometrium, 54; Breast, 57 
Brother - Colorectal, 28; Maternal aunt x2 - 
Unknown primary ? Age. 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Breast, 50 (DCIS); Kidney, 62; GINET (appendix 
neuroendocrine tumour), 63; Haematological 
myeloid (CML), 65 
Daughter - Neuroendocrine tumour of appendix, 
25; Maternal aunt - CLL, 63; Maternal aunt - Breast, 
50 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 31; Gastric, 49 Nil 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Breast, 45; Breast, 54; Breast (DCIS), 55 Maternal aunt - Gastric, 65 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Colorectal (ascending colon), 27; Endometrium, 
53; Colorectal (hepatic flexure), 56; NMSC 
(multiple BCC), <64 
Father - Liver ? age; Paternal uncle - Colorectal ? 
age. 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift Thyroid, 45; Pancreas, 48 Unavailable 
ENST00000382580 chr22:29091856 c.1229delC (p.Thr410fs) Frameshift 
Breast, 40; Pancreas benign (solid 
pseudopapillary tumour), 41 
Paternal lineage: Father - Parotid, ? age; Paternal 
aunt - Breast, 42; Paternal grandmother - Kidney 
80. Maternal lineage: Mother - Breast, 54; 
Maternal cousin - Breast, 39; Maternal aunt - Lung, 
53. 
ENST00000382580 chr22:29105993 c.1051+1C>T 
Splice site 
(donor) 
Breast, 46; Ovary, 49 (bilateral endometrioid); 
Ovary (bilateral endometrioid), 49; Endometrium 
(endometrioid), 49 
Sister - Breast, 49; Mother - Breast, 46; Maternal 
uncle - Bladder, 50-59; Maternal grandmother - 
Breast, 50-59 
ENST00000382580 chr22:29115410 c.784delG (p.Glu262fs) Frameshift 
Colorectal polyps (tubulovillous adenomas), 46; 
Parathyroid (adenoma), 48; Parathyroid 
(adenoma), 55; Parathyroid (adenoma), 59 
Mother - Lung, 53 
 
*Also has translocation with breakpoint in FLCN. BCC – Basal cell carcinoma, CLL – Chronic lymphocytic leukaemia, CML – Chronic Myeloid Leukaemia, DCIS – Ductal carcinoma in-situ, GINET – 
Gastrointestinal stromal tumour, NMSC – Non-melanoma skin cancer 
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Table 6.14 – Truncating variants in NF1 (heterozygous) 
Transcript Coordinate Description Consequence Phenotype with age at diagnosis Family history of neoplasia reported 
ENST00000358273 chr17:29546035 
c.1541-1542delAG 
(p.Gln514fs) 
Frameshift 
Nerve sheath benign (multiple 
cutaneous neurofibromas), <30; GIST 
(jejunal), 46; CNS Nerve sheath (spinal 
neurofibroma), 51 
Clinically NF1 in proband, brother, mother and further 2nd 
degree relatives. Brother - Adrenal gland tumour, ? age; 
Mother - Bone tumour ? age. 
ENST00000358273 chr17:29684007 
c.7768-7769insA 
(p.His2590fs) 
Frameshift 
PNS Nerve sheath (MPSNT), 20; GIST 
(wild type duodenal), 41 
Father - Phaeochromocytoma, >59. 
ENST00000358273 chr17:29588770 
c.4620delA 
(p.Ala1540fs) 
Frameshift Lipoma (back), 29; GIST (duodenal), 44 
Clinically NF1 in proband, mother and maternal grandfather. 
Mother - Unknown primary, 40 
ENST00000358273 chr17:29661873 
c.5831delT 
(p.Leu1944fs) 
Frameshift GIST (multiple jejunal), 36 
Clinically NF1 in proband, daughter, brother and mother. 
Brother - Optic glioma, 5; Daughter - Rhabdomyosarcoma, 3 
 
CNS – Central nervous system, NF1 - Neurofibromatosis type 1, GIST – Gastrointestinal stromal tumour, MPSNT – Malignant peripheral nerve sheath tumour, PNS – Peripheral nervous system. 
 
Table 6.15 - Truncating variants in PALB2 (heterozygous) 
Transcript Coordinate Description Consequence Phenotype with age at diagnosis Family history of neoplasia reported 
ENST00000261584 chr16:23625409 
c.3116delA 
(p.Asn1039fs) 
Frameshift 
Breast, 35; Skin sarcoma 
(angiosarcoma in radiotherapy 
field), 37; Aerodigestive tract (nasal 
cavity SCC), 43 
Sister - Breast, 48; Mother - Breast, 35 
ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Anus, 37; Breast, 42 
Father - Gastric, 69; Paternal uncle - NMSC, 66; Paternal 
grandmother - Unknown primary, 87; Paternal cousin once 
removed - Unknown primary, 48; Paternal cousin once removed 
- Aerodigestive tract, 48; Paternal great aunt - Ovary, 53; 
Paternal great uncle - Liver, 40; Paternal great uncle - Lung, 60; 
Paternal great grandfather - Gastric, 43 
ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Melanoma, 31; Breast, 40 Father - Breast, 68; Paternal great aunt - Breast, 30 
ENST00000261584 chr16:23632683 c.3113G>A (p.Trp1038*) Stop gain Melanoma, 38; Breast, 47 
Sister - Breast, 58; Sister - Breast, 51; Mother - Breast, 48; 
Maternal grandmother - Breast, 48; Maternal cousin - Breast, 43 
ENST00000261584 chr16:23649437 c.62T>G (p.Leu21*) Stop gain Colorectal, 51; Breast, 54 
Sister - Breast, 43; Sister - Breast, 43; Sister - NHL, 53; Brother - 
Prostate, 67; Brother - Colorectal, 40; Paternal grandfather - 
Colorectal, 65 
 
NHL – Non-Hodgkin’s lymphoma, NMSC – Non-melanoma skin cancer, SCC – Squamous cell carcinoma 
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Table 6.16 – Truncating variants in MAX (heterozygous) 
Transcript Coordinate Description Consequence Phenotype with age at diagnosis 
Family history of neoplasia 
reported 
ENST00000358664 chr14:65544637 c.289C>T (p.Gln97*) Stop gain 
Phaeochromocytoma, 16; 
Phaeochromocytoma, 35 
Sister - Phaeochromocytoma, <49 
ENST00000358664 chr14:65560500 c.228C>T (p.Arg33*) Stop gain Phaeochromocytoma, 43; Kidney, 43 Father - Testicular, 60-69 
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Counts of structural variants affecting each gene on the gene lists were also compared in cases vs 
controls. One result returned a q-value below the chosen significance threshold of 0.05 and was 
produced by the occurrence of a heterozygous translocation (review of BAM file with Integrated 
Genomics Viewer (IGV) showed some reads supporting this call but only when viewed from one end 
of the translocation (Appendix 5, variant 8)) affecting HABP2 in a single individual with breast, 
colorectal and pancreatic cancer (Table 6.17) vs two controls in nine phenotypic subgroups (All MPT 
cases; 1 From 3 Breast, Thyroid, Endometrium; 1 From 8 Breast, Adrenocortical carcinoma (ACC), 
Central nervous system (CNS) tumours, Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma; 1 From 4 Colorectal, Breast, Gastric, Ovary sex cord-gonadal stromal; 1 From 2 
Breast, Gastric; 1 From 1 Breast; 1 From 2 Breast, Pancreas; 1 From 4 Breast, Aerodigestive tract, 
Lung , Ovary and 1 From 2 Breast Ovary). 
 
This individual with the HABP2 translocation also contributed to one of a number of gene level 
results with q-values below the significance thresholds when counts of individuals with SVs and 
SNVs/indels were combined (Table 6.18). Three individuals with heterozygous HABP2 truncating 
variants contributed to a total of three cases among two subgroups producing such results (Tables 6.19 
and 6.20). One individual with a heterozygous nonsense BMPR1A variant and a one with a 
translocation affecting that gene produced a significant result in the analysis of all MPT cases as well 
as other phenotypic subgroups involving breast cancer (two cases vs 11 controls) (Tables 6.21 and 
6.22). The BMPR1A translocation was predicted to have a breakpoint between exons 1 and 2, which 
are both non-coding. Review of reads supporting the variant call in IGV demonstrated that all of them 
were due to discordant mate pairs (rather than split reads) aligning to chromosome 5, where the 
counterpart predicted breakpoint was located, and chromosome 10, where BMPR1A is located 
(Appendix 5, variant 9). Other highlighted results were produced due to a single case with an SNV or 
indel in APCS or MSH6. These latter results were not considered further as no contribution to them 
was made by the addition of SVs to the analysis. The reduction in q-value is likely to have been due to 
the reduction in size of phenotypic subgroups (due to non-availability of SV calls for some 
individuals) leading to individuals with variants making up a greater proportion of cases. 
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Table 6.17 - Predicted structural variant affecting HABP2 (heterozygous) 
Chromosome Predicted start Predicted end Algorithm Predicted consequence 
Phenotype with age at 
diagnosis 
Family history of neoplasia reported 
10 Chr10:115318616 chr6:7227789 Manta 
Translocation with 
breakpoint between exons 
1 and 2 (both coding) 
Breast (bilateral), 46; 
Colorectal, 51; Pancreas, 52 
Mother - Fibrosarcoma, 50; Maternal aunt - 
Breast, 70; Maternal grandfather – Prostate, 52 
 
Table 6.18 – Genes in which truncating variants over-represented in cases vs controls where combination of counts of single nucleotide variants, indels and 
structural variants considered 
Gene Phenotypic subgroup 
Gene 
list/s 
Het 
cases 
Proportion 
cases het (%) 
Het 
controls 
Proportion 
controls het (%) 
q value 
for hets 
HABP2 1 From 4 - Colorectal, Breast, Gastric, Ovarysexcord-gonadalstromal full 3 1.30 45 1.16 0.001 
HABP2 
1 From 8 - Breast ACC CNS Connective tissue soft tissue sarcoma 
Bonesarcoma GIST Skinsarcoma Uterinesarcoma 
full 3 1.43 45 1.16 0.001 
BMPR1A 1 From 2 - Breast Gastric mania 2 1.08 11 0.28 0.042 
BMPR1A 1 From 2 - Breast Pancreas mania 2 1.06 11 0.28 0.02 
BMPR1A 1 From 3 - Breast Thyroid Endometrium mania 2 0.91 11 0.28 0.013 
BMPR1A 1 From 4 - Colorectal Breast Gastric Ovarysexcord-gonadalstromal mania 2 0.87 11 0.28 0.042 
BMPR1A All mania 2 0.56 11 0.28 0.005 
BMPR1A 1 From 1 – Breast mania 2 1.08 11 0.28 0.042 
MSH6 1 From 3 - Haemmyeloid Aerodigestivetract Anus mania 1 7.69 10 0.26 0.021 
MSH6 1 From 4 - Haemmyeloid Aerodigestivetract Anus Melanoma mania 1 2.22 10 0.26 0.003 
APCS 1 From 4 - Colorectal Breast Gastric Ovarysexcord-gonadalstromal full 1 0.43 10 0.26 0.047 
APCS 1 From 4 - Colorectal Endometrium Ovary Sebaceous full 1 0.70 10 0.26 0.025 
APCS 
1 From 8 - Breast ACC CNS Connectivetissuesofttissuesarcoma Bonesarcoma 
GIST Skinsarcoma Uterinesarcoma 
full 1 0.48 10 0.26 0.04 
APCS All full 1 0.28 10 0.26 0.0001 
 
ACC – Adrenocortical carcinoma, CNS – Central nervous system, GIST – Gastrointestinal stromal tumour, Het - Heterozygous, Hom – homozygous 
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Table 6.19 - Truncating variants in HABP2 (heterozygous) amongst 1 From 4 Colorectal, Breast, Gastric, Ovary sex cord-gonadal stromal (Peutz-Jeghers like) 
phenotypic subgroup 
Transcript Coordinate Description Consequence 
Phenotype with age at 
diagnosis 
Family history of neoplasia reported 
ENST00000351270 chr10: 115341778 c.982C>T (p.Q328*) Stop gain 
Thrombocythaemia, 56; 
Breast, 56 
Mother – Breast, 79; Daughter – Breast, 34; Maternal 
aunt – Breast, 80 
ENST00000351270703 chr10: 115338424 c.607C>T (p.R203*) Stop gain 
Retinoblastoma, 2; 
Colorectal, 49 
Father – Colorectal, 79; Paternal cousin – Colorectal, 55  
 
 
Table 6.20 - Truncating variants in HABP2 (heterozygous) amongst 1 From 8 Breast, ACC, CNS, Soft tissue sarcoma, Bone sarcoma, GIST, Skin sarcoma, 
Uterine sarcoma (Li Fraumeni like) phenotypic subgroup 
Transcript Coordinate Description Consequence 
Phenotype with age at 
diagnosis 
Family history of neoplasia reported 
ENST00000351270 Chr10:115338424 
c.607C>T 
(p.R203*) 
Stop gain GIST, 16; Paraganglioma, <30 Nil 
ENST00000351270703 Chr10:115341778 
c.982C>T 
(p.Q328*) 
Stop gain 
Thrombocythaemia, 56; 
Breast, 56 
Mother – Breast, 79; Daughter – Breast, 34; 
Maternal aunt – Breast, 80 
 
GIST – Gastrointestinal stromal tumour 
 
Table 6.21 - Predicted structural variant affecting BMPR1A (heterozygous) 
Chromosome Predicted start Predicted end Algorithm Predicted consequence Phenotype with age at diagnosis 
Family history of 
neoplasia reported 
10 Chr10:88559247 chr5:107163219 Manta 
Translocation with 
breakpoint between exons 1 
and 2 (both non-coding) 
Breast, 52; CNS meningioma, 56; 
Breast, 58; Aerodigestive tract, 63 
Paternal grandmother – 
Unknown primary, 75 
 
CNS – Central nervous system 
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Table 6.22 - Truncating variant in BMPR1A (heterozygous) 
Transcript Coordinate Description Consequence Phenotype with age at diagnosis Family history of neoplasia reported 
ENST00000372037 chr10:88676945 c.730 C>T (p.R244*) Stop gain Colorectal, 50; Breast, 57 Paternal aunt – Ovarian, 70-79 
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6.7.2 - Enhancers and promoters (see methods in 6.5.2.1) 
Analysis of variants affecting enhancers and promoters of CPGs yielded no results with q-values 
below the chosen significance threshold when counts of individuals SNVs/indels were compared or 
when SVs were considered in a separate analysis. 
 
When counts of individuals with either an SNV/indel or SV affecting each enhancer/promoter were 
considered, one result was highlighted in the 2 From 3 Breast, Thyroid, Endometrium subgroup. Here, 
five cases (14%) had heterozygous SNVs or indels affecting enhancer GH17G058351 vs 299 (8%) 
controls (q=0.02). GH17G058351 is reported to be a RAD51C enhancer but ovarian cancer 
(associated with RAD51C variants) is not part of this phenotypic subgroup and no SVs accounted for 
the five cases. Therefore, the reduction in q-value compared to other analyses is likely due to the 
reduction in phenotypic subgroup size from 43 to 35, leading to individuals with variants representing 
a greater proportion of the subgroup. 
 
6.7.3 - Expression quantitative trait loci observed in cancer tissues (see methods in 6.5.2.3) 
Case control analyses comparing frequency of variants in eQTL observed in cancer tissues was made 
as per truncating variants. Given that these are non-coding regions, counts of individuals with variants 
within a given gene were replaced with counts of individuals harbouring a variant within an eQTL 
reported to affect the expression of a gene. 
 
Individuals with variants reported to affect the expression of three genes (TAS2R5, ENPP2 and 
C2orf27A) contributed to observed results with a q-value below 0.05 (Table 6.23).  
 
The occurrence of the chr7:141437957 T>C variant (reported to affect TAS2R5 expression) in four 
individuals accounted for significant results at both gene (Table 6.23) and variant (Table 6.24) level in 
a number of phenotypic subgroups, all including colorectal or aerodigestive tract cancer (Figure 6.10). 
Individuals with this variant are described in Table 6.25. chr7:141437957 T>C is reported to reduce 
TAS2R5 expression in breast invasive carcinoma, colon/rectum adenocarcinoma, acute myeloid 
leukaemia, kidney chromophobe tumours, kidney renal papillary cell carcinoma, glioblastoma 
multiformae, lung adenocarcinoma and sarcoma. Between two and four individuals harboured the 
variant in each subgroup. Two individuals had been identified in an earlier analysis (see Chapter 4) as 
harbouring homozygous pathogenic NTHL1 variants. No sequencing quality issues were evident with 
the variants on review of bam files with IGV.  
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Figure 6.10 - Hypothesis tests (individual variants in cancer tissue eQTL) from analysis of 
colorectal cases (n=98) - Heterozygous individuals. 
 
Plot shows data points corresponding to variants that were present in any BRIDGE or 1958BC sample 
 
Frequency of heterozygous variants in eQTL upregulating ENPP2 expression in acute myeloid 
leukaemia, colon/rectum adenocarcinoma, lung squamous cell carcinoma and ovarian serous 
cystadenocarcinoma was found to be significantly elevated in individuals diagnosed with both breast 
and ovarian cancer. Ten individuals with variants (Tables 6.26 and 6.27) in that eQTL region were 
recorded but one of these variants was excluded following review of the relevant bam file in IGV. The 
count of individuals with variants was therefore more likely to be 9/24 (37.5%) vs 583/4053 (14%) 
controls.  
 
2/14 (14%) individuals with both breast and kidney cancer had variants (Table 6.28) in an eQTL 
associated with reduced expression of C2orf27A in glioblastoma multiformae, lung adenocarcinoma, 
ovarian serous cystadenocarcinoma, prostate adenocarcinoma, sarcoma and stomach adenocarcinoma 
compared with 13/4053 (0.003%) controls, a sufficient count to produce a q value of <0.05. Review 
of BAM files with IGV showed multiple reads supporting the variant call but the relevant bases were 
predominantly covered by reads with low mapping quality. 
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Table 6.23 - Genes where variants at expression quantitative trait loci reported to affect 
expression are over-represented in cases vs controls 
Gene Phenotypic subgroup 
Zygosity 
considered 
Case 
count 
Proportion 
cases (%) 
Controls 
count 
Proportion 
controls (%) 
q 
value 
TAS2R5 1 From 1 - Aerodigestive tract Het 2 18 9 0.2 0.01 
TAS2R5 1 From 1 - Aerodigestive tract Het or hom 2 18 9 0.2 0.01 
ENPP2 2 From 2 – Breast, Ovary Het or hom 11 46 656 16 0.018 
TAS2R5 
1 From 3 - Haematological 
myeloid, Aerodigestive tract, 
Anus 
Het 2 12 9 0.2 0.024 
TAS2R5 
1 From 3 - Haematological 
myeloid, Aerodigestive tract, 
Anus 
Het or hom 2 12 9 0.22 0.024 
ENPP2 2 From 2 – Breast, Ovary Het 10 42 583 14 0.03 
C2orf27A 2 From 2 – Breast, Kidney Het 2 14 13 0.3 0.03 
C2orf27A 2 From 2 – Breast, Kidney Het or hom 2 14 13 0.3 0.03 
 
Het – Heterozygous, Hom - Homozygous 
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Table 6.24 – Variants in somatic expression quantitative trait locus (region 1bp in length) where variants reported to reduce TAS2R5 expression 
Coordinate Ref Alt Phenotypic subgroup Coefficient 
Distance to 
transcription 
start site (bp) 
Case 
count 
Controls 
count (n 
=4053) 
Zygosity 
considered 
q value 
Participant 
with variant 
(see Table 
6.25) 
Chr7:141437957 T C 1 From 1 - Aerodigestive tract -0.57 -52060 2 1 Het 0.01 1,2 
Chr7:141437957 T C 1 From 1 - Aerodigestive tract -0.57 -52060 2 1 
Het or 
hom 
0.01 1,2 
Chr7:141437957 T C 
1 From 3 - Haematological myeloid, 
Aerodigestive tract, Anus 
-0.57 -52060 2 1 Het 0.025 1,2 
Chr7:141437957 T C 
1 From 3 - Haematological myeloid, 
Aerodigestive tract, Anus 
-0.57 -52060 2 1 
Het or 
hom 
0.025 1,2 
Chr7:141437957 T C 1 From 1 – Colorectal -0.57 -52060 3 1 Het 0.026 1,2,3 
Chr7:141437957 T C 1 From 1 – Colorectal -0.57 -52060 3 1 
Het or 
hom 
0.026 1,2,3 
Chr7:141437957 T C 1 From 2 – Colorectal, Gastric -0.57 -52060 3 1 Het 0.027 1,2,3 
Chr7:141437957 T C 1 From 2 – Colorectal, Gastric -0.57 -52060 3 1 
Het or 
hom 
0.02689 1,2,3 
Chr7:141437957 T C 
1 From 4 – Colorectal, Breast, Gastric, 
Ovary sex cord-gonadal stromal 
-0.57 -52060 4 1 Het 0.038 1,2,3 
Chr7:141437957 T C 
1 From 4 – Colorectal, Breast, Gastric, 
Ovary sex cord-gonadal stromal 
-0.57 -52060 4 1 
Het or 
hom 
0.038 1,2,3,4 
 
Coefficient describes effect and magnitude of effect on gene expression of variants in eQTL (range -1.29 – 1.15 amongst higher confidence eQTL reported in cancer tissues) 
Het – Heterozygous, Hom - Homozygous 
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Table 6.25 – Four cases with chr7:141437957 T>C variant (heterozygous) contributing to statistically significant results involving eQTL where variants 
reported to reduce TAS2R5 expression. 
Participant Phenotype with age at diagnosis Family history of neoplasia reported Clinically relevant coding variants detected 
1 
Aerodigestive tract, 50; Breast, 66; Lung, 67; 
Colorectal, 68 
Nil Nil 
2 Colorectal, 48; Aerodigestive tract, 50  
Sister – Colorectal, 57, Breast, 51; Sister – Colorectal, 44; 
Brother – Pancreas, 50; Nephew – Lymphoma, 24; Maternal 
uncle – Prostate, 55; Maternal grandfather – Leukaemia, 50 
NTHL1 ENST00000219066 c.268C>T 
(p.Gln90*) homozygote. Assessed as 
pathogenic (see Chapter 4) 
3 
CNS meningioma, 42; CNS meningioma, 42; 
Colorectal, 44 
Unavailable 
NTHL1 ENST00000219066 c.268C>T 
(p.Gln90*) homozygote. Assessed as 
pathogenic (see Chapter 4) 
4 
NMSC, 40; Ovary sex cord-gonadal stromal (sertoli 
leydig), 55 
Sister – Breast, 45 Nil 
 
CNS – Central nervous system, NMSC – Non-melanoma skin cancer 
 
Table 6.26– Variants in eQTL where variants reported to increase ENPP2 expression (heterozygous) 
Coordinate Reference allele Alternate allele eQTL start eQTL end 
Participant 
with variant 
(see Table 
6.27) 
Coefficient 
Case count 
(n=24) 
chr8:120719000 TTTTC T 120718851 120719000 1 1.15 1 
chr8:120718978 T TTTTC 120718851 120719000 2, 3 1.15 2 
chr8:120718978 T TTTTCTTTCTTTCTTTCTTTC 120718851 120719000 4, 5, 6 1.15 3 
chr8:120718999 T C 120718851 120719000 7 1.15 1 
chr8:120718978 T TTTTCTTTCTTTCTTTCTTTCTTTCTTTC 120718851 120719000 5 1.15 1 
chr8:120718980 TTC T 120718851 120719000 8 1.15 1 
chr8:120718864 CT C 120718851 120719000 9 1.15 1 
chr8:120718982 CTTTCTTTCTTTCTTTCTT C 120718851 120719000 10 1.15 1 
 
Coefficient describes effect and magnitude of effect on gene expression of variants in eQTL (range -1.29 – 1.15 amongst higher confidence eQTL reported in cancer tissues)  
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Table 6.27 – Summary of cases with variants in eQTL where variants reported to affect ENPP2 expression 
Participant Phenotype with age at diagnosis Family history of neoplasia reported 
Clinically relevant 
coding variants 
detected 
1 Ovary, 34; Breast, 47 Mother – NMSC, 69; Maternal grandfather – Colorectal, 54 Nil 
2 Breast, 42; Ovary, 47 Mother – Breast, 56; Maternal uncle – Myeloma, ? age Nil 
3 Breast, 27; Ovary, 49; Endometrium, 49 Paternal grandmother – Unknown primary, 67 Nil 
4 (no evidence 
of variant on 
review with 
IGV) 
Breast, 46; Ovary, 49 
Father – Colorectal, 44; Paternal uncle – Lung, ? age; Paternal cousin – Breast, ? 
age;  Paternal cousin – Breast, ? age;  Paternal cousin – Unknown primary, ? age 
Nil 
5 Ovary, 60; Endometrium, 60; Breast, 62 Sister (monozygotic twin) – Breast, 58; Maternal aunt – Gastric, ? age Nil 
6 
Breast, 46; Ovary, 49; Ovary, 49; 
Endometrium, 49.  
Sister – Breast, 49; Mother – Breast, 46; Maternal grandmother – Breast, 50-59; 
Maternal uncle – Bladder, 50-59 
CHEK2 splice donor 
variant 
7 Ovary, 49; Breast, 50 Maternal grandmother – Gastric, 55 Nil 
8 
Breast, 48; Ovary, 53; Endometrium, 53; 
Cervix, 53 
Sister – Breast, 63; Niece – Breast, 48; Maternal aunt – Colorectal, ? age; Maternal 
uncle – Colorectal, ? age 
Nil 
9 Breast, 60; Breast, 65; Ovary, 67 Nil Nil 
10 
Breast, 54; Breast, 54; Oesophagus, 54; 
Ovary, 67 
Daughter – Colorectal, 34; Mother – NMSC, 87; Maternal grandmother – Breast, 42; 
Sister (half) – Breast, 60-69 
Nil 
 
IGV – Integrated Genomics Viewer, NMSC – Non-melanoma skin cancer 
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Table 6.28 – Single nucleotide variant and indel in eQTL region where variants reported to reduce C2orf27A expression (heterozygous) 
Coordinate 
Reference 
allele 
Alternate 
allele 
eQTL start eQTL end Coefficient 
Distance to 
transcription 
start site (bp) 
Case 
count 
(n=14) 
Phenotype with age at diagnosis Family history 
Clinically 
relevant coding 
variants 
detected 
chr2:133024749 G C 133024749 133024808 -1.23 544715 1 
Haematological lymphoid (NHL), 57; 
Breast, 64; Kidney (papillary type 2), 
65; Colorectal, 72; Colorectal, 72 
Mother – Breast, 
42; Sister – 
Kidney, 49 
Nil 
chr2:133024753 CAG C 133024749 133024808 -1.23 544715 1 
Thyroid, 32; Kidney (? subtype), 58; 
Breast, 63 
Unavailable Nil 
 
Coefficient describes effect and magnitude of effect on gene expression of variants in eQTL (range -1.29 – 1.15 amongst higher confidence eQTL reported in cancer tissues 
NHL – Non-Hodgkin’s lymphoma
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No results with q-values below the chosen significance threshold of 0.05 were produced by analysis 
of SVs affecting eQTL observed in cancer tissues. When counts of individuals with SVs per eQTL 
were combined with counts of individuals with an SNV or indel per eQTL, a number of results with 
q-values <0.05 were produced (Table 6.29) but none of these except one were contributed to by SV 
counts and are likely to be due to a reduction in the phenotypic subgroup size used, leading to cases 
with variants representing a greater proportion of the subgroup compared with analyses only 
involving SNVs and indels. 
 
The result that was contributed to by both SVs and SNVs/indels was the over-representation of 
individuals with heterozygous variants affecting eQTL reported to affect ZNF284 expression amongst 
cases with at least one tumour from colorectal, breast, gastric or ovary sex cord-gonadal stromal 
(STK11 like) vs controls (Table 6.30 and 6.31). One individual with a predicted deletion of the eQTL 
(Appendix 5, variant 10) and one individual with an SNV within it contributed to the result but no 
tumour types were common to both of them. Additionally, it was difficult to find evidence to support 
or refute the presence of the large predicted deletion through review of the BAM file with IGV.   
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Table 6.29 - Genes where eQTL affecting expression over-represented in cases vs controls where combination of counts of single nucleotide variants, indels and 
structural variants considered 
Gene Phenotypic subgroup 
Het 
cases 
Proportion 
cases het (%) 
Het 
controls 
Proportion 
controls 
het (%) 
q value 
for hets 
Hom 
cases 
Hom 
controls 
Het or 
hom 
cases 
Proportion 
cases het 
or hom (%) 
Het or 
hom 
controls 
Proportion 
controls het or 
hom (%) 
q value 
for het 
or hom 
C6orf136 1 From 2 - Breast, Ovary 65 31.55 816 20.98 0.044 1 17 66 32.04 833 21.42 0.049 
C6orf136 
1 From 4 - Colorectal, Breast, Gastric, 
Ovary sex cord-gonadal stromal 
71 30.74 816 20.98 0.043 2 17 73 31.60 833 21.42 0.043 
C6orf136 2 From 2 - Breast, Kidney 5 38.46 816 20.98 0.021 1 17 6 46.15 833 21.42 0.021 
HERC3 1 From 2 - Colorectal, Gastric 3 3.66 71 1.83 0.044 0 0 3 3.66 71 1.83 0.044 
HERC3 
1From 4 - Colorectal, Breast, Gastric, 
Ovary sex cord-gonadal stromal 
8 3.46 71 1.83 0.031 0 0 8 3.46 71 1.83 0.031 
HERC3 1 From 1 – Colorectal 3 3.70 71 1.83 0.043 0 0 3 3.70 71 1.83 0.043 
ZNF284 1 From 2 - Breast, Ovary 1 0.49 5 0.13 0.044 0 0 1 0.49 5 0.13 0.050 
ZNF284 
1 From 4 - Colorectal, Breast, Gastric, 
Ovary sex cord-gonadal stromal 
2 0.87 5 0.13 0.031 0 0 2 0.87 5 0.13 0.031 
 
Het - Heterozygous, Hom - homozygous 
 
Table 6.30 - Structural variant affecting eQTL where variants reported to reduce ZNF284 expression (heterozygous) 
Chromosome 
Predicted 
start 
Predicted 
end 
Algorithm 
Predicted 
consequence 
eQTL 
start 
eQTL end Coefficient 
Distance to 
transcription 
start site 
(bp) 
Phenotype 
with age at 
diagnosis 
Family history of neoplasia reported 
Clinically 
relevant 
coding 
variants 
detected 
19 43765327 43848192 Canvas 
Deletion of 
entire eQTL 
region 
43772478 43772537 -0.99 -803790 
Prostate, 54; 
Colorectal, 
54 
Mother – Non-Hodgkin’s lymphoma, 
56; Maternal aunt – Leukaemia, 60; 
Maternal aunt – Breast, 65 
Nil 
 
Coefficient describes effect and magnitude of effect on gene expression of variants in eQTL (range -1.29 – 1.15 amongst higher confidence eQTL reported in cancer tissue
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Table 6.31 - Single nucleotide variant affecting eQTL where variants reported to reduce ZNF284 expression (heterozygous) 
Transcript Coordinate 
Reference 
allele 
Alternate 
allele 
eQTL start eQTL end Coefficient 
Distance to 
transcription 
start site (bp) 
Phenotype with age at 
diagnosis 
Family history 
Clinically relevant 
coding variants 
detected 
ENST00000270077 chr19:43772519 C G 43772478 43772537 -0.99 -803790 
Hemangiopericytoma, 51; 
Breast, 53 
Other – Breast, 31 
and oral cancer, 31. 
Nil 
 
Coefficient describes effect and magnitude of effect on gene expression of variants in eQTL (range -1.29 – 1.15 amongst higher confidence eQTL reported in cancer tissues)
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6.7.4 - Putative proto-oncogenes, genes associated with telomere function, ultra-conserved 
regions or expression quantitative trait loci reported by GTEx project (see methods in 6.3, 6.4, 
6.5.2.2 and 6.5.2.3) 
Case-control comparisons were performed as described. No comparisons with q value <0.05 were 
noted at gene/region or variant level in any analysis including those incorporating counts of SNVs and 
indels, structural variants or the sum of both. 
 
6.7.5 - Analysis for causative variants in a family with suspected recessive tumour predisposition 
(see methods in 6.6) 
For the homozygous hypothesis, two variants passed filters (Table 6.32). The inframe deletion in 
MSH3 affects a mismatch repair gene, a number of which are associated with Lynch syndrome and 
constitutional mismatch repair syndrome. Allele frequency of this variant is low in European 
populations (1000 Genomes 0.003, gnomAD 0.01) but is observed at a maximum of 0.34 in the 
gnomAD South Asian population and was not considered further on this basis. 
 
ARVCF ENST00000263207 c.1616G>A (p.R539Q) does not occur in any gnomAD or 1000 Genomes 
population at a frequency above 0.01. Combined Annotation Dependent Depletion (CADD) score 
(phred scaled) for the variant is 31. 12 homozygotes are observed in gnomAD but this dataset contains 
TCGA data. 1 homozygote was observed in both the BRIDGE control series used for case control 
analyses and the 1958 birth cohort. A homozygote was also observed in the MPT series who had 
previously been diagnosed with bilateral phaeochromocytoma at the age of 59 years.  
 
Table 6.32 - Variants passing filters according to a homozygous hypothesis 
Chromosome Position Consequence Gene Transcript Description 
22 19965563 Missense ARVCF ENST00000263207 c.1616G>A (p.R539Q) 
5 79950699 Inframe deletion MSH3 ENST00000265081 
c.154delGCAGCGGCTGCAGCGGCC 
(p.154del6) 
 
One variant pair was identified by the filtering designed to identify compound heterozygote variants 
(Table 6.33). COL6A2 ENST00000300527 c.679G>A p.(D227N) was identified in the father and 
c.988G>A (p.D330N) in the mother. Phred scaled CADD scores were 16.95 and 33 for each variant 
respectively. 
 
Table 6.33 - Variants passing filters according to a compound heterozygous hypothesis 
Chromosome Position Consequence Gene Transcript Description 
21 47532456 Missense COL6A2 ENST00000300527 c.679G>A p.(D227N) 
21 47536717 Missense COL6A2 ENST00000300527 c.988G>A (p.D330N) 
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6.8 Discussion 
Case control based analysis of a number of variant modalities and phenotypic subgroups revealed few 
loci where the evidence was indicative of a role in tumour predisposition.  
 
Results that proposed causative loci with greatest confidence arose from truncating variant analysis, 
where variants in known CPGs contributed to results crossing the chosen significance thresholds. 
Consequently, there is considerable overlap between the results of this analysis and the WGS-based 
comprehensive CPG analysis described in a Chapter 4. For counts of individuals with truncating 
variants per gene, CHEK2, PALB2, MAX and NF1 were over-represented in various phenotypic 
subgroups. Occurrence of individuals with two specific variants in PALB2 and CHEK2 was 
significantly higher in one subgroup each. The appearance of these results involving known CPGs 
indicates that the experimental design was able to propose regions in which constitutional variants 
cause susceptibility to neoplasia. 
 
Genes producing top results in the analysis have characteristics (apart from being CPGs) leading to a 
greater probability of variants affecting them appearing in pre-assessed clinical genetics referral-based 
series. At the point of consultation for most participants, none of them were routinely tested. This is in 
contrast to genes such as BRCA1 where molecular diagnosis would likely have been made in the 
clinic and study recruitment not undertaken. CHEK2, and PALB2 are well established as being 
associated with breast cancer predisposition but uncertainties regarding penetrance or clinical utility 
of testing have previously inhibited frequent molecular investigation. MAX is a relatively recently 
described CPG and the individuals harbouring truncating variants affecting it would likely be detected 
by clinical services if presenting now. Neurofibromatosis type 1 is commonly seen in genetics clinics 
but has historically been a largely clinical diagnosis with molecular testing of NF1 generally not 
performed.  
 
Phenotypic subgroups producing top results generally contained tumours that were characteristically 
associated with the relevant gene.  Although some subgroups appeared to suggest novel tumour types 
arising from variants in particular genes, further delineation of the phenotype of cases contributing to 
those results revealed they had also been diagnosed with typical tumours e.g. PALB2 in individuals 
with ≥1 tumour from haematological myeloid, aerodigestive tract, anal and melanoma. The only result 
reaching the chosen significance threshold in the pan-cancer analysis of all cases arose from 
comparison of the count of individuals with CHEK2 truncating variants. Variants in CHEK2 have 
been associated with a wide variety of cancers206,385 and the most robust of these associations is with 
breast cancer.42,198,386 Consistent with this, most individuals with CHEK2 truncating variants had 
previously been diagnosed with that tumour. Other associations might be suggested by non-breast 
tumours occurring in variant carriers (where an individual may or may not have had breast cancer). 
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Only RCC appeared with sufficient frequency to suggest an association here but was not significantly 
over-represented in truncating variant carriers vs non-carriers. Further research to investigate a 
possible relationship to the development of RCC include larger studies of variant carriers (including 
non-c.1229delC/c.1100delC) or tumour studies such as loss of heterozygosity analysis. 
 
When counts of individuals with single nucleotide variants or indels were considered in combination 
with SV counts, BMPR1A variants were over-represented amongst all MPT cases and in various 
subgroups involving colorectal cancer although this result was due to only two individuals, one of 
whom did not have colorectal cancer and had an SV. This was a translocation with a breakpoint 
within the gene but between exons 1 and 2, which are both non-coding. Additionally, review in IGV 
suggested this SV may be an artefact due to multiple alignments of supporting sequencing reads. 
BMPR1A is associated with Juvenile Polyposis and colorectal cancer and the other individual with the 
SNV in this gene (nonsense) had previously been diagnosed with the latter. They have previously 
been described in chapters 4 and 5 and also harboured a truncating PMS2 variant. Taking these factors 
into consideration, there is no evidence for a novel CPG locus from this result and little evidence for a 
novel phenotype caused by BMPR1A variants. 
 
The other gene highlighted by incorporation of SVs into variant counts was HABP2, where one 
individual had a predicted translocation with a breakpoint between (coding) exons 1 and 2 and three 
other individuals had nonsense variants. These individuals contributed to highlighted results in two 
phenotypic subgroups incorporating a wide variety of tumour types that were assembled to emulate 
those seen in Peutz-Jeghers Syndrome and Li Fraumeni Syndrome. Indeed, apart from breast cancer 
shared between two of these participants the neoplastic manifestations in them were disparate. HABP2 
is a serine protease,380 variants in which are associated with susceptibility to non-medullary thyroid 
cancer due to a report concerning a missense variant in single family that proposed HABP2 as a 
tumour suppressor gene.387 No thyroid cancers were reported in the individuals with HABP2 variants 
in the currently presented MPT series. This gene is somatically mutated in a large proportion of some 
cancer types in cBioPortal, including colon cancer, but these percentages result from small sample 
sizes.34 Expression data from the cancer genome atlas does not indicate under-expression of HABP2 
in TCGA provisional datasets relevant to the tumours observed in variant carrying individuals (mean 
z-score between -0.04 and 0.07 for invasive breast carcinoma (n=1100),388 colorectal adenocarcinoma 
(n=382)336 and phaeochromocytoma/paraganglioma (n=184)389). Given the marginal difference in the 
proportion of cases and controls with HABP2 variants and lack of further information from 
investigation of participants tumours, it cannot be concluded that disruption of this gene was relevant 
in the causation of the neoplasms observed.   
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All other results highlighted by a q-value of <0.05 arose from analysis of variants in eQTL previously 
reported in cancer tissues but variant counts were small and causative effects appeared unlikely based 
on other lines of evidence. Four individuals were observed with a single eQTL variant 
(chr7:141437957 T>C) reported to reduce TAS2R5 expression (in tumours including colorectal 
cancer), leading to significant results in phenotypic subgroups incorporating colorectal and/or 
aerodigestive tract cancer. Notably, two of the individuals with colorectal cancer carried a 
homozygous pathogenic variant in NTHL1, which is likely to have caused their tumours although a 
modifying effect of the eQTL variant is feasible. TAS2R5 encodes a bitter taste receptor,380,390 a 
function that is unlikely to be related to neoplastic processes and its product does not have any 
physical interactions with known CPGs in Gene Mania.346 TAS2R5 is not significantly under-
expressed in colorectal adenocarcinoma (n=382, mean z-score 0.2)34,391 or head and neck squamous 
cell carcinoma TCGA studies (n=521, mean z-score 0.03).34,392 It is mutated or deleted in <1% of 
those cancer types in cBioPortal and the most frequent aberration is amplification in 21% of prostate 
cancers.34 
 
Variants in an eQTL reported to upregulate ENPP2 expression (in tumours including ovarian serous 
cystadenocarcinoma) were observed in 37.5% of individuals with both breast and ovarian cancer 
compared with 14% of controls. Mechanistically, ENPP2 has a number of functions to suggest a role 
in tumourigenesis as it has been shown to promote angiogenesis and tumour cell motility. Its 
expression is upregulated in various carcinomas380,390 but no over-expression is reported in the TCGA 
breast invasive carcinoma (n=1100, mean z-score 0.12)34,388 or ovarian cystadenocarcinoma (n=307, 
mean z-score 0.09).34,393 Amplification, however, is observed in 20% of ovarian and 10.5% of breast 
cancers (as well as 40.3% prostate cancers) in cBioPortal.34 There are some indications, therefore, that 
further studies of variants at this eQTL in breast-ovarian cancer cases may be rewarding. These might 
include assessing their frequency in larger cohorts or analysing ENPP2 expression in the tumours of 
individuals found to carry variants. However, caution should be drawn from the observation of 
multiple indel alleles at matching or nearby sites contributing to the results in this analysis, which may 
indicate sequencing or variant calling error. 
 
Two individuals with variants in an eQTL reported to lead to reduced expression of C2orf27A were 
sufficient to produce results with q-values below the significance threshold for cases with both breast 
and kidney cancer. The effect on expression was not noted in breast or kidney cancer in the original 
publication, no under-expression of C2orf27A is noted in these tumours in the relevant TCGA 
studies388 (Breast invasive carcinoma TCGA provisional, Kidney Renal Papillary Cell Carcinoma 
TCGA Provisional394 and Kidney Renal Clear Cell Carcinoma TCGA Provisional395) and the gene is 
deleted, amplified or mutated in <1% breast or kidney cancers in cBioPortal.34 There is little known 
about the function of C2orf27A.380 Furthermore, inspection of BAM files from the two individuals 
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with variants in IGV showed a majority of reads at this region being of low mapping quality, bringing 
the variant call into doubt. 
 
Combination of counts of individuals with SNVs/indels or SVs affecting eQTL and comparison in 
cases and controls produced one result where the q-value was below the significance threshold and 
where both SNVs/indels and SVs contributed to the result. This was contributed to by variants in an 
eQTL reported to reduce ZNF284 expression in breast invasive carcinoma, colon 
adenocarcinoma/rectum adenocarcinoma, ovarian serous cystadenocarcinoma, liver hepatocellular 
carcinoma and lung adenocarcinoma. Two individuals amongst cases with at least one tumour from 
colorectal, breast, gastric or ovary sex cord-gonadal stromal (Peutz-Jeghers like) had a variant 
affecting this eQTL, although one of these was a predicted deletion where review in IGV offered little 
evidence to confirm or refute the variant. ZNF284 encodes a zinc finger protein with nucleic acid 
binding properties.380 Considering the tumours that occurred in the two variant carrying individuals, 
the gene is mutated in 2.28% of 439 colorectal adenocarcinomas and less than 1% and soft tissue 
sarcomas in cBioPortal. Higher aberration rates are seen in prostate cancers but this refers to 
amplification rather than mutation or deletion as would fit with the proposed mechanism here.34 
mRNA expression data from TCGA provisional studies does not indicate under expression in any of 
the cancer types observed in these individuals in terms of mean z-score.336,388,396,397 Taken together 
with the small number of variant carrying cases without a shared phenotype, these lines of evidence 
do not suggest that further investigation of this locus would be rewarding in this context. 
 
Analysis of a family with possible recessive inheritance of predisposition to osteomas resulted in a 
homozygous variant in ARVCF for further consideration as well as a pair of COL6A2 variants under a 
compound heterozygous hypothesis. ARVCF is located in the 22q11 deletion region associated with a 
developmental syndrome (heterozygous deletions) primarily causing congenital heart disease, cleft 
palate, learning difficulties and immunodeficiency rather than neoplasia. There is little suggestion of 
phenotypic overlap with that syndrome in the studied family but ARVCF is a member of the catenin 
family and is involved in the formation of adherens junction complexes. A recognised CPG that 
shares this function is CDH1, variants in which are associated with hereditary diffuse gastric cancer 
and lobular breast carcinoma.96,398 ARVCF interacts with the CDH1 gene product e-cadherin and the 
ARVCF domain that this variant occurs within has been reported to be necessary for binding between 
the two proteins.399 A single submission of this variant in ClinVar reports the variant as benign but no 
phenotype for which this assertion is made is given. cBioPortal was interrogated for variants in 
ARVCF, which is mutated in around 17% of central nervous system tumours but this figure is 
contributed to by a single case only. A limitation of this query is the fact that, as for a number of rarer 
and/or benign tumours, there is no osteoma study available via that platform. Validation cohorts with 
similar phenotype are often crucial to CPG discovery. The recent elucidation of POLE and POLD1 as 
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polyposis/colorectal cancer predisposition genes initially identified variants in them in a single family 
but further occurrences in a cohort of individuals with colorectal cancer (and absence in controls) 
indicated a causative effect.35 Despite the functional evidence suggesting a possible role for this 
variant in neoplasia, there is little else to suggest a causative role in the studied family and there was 
no apparent phenotypic overlap with the other homozygote in the MPT series. Similarly, there was 
insufficient evidence that the compound heterozygous variants in COL6A2 had a role in the 
development of osteomas in these individuals. COL6A2 is a type VI collagen gene, pathogenic 
variants in which are associated with myopathies400 but not with neoplastic phenotypes. Entries in 
ClinVar exist for both variants but only with pathogenicity assertions relating to myopathy and no 
entry reporting either variant as pathogenic. SNVs/indels are not noted in any cancer type in 
cBioPortal at a frequency of 10% or more and no physical interactions between COL6A2 and known 
CPGs are highlighted by the GeneMania platform.346  
 
The paucity of novel loci highlighted as potentially causative by these analyses is likely due to a 
number of factors. Aside from truncating variants in known CPGs, the prior probability of causative 
variants in the analysed regions can be assumed to be low as to date, relatively few CPGs have been 
described in which variants lead to levels of tumour risk amenable to genetic counselling and risk 
mitigation. In the case of non-coding variants, prioritisation of variants and regions likely to be 
relevant to disease states is less developed than for coding regions. In this project, ultra-conserved 
regions, enhancers, promoters and eQTL were used. These resources are likely to be expanded and 
refined with time and other strategies are likely to improve estimation of non-coding variant 
pathogenicity. For example, the FUN-LDA tool utilises epigenetic information from large epigenetic 
data sources to assess likelihood of the significance of a genomic region to gene expression in a tissue 
specific manner and prioritise variants accordingly.401 Functional assays are also likely to be an 
important tool and can be designed as high throughput techniques to maximise information obtained 
regarding the impact of induced variants. Strategies include the generation of multiple plasmids with 
different variations in putative regulatory regions and the observation of their effect on transcription 
via transfection and reporter assay. CRISPR-Cas9 based systems have also been used to generate 
multiple cell lines with distinct regulatory region variants with subsequent observation of the chosen 
phenotypic effect.217 
 
To minimise false positives amongst the results, stringent filtering for genotype quality, sequencing 
depth and variant allele fraction was used. These measures were deemed necessary to avoid variant 
calls due to sequencing artefact but may have excluded some genuine variants. Given that a small 
number of rare variants can produce a low q-value in analyses such as those undertaken here, some 
overrepresented variants or regions may not have been highlighted. 
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Power of case-control based analyses is enhanced by large numbers of cases with a specific 
commonality between them. The identification of PALB2 as a CPG was based on the observation of 
ten truncating variants in 923 breast cancer cases. These were familial, enhancing the probability of 
constitutional predisposing factors being present.39 NTHL1 was reported as predisposing to colorectal 
polyps and cancer through exome sequencing of samples from a lower number (n=51) of individuals 
but all had the relatively specific phenotype of multiple colorectal adenomas (48/51 had >10 
recorded).36 MAX was discovered as a CPG using exome sequencing on samples from only three 
individuals with phaeochromocytoma but these cases were familial and phaeochromocytoma is a 
highly heritable neoplasm.286 The largest phenotypic group defined in these analyses was that 
comprising all MPT cases fulfilling inclusion criteria (n=424) though this subset was highly 
heterogeneous in terms of diagnosed tumours. Phenotypic subgroups were defined to decrease 
heterogeneity but this led to significant decreases in the number of individuals included in each group. 
For example, the largest group defined by a single tumour type was breast cancer, which included 215 
participants. The largest group defined by a specific tumour combination was breast-colorectal but 
only 42 individuals were included. Although some results highlighted likely causal relationships with 
low numbers of participants (e.g. NF1 truncations in 15 GIST cases), others may have remained 
undetected.  
 
An alternative strategy to identify candidate causal variants that does not require a large number of 
probands is segregation analysis within families according to a hypothesised mode of inheritance. 
Recessive inheritance was proposed in a family where two siblings, born to unaffected parents, 
developed osteomas in childhood. Although it cannot be concluded that the filtered variants are 
causative, the process highlights the ability of the technique to efficiently narrow down candidates. 
The MPT series is largely composed of probands and although participants were contacted with the 
aim of recruiting family members, the cohort contained no other families where data from both 
parents was available and more than one individual was affected. Segregation based analysis could 
therefore not be performed in multiple families, which may have yielded positive results. 
 
Discrepancies between estimated heritability of cancer types and the proportion of cases explained by 
known constitutional genetic factors402,403 suggest that continued investigation may yield novel CPGs, 
although this can be stated with lower confidence for rarer tumour types without a robust heritability 
estimate. Missing heritability, however, does not necessarily imply a significant role for high 
penetrance variants in single genes and a proportion can be accounted for by more common, lower 
penetrance variants identified through genome wide association studies.402,404 Under a polygenic risk 
model, co-occurrence of such variants in an individual may confer additional risk and scores to assess 
risk based on the burden of selected risk variants have been previously applied to investigate their 
clinical utility.43,44,405,406 Missing heritability may also be accounted for by modalities of variation that 
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are not typically considered in studies to identify predisposing factors, most obviously non-coding or 
epigenetic variation. 
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Chapter 7 – Reflections and future perspectives 
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This research applied massively parallel sequencing techniques, in particular whole genome 
sequencing (WGS) to a series of individuals with multiple primary tumours (MPT). MPT was taken 
as an observation indicating an increased probability of a cancer predisposition syndrome due to a 
constitutional deleterious variant in a cancer predisposition gene (CPG). 
 
Investigations were undertaken to elucidate causative variants affecting known CPGs that would be of 
immediate clinical relevance. A key finding of these analyses was that the use of MPT (as defined by 
the study eligibility criteria) per se as an indication for application of agnostic genetic testing would 
yield a substantial number of variants associated with clinical utility. Occasionally multiple such 
variants would be revealed in the same individual. The detection rate is enhanced by the use of WGS 
due to its ability to detect structural variants and interrogate any region of interest but these 
advantages are limited at present. They are likely to become more prominent as the cost of WGS 
decreases and greater characterisation of clinically relevant non-coding regions takes place. 
 
7.1 - Variant assessment 
Defining phenotypic effects caused by non-coding variation is a developing field but interpretation of 
coding variants in the context of human disease also remains challenging. In the assessment of 
variants for clinical relevance in this project, multiple exclusions were made on the basis of 
insufficient evidence leading to variant of uncertain significance (VUS) classification. This is a 
prominent issue in clinical and research settings. A large amount of work has previously been 
undertaken to improve the situation and define the risks associated with individual CPG variants.  
 
A recent advancement, used extensively in this project, has been to build on previous efforts and 
formulate a consensus as to what lines of evidence should be used to assign pathogenic or benign 
status, including how each of them should be weighted. The American College of Medical Genetics 
(ACMG) guidelines192 have been widely adopted but this body recognises that the criteria leave room 
for ambiguity as to whether a threshold should be crossed for a given line of evidence. For example, 
what functional assays qualify as “well established” and what result of that assay can be taken as 
evidence of a damaging effect? A study involving four diagnostic laboratories in the United States 
observed pathogenicity assessments (not using ACMG criteria) of any variant that had been submitted 
to ClinVar by two or more of them. 242 discordant variants were reassessed by the respective 
laboratories using the ACMG criteria but a 12.8% discordance rate remained.407 A response to 
inconsistencies such as these has been to form working groups that apply guidelines in a manner 
specific to the disease or gene in question. A published example of this approach is the refinement of 
ACMG criteria application in the context of MYH7-associated inherited cardiomyopathies.408 Here, 
nine criteria were deemed not applicable and clarifications were made regarding aspects such as 
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degree of segregation considered sufficient to support pathogenicity. For cancer predisposition 
syndromes, the UK Cancer Genetics Group is undertaking a similar process.  
 
Work to improve the ACMG guidelines may also focus on individual criteria rather than diseases or 
genes. To this end, a working group of clinical and laboratory geneticists was assembled to discuss 
application of the criterion fulfilled if the assessed variant has a predicted loss of function 
consequence (PVS1).409 Prior to this, the ACMG had issued a recommendation that the weighting 
assigned to a fulfilled criterion (very strong, strong, moderate or supporting) could be shifted on the 
basis of further evidence (e.g. a supporting line of evidence could become strong).410 
Recommendations from the working group included consideration of whether a nonsense variant 
affects a biologically relevant transcript, the proportion of a protein lost as a result of a variant and, in 
the case of splice variants, the presence of nearby consensus splice sequences that may re-establish in 
frame splicing. In this project, the former two aspects were taken into consideration in predicted loss 
of function variant assessment but guidance such as this will promote consistency in future assertions 
of pathogenicity.  
 
Aside from consensus, work to provide further evidence as to the phenotypic effects of constitutional 
sequence variants is ongoing. The ClinVar database continues to expand and now exists in partnership 
with the ClinGen programme411 to enhance expert curation in terms of whether genes are associated 
with a given disease, whether variants are pathogenic and what clinical action can be taken as a result 
of their detection. The array of in-silico tools to predict variant consequences continues to grow and 
can be improved by expanded variant databases on which to base algorithms. A recent example is 
ClinPred,412 which formulates a score based on existing in-silico tools (e.g. Combined Annotation 
Dependent Depletion (CADD)) as well as allele frequency information from the gnomAD dataset. 
ClinVar variants were used as a training dataset, which was considered to be superior to other curated 
variant databases due to its size and pathogenicity assertions based on ACMG criteria. 
 
A valuable source of information regarding the phenotypic consequence of a variant is the results of 
functional assays designed to observe its effect in a model system. Execution of these experiments is 
laborious and evidence relating to individual variants is frequently unavailable but higher throughput 
techniques are being utilised that have the potential to dramatically expand the range of variants for 
which functional studies have been undertaken. A notable recent report analysed the effect of 1,056 
BRCA1 missense variants on repair of double stranded breaks (DSBs) by homologous 
recombination.413 A cell line was utilised where effective DSB repair is observed through expression 
of a GFP gene from a genomic insertion designed with a target site for a transfected DSB inducing 
enzyme. A second inactive (due to an absent promoter) copy of GFP was also included in the insert 
and used as a template for repair if that process was functional. Multiplexed reporter assays and 
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mutagenesis to generate plasmids for them allowed the high number of variants to be generated and 
analysed. 
 
7.2 - Atypical phenotypes 
A further key finding of this project was the high rate of tumour types in pathogenic/likely pathogenic 
CPG variant carriers that were not characteristically associated with disrupted function of the relevant 
CPG. In the presented analysis, around 40% of studied probands had been diagnosed with at least one 
atypical tumour. The preferential consideration of MPT cases is likely to elevate this figure but other 
(non-MPT based) reports also report high rates of discordant neoplasms.200,203 These observations are 
becoming more frequent as genetic testing is more broadly applied and a significant challenge is to 
distinguish incidental tumours from those which have been contributed to by the identified 
constitutional CPG variant. Functional assays are less likely to be helpful in answering this question 
as results from cell lines cannot be readily extrapolated to in vivo tumour subtypes. Variant databases 
such as ClinVar give valuable information as to the pathogenicity of a variant in the context reported 
by the submitter but do not provide numerical risks of tumours as a result of the variant.   
 
Success in defining the risks associated with variants in CPGs has been achieved by collating variant 
carriers in a manner that seeks to minimise ascertainment biases. Examples include a prospective 
study of carriers of pathogenic mismatch repair gene variants69 and an analysis of succinate 
dehydrogenase subunit gene variant carriers that considers the rate of 
phaeochromocytoma/paraganglioma in relatives testing positive through predictive testing.414 These 
strategies are generally focused on recording tumours already known to be associated with variants in 
the studied syndrome or gene but are also well placed to highlight novel associations. A difficulty is 
collating sufficient numbers of individuals with rare CPG variants in a given gene but an initiative to 
address this issue is proposed as part of the “Cancer Moonshot” initiative by the National Cancer 
Institute. A “Pre Cancer Genome Atlas” is planned that aims to assemble CPG variant carriers 
identified through genetic testing and create an information sharing platform from their data.415 
 
7.3 - Identifying novel loci relevant to tumour predisposition 
A number of interrogations of WGS data were made as part of this research that aimed to identify 
novel loci associated with tumour predisposition. These were predominantly based on defining 
putative regions of relevance (e.g. genes recurrently somatically mutated in cancer, ultra-conserved 
regions, gene enhancers) and comparing the frequency of variants within them in various 
phenotypically defined case groups vs controls. Truncating variants in some genes (NF1, PALB2, 
MAX, CHEK2) were found to be over-represented in some case groups vs controls, illustrating the 
potential efficacy of this approach. However, these results did not represent novel CPG loci or robust  
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gene-tumour phenotype associations and other interrogations did not produce convincing evidence of 
causative variants.  
 
Studies utilising massively parallel sequencing data to identify disease associated variants frequently 
generate large numbers of potentially causative variants that require prioritisation based on one or 
more lines of evidence to reduce the number of candidates. In each of the analyses for novel loci, 
prioritisation was undertaken in this manner but the number of candidate regions remained large in 
many instances, resulting in a large number of tests informing calculations to adjust p-values in light 
of multiple hypotheses. Some pertinent results might not have crossed chosen statistical significance 
thresholds for this reason and further information to narrow candidate regions may have avoided this.  
 
A further limitation of attempts to elucidate novel loci in this project was the phenotypic 
heterogeneity of studied individuals. The over-representation of variants in a particular region that is 
associated with a phenotype is more likely to be detected where the phenotype that defines the case 
group is more specific. An increase in heterogeneity will dilute any cases with a shared genetic cause 
and may lead to pertinent results not being highlighted through hypothesis testing. The analyses 
undertaken here took steps to increase phenotypic specificity through subgrouping individuals by 
tumour type but this led to a large reduction in the number of cases in most subgroups, itself a cause 
of failure to detect regions in which variants were over-represented. 
 
7.4 - Tumour sequencing 
An undertaking that has the potential to address many of the difficulties highlighted above is the 
expansion of tumour (as well as concurrent germline) sequencing in diagnostic settings and resultant 
use of generated data/information in research contexts. This practice promises to enhance the 
identification and collation of CPG variant carriers as well as provide molecular data that could assist 
with variant interpretation, defining phenotypic subgroups for research and prioritising putative 
candidate regions containing tumour predisposing variants. 
 
Genotyping of tumour samples is frequently undertaken as part of cancer management but the testing 
is usually narrow in scope and designed to detect variants in specific genes that will inform prognosis 
and/or treatment of that cancer type. Examples include analysis for HER2 amplification in breast 
cancer that would prompt Trastuzumab therapy and EGFR mutations in non-small cell lung cancer to 
guide the use of Afatinib. Next generation sequencing assays provide the opportunity to perform most 
of the tests in current clinical use with a single assay that would also generate data to identify other 
useful markers or apply existing markers in other tumours. The widespread use of this strategy has 
been advocated in the Chief Medical Officer’s 2016 “Generation Genome” report416 and 
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establishment of workflows for routine WGS of tumours is a key aim of the 100,000 Genome Project, 
an initiative that also analyses constitutional DNA from blood samples. 
 
Enhanced sequencing of tumours as part of routine care pathways has great potential to increase 
identification of individuals harbouring constitutional pathogenic CPG variants. One adopted strategy 
might be to use a gene panel assay of cancer driver genes, which overlap extensively with CPGs. 
Detection of a variant that could be relevant to tumour predisposition could prompt analysis of a 
blood sample to assess somatic vs germline status and indicate whether referral to genetics services 
was appropriate. A more comprehensive approach would be to routinely perform extensive 
sequencing on both tumour and non-tumour (e.g. adjacent normal or blood) tissue, allowing a number 
of inferences to be made. Presence of a CPG variant in a tumour but not the germline would indicate a 
somatic variant but the possibility of mosaicism would need to be considered if other tumours from 
the same individual contained the same variant or if it was detectable at a low variant allele fraction in 
blood. Detection of a CPG variant in tumour and blood may indicate a possible cancer predisposition 
syndrome and further assessment by genetics services would be indicated. Further useful information 
as to the variant’s role in the development of the tumour might be obtained if loss of the wild type 
allele was demonstrated in the tumour, an observation that would require reasonable sequencing depth 
to make with confidence. A further scenario is the identification of a CPG variant in a blood sample 
but not in the tumour. This might imply that it was not significant to tumourigenesis in the sample in 
hand but does not necessarily provide reassurance that the individual or their family are not at risk of 
other tumours. Furthermore, constitutional variants can be lost in tumours. In a study of 198 advanced 
cancer cases with pathogenic assessed CPG variants identified through tumour-normal sequencing (of 
341 genes), 13 had a monoallelic CPG variant lost in the tumour sample.200 Loss of variant alleles 
may occur through genomic instability and not be relevant to tumour progression but the possibility 
also exists of a variant that is important for tumour initiation (i.e. acting as a pathogenic CPG variant) 
but incompatible with survival of the later neoplastic clone.  
 
Another possible future mechanism whereby carriers of constitutional pathogenic CPG variants might 
be detected is through population screening. It would be feasible for this to take the form of directly 
sequencing germline DNA samples to detect rare deleterious CPG variants. This idea has been 
discussed for BRCA1 and BRCA2 screening, particularly in Ashkenazi Jewish populations where 
prevalence is higher. The approach would certainly reduce ascertainment biases influencing risk 
estimates surrounding CPGs but may come with unacceptable costs in terms of economics and 
negative impact of variant detection such as psychological distress or prophylactic surgery in lower 
risk carriers.417–419 An intriguing alternative form of population screening that might identify 
unaffected individuals with cancer predisposition syndromes is analysis of circulating tumour DNA 
(ctDNA), in effect performing tumour sequencing without prior knowledge of a neoplasm to biopsy. 
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Many suggested applications of ctDNA based techniques relate to monitoring of drug response or 
recurrence but a recent study reported good sensitivity and specificity in detecting a range of non-
metastatic (but clinically detectable) common cancers through a test utilising ctDNA in combination 
with protein biomarkers.420 This “CancerSEEK” test is proposed as a possible basis for future 
population screening for common cancers rather than cancer predisposition syndromes but there is 
frequently overlap between genes containing known somatic driver mutations and CPGs. 
CancerSEEK generates sequence data for 16 genes and five of these are known CPGs (APC, EGFR, 
PTEN, TP53, HRAS). In the CancerSEEK study, detection of a potential cancer driver mutation in 
plasma DNA prompted interrogation for the same variant in lymphocyte DNA to exclude it if present 
in the germline. However, presence of CPG variants identified in this way that were also present in 
lymphocytes might prompt further assessment of the individual for a predisposition syndrome. 
Notably, the test only utilised 61 amplicons to assess common driver mutations rather than sequence 
large areas of genes but future assays might broaden the sequence information generated. 
 
Apart from identifying CPG variant carriers, expansion of tumour sequencing would also assist with 
clinical decision making and research projects in other ways depending on the assay performed. 
 
Although not applicable to all tumour predisposition syndromes (e.g. those due to gain of function 
variants in proto-oncogenes), demonstration of loss of the wild type allele in a tumour sample where a 
constitutional CPG variant is present provides evidence of a role for that variant in tumourigenesis, 
assuming a tumour suppressor gene two-hit model. Such loss of heterozygosity (LOH) may be due to 
deletion of the wild type allele or be copy number neutral due to somatic uniparental disomy. It may 
also occur through mutation of the wild type allele or due to an epimutation, the latter of which is not 
detectable without specialised sequencing techniques.   
 
In clinical practice, the use of LOH analysis in variant assessment is well established but often 
performed on a post hoc basis for specific variants and tumour tissue is frequently unavailable. More 
use of routine tumour sequencing in diagnostic laboratories would provide greater opportunity to 
interrogate regions corresponding to putative pathogenic CPG variants to observe the relative allelic 
ratios in a tumour vs blood sample. Detection of LOH may not require WGS or exome sequencing of 
tumours and necessary data could be obtained through potentially cheaper assays designed for other 
purposes. The recently reported Karyogene assay was developed for myeloid malignancies (i.e. not 
for concurrent solid tumour-blood sequencing) but illustrates how a diagnostic assay may reveal LOH 
for a detected CPG variant. Here, high depth sequencing was based on capture by a series of 
oligonucleotide baits targeting exons of genes of interest, breakpoints of known translocations and 
also single nucleotide polymorphisms (SNPs) every 300kb.421 The latter is used to identify regions of 
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homozygosity to detect copy number variants causing myeloid malignancies but could be used for 
other applications. 
 
In research studies attempting to identify novel tumour suppressor CPGs in constitutional DNA, 
regions of homozygosity identified in tumour through WGS, exome sequencing or (lower cost) SNP 
based approaches could be used to narrow candidate regions. The reduction in putative causative 
variants from this approach may allow analytical time and resources to be better focused. 
 
Genetic analysis of tumours has most frequently focused on specific regions (such as genes) where 
variation can be interpreted as having a biological effect. This kind of analysis can be performed with 
sequence data covering a relatively small area of the tumour genome but more expansive techniques 
such as WGS can observe accumulated variants across all the genome. Consequently, a picture of the 
mutational processes that have taken place can be obtained with commonalities and differences 
between neoplasms analysed. These mutational signatures have been conceptualised and defined in 
recent years and can reflect the known environmental exposures relevant to specific cancer types (e.g. 
higher rate of C>T mutations in melanoma due to nucleotide excision repair of ultraviolet induced 
pyrimidine dimers).281 They can also demonstrate underlying tumourigenic genetic abnormalities, 
which may produce a contrasting signature to that usually seen in a given tumour type. For example, 
mismatch repair deficiency can be identified and a characteristic pattern of indels is observed in breast 
cancers from individuals with pathogenic BRCA1 or BRCA2 variants, which is taken to indicate 
deficient double stranded break repair by non-homologous end joining.422,423  
 
Mutational signatures in tumours undergoing WGS by diagnostic services could be exploited in a 
number of ways. In the clinic, the presence or absence of a signature associated with deleterious 
variants in a particular gene could be used to infer the pathogenicity status of a constitutional variant 
in that gene following identification in a blood sample. In research settings, signatures could be used 
to define participant subgroups and enhance phenotypic specificity. Strategies might include 
excluding individuals whose tumours show a typical or environmental exposure related signature. 
Additionally, research participants could be grouped according to a common mutational signature in 
their tumours that may be unexplained and/or be present in neoplasms from multiple anatomical sites 
or tissues. 
 
The analyses of tumour genomes described above are reliant on good quality DNA in sufficient 
quantity that has been extracted from tumour tissue. Historically, tissue obtained through biopsy or 
surgical resection has been fixated using formalin and embedded in paraffin. This has served 
pathologists well as structures are preserved for microscopy and samples can be easily stored at room 
temperature. However, formaldehyde interacts with DNA through a number of chemical reactions that 
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can lead to sequencing artefacts via disruption of DNA polymerases used in polymerase chain 
reactions.424 Cross linking of nucleic acids and proteins induced by formaldehyde induces 
fragmentation425 that can compromise DNA library preparation. Nucleic acids extracted from formalin 
fixed paraffin embedded (FFPE) tissue are frequently used for genetic analysis but the probability of 
obtaining a high-quality result declines as the scope of the test increases. WGS requires higher yields 
of DNA and is unlikely to be successful using FFPE tumour samples.  
 
These issues can be overcome by the use of fresh frozen samples as this process does not induce the 
reactions and cross linkages associated with formalin. Practical difficulties with frozen tissue include 
the necessity to freeze the sample quickly after removal from the patient and storage in freezers rather 
than at room temperature. Nevertheless, a transition towards this procedure in surgical departments 
and histology laboratories is necessary if the full potential of cancer genomic medicine is to be 
realised. The 100,000 Genomes Project cancer arm has taken the decision to only accept fresh frozen 
tissue for sequencing apart from in exceptional circumstances.426 As a major aim of project is to 
establish optimal workflows for genomic medicine in healthcare settings, it is hoped that this initiative 
will pave the way for extensive sequencing of cancer tissues to be performed routinely.   
 
Cancer predisposition syndromes, although not common, represent a good target for high impact 
preventative strategies given the level of risk they frequently confer and the potentially severe 
consequences of neoplastic disease. Work to characterise them, identify them in patients and mitigate 
risk have led to significant benefits for affected individuals due to extensive work over a long period 
of time. This work has hitherto been restricted by limitations in capability to sequence patient samples 
but advancements in this area have begun to lift them. The combination of accumulated knowledge 
and application of genomic technologies offers great opportunities in the continuation of efforts to 
improve risk estimation and preventative strategies for those at increased risk of cancer. 
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Appendix 1 - Tumour categorisation (including for registry and treatment centre-based series) and frequency in MPT series 
 
Table A1 - Tumour categorisation (including for registry and treatment centre-based series) and frequency in MPT series 
 
Tumour category Occurrences in series 
Topographical sites 
included in category if 
applicable 
Morphological descriptors included in category if applicable 
Breast 281  Ductal carcinoma, lobular carcinoma 
Colorectal 113 Colon, rectum  
Kidney 83  Clear cell carcinoma, papillary carcinoma, chromophobe carcinoma, oncocytic carcinoma 
Non-melanoma skin cancer 67 Any cutaneous site Basal cell carcinoma, squamous cell carcinoma, Bowens disease 
Ovary 58  
Carcinoma, endometrioid carcinoma, papillary carcinoma, serous cystadenocarcinoma, 
mucinous adenocarcinoma, primary serous papillary carcinoma of peritoneum, 
carcinosarcoma 
Endometrium 52  Carcinoma, adenocarcinoma, carcinosarcoma 
Melanoma 51 Any cutaneous site Malignant melanoma, melanoma in situ, superficial spreading melanoma 
Thyroid 44  Papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma 
Haematological lymphoid 38  
Lymphoma, lymphocytic leukaemia, myeloma, hairy cell leukaemia, leukaemia, Waldenstroms 
macroglobulinaemia 
Prostate 22  Adenocarcinoma 
Lung 21  Adenocarcinoma, squamous cell carcinoma, small cell.  
Paraganglioma 20   
Gastrointestinal stromal 
tumour 
17 
Gastric, small bowel, 
gastrointestinal tract, 
unspecified.  
 
Soft tissue Sarcoma 17  
Sarcoma, hemangiopericytoma, rhabdomyosarcoma, spindle cell sarcoma, fibrosarcoma, 
myxoid liposarcoma, liposarcoma, malignant solitary fibrous tumour, leiomyosarcoma, giant 
cell tumour of tendon sheath, fibromyxosarcoma 
Pheochromocytoma 17   
CNS meningioma 14   
Aerodigestive tract 13 
Sinus, larynx, nasal cavity, 
nasopharynx, vocal cord, 
tongue 
Squamous cell carcinoma, small cell carcinoma 
Pituitary 13  Pituitary adenoma, prolactinoma, adenoma 
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Bladder 10  
Transitional cell carcinoma, papillary transitional cell carcinoma, papillary urothelial carcinoma, 
urothelial carcinoma in situ 
Pancreatic neuroendocrine 
tumour 
10  Neuroendocrine carcinoma, neuroendocrine tumour, glucagonoma 
Central nervous system 10  Glioblastoma, oligodendroglioma, astrocytoma, myxopapillary ependymoma, ganglioglioma 
Cervix 8  Squamous cell carcinoma, adenocarcinoma 
Gastrointestinal 
neuroendocrine tumour 
8 
Appendix, small bowel, large 
bowel, gastrointestinal tract 
Carcinoid (unless non-gastrointestinal site specified) 
Testicular 8  Teratoma, seminoma 
Central nervous system (nerve 
sheath)   
7  Schwannoma, neurofibroma 
Pancreas 7  Solid pseudopapillary tumour, neoplasms 
Parathyroid 7  Carcinoma, adenoma 
Uveal melanoma 6   
Bone benign 6  Exostoses, osteochondroma, haemangioma 
Lung carcinoid 5   
Haematological myeloid 4  Myelogenous leukaemia, myelodysplastic syndromes, myeloproliferative diseases 
Ovary sex cord-gonadal 
stromal 
4  Granulosa cell tumour, yolk sac tumour, germ cell tumour, Sertoli leydig tumour 
Peripheral nervous system 
(nerve sheath) benign 
4  Neurofibroma, schwannoma 
Small bowel 4   
Adrenocortical carcinoma 4   
Central nervous system 
hemangioblastoma 
4   
Kidney oncocytoma 4   
Oesophagus 4   
Colorectal polyps 3 
Any lower gastrointestinal site 
if >10 identified 
Serrated adenoma, tubular adenoma, tubulovillous adenoma, hyperplastic polyps, 
adenomatous polyps, adenoma, adenopapilloma 
Salivary gland 3  Acinar cell carcinoma, lymphoepithelial carcinoma 
Gastric 3   
Lipoma 3  Angiolipoma 
Thymus 3   
Biliary tract 2  Adenocarcinoma, cholangiocarcinoma 
Cardiac myxoma 2  Myxoma 
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Congenital hypertrophy of 
retinal pigment epithelium 
2   
Cutaneous leiomyoma 2   
Desmoid 2   
Fibrofolliculoma 2   
Odontogenic 2  Ameloblastoma, odontogenic tumour 
Ovary benign 2  Mucinous cystadenoma, borderline tumours 
Pancreas benign 2   
Salivary gland benign 2   
Sebaceous 2  Sebaceous adenoma 
Thyroid benign 2  Hurthle cell adenoma, adenoma 
Uterine leiomyoma 2   
Uterine sarcoma 2  Sarcoma, leiomyosarcoma 
Adrenal adenoma 2   
Bone sarcoma 2   
Colorectal benign 2   
Unknown primary 2  Adenocarcinoma of gastrointestinal origin 
Anus 1  Squamous cell carcinoma 
Breast phyllodes 1   
Soft tissue benign 1   
Haematological polycythaemia 1   
Haematological 
thrombocythemia 
1   
Kidney angiomyolipoma 1   
Liver benign 1  Adenoma 
Lung chondroma 1   
Lung hamartoma 1   
Nerve sheath benign 1   
Ovary neuroendocrine 1   
Penis 1   
Placenta 1  Placental site trophoblastic tumour 
Peripheral nervous system 
(nerve sheath) benign 
1  Malignant peripheral nerve sheath tumour 
Pulmonary 
lymphangioleiomyomatosis 
1   
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Retinoblastoma 1   
Skin benign 1   
Skin Merkel cell 1  Merkell cell tumour 
Skin sarcoma 1  Angiosarcoma 
Sweat gland 1  Adenocarcinoma 
Thyroid medullary 1  Medullary thyroid cancer 
Ureter 1   
Vulva 1   
Wilms tumour 1   
Adrenal oncocytoma 1   
Eye Benign 1  Retinal angioma 
Eye 0 
Retina, conjunctiva, orbit, 
choroid 
Haemangiopericytoma, carcinoma 
Lacrimal duct 0   
Liver 0  Hepatocellular carcinoma 
Mesothelioma 0 Pleura, peritoneum  
Neuroblastoma 0 
Peripheral nerves, ethmoidal 
sinus, adrenal gland 
 
Vagina 0   
Vulva 0   
 
Individual categories only assignable once per individual for purposes of counting tumour frequencies. Neoplasms recorded non-specifically e.g. "cancer" assigned to most likely morphological category for 
site e.g. breast cancer assigned to Breast not Breast phyllodes. Non-melanoma skin cancer includes basal cell carcinoma and squamous cell carcinoma
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Appendix 2 - Comprehensive cancer predisposition gene analysis original and filtered 
gene list 
 
Table A2 – Comprehensive cancer predisposition gene analysis original and filtered gene list 
 
Gene on original list (n=133)a Gene retained for final list (n=83)b 
ABCB11 AIP 
AIP ALK 
ALK APC 
APC ATM 
ATM AXIN2 
AXIN2 BAP1 
BAP1 BMPR1A 
BLM BRCA1 
BMPR1A BRCA2 
BRCA1 BRIP1 
BRCA2 CDC73 
BRIP1 CDH1 
BUB1B CDK4 
CBL CDKN1B 
CDC73 CDKN2A 
CDH1 CDKN2B 
CDK4 CEBPA 
CDKN1B CHEK2 
CDKN1C CYLD 
CDKN2A DDB2 
CDKN2B DICER1 
CEBPA EGFR 
CEP57 EPCAM 
CHEK2 ERCC2 
COL7A1 ERCC3 
CYLD ERCC4 
DDB2 ERCC5 
DICER1 EXT1 
DIS3L2 EXT2 
DKC1 FH 
DOCK8 FLCN 
EGFR GATA2 
ELANE HFE 
EPCAM HNF1A 
ERCC2 KIT 
ERCC3 MAX 
ERCC4 MEN1 
ERCC5 MET 
EXT1 MLH1 
EXT2 MSH2 
EZH2 MSH6 
FAH MUTYH 
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FANCA NF1 
FANCB NF2 
FANCC NTHL1 
FANCD2 PALB2 
FANCE PDGFRA 
FANCF PHOX2B 
FANCG PMS2 
FANCI POLD1 
FANCL POLE 
FANCM POLH 
FAS PRKAR1A 
FH PTCH1 
FLCN PTEN 
GATA2 RAD51C 
GBA RAD51D 
GJB2 RB1 
GPC3 RET 
HFE RHBDF2 
HMBS RUNX1 
HNF1A SDHA 
HRAS SDHAF2 
ITK SDHB 
KIT SDHC 
MAX SDHD 
MEN1 SERPINA1 
MET SMAD4 
MLH1 SMARCA4 
MSH2 SMARCB1 
MSH6 SMARCE1 
MTAP SRY 
MUTYH STK11 
NBN SUFU 
NF1 TGFBR1 
NF2 TMEM127 
NSD1 TP53 
NTHL1 TSC1 
PALB2 TSC2 
PDGFRA VHL 
PHOX2B WT1 
PMS1 XPA 
PMS2 XPC 
POLD1  
POLE  
POLH  
PRF1  
PRKAR1A  
PRSS1  
PTCH1  
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PTEN  
PTPN11  
RAD51C  
RAD51D  
RB1  
RECQL4  
RET  
RHBDF2  
RMRP  
RUNX1  
SBDS  
SDHA  
SDHAF2  
SDHB  
SDHC  
SDHD  
SERPINA1  
SH2D1A  
SLC25A13  
SLX4  
SMAD4  
SMARCA4  
SMARCB1  
SMARCE1  
SOS1  
SRY  
STAT3  
STK11  
SUFU  
TERT  
TGFBR1  
TMEM127  
TP53  
TRIM37   
TSC1  
TSC2  
UROD  
VHL  
WAS  
WRN  
WT1  
XPA  
XPC  
 
a - Sequenced by Illumina TruSight Cancer panel, appearing in Rahman 20141 or included from further literature review 
(CDKN2B, NTHL1) 
b - Considered consistent with non-syndromic adult presentation where deleterious 
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Appendix 3 – Gene lists used in analysis for variants in putative novel loci associated 
with cancer predisposition 
 
Table A3 - Gene list used for analysis of truncating variants based on somatically mutated genes and 
cancer known CPGs 
 
Gene identifier Gene name 
Canonical 
transcript 
Gene identifier Gene name 
Canonical 
transcript 
ENSG00000115977 AAK1 ENST00000409085 ENSG00000184634 MED12 ENST00000374080 
ENSG00000181409 AATK ENST00000326724 ENSG00000133895 MEN1 ENST00000337652 
ENSG00000085563 ABCB1 ENST00000265724 ENSG00000152595 MEPE ENST00000424957 
ENSG00000073734 ABCB11 ENST00000263817 ENSG00000105976 MET ENST00000318493 
ENSG00000103222 ABCC1 ENST00000399410 ENSG00000165819 METTL3 ENST00000298717 
ENSG00000069431 ABCC9 ENST00000261200 ENSG00000168958 MFF ENST00000353339 
ENSG00000177465 ACOT4 ENST00000326303 ENSG00000204516 MICB ENST00000252229 
ENSG00000123983 ACSL3 ENST00000357430 ENSG00000155545 MIER3 ENST00000381213 
ENSG00000075624 ACTB ENST00000331789 ENSG00000076242 MLH1 ENST00000231790 
ENSG00000184009 ACTG1 ENST00000575842 ENSG00000143674 MLK4 ENST00000366624 
ENSG00000077080 ACTL6B ENST00000160382 ENSG00000171843 MLLT3 ENST00000380338 
ENSG00000148156 ACTL7B ENST00000374667 ENSG00000169184 MN1 ENST00000302326 
ENSG00000135503 ACVR1B ENST00000541224 ENSG00000164172 MOCS2 ENST00000396954 
ENSG00000140955 ADAD2 ENST00000268624 ENSG00000005381 MPO ENST00000225275 
ENSG00000168594 ADAM29 ENST00000359240 ENSG00000150054 MPP7 ENST00000337532 
ENSG00000138316 ADAMTS14 ENST00000373208 ENSG00000132313 MRPL35 ENST00000337109 
ENSG00000145536 ADAMTS16 ENST00000274181 ENSG00000095002 MSH2 ENST00000233146 
ENSG00000087116 ADAMTS2 ENST00000251582 ENSG00000113318 MSH3 ENST00000265081 
ENSG00000106624 AEBP1 ENST00000223357 ENSG00000116062 MSH6 ENST00000234420 
ENSG00000155966 AFF2 ENST00000370460 ENSG00000163132 MSX1 ENST00000382723 
ENSG00000204149 AGAP6 ENST00000412531 ENSG00000099810 MTAP ENST00000380172 
ENSG00000144891 AGTR1 ENST00000542281 ENSG00000103707 MTFMT ENST00000220058 
ENSG00000113492 AGXT2 ENST00000231420 ENSG00000198793 MTOR ENST00000361445 
ENSG00000110711 AIP ENST00000279146 ENSG00000185499 MUC1 ENST00000368395 
ENSG00000196581 AJAP1 ENST00000378191 ENSG00000169876 MUC17 ENST00000306151 
ENSG00000129474 AJUBA ENST00000262713 ENSG00000198788 MUC2 ENST00000441003 
ENSG00000151320 AKAP6 ENST00000280979 ENSG00000204544 MUC21 ENST00000376296 
ENSG00000142208 AKT1 ENST00000554581 ENSG00000145113 MUC4 ENST00000463781 
ENSG00000163631 ALB ENST00000295897 ENSG00000117983 MUC5B ENST00000529681 
ENSG00000171094 ALK ENST00000389048 ENSG00000184956 MUC6 ENST00000421673 
ENSG00000163286 ALPPL2 ENST00000295453 ENSG00000171195 MUC7 ENST00000413702 
ENSG00000139344 AMDHD1 ENST00000266736 ENSG00000132781 MUTYH ENST00000372098 
ENSG00000184675 AMER1 ENST00000330258 ENSG00000110921 MVK ENST00000228510 
ENSG00000135409 AMHR2 ENST00000257863 ENSG00000118513 MYB ENST00000341911 
ENSG00000130812 ANGPTL6 ENST00000253109 ENSG00000172936 MYD88 ENST00000417037 
ENSG00000166839 ANKDD1A ENST00000380230 ENSG00000133020 MYH8 ENST00000403437 
ENSG00000101745 ANKRD12 ENST00000262126 ENSG00000128641 MYO1B ENST00000392318 
ENSG00000172014 ANKRD20A4 ENST00000357336 ENSG00000173418 NAA20 ENST00000334982 
ENSG00000148513 ANKRD30A ENST00000361713 ENSG00000186462 NAP1L2 ENST00000373517 
ENSG00000135976 ANKRD36 ENST00000420699 ENSG00000131400 NAPSA ENST00000253719 
ENSG00000143401 ANP32E ENST00000314136 ENSG00000144035 NAT8 ENST00000272425 
ENSG00000134982 APC ENST00000457016 ENSG00000067798 NAV3 ENST00000536525 
ENSG00000132703 APCS ENST00000255040 ENSG00000104320 NBN ENST00000265433 
ENSG00000130203 APOE ENST00000252486 ENSG00000163386 NBPF10 ENST00000342960 
ENSG00000178878 APOLD1 ENST00000326765 ENSG00000243452 NBPF15 ENST00000442702 
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ENSG00000184945 AQP12A ENST00000337801 ENSG00000158092 NCK1 ENST00000481752 
ENSG00000165269 AQP7 ENST00000297988 ENSG00000124151 NCOA3 ENST00000371998 
ENSG00000103375 AQP8 ENST00000219660 ENSG00000141027 NCOR1 ENST00000268712 
ENSG00000169083 AR ENST00000374690 ENSG00000184983 NDUFA6 ENST00000498737 
ENSG00000120318 ARAP3 ENST00000239440 ENSG00000129559 NEDD8 ENST00000250495 
ENSG00000163219 ARHGAP25 ENST00000409202 ENSG00000100285 NEFH ENST00000310624 
ENSG00000117713 ARID1A ENST00000324856 ENSG00000171208 NETO2 ENST00000562435 
ENSG00000189079 ARID2 ENST00000334344 ENSG00000196712 NF1 ENST00000358273 
ENSG00000228696 ARL17B ENST00000450673 ENSG00000186575 NF2 ENST00000338641 
ENSG00000163466 ARPC2 ENST00000295685 ENSG00000116044 NFE2L2 ENST00000397062 
ENSG00000140450 ARRDC4 ENST00000268042 ENSG00000187566 NHLRC1 ENST00000340650 
ENSG00000006756 ARSD ENST00000381154 ENSG00000140157 NIPA2 ENST00000337451 
ENSG00000161664 ASB16 ENST00000293414 ENSG00000164190 NIPBL ENST00000282516 
ENSG00000164122 ASB5 ENST00000296525 ENSG00000167034 NKX3-1 ENST00000380871 
ENSG00000187855 ASCL4 ENST00000342331 ENSG00000087095 NLK ENST00000407008 
ENSG00000204653 ASPDH ENST00000389208 ENSG00000158077 NLRP14 ENST00000299481 
ENSG00000148219 ASTN2 ENST00000361209 ENSG00000171487 NLRP5 ENST00000390649 
ENSG00000143970 ASXL2 ENST00000435504 ENSG00000174885 NLRP6 ENST00000312165 
ENSG00000215915 ATAD3C ENST00000378785 ENSG00000179709 NLRP8 ENST00000291971 
ENSG00000085978 ATG16L1 ENST00000392017 ENSG00000197696 NMB ENST00000394588 
ENSG00000149311 ATM ENST00000278616 ENSG00000169251 NMD3 ENST00000460469 
ENSG00000111676 ATN1 ENST00000356654 ENSG00000109255 NMU ENST00000264218 
ENSG00000168874 ATOH8 ENST00000306279 ENSG00000162408 NOL9 ENST00000377705 
ENSG00000116039 ATP6V1B1 ENST00000234396 ENSG00000146909 NOM1 ENST00000275820 
ENSG00000166377 ATP9B ENST00000426216 ENSG00000148400 NOTCH1 ENST00000277541 
ENSG00000085224 ATRX ENST00000373344 ENSG00000134250 NOTCH2 ENST00000256646 
ENSG00000124788 ATXN1 ENST00000244769 ENSG00000213240 NOTCH2NL ENST00000369340 
ENSG00000066427 ATXN3 ENST00000393287 ENSG00000188747 NOXA1 ENST00000341349 
ENSG00000105778 AVL9 ENST00000318709 ENSG00000056291 NPFFR2 ENST00000308744 
ENSG00000103126 AXIN1 ENST00000262320 ENSG00000135838 NPL ENST00000367553 
ENSG00000168646 AXIN2 ENST00000307078 ENSG00000181163 NPM1 ENST00000296930 
ENSG00000166710 B2M ENST00000558401 ENSG00000171246 NPTX1 ENST00000306773 
ENSG00000198488 B3GNT6 ENST00000533140 ENSG00000183971 NPW ENST00000329610 
ENSG00000175866 BAIAP2 ENST00000321300 ENSG00000181019 NQO1 ENST00000320623 
ENSG00000163930 BAP1 ENST00000460680 ENSG00000213281 NRAS ENST00000369535 
ENSG00000127152 BCL11B ENST00000357195 ENSG00000106459 NRF1 ENST00000393232 
ENSG00000110987 BCL7A ENST00000538010 ENSG00000123572 NRK ENST00000428173 
ENSG00000180828 BHLHE22 ENST00000321870 ENSG00000165671 NSD1 ENST00000439151 
ENSG00000197299 BLM ENST00000355112 ENSG00000205309 NT5M ENST00000389022 
ENSG00000183682 BMP8A ENST00000331593 ENSG00000065057 NTHL1 ENST00000219066 
ENSG00000107779 BMPR1A ENST00000372037 ENSG00000074590 NUAK1 ENST00000261402 
ENSG00000145919 BOD1 ENST00000311086 ENSG00000196368 NUDT11 ENST00000375992 
ENSG00000157764 BRAF ENST00000288602 ENSG00000105245 NUMBL ENST00000252891 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000102900 NUP93 ENST00000308159 
ENSG00000139618 BRCA2 ENST00000544455 ENSG00000137804 NUSAP1 ENST00000559596 
ENSG00000112983 BRD8 ENST00000254900 ENSG00000122136 OBP2A ENST00000539850 
ENSG00000162670 BRINP3 ENST00000367462 ENSG00000154358 OBSCN ENST00000570156 
ENSG00000136492 BRIP1 ENST00000259008 ENSG00000181781 ODF3L2 ENST00000315489 
ENSG00000151136 BTBD11 ENST00000280758 ENSG00000087263 OGFOD1 ENST00000566157 
ENSG00000159388 BTG2 ENST00000290551 ENSG00000130558 OLFM1 ENST00000252854 
ENSG00000165810 BTNL9 ENST00000327705 ENSG00000116329 OPRD1 ENST00000234961 
ENSG00000156970 BUB1B ENST00000287598 ENSG00000234560 OR10G8 ENST00000431524 
ENSG00000005379 BZRAP1 ENST00000343736 ENSG00000257019 OR13C2 ENST00000542196 
ENSG00000171987 C11orf40 ENST00000307616 ENSG00000172150 OR1A2 ENST00000381951 
ENSG00000184601 C14orf180 ENST00000557649 ENSG00000197887 OR1S2 ENST00000302592 
ENSG00000186073 C15orf41 ENST00000566621 ENSG00000221938 OR2A14 ENST00000408899 
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ENSG00000187013 C17orf82 ENST00000335108 ENSG00000221989 OR2A2 ENST00000408979 
ENSG00000074842 C19orf10 ENST00000262947 ENSG00000188558 OR2G6 ENST00000343414 
ENSG00000163362 C1orf106 ENST00000413687 ENSG00000196071 OR2L13 ENST00000366478 
ENSG00000173369 C1QB ENST00000314933 ENSG00000196936 OR2L8 ENST00000357191 
ENSG00000223953 C1QTNF5 ENST00000445041 ENSG00000162727 OR2M5 ENST00000366476 
ENSG00000182326 C1S ENST00000406697 ENSG00000177201 OR2T12 ENST00000317996 
ENSG00000159239 C2orf81 ENST00000290390 ENSG00000196240 OR2T2 ENST00000342927 
ENSG00000187068 C3orf70 ENST00000335012 ENSG00000177212 OR2T33 ENST00000318021 
ENSG00000174749 C4orf32 ENST00000309733 ENSG00000183310 OR2T34 ENST00000328782 
ENSG00000163633 C4orf36 ENST00000473559 ENSG00000196944 OR2T4 ENST00000366475 
ENSG00000039537 C6 ENST00000263413 ENSG00000177462 OR2T8 ENST00000319968 
ENSG00000112539 C6orf118 ENST00000230301 ENSG00000221840 OR4A5 ENST00000319760 
ENSG00000112936 C7 ENST00000313164 ENSG00000181935 OR4C16 ENST00000314634 
ENSG00000146540 C7orf50 ENST00000397098 ENSG00000176547 OR4C3 ENST00000319856 
ENSG00000157131 C8A ENST00000361249 ENSG00000141194 OR4D1 ENST00000268912 
ENSG00000213865 C8orf44 ENST00000519561 ENSG00000176200 OR4D11 ENST00000313253 
ENSG00000183784 C9orf66 ENST00000382387 ENSG00000182854 OR4F15 ENST00000332238 
ENSG00000105507 CABP5 ENST00000293255 ENSG00000182974 OR4M2 ENST00000332663 
ENSG00000004948 CALCR ENST00000359558 ENSG00000176294 OR4N2 ENST00000315947 
ENSG00000108509 CAMTA2 ENST00000414043 ENSG00000176895 OR51A7 ENST00000359350 
ENSG00000064012 CASP8 ENST00000358485 ENSG00000184881 OR51B2 ENST00000328813 
ENSG00000118729 CASQ2 ENST00000261448 ENSG00000242180 OR51B5 ENST00000300773 
ENSG00000067955 CBFB ENST00000412916 ENSG00000176879 OR51G1 ENST00000321961 
ENSG00000110395 CBL ENST00000264033 ENSG00000176893 OR51G2 ENST00000322013 
ENSG00000054803 CBLN4 ENST00000064571 ENSG00000181609 OR52D1 ENST00000322641 
ENSG00000122565 CBX3 ENST00000337620 ENSG00000176937 OR52R1 ENST00000356069 
ENSG00000135736 CCDC102A ENST00000258214 ENSG00000172459 OR5AR1 ENST00000302969 
ENSG00000160994 CCDC105 ENST00000292574 ENSG00000198877 OR5D13 ENST00000361760 
ENSG00000128596 CCDC136 ENST00000297788 ENSG00000149133 OR5F1 ENST00000278409 
ENSG00000248712 CCDC153 ENST00000503566 ENSG00000231192 OR5H1 ENST00000354565 
ENSG00000180376 CCDC66 ENST00000394672 ENSG00000236032 OR5H14 ENST00000437310 
ENSG00000123106 CCDC91 ENST00000545336 ENSG00000233412 OR5H15 ENST00000356526 
ENSG00000142039 CCDC97 ENST00000269967 ENSG00000186117 OR5L1 ENST00000333973 
ENSG00000106178 CCL24 ENST00000416943 ENSG00000205030 OR5L2 ENST00000378397 
ENSG00000110092 CCND1 ENST00000227507 ENSG00000174937 OR5M3 ENST00000312240 
ENSG00000158488 CD1E ENST00000368167 ENSG00000174942 OR5R1 ENST00000312253 
ENSG00000167775 CD320 ENST00000301458 ENSG00000172489 OR5T3 ENST00000303059 
ENSG00000010610 CD4 ENST00000011653 ENSG00000187612 OR5W2 ENST00000344514 
ENSG00000114013 CD86 ENST00000330540 ENSG00000169214 OR6F1 ENST00000302084 
ENSG00000004897 CDC27 ENST00000531206 ENSG00000203757 OR6K3 ENST00000368145 
ENSG00000134371 CDC73 ENST00000367435 ENSG00000198657 OR8B4 ENST00000356130 
ENSG00000039068 CDH1 ENST00000261769 ENSG00000172154 OR8I2 ENST00000302124 
ENSG00000040731 CDH10 ENST00000264463 ENSG00000181689 OR8K3 ENST00000312711 
ENSG00000154162 CDH12 ENST00000382254 ENSG00000181752 OR8K5 ENST00000313447 
ENSG00000145526 CDH18 ENST00000507958 ENSG00000197376 OR8S1 ENST00000310194 
ENSG00000113100 CDH9 ENST00000231021 ENSG00000070882 OSBPL3 ENST00000313367 
ENSG00000148600 CDHR1 ENST00000372117 ENSG00000079156 OSBPL6 ENST00000392505 
ENSG00000167258 CDK12 ENST00000447079 ENSG00000164164 OTUD4 ENST00000454497 
ENSG00000135446 CDK4 ENST00000257904 ENSG00000165588 OTX2 ENST00000339475 
ENSG00000124762 CDKN1A ENST00000405375 ENSG00000085465 OVGP1 ENST00000369732 
ENSG00000111276 CDKN1B ENST00000228872 ENSG00000155463 OXA1L ENST00000285848 
ENSG00000129757 CDKN1C ENST00000414822 ENSG00000182162 P2RY8 ENST00000381297 
ENSG00000147889 CDKN2A ENST00000498124 ENSG00000070756 PABPC1 ENST00000318607 
ENSG00000147883 CDKN2B ENST00000276925 ENSG00000151846 PABPC3 ENST00000281589 
ENSG00000105352 CEACAM4 ENST00000221954 ENSG00000174740 PABPC5 ENST00000312600 
ENSG00000245848 CEBPA ENST00000498907 ENSG00000083093 PALB2 ENST00000261584 
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ENSG00000093072 CECR1 ENST00000399839 ENSG00000149090 PAMR1 ENST00000278360 
ENSG00000139610 CELA1 ENST00000293636 ENSG00000125779 PANK2 ENST00000316562 
ENSG00000166037 CEP57 ENST00000325542 ENSG00000162073 PAQR4 ENST00000318782 
ENSG00000111642 CHD4 ENST00000357008 ENSG00000171053 PATE1 ENST00000305738 
ENSG00000016391 CHDH ENST00000315251 ENSG00000007372 PAX6 ENST00000419022 
ENSG00000183765 CHEK2 ENST00000382580 ENSG00000163939 PBRM1 ENST00000394830 
ENSG00000133063 CHIT1 ENST00000367229 ENSG00000165494 PCF11 ENST00000298281 
ENSG00000131873 CHSY1 ENST00000254190 ENSG00000056661 PCGF2 ENST00000580830 
ENSG00000141977 CIB3 ENST00000269878 ENSG00000156374 PCGF6 ENST00000369847 
ENSG00000079432 CIC ENST00000575354 ENSG00000168300 PCMTD1 ENST00000360540 
ENSG00000113946 CLDN16 ENST00000264734 ENSG00000249915 PDCD6 ENST00000264933 
ENSG00000253958 CLDN23 ENST00000519106 ENSG00000134853 PDGFRA ENST00000257290 
ENSG00000256660 CLEC12B ENST00000338896 ENSG00000101327 PDYN ENST00000217305 
ENSG00000159212 CLIC6 ENST00000349499 ENSG00000049246 PER3 ENST00000361923 
ENSG00000174600 CMKLR1 ENST00000312143 ENSG00000154330 PGM5 ENST00000396396 
ENSG00000176571 CNBD1 ENST00000518476 ENSG00000082175 PGR ENST00000325455 
ENSG00000155052 CNTNAP5 ENST00000431078 ENSG00000164040 PGRMC2 ENST00000520121 
ENSG00000060718 COL11A1 ENST00000370096 ENSG00000156531 PHF6 ENST00000332070 
ENSG00000164692 COL1A2 ENST00000297268 ENSG00000109132 PHOX2B ENST00000226382 
ENSG00000169436 COL22A1 ENST00000303045 ENSG00000107537 PHYH ENST00000263038 
ENSG00000163359 COL6A3 ENST00000295550 ENSG00000124102 PI3 ENST00000243924 
ENSG00000114270 COL7A1 ENST00000328333 ENSG00000105229 PIAS4 ENST00000262971 
ENSG00000173085 COQ2 ENST00000311469 ENSG00000121879 PIK3CA ENST00000263967 
ENSG00000021826 CPS1 ENST00000430249 ENSG00000145675 PIK3R1 ENST00000521381 
ENSG00000147183 CPXCR1 ENST00000276127 ENSG00000170890 PLA2G1B ENST00000308366 
ENSG00000203710 CR1 ENST00000367049 ENSG00000214456 PLIN5 ENST00000381848 
ENSG00000134376 CRB1 ENST00000367400 ENSG00000106397 PLOD3 ENST00000223127 
ENSG00000137504 CREBZF ENST00000527447 ENSG00000064933 PMS1 ENST00000441310 
ENSG00000213145 CRIP1 ENST00000330233 ENSG00000122512 PMS2 ENST00000265849 
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ENSG00000143603 KCNN3 ENST00000271915 ENSG00000108395 TRIM37 ENST00000262294 
ENSG00000162687 KCNT2 ENST00000294725 ENSG00000150244 TRIM48 ENST00000417545 
ENSG00000215262 KCNU1 ENST00000399881 ENSG00000147573 TRIM55 ENST00000315962 
ENSG00000155729 KCTD18 ENST00000359878 ENSG00000162722 TRIM58 ENST00000366481 
ENSG00000136636 KCTD3 ENST00000259154 ENSG00000179046 TRIML2 ENST00000512729 
ENSG00000126012 KDM5C ENST00000375401 ENSG00000100106 TRIOBP ENST00000406386 
ENSG00000147050 KDM6A ENST00000377967 ENSG00000165699 TSC1 ENST00000298552 
ENSG00000079999 KEAP1 ENST00000171111 ENSG00000103197 TSC2 ENST00000219476 
ENSG00000197993 KEL ENST00000355265 ENSG00000196428 TSC22D2 ENST00000361875 
ENSG00000235750 KIAA0040 ENST00000545251 ENSG00000126467 TSKS ENST00000246801 
ENSG00000134313 KIDINS220 ENST00000256707 ENSG00000231738 TSPAN19 ENST00000532498 
ENSG00000157404 KIT ENST00000288135 ENSG00000155657 TTN ENST00000589042 
ENSG00000109787 KLF3 ENST00000261438 ENSG00000104723 TUSC3 ENST00000503731 
ENSG00000102554 KLF5 ENST00000377687 ENSG00000077498 TYR ENST00000263321 
ENSG00000205810 KLRC3 ENST00000381903 ENSG00000092445 TYRO3 ENST00000263798 
ENSG00000055609 KMT2C ENST00000262189 ENSG00000160201 U2AF1 ENST00000291552 
ENSG00000167548 KMT2D ENST00000301067 ENSG00000130560 UBAC1 ENST00000371756 
ENSG00000171798 KNDC1 ENST00000304613 ENSG00000077721 UBE2A ENST00000371558 
ENSG00000133703 KRAS ENST00000256078 ENSG00000158062 UBXN11 ENST00000374222 
ENSG00000171346 KRT15 ENST00000254043 ENSG00000135220 UGT2A3 ENST00000251566 
ENSG00000172867 KRT2 ENST00000309680 ENSG00000083290 ULK2 ENST00000395544 
ENSG00000139648 KRT71 ENST00000267119 ENSG00000168038 ULK4 ENST00000301831 
ENSG00000161849 KRT84 ENST00000257951 ENSG00000115446 UNC50 ENST00000357765 
ENSG00000221859 KRTAP10-10 ENST00000380095 ENSG00000169021 UQCRFS1 ENST00000304863 
ENSG00000243489 KRTAP10-11 ENST00000334670 ENSG00000126088 UROD ENST00000246337 
ENSG00000205441 KRTAP10-7 ENST00000380102 ENSG00000143258 USP21 ENST00000368002 
ENSG00000188581 KRTAP1-1 ENST00000306271 ENSG00000131864 USP29 ENST00000254181 
ENSG00000187026 KRTAP21-2 ENST00000333892 ENSG00000106346 USP42 ENST00000306177 
ENSG00000214518 KRTAP2-2 ENST00000398477 ENSG00000181408 UTS2R ENST00000313135 
ENSG00000188694 KRTAP24-1 ENST00000340345 ENSG00000177504 VCX2 ENST00000317103 
ENSG00000206107 KRTAP27-1 ENST00000382835 ENSG00000150630 VEGFC ENST00000280193 
ENSG00000212721 KRTAP4-11 ENST00000391413 ENSG00000134086 VHL ENST00000256474 
ENSG00000198271 KRTAP4-5 ENST00000343246 ENSG00000178201 VN1R1 ENST00000321039 
ENSG00000240871 KRTAP4-7 ENST00000391417 ENSG00000188730 VWC2 ENST00000340652 
ENSG00000205869 KRTAP5-1 ENST00000382171 ENSG00000015285 WAS ENST00000376701 
ENSG00000185940 KRTAP5-5 ENST00000399676 ENSG00000239779 WBP1 ENST00000233615 
ENSG00000244411 KRTAP5-7 ENST00000398536 ENSG00000119333 WDR34 ENST00000372715 
ENSG00000239886 KRTAP9-2 ENST00000377721 ENSG00000174776 WDR49 ENST00000308378 
ENSG00000241595 KRTAP9-4 ENST00000334109 ENSG00000206530 WDR52 ENST00000393845 
ENSG00000103642 LACTB ENST00000261893 ENSG00000060237 WNK1 ENST00000315939 
ENSG00000107929 LARP4B ENST00000316157 ENSG00000002745 WNT16 ENST00000222462 
ENSG00000196734 LCE1B ENST00000360090 ENSG00000105989 WNT2 ENST00000265441 
ENSG00000240386 LCE1F ENST00000334371 ENSG00000165392 WRN ENST00000298139 
ENSG00000187173 LCE2A ENST00000368779 ENSG00000184937 WT1 ENST00000332351 
ENSG00000163202 LCE3D ENST00000368787 ENSG00000136936 XPA ENST00000375128 
ENSG00000169744 LDB2 ENST00000304523 ENSG00000154767 XPC ENST00000285021 
ENSG00000182909 LENG9 ENST00000333834 ENSG00000015532 XYLT2 ENST00000017003 
ENSG00000168924 LETM1 ENST00000302787 ENSG00000174851 YIF1A ENST00000376901 
ENSG00000050426 LETMD1 ENST00000418425 ENSG00000182223 ZAR1 ENST00000327939 
ENSG00000138039 LHCGR ENST00000294954 ENSG00000169064 ZBBX ENST00000455345 
ENSG00000182508 LHFPL1 ENST00000371968 ENSG00000181722 ZBTB20 ENST00000474710 
ENSG00000239998 LILRA2 ENST00000251377 ENSG00000160685 ZBTB7B ENST00000417934 
ENSG00000182541 LIMK2 ENST00000340552 ENSG00000178199 ZC3H12D ENST00000409806 
ENSG00000101670 LIPG ENST00000261292 ENSG00000177764 ZCCHC3 ENST00000382352 
ENSG00000074695 LMAN1 ENST00000251047 ENSG00000156599 ZDHHC5 ENST00000287169 
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ENSG00000170807 LMOD2 ENST00000458573 ENSG00000169554 ZEB2 ENST00000558170 
ENSG00000164715 LMTK2 ENST00000297293 ENSG00000140836 ZFHX3 ENST00000268489 
ENSG00000203782 LOR ENST00000368742 ENSG00000185650 ZFP36L1 ENST00000439696 
ENSG00000117600 LPPR4 ENST00000370185 ENSG00000152518 ZFP36L2 ENST00000282388 
ENSG00000144749 LRIG1 ENST00000273261 ENSG00000179588 ZFPM1 ENST00000319555 
ENSG00000120256 LRP11 ENST00000239367 ENSG00000122515 ZMIZ2 ENST00000309315 
ENSG00000158113 LRRC43 ENST00000339777 ENSG00000160321 ZNF208 ENST00000397126 
ENSG00000131409 LRRC4B ENST00000599957 ENSG00000267508 ZNF285 ENST00000330997 
ENSG00000148948 LRRC4C ENST00000278198 ENSG00000105136 ZNF419 ENST00000424930 
ENSG00000171017 LRRC8E ENST00000306708 ENSG00000229676 ZNF492 ENST00000456783 
ENSG00000162620 LRRIQ3 ENST00000354431 ENSG00000197363 ZNF517 ENST00000359971 
ENSG00000125872 LRRN4 ENST00000378858 ENSG00000197701 ZNF595 ENST00000526473 
ENSG00000168056 LTBP3 ENST00000301873 ENSG00000167962 ZNF598 ENST00000431526 
ENSG00000062524 LTK ENST00000263800 ENSG00000257591 ZNF625 ENST00000439556 
ENSG00000139329 LUM ENST00000266718 ENSG00000188171 ZNF626 ENST00000601440 
ENSG00000187398 LUZP2 ENST00000336930 ENSG00000197483 ZNF628 ENST00000598519 
ENSG00000099949 LZTR1 ENST00000215739 ENSG00000196109 ZNF676 ENST00000397121 
ENSG00000061337 LZTS1 ENST00000381569 ENSG00000197123 ZNF679 ENST00000421025 
ENSG00000099866 MADCAM1 ENST00000215637 ENSG00000196946 ZNF705A ENST00000359286 
ENSG00000110514 MADD ENST00000311027 ENSG00000182141 ZNF708 ENST00000356929 
ENSG00000177689 MAGEB10 ENST00000356790 ENSG00000141579 ZNF750 ENST00000269394 
ENSG00000099399 MAGEB2 ENST00000378988 ENSG00000198146 ZNF770 ENST00000356321 
ENSG00000155495 MAGEC1 ENST00000285879 ENSG00000196456 ZNF775 ENST00000329630 
ENSG00000147676 MAL2 ENST00000276681 ENSG00000170396 ZNF804A ENST00000302277 
ENSG00000130479 MAP1S ENST00000324096 ENSG00000182348 ZNF804B ENST00000333190 
ENSG00000065559 MAP2K4 ENST00000353533 ENSG00000204514 ZNF814 ENST00000435989 
ENSG00000076984 MAP2K7 ENST00000397979 ENSG00000257446 ZNF878 ENST00000547628 
ENSG00000095015 MAP3K1 ENST00000399503 ENSG00000234284 ZNF879 ENST00000444149 
ENSG00000135525 MAP7 ENST00000454590 ENSG00000221923 ZNF880 ENST00000422689 
ENSG00000100030 MAPK1 ENST00000215832 ENSG00000213973 ZNF99 ENST00000596209 
ENSG00000186868 MAPT ENST00000344290 ENSG00000188372 ZP3 ENST00000394857 
ENSG00000007047 MARK4 ENST00000262891 ENSG00000042813 ZPBP ENST00000046087 
ENSG00000125952 MAX ENST00000358664 ENSG00000131848 ZSCAN5A ENST00000587340 
ENSG00000166987 MBD6 ENST00000355673 ENSG00000122952 ZWINT ENST00000373944 
ENSG00000213920 MDP1 ENST00000288087    
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Table A4 - Gene list used for analysis of truncating variants based on somatically mutated genes and 
cancer known CPGs – Refined with LOFTOOL 
 
Gene identifier Gene name 
Canonical 
transcript 
Gene identifier Gene name 
Canonical 
transcript 
ENSG00000115977 AAK1 ENST00000409085 ENSG00000061337 LZTS1 ENST00000381569 
ENSG00000181409 AATK ENST00000326724 ENSG00000099866 MADCAM1 ENST00000215637 
ENSG00000085563 ABCB1 ENST00000265724 ENSG00000177689 MAGEB10 ENST00000356790 
ENSG00000073734 ABCB11 ENST00000263817 ENSG00000147676 MAL2 ENST00000276681 
ENSG00000103222 ABCC1 ENST00000399410 ENSG00000130479 MAP1S ENST00000324096 
ENSG00000069431 ABCC9 ENST00000261200 ENSG00000065559 MAP2K4 ENST00000353533 
ENSG00000075624 ACTB ENST00000331789 ENSG00000076984 MAP2K7 ENST00000397979 
ENSG00000184009 ACTG1 ENST00000575842 ENSG00000100030 MAPK1 ENST00000215832 
ENSG00000148156 ACTL7B ENST00000374667 ENSG00000186868 MAPT ENST00000344290 
ENSG00000135503 ACVR1B ENST00000541224 ENSG00000007047 MARK4 ENST00000262891 
ENSG00000140955 ADAD2 ENST00000268624 ENSG00000125952 MAX ENST00000358664 
ENSG00000087116 ADAMTS2 ENST00000251582 ENSG00000166987 MBD6 ENST00000355673 
ENSG00000106624 AEBP1 ENST00000223357 ENSG00000184634 MED12 ENST00000374080 
ENSG00000155966 AFF2 ENST00000370460 ENSG00000133895 MEN1 ENST00000337652 
ENSG00000204149 AGAP6 ENST00000412531 ENSG00000076242 MLH1 ENST00000231790 
ENSG00000110711 AIP ENST00000279146 ENSG00000143674 MLK4 ENST00000366624 
ENSG00000196581 AJAP1 ENST00000378191 ENSG00000171843 MLLT3 ENST00000380338 
ENSG00000129474 AJUBA ENST00000262713 ENSG00000169184 MN1 ENST00000302326 
ENSG00000171094 ALK ENST00000389048 ENSG00000095002 MSH2 ENST00000233146 
ENSG00000163286 ALPPL2 ENST00000295453 ENSG00000113318 MSH3 ENST00000265081 
ENSG00000184675 AMER1 ENST00000330258 ENSG00000116062 MSH6 ENST00000234420 
ENSG00000135409 AMHR2 ENST00000257863 ENSG00000163132 MSX1 ENST00000382723 
ENSG00000130812 ANGPTL6 ENST00000253109 ENSG00000198793 MTOR ENST00000361445 
ENSG00000172014 ANKRD20A4 ENST00000357336 ENSG00000198788 MUC2 ENST00000441003 
ENSG00000135976 ANKRD36 ENST00000420699 ENSG00000117983 MUC5B ENST00000529681 
ENSG00000134982 APC ENST00000457016 ENSG00000132781 MUTYH ENST00000372098 
ENSG00000130203 APOE ENST00000252486 ENSG00000110921 MVK ENST00000228510 
ENSG00000178878 APOLD1 ENST00000326765 ENSG00000133020 MYH8 ENST00000403437 
ENSG00000184945 AQP12A ENST00000337801 ENSG00000128641 MYO1B ENST00000392318 
ENSG00000165269 AQP7 ENST00000297988 ENSG00000067798 NAV3 ENST00000536525 
ENSG00000169083 AR ENST00000374690 ENSG00000163386 NBPF10 ENST00000342960 
ENSG00000117713 ARID1A ENST00000324856 ENSG00000129559 NEDD8 ENST00000250495 
ENSG00000163466 ARPC2 ENST00000295685 ENSG00000100285 NEFH ENST00000310624 
ENSG00000006756 ARSD ENST00000381154 ENSG00000196712 NF1 ENST00000358273 
ENSG00000187855 ASCL4 ENST00000342331 ENSG00000186575 NF2 ENST00000338641 
ENSG00000143970 ASXL2 ENST00000435504 ENSG00000116044 NFE2L2 ENST00000397062 
ENSG00000168874 ATOH8 ENST00000306279 ENSG00000187566 NHLRC1 ENST00000340650 
ENSG00000166377 ATP9B ENST00000426216 ENSG00000140157 NIPA2 ENST00000337451 
ENSG00000085224 ATRX ENST00000373344 ENSG00000164190 NIPBL ENST00000282516 
ENSG00000124788 ATXN1 ENST00000244769 ENSG00000167034 NKX3-1 ENST00000380871 
ENSG00000105778 AVL9 ENST00000318709 ENSG00000087095 NLK ENST00000407008 
ENSG00000103126 AXIN1 ENST00000262320 ENSG00000148400 NOTCH1 ENST00000277541 
ENSG00000168646 AXIN2 ENST00000307078 ENSG00000134250 NOTCH2 ENST00000256646 
ENSG00000166710 B2M ENST00000558401 ENSG00000171246 NPTX1 ENST00000306773 
ENSG00000198488 B3GNT6 ENST00000533140 ENSG00000183971 NPW ENST00000329610 
ENSG00000127152 BCL11B ENST00000357195 ENSG00000213281 NRAS ENST00000369535 
ENSG00000180828 BHLHE22 ENST00000321870 ENSG00000106459 NRF1 ENST00000393232 
ENSG00000183682 BMP8A ENST00000331593 ENSG00000123572 NRK ENST00000428173 
ENSG00000107779 BMPR1A ENST00000372037 ENSG00000165671 NSD1 ENST00000439151 
ENSG00000157764 BRAF ENST00000288602 ENSG00000196368 NUDT11 ENST00000375992 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000105245 NUMBL ENST00000252891 
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ENSG00000139618 BRCA2 ENST00000544455 ENSG00000154358 OBSCN ENST00000570156 
ENSG00000162670 BRINP3 ENST00000367462 ENSG00000181781 ODF3L2 ENST00000315489 
ENSG00000163362 C1orf106 ENST00000413687 ENSG00000130558 OLFM1 ENST00000252854 
ENSG00000173369 C1QB ENST00000314933 ENSG00000196071 OR2L13 ENST00000366478 
ENSG00000182326 C1S ENST00000406697 ENSG00000177462 OR2T8 ENST00000319968 
ENSG00000159239 C2orf81 ENST00000290390 ENSG00000242180 OR51B5 ENST00000300773 
ENSG00000174749 C4orf32 ENST00000309733 ENSG00000165588 OTX2 ENST00000339475 
ENSG00000183784 C9orf66 ENST00000382387 ENSG00000182162 P2RY8 ENST00000381297 
ENSG00000067955 CBFB ENST00000412916 ENSG00000070756 PABPC1 ENST00000318607 
ENSG00000054803 CBLN4 ENST00000064571 ENSG00000174740 PABPC5 ENST00000312600 
ENSG00000135736 CCDC102A ENST00000258214 ENSG00000149090 PAMR1 ENST00000278360 
ENSG00000128596 CCDC136 ENST00000297788 ENSG00000125779 PANK2 ENST00000316562 
ENSG00000110092 CCND1 ENST00000227507 ENSG00000007372 PAX6 ENST00000419022 
ENSG00000167775 CD320 ENST00000301458 ENSG00000163939 PBRM1 ENST00000394830 
ENSG00000114013 CD86 ENST00000330540 ENSG00000165494 PCF11 ENST00000298281 
ENSG00000134371 CDC73 ENST00000367435 ENSG00000134853 PDGFRA ENST00000257290 
ENSG00000167258 CDK12 ENST00000447079 ENSG00000101327 PDYN ENST00000217305 
ENSG00000124762 CDKN1A ENST00000405375 ENSG00000082175 PGR ENST00000325455 
ENSG00000111276 CDKN1B ENST00000228872 ENSG00000164040 PGRMC2 ENST00000520121 
ENSG00000129757 CDKN1C ENST00000414822 ENSG00000156531 PHF6 ENST00000332070 
ENSG00000147889 CDKN2A ENST00000498124 ENSG00000109132 PHOX2B ENST00000226382 
ENSG00000093072 CECR1 ENST00000399839 ENSG00000107537 PHYH ENST00000263038 
ENSG00000111642 CHD4 ENST00000357008 ENSG00000105229 PIAS4 ENST00000262971 
ENSG00000131873 CHSY1 ENST00000254190 ENSG00000214456 PLIN5 ENST00000381848 
ENSG00000079432 CIC ENST00000575354 ENSG00000106397 PLOD3 ENST00000223127 
ENSG00000113946 CLDN16 ENST00000264734 ENSG00000064933 PMS1 ENST00000441310 
ENSG00000159212 CLIC6 ENST00000349499 ENSG00000183206 POTEC ENST00000358970 
ENSG00000060718 COL11A1 ENST00000370096 ENSG00000222036 POTEG ENST00000409832 
ENSG00000164692 COL1A2 ENST00000297268 ENSG00000138814 PPP3CA ENST00000394854 
ENSG00000169436 COL22A1 ENST00000303045 ENSG00000197870 PRB3 ENST00000381842 
ENSG00000163359 COL6A3 ENST00000295550 ENSG00000057657 PRDM1 ENST00000369096 
ENSG00000114270 COL7A1 ENST00000328333 ENSG00000180644 PRF1 ENST00000441259 
ENSG00000021826 CPS1 ENST00000430249 ENSG00000146143 PRIM2 ENST00000607273 
ENSG00000203710 CR1 ENST00000367049 ENSG00000108946 PRKAR1A ENST00000589228 
ENSG00000134376 CRB1 ENST00000367400 ENSG00000188191 PRKAR1B ENST00000406797 
ENSG00000137504 CREBZF ENST00000527447 ENSG00000116132 PRRX1 ENST00000239461 
ENSG00000204414 CSHL1 ENST00000309894 ENSG00000204983 PRSS1 ENST00000311737 
ENSG00000102974 CTCF ENST00000264010 ENSG00000108671 PSMD11 ENST00000261712 
ENSG00000168036 CTNNB1 ENST00000349496 ENSG00000185920 PTCH1 ENST00000331920 
ENSG00000158290 CUL4B ENST00000404115 ENSG00000171862 PTEN ENST00000371953 
ENSG00000083799 CYLD ENST00000427738 ENSG00000179295 PTPN11 ENST00000351677 
ENSG00000126733 DACH2 ENST00000373125 ENSG00000163348 PYGO2 ENST00000368457 
ENSG00000189186 DCAF8L2 ENST00000451261 ENSG00000112531 QKI ENST00000361752 
ENSG00000100523 DDHD1 ENST00000323669 ENSG00000136238 RAC1 ENST00000356142 
ENSG00000100697 DICER1 ENST00000526495 ENSG00000185379 RAD51D ENST00000590016 
ENSG00000130826 DKC1 ENST00000369550 ENSG00000145715 RASA1 ENST00000274376 
ENSG00000186047 DLEU7 ENST00000400393 ENSG00000105538 RASIP1 ENST00000222145 
ENSG00000137090 DMRT1 ENST00000382276 ENSG00000139687 RB1 ENST00000267163 
ENSG00000187957 DNER ENST00000341772 ENSG00000182872 RBM10 ENST00000377604 
ENSG00000130816 DNMT1 ENST00000359526 ENSG00000173933 RBM4 ENST00000409406 
ENSG00000119772 DNMT3A ENST00000264709 ENSG00000163694 RBM47 ENST00000381793 
ENSG00000175920 DOK7 ENST00000340083 ENSG00000147274 RBMX ENST00000320676 
ENSG00000167130 DOLPP1 ENST00000372546 ENSG00000168214 RBPJ ENST00000342295 
ENSG00000167261 DPEP2 ENST00000412757 ENSG00000166965 RCCD1 ENST00000394258 
ENSG00000152591 DSPP ENST00000399271 ENSG00000165731 RET ENST00000355710 
ENSG00000146648 EGFR ENST00000275493 ENSG00000223638 RFPL4A ENST00000434937 
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ENSG00000197561 ELANE ENST00000590230 ENSG00000132005 RFX1 ENST00000254325 
ENSG00000163435 ELF3 ENST00000359651 ENSG00000174136 RGMB ENST00000308234 
ENSG00000126749 EMG1 ENST00000261406 ENSG00000169629 RGPD8 ENST00000302558 
ENSG00000163508 EOMES ENST00000295743 ENSG00000132677 RHBG ENST00000368249 
ENSG00000100393 EP300 ENST00000263253 ENSG00000067560 RHOA ENST00000418115 
ENSG00000183495 EP400 ENST00000389561 ENSG00000136104 RNASEH2B ENST00000336617 
ENSG00000116016 EPAS1 ENST00000263734 ENSG00000181481 RNF135 ENST00000328381 
ENSG00000086289 EPDR1 ENST00000199448 ENSG00000189051 RNF222 ENST00000399398 
ENSG00000141736 ERBB2 ENST00000269571 ENSG00000204618 RNF39 ENST00000244360 
ENSG00000187017 ESPN ENST00000377828 ENSG00000156313 RPGR ENST00000378505 
ENSG00000196482 ESRRG ENST00000366937 ENSG00000165496 RPL10L ENST00000298283 
ENSG00000182197 EXT1 ENST00000378204 ENSG00000122406 RPL5 ENST00000370321 
ENSG00000151348 EXT2 ENST00000395673 ENSG00000117676 RPS6KA1 ENST00000531382 
ENSG00000188107 EYS ENST00000503581 ENSG00000144580 RQCD1 ENST00000273064 
ENSG00000106462 EZH2 ENST00000320356 ENSG00000124782 RREB1 ENST00000379938 
ENSG00000198734 F5 ENST00000367797 ENSG00000159216 RUNX1 ENST00000300305 
ENSG00000103876 FAH ENST00000407106 ENSG00000124813 RUNX2 ENST00000371438 
ENSG00000183688 FAM101B ENST00000329099 ENSG00000186350 RXRA ENST00000481739 
ENSG00000184731 FAM110C ENST00000327669 ENSG00000119042 SATB2 ENST00000417098 
ENSG00000147724 FAM135B ENST00000395297 ENSG00000185313 SCN10A ENST00000449082 
ENSG00000182230 FAM153B ENST00000515817 ENSG00000168356 SCN11A ENST00000302328 
ENSG00000183807 FAM162B ENST00000368557 ENSG00000170616 SCRT1 ENST00000332135 
ENSG00000185442 FAM174B ENST00000327355 ENSG00000167985 SDHAF2 ENST00000301761 
ENSG00000047662 FAM184B ENST00000265018 ENSG00000117118 SDHB ENST00000375499 
ENSG00000165837 FAM194B ENST00000298738 ENSG00000204370 SDHD ENST00000375549 
ENSG00000183508 FAM46C ENST00000369448 ENSG00000255292 SDHD ENST00000532699 
ENSG00000174016 FAM46D ENST00000538312 ENSG00000197249 SERPINA1 ENST00000448921 
ENSG00000188610 FAM72B ENST00000369390 ENSG00000057149 SERPINB3 ENST00000283752 
ENSG00000180921 FAM83H ENST00000388913 ENSG00000139718 SETD1B ENST00000267197 
ENSG00000145002 FAM86B2 ENST00000262365 ENSG00000181555 SETD2 ENST00000409792 
ENSG00000187741 FANCA ENST00000389301 ENSG00000168066 SF1 ENST00000377387 
ENSG00000181544 FANCB ENST00000398334 ENSG00000115524 SF3B1 ENST00000335508 
ENSG00000183161 FANCF ENST00000327470 ENSG00000158352 SHROOM4 ENST00000376020 
ENSG00000026103 FAS ENST00000355740 ENSG00000090402 SI ENST00000264382 
ENSG00000165323 FAT3 ENST00000298047 ENSG00000254415 SIGLEC14 ENST00000360844 
ENSG00000112787 FBRSL1 ENST00000434748 ENSG00000184302 SIX6 ENST00000327720 
ENSG00000109670 FBXW7 ENST00000281708 ENSG00000157933 SKI ENST00000378536 
ENSG00000146618 FERD3L ENST00000275461 ENSG00000091137 SLC26A4 ENST00000265715 
ENSG00000066468 FGFR2 ENST00000457416 ENSG00000139209 SLC38A4 ENST00000447411 
ENSG00000068078 FGFR3 ENST00000340107 ENSG00000188687 SLC4A5 ENST00000377634 
ENSG00000091483 FH ENST00000366560 ENSG00000188827 SLX4 ENST00000294008 
ENSG00000154803 FLCN ENST00000285071 ENSG00000175387 SMAD2 ENST00000402690 
ENSG00000136068 FLNB ENST00000490882 ENSG00000141646 SMAD4 ENST00000342988 
ENSG00000122025 FLT3 ENST00000241453 ENSG00000127616 SMARCA4 ENST00000429416 
ENSG00000129514 FOXA1 ENST00000250448 ENSG00000099956 SMARCB1 ENST00000263121 
ENSG00000125798 FOXA2 ENST00000419308 ENSG00000073584 SMARCE1 ENST00000348513 
ENSG00000184492 FOXD4L1 ENST00000306507 ENSG00000072501 SMC1A ENST00000322213 
ENSG00000178919 FOXE1 ENST00000375123 ENSG00000108055 SMC3 ENST00000361804 
ENSG00000164379 FOXQ1 ENST00000296839 ENSG00000188176 SMTNL2 ENST00000389313 
ENSG00000151474 FRMD4A ENST00000357447 ENSG00000132639 SNAP25 ENST00000254976 
ENSG00000167996 FTH1 ENST00000273550 ENSG00000162804 SNED1 ENST00000310397 
ENSG00000162613 FUBP1 ENST00000370768 ENSG00000100028 SNRPD3 ENST00000215829 
ENSG00000157240 FZD1 ENST00000287934 ENSG00000115904 SOS1 ENST00000426016 
ENSG00000109158 GABRA4 ENST00000264318 ENSG00000164736 SOX17 ENST00000297316 
ENSG00000113327 GABRG2 ENST00000414552 ENSG00000124766 SOX4 ENST00000244745 
ENSG00000179348 GATA2 ENST00000341105 ENSG00000125398 SOX9 ENST00000245479 
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ENSG00000107485 GATA3 ENST00000379328 ENSG00000164651 SP8 ENST00000418710 
ENSG00000177628 GBA ENST00000327247 ENSG00000203923 SPANXN1 ENST00000370493 
ENSG00000100116 GCAT ENST00000323205 ENSG00000133104 SPG20 ENST00000451493 
ENSG00000123159 GIPC1 ENST00000393033 ENSG00000147059 SPIN2A ENST00000374908 
ENSG00000165474 GJB2 ENST00000382844 ENSG00000121067 SPOP ENST00000393331 
ENSG00000106571 GLI3 ENST00000395925 ENSG00000167978 SRRM2 ENST00000301740 
ENSG00000088256 GNA11 ENST00000078429 ENSG00000157216 SSBP3 ENST00000371320 
ENSG00000156052 GNAQ ENST00000286548 ENSG00000101972 STAG2 ENST00000218089 
ENSG00000087460 GNAS ENST00000371100 ENSG00000168610 STAT3 ENST00000264657 
ENSG00000172380 GNG12 ENST00000370982 ENSG00000118046 STK11 ENST00000326873 
ENSG00000215405 GOLGA6L6 ENST00000427390 ENSG00000107882 SUFU ENST00000369902 
ENSG00000147257 GPC3 ENST00000394299 ENSG00000122012 SV2C ENST00000502798 
ENSG00000146360 GPR6 ENST00000275169 ENSG00000176438 SYNE3 ENST00000334258 
ENSG00000204175 GPRIN2 ENST00000374314 ENSG00000148835 TAF5 ENST00000369839 
ENSG00000109519 GRPEL1 ENST00000264954 ENSG00000122145 TBX22 ENST00000373294 
ENSG00000148702 HABP2 ENST00000351270 ENSG00000135111 TBX3 ENST00000257566 
ENSG00000223609 HBD ENST00000380299 ENSG00000121075 TBX4 ENST00000240335 
ENSG00000196565 HBG2 ENST00000380259 ENSG00000204065 TCEAL5 ENST00000372680 
ENSG00000002746 HECW1 ENST00000395891 ENSG00000148737 TCF7L2 ENST00000543371 
ENSG00000182218 HHIPL1 ENST00000330710 ENSG00000164362 TERT ENST00000310581 
ENSG00000256269 HMBS ENST00000278715 ENSG00000106799 TGFBR1 ENST00000374994 
ENSG00000135100 HNF1A ENST00000257555 ENSG00000163513 TGFBR2 ENST00000359013 
ENSG00000165119 HNRNPK ENST00000376263 ENSG00000153779 TGIF2LX ENST00000561129 
ENSG00000174775 HRAS ENST00000451590 ENSG00000144229 THSD7B ENST00000272643 
ENSG00000196196 HRCT1 ENST00000354323 ENSG00000135956 TMEM127 ENST00000258439 
ENSG00000108786 HSD17B1 ENST00000585807 ENSG00000206432 TMEM200C ENST00000581347 
ENSG00000102878 HSF4 ENST00000264009 ENSG00000234224 TMEM229A ENST00000455783 
ENSG00000127415 IDUA ENST00000247933 ENSG00000157873 TNFRSF14 ENST00000355716 
ENSG00000162783 IER5 ENST00000367577 ENSG00000106952 TNFSF8 ENST00000223795 
ENSG00000142089 IFITM3 ENST00000399808 ENSG00000141510 TP53 ENST00000269305 
ENSG00000254709 IGLL5 ENST00000526893 ENSG00000095917 TPSD1 ENST00000211076 
ENSG00000168310 IRF2 ENST00000393593 ENSG00000166157 TPTE ENST00000361285 
ENSG00000137265 IRF4 ENST00000380956 ENSG00000132958 TPTE2 ENST00000400230 
ENSG00000133124 IRS4 ENST00000372129 ENSG00000131323 TRAF3 ENST00000560371 
ENSG00000177508 IRX3 ENST00000329734 ENSG00000100106 TRIOBP ENST00000406386 
ENSG00000152409 JMY ENST00000396137 ENSG00000165699 TSC1 ENST00000298552 
ENSG00000186994 KANK3 ENST00000330915 ENSG00000103197 TSC2 ENST00000219476 
ENSG00000083168 KAT6A ENST00000396930 ENSG00000196428 TSC22D2 ENST00000361875 
ENSG00000234438 KBTBD13 ENST00000432196 ENSG00000231738 TSPAN19 ENST00000532498 
ENSG00000180509 KCNE1 ENST00000337385 ENSG00000077498 TYR ENST00000263321 
ENSG00000164626 KCNK5 ENST00000359534 ENSG00000092445 TYRO3 ENST00000263798 
ENSG00000143603 KCNN3 ENST00000271915 ENSG00000160201 U2AF1 ENST00000291552 
ENSG00000162687 KCNT2 ENST00000294725 ENSG00000077721 UBE2A ENST00000371558 
ENSG00000126012 KDM5C ENST00000375401 ENSG00000169021 UQCRFS1 ENST00000304863 
ENSG00000147050 KDM6A ENST00000377967 ENSG00000126088 UROD ENST00000246337 
ENSG00000197993 KEL ENST00000355265 ENSG00000181408 UTS2R ENST00000313135 
ENSG00000235750 KIAA0040 ENST00000545251 ENSG00000177504 VCX2 ENST00000317103 
ENSG00000157404 KIT ENST00000288135 ENSG00000150630 VEGFC ENST00000280193 
ENSG00000109787 KLF3 ENST00000261438 ENSG00000134086 VHL ENST00000256474 
ENSG00000102554 KLF5 ENST00000377687 ENSG00000178201 VN1R1 ENST00000321039 
ENSG00000055609 KMT2C ENST00000262189 ENSG00000188730 VWC2 ENST00000340652 
ENSG00000167548 KMT2D ENST00000301067 ENSG00000015285 WAS ENST00000376701 
ENSG00000133703 KRAS ENST00000256078 ENSG00000184937 WT1 ENST00000332351 
ENSG00000171346 KRT15 ENST00000254043 ENSG00000181722 ZBTB20 ENST00000474710 
ENSG00000172867 KRT2 ENST00000309680 ENSG00000160685 ZBTB7B ENST00000417934 
ENSG00000139648 KRT71 ENST00000267119 ENSG00000178199 ZC3H12D ENST00000409806 
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ENSG00000161849 KRT84 ENST00000257951 ENSG00000177764 ZCCHC3 ENST00000382352 
ENSG00000212721 KRTAP4-11 ENST00000391413 ENSG00000156599 ZDHHC5 ENST00000287169 
ENSG00000240871 KRTAP4-7 ENST00000391417 ENSG00000169554 ZEB2 ENST00000558170 
ENSG00000107929 LARP4B ENST00000316157 ENSG00000140836 ZFHX3 ENST00000268489 
ENSG00000169744 LDB2 ENST00000304523 ENSG00000152518 ZFP36L2 ENST00000282388 
ENSG00000168924 LETM1 ENST00000302787 ENSG00000179588 ZFPM1 ENST00000319555 
ENSG00000182541 LIMK2 ENST00000340552 ENSG00000122515 ZMIZ2 ENST00000309315 
ENSG00000101670 LIPG ENST00000261292 ENSG00000267508 ZNF285 ENST00000330997 
ENSG00000164715 LMTK2 ENST00000297293 ENSG00000167962 ZNF598 ENST00000431526 
ENSG00000203782 LOR ENST00000368742 ENSG00000197123 ZNF679 ENST00000421025 
ENSG00000120256 LRP11 ENST00000239367 ENSG00000196456 ZNF775 ENST00000329630 
ENSG00000131409 LRRC4B ENST00000599957 ENSG00000204514 ZNF814 ENST00000435989 
ENSG00000148948 LRRC4C ENST00000278198 ENSG00000234284 ZNF879 ENST00000444149 
ENSG00000125872 LRRN4 ENST00000378858 ENSG00000213973 ZNF99 ENST00000596209 
ENSG00000168056 LTBP3 ENST00000301873 ENSG00000188372 ZP3 ENST00000394857 
ENSG00000062524 LTK ENST00000263800       
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Table A5 - Gene list used for analysis of truncating variants based on somatically mutated genes and 
cancer known CPGs – Refined with WebGestalt 
 
 
Gene identifier Gene name 
Canonical 
transcript 
Gene identifier Gene name 
Canonical 
transcript 
ENSG00000115977 AAK1 ENST00000409085 ENSG00000133020 MYH8 ENST00000403437 
ENSG00000085563 ABCB1 ENST00000265724 ENSG00000128641 MYO1B ENST00000392318 
ENSG00000069431 ABCC9 ENST00000261200 ENSG00000186462 NAP1L2 ENST00000373517 
ENSG00000123983 ACSL3 ENST00000357430 ENSG00000144035 NAT8 ENST00000272425 
ENSG00000075624 ACTB ENST00000331789 ENSG00000104320 NBN ENST00000265433 
ENSG00000184009 ACTG1 ENST00000575842 ENSG00000158092 NCK1 ENST00000481752 
ENSG00000077080 ACTL6B ENST00000160382 ENSG00000124151 NCOA3 ENST00000371998 
ENSG00000135503 ACVR1B ENST00000541224 ENSG00000141027 NCOR1 ENST00000268712 
ENSG00000145536 ADAMTS16 ENST00000274181 ENSG00000129559 NEDD8 ENST00000250495 
ENSG00000087116 ADAMTS2 ENST00000251582 ENSG00000100285 NEFH ENST00000310624 
ENSG00000106624 AEBP1 ENST00000223357 ENSG00000196712 NF1 ENST00000358273 
ENSG00000144891 AGTR1 ENST00000542281 ENSG00000186575 NF2 ENST00000338641 
ENSG00000113492 AGXT2 ENST00000231420 ENSG00000116044 NFE2L2 ENST00000397062 
ENSG00000110711 AIP ENST00000279146 ENSG00000164190 NIPBL ENST00000282516 
ENSG00000129474 AJUBA ENST00000262713 ENSG00000167034 NKX3-1 ENST00000380871 
ENSG00000151320 AKAP6 ENST00000280979 ENSG00000087095 NLK ENST00000407008 
ENSG00000142208 AKT1 ENST00000554581 ENSG00000171487 NLRP5 ENST00000390649 
ENSG00000171094 ALK ENST00000389048 ENSG00000174885 NLRP6 ENST00000312165 
ENSG00000184675 AMER1 ENST00000330258 ENSG00000197696 NMB ENST00000394588 
ENSG00000135409 AMHR2 ENST00000257863 ENSG00000169251 NMD3 ENST00000460469 
ENSG00000130812 ANGPTL6 ENST00000253109 ENSG00000109255 NMU ENST00000264218 
ENSG00000148513 ANKRD30A ENST00000361713 ENSG00000148400 NOTCH1 ENST00000277541 
ENSG00000134982 APC ENST00000457016 ENSG00000134250 NOTCH2 ENST00000256646 
ENSG00000132703 APCS ENST00000255040 ENSG00000188747 NOXA1 ENST00000341349 
ENSG00000130203 APOE ENST00000252486 ENSG00000056291 NPFFR2 ENST00000308744 
ENSG00000178878 APOLD1 ENST00000326765 ENSG00000181163 NPM1 ENST00000296930 
ENSG00000169083 AR ENST00000374690 ENSG00000171246 NPTX1 ENST00000306773 
ENSG00000117713 ARID1A ENST00000324856 ENSG00000213281 NRAS ENST00000369535 
ENSG00000189079 ARID2 ENST00000334344 ENSG00000106459 NRF1 ENST00000393232 
ENSG00000163466 ARPC2 ENST00000295685 ENSG00000123572 NRK ENST00000428173 
ENSG00000161664 ASB16 ENST00000293414 ENSG00000165671 NSD1 ENST00000439151 
ENSG00000187855 ASCL4 ENST00000342331 ENSG00000065057 NTHL1 ENST00000219066 
ENSG00000148219 ASTN2 ENST00000361209 ENSG00000074590 NUAK1 ENST00000261402 
ENSG00000143970 ASXL2 ENST00000435504 ENSG00000105245 NUMBL ENST00000252891 
ENSG00000149311 ATM ENST00000278616 ENSG00000102900 NUP93 ENST00000308159 
ENSG00000111676 ATN1 ENST00000356654 ENSG00000154358 OBSCN ENST00000570156 
ENSG00000168874 ATOH8 ENST00000306279 ENSG00000087263 OGFOD1 ENST00000566157 
ENSG00000116039 ATP6V1B1 ENST00000234396 ENSG00000130558 OLFM1 ENST00000252854 
ENSG00000085224 ATRX ENST00000373344 ENSG00000116329 OPRD1 ENST00000234961 
ENSG00000124788 ATXN1 ENST00000244769 ENSG00000234560 OR10G8 ENST00000431524 
ENSG00000066427 ATXN3 ENST00000393287 ENSG00000257019 OR13C2 ENST00000542196 
ENSG00000103126 AXIN1 ENST00000262320 ENSG00000172150 OR1A2 ENST00000381951 
ENSG00000168646 AXIN2 ENST00000307078 ENSG00000197887 OR1S2 ENST00000302592 
ENSG00000166710 B2M ENST00000558401 ENSG00000221938 OR2A14 ENST00000408899 
ENSG00000175866 BAIAP2 ENST00000321300 ENSG00000221989 OR2A2 ENST00000408979 
ENSG00000163930 BAP1 ENST00000460680 ENSG00000188558 OR2G6 ENST00000343414 
ENSG00000127152 BCL11B ENST00000357195 ENSG00000196071 OR2L13 ENST00000366478 
ENSG00000110987 BCL7A ENST00000538010 ENSG00000196936 OR2L8 ENST00000357191 
ENSG00000180828 BHLHE22 ENST00000321870 ENSG00000162727 OR2M5 ENST00000366476 
ENSG00000197299 BLM ENST00000355112 ENSG00000177201 OR2T12 ENST00000317996 
267 
 
ENSG00000183682 BMP8A ENST00000331593 ENSG00000196240 OR2T2 ENST00000342927 
ENSG00000107779 BMPR1A ENST00000372037 ENSG00000177212 OR2T33 ENST00000318021 
ENSG00000157764 BRAF ENST00000288602 ENSG00000183310 OR2T34 ENST00000328782 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000196944 OR2T4 ENST00000366475 
ENSG00000139618 BRCA2 ENST00000544455 ENSG00000177462 OR2T8 ENST00000319968 
ENSG00000112983 BRD8 ENST00000254900 ENSG00000221840 OR4A5 ENST00000319760 
ENSG00000162670 BRINP3 ENST00000367462 ENSG00000181935 OR4C16 ENST00000314634 
ENSG00000136492 BRIP1 ENST00000259008 ENSG00000176547 OR4C3 ENST00000319856 
ENSG00000151136 BTBD11 ENST00000280758 ENSG00000141194 OR4D1 ENST00000268912 
ENSG00000159388 BTG2 ENST00000290551 ENSG00000176200 OR4D11 ENST00000313253 
ENSG00000156970 BUB1B ENST00000287598 ENSG00000182854 OR4F15 ENST00000332238 
ENSG00000039537 C6 ENST00000263413 ENSG00000182974 OR4M2 ENST00000332663 
ENSG00000157131 C8A ENST00000361249 ENSG00000176294 OR4N2 ENST00000315947 
ENSG00000004948 CALCR ENST00000359558 ENSG00000176895 OR51A7 ENST00000359350 
ENSG00000108509 CAMTA2 ENST00000414043 ENSG00000184881 OR51B2 ENST00000328813 
ENSG00000064012 CASP8 ENST00000358485 ENSG00000242180 OR51B5 ENST00000300773 
ENSG00000118729 CASQ2 ENST00000261448 ENSG00000176879 OR51G1 ENST00000321961 
ENSG00000067955 CBFB ENST00000412916 ENSG00000176893 OR51G2 ENST00000322013 
ENSG00000110395 CBL ENST00000264033 ENSG00000181609 OR52D1 ENST00000322641 
ENSG00000122565 CBX3 ENST00000337620 ENSG00000176937 OR52R1 ENST00000356069 
ENSG00000128596 CCDC136 ENST00000297788 ENSG00000172459 OR5AR1 ENST00000302969 
ENSG00000180376 CCDC66 ENST00000394672 ENSG00000198877 OR5D13 ENST00000361760 
ENSG00000106178 CCL24 ENST00000416943 ENSG00000149133 OR5F1 ENST00000278409 
ENSG00000110092 CCND1 ENST00000227507 ENSG00000231192 OR5H1 ENST00000354565 
ENSG00000010610 CD4 ENST00000011653 ENSG00000236032 OR5H14 ENST00000437310 
ENSG00000114013 CD86 ENST00000330540 ENSG00000233412 OR5H15 ENST00000356526 
ENSG00000004897 CDC27 ENST00000531206 ENSG00000186117 OR5L1 ENST00000333973 
ENSG00000134371 CDC73 ENST00000367435 ENSG00000205030 OR5L2 ENST00000378397 
ENSG00000039068 CDH1 ENST00000261769 ENSG00000174937 OR5M3 ENST00000312240 
ENSG00000167258 CDK12 ENST00000447079 ENSG00000174942 OR5R1 ENST00000312253 
ENSG00000135446 CDK4 ENST00000257904 ENSG00000172489 OR5T3 ENST00000303059 
ENSG00000124762 CDKN1A ENST00000405375 ENSG00000187612 OR5W2 ENST00000344514 
ENSG00000111276 CDKN1B ENST00000228872 ENSG00000169214 OR6F1 ENST00000302084 
ENSG00000129757 CDKN1C ENST00000414822 ENSG00000203757 OR6K3 ENST00000368145 
ENSG00000147889 CDKN2A ENST00000498124 ENSG00000198657 OR8B4 ENST00000356130 
ENSG00000147883 CDKN2B ENST00000276925 ENSG00000172154 OR8I2 ENST00000302124 
ENSG00000245848 CEBPA ENST00000498907 ENSG00000181689 OR8K3 ENST00000312711 
ENSG00000139610 CELA1 ENST00000293636 ENSG00000181752 OR8K5 ENST00000313447 
ENSG00000166037 CEP57 ENST00000325542 ENSG00000197376 OR8S1 ENST00000310194 
ENSG00000111642 CHD4 ENST00000357008 ENSG00000165588 OTX2 ENST00000339475 
ENSG00000183765 CHEK2 ENST00000382580 ENSG00000155463 OXA1L ENST00000285848 
ENSG00000131873 CHSY1 ENST00000254190 ENSG00000182162 P2RY8 ENST00000381297 
ENSG00000079432 CIC ENST00000575354 ENSG00000070756 PABPC1 ENST00000318607 
ENSG00000174600 CMKLR1 ENST00000312143 ENSG00000083093 PALB2 ENST00000261584 
ENSG00000060718 COL11A1 ENST00000370096 ENSG00000125779 PANK2 ENST00000316562 
ENSG00000164692 COL1A2 ENST00000297268 ENSG00000162073 PAQR4 ENST00000318782 
ENSG00000114270 COL7A1 ENST00000328333 ENSG00000007372 PAX6 ENST00000419022 
ENSG00000021826 CPS1 ENST00000430249 ENSG00000163939 PBRM1 ENST00000394830 
ENSG00000203710 CR1 ENST00000367049 ENSG00000165494 PCF11 ENST00000298281 
ENSG00000134376 CRB1 ENST00000367400 ENSG00000056661 PCGF2 ENST00000580830 
ENSG00000137504 CREBZF ENST00000527447 ENSG00000156374 PCGF6 ENST00000369847 
ENSG00000213145 CRIP1 ENST00000330233 ENSG00000249915 PDCD6 ENST00000264933 
ENSG00000121552 CSTA ENST00000264474 ENSG00000134853 PDGFRA ENST00000257290 
ENSG00000102974 CTCF ENST00000264010 ENSG00000049246 PER3 ENST00000361923 
ENSG00000118523 CTGF ENST00000367976 ENSG00000082175 PGR ENST00000325455 
ENSG00000168036 CTNNB1 ENST00000349496 ENSG00000164040 PGRMC2 ENST00000520121 
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ENSG00000158290 CUL4B ENST00000404115 ENSG00000156531 PHF6 ENST00000332070 
ENSG00000083799 CYLD ENST00000427738 ENSG00000109132 PHOX2B ENST00000226382 
ENSG00000172817 CYP7B1 ENST00000310193 ENSG00000105229 PIAS4 ENST00000262971 
ENSG00000152207 CYSLTR2 ENST00000282018 ENSG00000121879 PIK3CA ENST00000263967 
ENSG00000126733 DACH2 ENST00000373125 ENSG00000145675 PIK3R1 ENST00000521381 
ENSG00000133083 DCLK1 ENST00000255448 ENSG00000170890 PLA2G1B ENST00000308366 
ENSG00000134574 DDB2 ENST00000256996 ENSG00000214456 PLIN5 ENST00000381848 
ENSG00000013573 DDX11 ENST00000407793 ENSG00000106397 PLOD3 ENST00000223127 
ENSG00000124795 DEK ENST00000397239 ENSG00000064933 PMS1 ENST00000441310 
ENSG00000100697 DICER1 ENST00000526495 ENSG00000062822 POLD1 ENST00000440232 
ENSG00000211448 DIO2 ENST00000555750 ENSG00000177084 POLE ENST00000320574 
ENSG00000144535 DIS3L2 ENST00000325385 ENSG00000170734 POLH ENST00000372236 
ENSG00000130826 DKC1 ENST00000369550 ENSG00000170836 PPM1D ENST00000305921 
ENSG00000137090 DMRT1 ENST00000382276 ENSG00000105568 PPP2R1A ENST00000322088 
ENSG00000187957 DNER ENST00000341772 ENSG00000138814 PPP3CA ENST00000394854 
ENSG00000130816 DNMT1 ENST00000359526 ENSG00000116721 PRAMEF1 ENST00000332296 
ENSG00000119772 DNMT3A ENST00000264709 ENSG00000137509 PRCP ENST00000393399 
ENSG00000134516 DOCK2 ENST00000256935 ENSG00000057657 PRDM1 ENST00000369096 
ENSG00000107099 DOCK8 ENST00000453981 ENSG00000164256 PRDM9 ENST00000296682 
ENSG00000206052 DOK6 ENST00000382713 ENSG00000108946 PRKAR1A ENST00000589228 
ENSG00000175920 DOK7 ENST00000340083 ENSG00000116132 PRRX1 ENST00000239461 
ENSG00000121570 DPPA4 ENST00000335658 ENSG00000164985 PSIP1 ENST00000380733 
ENSG00000152591 DSPP ENST00000399271 ENSG00000108671 PSMD11 ENST00000261712 
ENSG00000112679 DUSP22 ENST00000344450 ENSG00000185920 PTCH1 ENST00000331920 
ENSG00000164176 EDIL3 ENST00000296591 ENSG00000171862 PTEN ENST00000371953 
ENSG00000136160 EDNRB ENST00000377211 ENSG00000179295 PTPN11 ENST00000351677 
ENSG00000146648 EGFR ENST00000275493 ENSG00000127947 PTPN12 ENST00000248594 
ENSG00000120738 EGR1 ENST00000239938 ENSG00000163348 PYGO2 ENST00000368457 
ENSG00000197561 ELANE ENST00000590230 ENSG00000112531 QKI ENST00000361752 
ENSG00000163435 ELF3 ENST00000359651 ENSG00000136238 RAC1 ENST00000356142 
ENSG00000155849 ELMO1 ENST00000310758 ENSG00000164754 RAD21 ENST00000297338 
ENSG00000163508 EOMES ENST00000295743 ENSG00000108384 RAD51C ENST00000337432 
ENSG00000100393 EP300 ENST00000263253 ENSG00000185379 RAD51D ENST00000590016 
ENSG00000183495 EP400 ENST00000389561 ENSG00000145715 RASA1 ENST00000274376 
ENSG00000116016 EPAS1 ENST00000263734 ENSG00000111344 RASAL1 ENST00000546530 
ENSG00000119888 EPCAM ENST00000263735 ENSG00000105538 RASIP1 ENST00000222145 
ENSG00000142627 EPHA2 ENST00000358432 ENSG00000139687 RB1 ENST00000267163 
ENSG00000080224 EPHA6 ENST00000389672 ENSG00000182872 RBM10 ENST00000377604 
ENSG00000141736 ERBB2 ENST00000269571 ENSG00000173933 RBM4 ENST00000409406 
ENSG00000065361 ERBB3 ENST00000267101 ENSG00000147274 RBMX ENST00000320676 
ENSG00000082805 ERC1 ENST00000397203 ENSG00000168214 RBPJ ENST00000342295 
ENSG00000104884 ERCC2 ENST00000391945 ENSG00000124232 RBPJL ENST00000343694 
ENSG00000163161 ERCC3 ENST00000285398 ENSG00000160957 RECQL4 ENST00000428558 
ENSG00000175595 ERCC4 ENST00000311895 ENSG00000115386 REG1A ENST00000233735 
ENSG00000134899 ERCC5 ENST00000355739 ENSG00000172023 REG1B ENST00000305089 
ENSG00000187017 ESPN ENST00000377828 ENSG00000172016 REG3A ENST00000393878 
ENSG00000196482 ESRRG ENST00000366937 ENSG00000143954 REG3G ENST00000272324 
ENSG00000182197 EXT1 ENST00000378204 ENSG00000165731 RET ENST00000355710 
ENSG00000151348 EXT2 ENST00000395673 ENSG00000132005 RFX1 ENST00000254325 
ENSG00000188107 EYS ENST00000503581 ENSG00000174136 RGMB ENST00000308234 
ENSG00000106462 EZH2 ENST00000320356 ENSG00000182901 RGS7 ENST00000366565 
ENSG00000101447 FAM83D ENST00000217429 ENSG00000186326 RGS9BP ENST00000334176 
ENSG00000180921 FAM83H ENST00000388913 ENSG00000067560 RHOA ENST00000418115 
ENSG00000183304 FAM9A ENST00000543214 ENSG00000143878 RHOB ENST00000272233 
ENSG00000187741 FANCA ENST00000389301 ENSG00000119729 RHOQ ENST00000238738 
ENSG00000181544 FANCB ENST00000398334 ENSG00000136104 RNASEH2B ENST00000336617 
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ENSG00000158169 FANCC ENST00000289081 ENSG00000181481 RNF135 ENST00000328381 
ENSG00000144554 FANCD2 ENST00000287647 ENSG00000189051 RNF222 ENST00000399398 
ENSG00000112039 FANCE ENST00000229769 ENSG00000108375 RNF43 ENST00000584437 
ENSG00000183161 FANCF ENST00000327470 ENSG00000117676 RPS6KA1 ENST00000531382 
ENSG00000221829 FANCG ENST00000378643 ENSG00000124782 RREB1 ENST00000379938 
ENSG00000140525 FANCI ENST00000310775 ENSG00000159216 RUNX1 ENST00000300305 
ENSG00000115392 FANCL ENST00000402135 ENSG00000079102 RUNX1T1 ENST00000436581 
ENSG00000187790 FANCM ENST00000267430 ENSG00000124813 RUNX2 ENST00000371438 
ENSG00000026103 FAS ENST00000355740 ENSG00000186350 RXRA ENST00000481739 
ENSG00000109670 FBXW7 ENST00000281708 ENSG00000119042 SATB2 ENST00000417098 
ENSG00000203747 FCGR3A ENST00000367969 ENSG00000126524 SBDS ENST00000246868 
ENSG00000146618 FERD3L ENST00000275461 ENSG00000170616 SCRT1 ENST00000332135 
ENSG00000171055 FEZ2 ENST00000379245 ENSG00000137575 SDCBP ENST00000260130 
ENSG00000066468 FGFR2 ENST00000457416 ENSG00000167985 SDHAF2 ENST00000301761 
ENSG00000068078 FGFR3 ENST00000340107 ENSG00000007908 SELE ENST00000333360 
ENSG00000134775 FHOD3 ENST00000257209 ENSG00000075223 SEMA3C ENST00000265361 
ENSG00000154803 FLCN ENST00000285071 ENSG00000082684 SEMA5B ENST00000451055 
ENSG00000143631 FLG ENST00000368799 ENSG00000057149 SERPINB3 ENST00000283752 
ENSG00000136068 FLNB ENST00000490882 ENSG00000181555 SETD2 ENST00000409792 
ENSG00000122025 FLT3 ENST00000241453 ENSG00000168066 SF1 ENST00000377387 
ENSG00000129514 FOXA1 ENST00000250448 ENSG00000115524 SF3B1 ENST00000335508 
ENSG00000125798 FOXA2 ENST00000419308 ENSG00000118515 SGK1 ENST00000367858 
ENSG00000184492 FOXD4L1 ENST00000306507 ENSG00000158352 SHROOM4 ENST00000376020 
ENSG00000184659 FOXD4L4 ENST00000377413 ENSG00000112246 SIM1 ENST00000369208 
ENSG00000178919 FOXE1 ENST00000375123 ENSG00000198053 SIRPA ENST00000358771 
ENSG00000164379 FOXQ1 ENST00000296839 ENSG00000184302 SIX6 ENST00000327720 
ENSG00000136877 FPGS ENST00000373247 ENSG00000157933 SKI ENST00000378536 
ENSG00000109536 FRG1 ENST00000226798 ENSG00000014824 SLC30A9 ENST00000264451 
ENSG00000167996 FTH1 ENST00000273550 ENSG00000148482 SLC39A12 ENST00000377369 
ENSG00000162613 FUBP1 ENST00000370768 ENSG00000188687 SLC4A5 ENST00000377634 
ENSG00000157240 FZD1 ENST00000287934 ENSG00000184564 SLITRK6 ENST00000400286 
ENSG00000104290 FZD3 ENST00000240093 ENSG00000188827 SLX4 ENST00000294008 
ENSG00000109158 GABRA4 ENST00000264318 ENSG00000175387 SMAD2 ENST00000402690 
ENSG00000145863 GABRA6 ENST00000274545 ENSG00000141646 SMAD4 ENST00000342988 
ENSG00000113327 GABRG2 ENST00000414552 ENSG00000127616 SMARCA4 ENST00000429416 
ENSG00000146276 GABRR1 ENST00000454853 ENSG00000099956 SMARCB1 ENST00000263121 
ENSG00000179348 GATA2 ENST00000341105 ENSG00000073584 SMARCE1 ENST00000348513 
ENSG00000107485 GATA3 ENST00000379328 ENSG00000072501 SMC1A ENST00000322213 
ENSG00000177628 GBA ENST00000327247 ENSG00000108055 SMC3 ENST00000361804 
ENSG00000179168 GGN ENST00000334928 ENSG00000116698 SMG7 ENST00000507469 
ENSG00000123159 GIPC1 ENST00000393033 ENSG00000132639 SNAP25 ENST00000254976 
ENSG00000165474 GJB2 ENST00000382844 ENSG00000104976 SNAPC2 ENST00000221573 
ENSG00000106571 GLI3 ENST00000395925 ENSG00000100028 SNRPD3 ENST00000215829 
ENSG00000104499 GML ENST00000220940 ENSG00000115904 SOS1 ENST00000426016 
ENSG00000088256 GNA11 ENST00000078429 ENSG00000164736 SOX17 ENST00000297316 
ENSG00000156052 GNAQ ENST00000286548 ENSG00000124766 SOX4 ENST00000244745 
ENSG00000087460 GNAS ENST00000371100 ENSG00000125398 SOX9 ENST00000245479 
ENSG00000172380 GNG12 ENST00000370982 ENSG00000105866 SP4 ENST00000222584 
ENSG00000147257 GPC3 ENST00000394299 ENSG00000164651 SP8 ENST00000418710 
ENSG00000183098 GPC6 ENST00000377047 ENSG00000163071 SPATA18 ENST00000295213 
ENSG00000146360 GPR6 ENST00000275169 ENSG00000141255 SPATA22 ENST00000573128 
ENSG00000132522 GPS2 ENST00000380728 ENSG00000133104 SPG20 ENST00000451493 
ENSG00000215203 GRXCR1 ENST00000399770 ENSG00000121067 SPOP ENST00000393331 
ENSG00000244067 GSTA2 ENST00000493422 ENSG00000169474 SPRR1A ENST00000307122 
ENSG00000010704 HFE ENST00000357618 ENSG00000163554 SPTA1 ENST00000368147 
ENSG00000182218 HHIPL1 ENST00000330710 ENSG00000167978 SRRM2 ENST00000301740 
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ENSG00000114455 HHLA2 ENST00000357759 ENSG00000184895 SRY ENST00000383070 
ENSG00000168298 HIST1H1E ENST00000304218 ENSG00000157216 SSBP3 ENST00000371320 
ENSG00000164508 HIST1H2AA ENST00000297012 ENSG00000101972 STAG2 ENST00000218089 
ENSG00000205581 HMGN1 ENST00000380749 ENSG00000168610 STAT3 ENST00000264657 
ENSG00000135100 HNF1A ENST00000257555 ENSG00000118046 STK11 ENST00000326873 
ENSG00000165119 HNRNPK ENST00000376263 ENSG00000107882 SUFU ENST00000369902 
ENSG00000099783 HNRNPM ENST00000325495 ENSG00000173597 SULT1B1 ENST00000310613 
ENSG00000174775 HRAS ENST00000451590 ENSG00000178691 SUZ12 ENST00000322652 
ENSG00000102878 HSF4 ENST00000264009 ENSG00000131018 SYNE1 ENST00000367255 
ENSG00000138413 IDH1 ENST00000415913 ENSG00000176438 SYNE3 ENST00000334258 
ENSG00000182054 IDH2 ENST00000330062 ENSG00000148835 TAF5 ENST00000369839 
ENSG00000142089 IFITM3 ENST00000399808 ENSG00000169777 TAS2R1 ENST00000382492 
ENSG00000136634 IL10 ENST00000423557 ENSG00000121318 TAS2R10 ENST00000240619 
ENSG00000115607 IL18RAP ENST00000264260 ENSG00000127362 TAS2R3 ENST00000247879 
ENSG00000016402 IL20RA ENST00000316649 ENSG00000255374 TAS2R43 ENST00000531678 
ENSG00000134352 IL6ST ENST00000381298 ENSG00000122145 TBX22 ENST00000373294 
ENSG00000153487 ING1 ENST00000375774 ENSG00000135111 TBX3 ENST00000257566 
ENSG00000168310 IRF2 ENST00000393593 ENSG00000121075 TBX4 ENST00000240335 
ENSG00000137265 IRF4 ENST00000380956 ENSG00000204065 TCEAL5 ENST00000372680 
ENSG00000133124 IRS4 ENST00000372129 ENSG00000113649 TCERG1 ENST00000296702 
ENSG00000177508 IRX3 ENST00000329734 ENSG00000140262 TCF12 ENST00000438423 
ENSG00000113263 ITK ENST00000422843 ENSG00000148737 TCF7L2 ENST00000543371 
ENSG00000152409 JMY ENST00000396137 ENSG00000164362 TERT ENST00000310581 
ENSG00000083168 KAT6A ENST00000396930 ENSG00000168769 TET2 ENST00000540549 
ENSG00000126012 KDM5C ENST00000375401 ENSG00000106799 TGFBR1 ENST00000374994 
ENSG00000147050 KDM6A ENST00000377967 ENSG00000163513 TGFBR2 ENST00000359013 
ENSG00000079999 KEAP1 ENST00000171111 ENSG00000136869 TLR4 ENST00000355622 
ENSG00000197993 KEL ENST00000355265 ENSG00000135956 TMEM127 ENST00000258439 
ENSG00000134313 KIDINS220 ENST00000256707 ENSG00000234224 TMEM229A ENST00000455783 
ENSG00000157404 KIT ENST00000288135 ENSG00000137747 TMPRSS13 ENST00000524993 
ENSG00000109787 KLF3 ENST00000261438 ENSG00000157873 TNFRSF14 ENST00000355716 
ENSG00000102554 KLF5 ENST00000377687 ENSG00000243509 TNFRSF6B ENST00000369996 
ENSG00000205810 KLRC3 ENST00000381903 ENSG00000106952 TNFSF8 ENST00000223795 
ENSG00000167548 KMT2D ENST00000301067 ENSG00000168884 TNIP2 ENST00000315423 
ENSG00000171798 KNDC1 ENST00000304613 ENSG00000141510 TP53 ENST00000269305 
ENSG00000133703 KRAS ENST00000256078 ENSG00000115705 TPO ENST00000345913 
ENSG00000171346 KRT15 ENST00000254043 ENSG00000131323 TRAF3 ENST00000560371 
ENSG00000172867 KRT2 ENST00000309680 ENSG00000112195 TREML2 ENST00000483722 
ENSG00000139648 KRT71 ENST00000267119 ENSG00000108395 TRIM37 ENST00000262294 
ENSG00000161849 KRT84 ENST00000257951 ENSG00000147573 TRIM55 ENST00000315962 
ENSG00000107929 LARP4B ENST00000316157 ENSG00000100106 TRIOBP ENST00000406386 
ENSG00000196734 LCE1B ENST00000360090 ENSG00000165699 TSC1 ENST00000298552 
ENSG00000240386 LCE1F ENST00000334371 ENSG00000103197 TSC2 ENST00000219476 
ENSG00000187173 LCE2A ENST00000368779 ENSG00000196428 TSC22D2 ENST00000361875 
ENSG00000163202 LCE3D ENST00000368787 ENSG00000155657 TTN ENST00000589042 
ENSG00000169744 LDB2 ENST00000304523 ENSG00000077498 TYR ENST00000263321 
ENSG00000168924 LETM1 ENST00000302787 ENSG00000092445 TYRO3 ENST00000263798 
ENSG00000050426 LETMD1 ENST00000418425 ENSG00000077721 UBE2A ENST00000371558 
ENSG00000138039 LHCGR ENST00000294954 ENSG00000083290 ULK2 ENST00000395544 
ENSG00000239998 LILRA2 ENST00000251377 ENSG00000168038 ULK4 ENST00000301831 
ENSG00000182541 LIMK2 ENST00000340552 ENSG00000169021 UQCRFS1 ENST00000304863 
ENSG00000101670 LIPG ENST00000261292 ENSG00000143258 USP21 ENST00000368002 
ENSG00000170807 LMOD2 ENST00000458573 ENSG00000181408 UTS2R ENST00000313135 
ENSG00000203782 LOR ENST00000368742 ENSG00000150630 VEGFC ENST00000280193 
ENSG00000144749 LRIG1 ENST00000273261 ENSG00000134086 VHL ENST00000256474 
ENSG00000131409 LRRC4B ENST00000599957 ENSG00000178201 VN1R1 ENST00000321039 
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ENSG00000148948 LRRC4C ENST00000278198 ENSG00000188730 VWC2 ENST00000340652 
ENSG00000125872 LRRN4 ENST00000378858 ENSG00000015285 WAS ENST00000376701 
ENSG00000168056 LTBP3 ENST00000301873 ENSG00000239779 WBP1 ENST00000233615 
ENSG00000062524 LTK ENST00000263800 ENSG00000060237 WNK1 ENST00000315939 
ENSG00000139329 LUM ENST00000266718 ENSG00000002745 WNT16 ENST00000222462 
ENSG00000099949 LZTR1 ENST00000215739 ENSG00000105989 WNT2 ENST00000265441 
ENSG00000061337 LZTS1 ENST00000381569 ENSG00000165392 WRN ENST00000298139 
ENSG00000099866 MADCAM1 ENST00000215637 ENSG00000184937 WT1 ENST00000332351 
ENSG00000130479 MAP1S ENST00000324096 ENSG00000136936 XPA ENST00000375128 
ENSG00000065559 MAP2K4 ENST00000353533 ENSG00000154767 XPC ENST00000285021 
ENSG00000076984 MAP2K7 ENST00000397979 ENSG00000181722 ZBTB20 ENST00000474710 
ENSG00000095015 MAP3K1 ENST00000399503 ENSG00000160685 ZBTB7B ENST00000417934 
ENSG00000100030 MAPK1 ENST00000215832 ENSG00000178199 ZC3H12D ENST00000409806 
ENSG00000186868 MAPT ENST00000344290 ENSG00000169554 ZEB2 ENST00000558170 
ENSG00000125952 MAX ENST00000358664 ENSG00000140836 ZFHX3 ENST00000268489 
ENSG00000166987 MBD6 ENST00000355673 ENSG00000185650 ZFP36L1 ENST00000439696 
ENSG00000184634 MED12 ENST00000374080 ENSG00000152518 ZFP36L2 ENST00000282388 
ENSG00000133895 MEN1 ENST00000337652 ENSG00000179588 ZFPM1 ENST00000319555 
ENSG00000152595 MEPE ENST00000424957 ENSG00000122515 ZMIZ2 ENST00000309315 
ENSG00000105976 MET ENST00000318493 ENSG00000105136 ZNF419 ENST00000424930 
ENSG00000165819 METTL3 ENST00000298717 ENSG00000229676 ZNF492 ENST00000456783 
ENSG00000076242 MLH1 ENST00000231790 ENSG00000188171 ZNF626 ENST00000601440 
ENSG00000171843 MLLT3 ENST00000380338 ENSG00000197483 ZNF628 ENST00000598519 
ENSG00000005381 MPO ENST00000225275 ENSG00000196109 ZNF676 ENST00000397121 
ENSG00000150054 MPP7 ENST00000337532 ENSG00000197123 ZNF679 ENST00000421025 
ENSG00000095002 MSH2 ENST00000233146 ENSG00000182141 ZNF708 ENST00000356929 
ENSG00000113318 MSH3 ENST00000265081 ENSG00000141579 ZNF750 ENST00000269394 
ENSG00000116062 MSH6 ENST00000234420 ENSG00000198146 ZNF770 ENST00000356321 
ENSG00000163132 MSX1 ENST00000382723 ENSG00000204514 ZNF814 ENST00000435989 
ENSG00000198793 MTOR ENST00000361445 ENSG00000234284 ZNF879 ENST00000444149 
ENSG00000185499 MUC1 ENST00000368395 ENSG00000221923 ZNF880 ENST00000422689 
ENSG00000169876 MUC17 ENST00000306151 ENSG00000188372 ZP3 ENST00000394857 
ENSG00000132781 MUTYH ENST00000372098 ENSG00000131848 ZSCAN5A ENST00000587340 
ENSG00000118513 MYB ENST00000341911 ENSG00000122952 ZWINT ENST00000373944 
ENSG00000172936 MYD88 ENST00000417037  
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Table A6 - Gene list used for analysis of truncating variants based on ratio of non-synonymous 
variants to synonymous per gene in Martincorena et al. 2017 
 
Gene identifier 
Gene 
name 
Canonical 
transcript Gene identifier Gene name 
Canonical 
transcript 
ENSG00000135503 ACVR1B ENST00000541224 ENSG00000105663 KMT2B ENST00000607650 
ENSG00000121989 ACVR2A ENST00000241416 ENSG00000055609 KMT2C ENST00000262189 
ENSG00000129474 AJUBA ENST00000262713 ENSG00000167548 KMT2D ENST00000301067 
ENSG00000142208 AKT1 ENST00000554581 ENSG00000133703 KRAS ENST00000256078 
ENSG00000163631 ALB ENST00000295897 ENSG00000186081 KRT5 ENST00000252242 
ENSG00000110497 AMBRA1 ENST00000314845 ENSG00000150457 LATS2 ENST00000382592 
ENSG00000184675 AMER1 ENST00000330258 ENSG00000099949 LZTR1 ENST00000215739 
ENSG00000134982 APC ENST00000457016 ENSG00000169032 MAP2K1 ENST00000307102 
ENSG00000160007 ARHGAP35 ENST00000404338 ENSG00000065559 MAP2K4 ENST00000353533 
ENSG00000100852 ARHGAP5 ENST00000345122 ENSG00000076984 MAP2K7 ENST00000397979 
ENSG00000117713 ARID1A ENST00000324856 ENSG00000095015 MAP3K1 ENST00000399503 
ENSG00000049618 ARID1B ENST00000346085 ENSG00000125952 MAX ENST00000358664 
ENSG00000189079 ARID2 ENST00000334344 ENSG00000103495 MAZ ENST00000219782 
ENSG00000150347 ARID5B ENST00000279873 ENSG00000166987 MBD6 ENST00000355673 
ENSG00000171456 ASXL1 ENST00000375687 ENSG00000133895 MEN1 ENST00000337652 
ENSG00000143970 ASXL2 ENST00000435504 ENSG00000105976 MET ENST00000318493 
ENSG00000149311 ATM ENST00000278616 ENSG00000174197 MGA ENST00000219905 
ENSG00000143153 ATP1B1 ENST00000367816 ENSG00000076242 MLH1 ENST00000231790 
ENSG00000085224 ATRX ENST00000373344 ENSG00000095002 MSH2 ENST00000233146 
ENSG00000103126 AXIN1 ENST00000262320 ENSG00000198793 MTOR ENST00000361445 
ENSG00000166710 B2M ENST00000558401 ENSG00000184956 MUC6 ENST00000421673 
ENSG00000163930 BAP1 ENST00000460680 ENSG00000136997 MYC ENST00000377970 
ENSG00000183337 BCOR ENST00000378444 ENSG00000141027 NCOR1 ENST00000268712 
ENSG00000204217 BMPR2 ENST00000374580 ENSG00000196712 NF1 ENST00000358273 
ENSG00000157764 BRAF ENST00000288602 ENSG00000186575 NF2 ENST00000338641 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000116044 NFE2L2 ENST00000397062 
ENSG00000166164 BRD7 ENST00000394689 ENSG00000050344 NFE2L3 ENST00000056233 
ENSG00000187068 C3orf70 ENST00000335012 ENSG00000164190 NIPBL ENST00000282516 
ENSG00000064012 CASP8 ENST00000358485 ENSG00000148400 NOTCH1 ENST00000277541 
ENSG00000067955 CBFB ENST00000412916 ENSG00000181163 NPM1 ENST00000296930 
ENSG00000110092 CCND1 ENST00000227507 ENSG00000213281 NRAS ENST00000369535 
ENSG00000116815 CD58 ENST00000369489 ENSG00000165671 NSD1 ENST00000439151 
ENSG00000039068 CDH1 ENST00000261769 ENSG00000130538 OR11H1 ENST00000252835 
ENSG00000040731 CDH10 ENST00000264463 ENSG00000257115 OR11H12 ENST00000550708 
ENSG00000167258 CDK12 ENST00000447079 ENSG00000176294 OR4N2 ENST00000315947 
ENSG00000124762 CDKN1A ENST00000405375 ENSG00000163939 PBRM1 ENST00000394830 
ENSG00000111276 CDKN1B ENST00000228872 ENSG00000101327 PDYN ENST00000217305 
ENSG00000147889 CDKN2A ENST00000498124 ENSG00000156531 PHF6 ENST00000332070 
ENSG00000123080 CDKN2C ENST00000262662 ENSG00000121879 PIK3CA ENST00000263967 
ENSG00000245848 CEBPA ENST00000498907 ENSG00000145675 PIK3R1 ENST00000521381 
ENSG00000111642 CHD4 ENST00000357008 ENSG00000221900 POM121L12 ENST00000408890 
ENSG00000141977 CIB3 ENST00000269878 ENSG00000188219 POTEE ENST00000356920 
ENSG00000079432 CIC ENST00000575354 ENSG00000170836 PPM1D ENST00000305921 
ENSG00000180917 CMTR2 ENST00000338099 ENSG00000105568 PPP2R1A ENST00000322088 
ENSG00000005339 CREBBP ENST00000262367 ENSG00000138814 PPP3CA ENST00000394854 
ENSG00000009307 CSDE1 ENST00000438362 ENSG00000119414 PPP6C ENST00000451402 
ENSG00000102974 CTCF ENST00000264010 ENSG00000108946 PRKAR1A ENST00000589228 
ENSG00000168036 CTNNB1 ENST00000349496 ENSG00000167371 PRRT2 ENST00000567659 
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ENSG00000036257 CUL3 ENST00000264414 ENSG00000243137 PSG4 ENST00000405312 
ENSG00000158290 CUL4B ENST00000404115 ENSG00000164985 PSIP1 ENST00000380733 
ENSG00000257923 CUX1 ENST00000360264 ENSG00000171862 PTEN ENST00000371953 
ENSG00000160882 CYP11B1 ENST00000292427 ENSG00000179295 PTPN11 ENST00000351677 
ENSG00000071626 DAZAP1 ENST00000233078 ENSG00000136238 RAC1 ENST00000356142 
ENSG00000215301 DDX3X ENST00000399959 ENSG00000161800 RACGAP1 ENST00000434422 
ENSG00000119772 DNMT3A ENST00000264709 ENSG00000172819 RARG ENST00000425354 
ENSG00000010219 DYRK4 ENST00000540757 ENSG00000145715 RASA1 ENST00000274376 
ENSG00000156508 EEF1A1 ENST00000316292 ENSG00000139687 RB1 ENST00000267163 
ENSG00000108947 EFNB3 ENST00000226091 ENSG00000182872 RBM10 ENST00000377604 
ENSG00000146648 EGFR ENST00000275493 ENSG00000067560 RHOA ENST00000418115 
ENSG00000173674 EIF1AX ENST00000379607 ENSG00000143878 RHOB ENST00000272233 
ENSG00000163435 ELF3 ENST00000359651 ENSG00000108375 RNF43 ENST00000584437 
ENSG00000100393 EP300 ENST00000263253 ENSG00000116251 RPL22 ENST00000234875 
ENSG00000142627 EPHA2 ENST00000358432 ENSG00000122406 RPL5 ENST00000370321 
ENSG00000151491 EPS8 ENST00000281172 ENSG00000177189 RPS6KA3 ENST00000379565 
ENSG00000141736 ERBB2 ENST00000269571 ENSG00000124782 RREB1 ENST00000379938 
ENSG00000065361 ERBB3 ENST00000267101 ENSG00000159216 RUNX1 ENST00000300305 
ENSG00000178568 ERBB4 ENST00000342788 ENSG00000186350 RXRA ENST00000481739 
ENSG00000104884 ERCC2 ENST00000391945 ENSG00000181555 SETD2 ENST00000409792 
ENSG00000106462 EZH2 ENST00000320356 ENSG00000175387 SMAD2 ENST00000402690 
ENSG00000133193 FAM104A ENST00000405159 ENSG00000141646 SMAD4 ENST00000342988 
ENSG00000147382 FAM58A ENST00000406277 ENSG00000127616 SMARCA4 ENST00000429416 
ENSG00000083857 FAT1 ENST00000441802 ENSG00000072501 SMC1A ENST00000322213 
ENSG00000109670 FBXW7 ENST00000281708 ENSG00000108055 SMC3 ENST00000361804 
ENSG00000066468 FGFR2 ENST00000457416 ENSG00000188176 SMTNL2 ENST00000389313 
ENSG00000068078 FGFR3 ENST00000340107 ENSG00000125398 SOX9 ENST00000245479 
ENSG00000122025 FLT3 ENST00000241453 ENSG00000065526 SPEN ENST00000375759 
ENSG00000075426 FOSL2 ENST00000264716 ENSG00000121067 SPOP ENST00000393331 
ENSG00000129514 FOXA1 ENST00000250448 ENSG00000197694 SPTAN1 ENST00000372739 
ENSG00000125798 FOXA2 ENST00000419308 ENSG00000101972 STAG2 ENST00000218089 
ENSG00000114861 FOXP1 ENST00000491238 ENSG00000118046 STK11 ENST00000326873 
ENSG00000164379 FOXQ1 ENST00000296839 ENSG00000250264 TAP2 ENST00000452392 
ENSG00000162613 FUBP1 ENST00000370768 ENSG00000135111 TBX3 ENST00000257566 
ENSG00000224659 GAGE12J ENST00000442437 ENSG00000140262 TCF12 ENST00000438423 
ENSG00000107485 GATA3 ENST00000379328 ENSG00000148737 TCF7L2 ENST00000543371 
ENSG00000127588 GNG13 ENST00000248150 ENSG00000168769 TET2 ENST00000540549 
ENSG00000132522 GPS2 ENST00000380728 ENSG00000042832 TG ENST00000220616 
ENSG00000077809 GTF2I ENST00000324896 ENSG00000163513 TGFBR2 ENST00000359013 
ENSG00000223609 HBD ENST00000380299 ENSG00000177426 TGIF1 ENST00000330513 
ENSG00000187837 HIST1H1C ENST00000343677 ENSG00000131747 TOP2A ENST00000423485 
ENSG00000180573 HIST1H2AC ENST00000602637 ENSG00000141510 TP53 ENST00000269305 
ENSG00000158373 HIST1H2BD ENST00000289316 ENSG00000165699 TSC1 ENST00000298552 
ENSG00000124693 HIST1H3B ENST00000244661 ENSG00000103197 TSC2 ENST00000219476 
ENSG00000184678 HIST2H2BE ENST00000369155 ENSG00000092445 TYRO3 ENST00000263798 
ENSG00000183598 HIST2H3D ENST00000331491 ENSG00000160201 U2AF1 ENST00000291552 
ENSG00000206503 HLA-A ENST00000396634 ENSG00000169062 UPF3A ENST00000375299 
ENSG00000234745 HLA-B ENST00000412585 ENSG00000048028 USP28 ENST00000003302 
ENSG00000204525 HLA-C ENST00000376228 ENSG00000134086 VHL ENST00000256474 
ENSG00000120093 HOXB3 ENST00000470495 ENSG00000184937 WT1 ENST00000332351 
ENSG00000174775 HRAS ENST00000451590 ENSG00000119596 YLPM1 ENST00000325680 
ENSG00000138413 IDH1 ENST00000415913 ENSG00000181722 ZBTB20 ENST00000474710 
ENSG00000182054 IDH2 ENST00000330062 ENSG00000160685 ZBTB7B ENST00000417934 
274 
 
ENSG00000134352 IL6ST ENST00000381298 ENSG00000140836 ZFHX3 ENST00000268489 
ENSG00000165458 INPPL1 ENST00000298229 ENSG00000185650 ZFP36L1 ENST00000439696 
ENSG00000162434 JAK1 ENST00000342505 ENSG00000152518 ZFP36L2 ENST00000282388 
ENSG00000120071 KANSL1 ENST00000262419 ENSG00000005889 ZFX ENST00000379177 
ENSG00000126012 KDM5C ENST00000375401 ENSG00000147130 ZMYM3 ENST00000353904 
ENSG00000147050 KDM6A ENST00000377967 ENSG00000197123 ZNF679 ENST00000421025 
ENSG00000079999 KEAP1 ENST00000171111 ENSG00000141579 ZNF750 ENST00000269394 
ENSG00000157404 KIT ENST00000288135 ENSG00000048405 ZNF800 ENST00000393313 
ENSG00000102554 KLF5 ENST00000377687 ENSG00000183579 ZNRF3 ENST00000544604 
ENSG00000118058 KMT2A ENST00000534358    
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Table A7 - Gene list used for analysis of truncating variants based on Gene Ontology terms 
indicating role in DNA repair 
 
Gene identifier 
Gene 
name 
Canonical 
transcript 
Gene identifier Gene name 
Canonical 
transcript 
ENSG00000097007 ABL1 ENST00000372348 ENSG00000041880 PARP3 ENST00000398755 
ENSG00000136518 ACTL6A ENST00000429709 ENSG00000102699 PARP4 ENST00000381989 
ENSG00000101442 ACTR5 ENST00000243903 ENSG00000138496 PARP9 ENST00000360356 
ENSG00000113812 ACTR8 ENST00000335754 ENSG00000185480 PARPBP ENST00000358383 
ENSG00000100601 ALKBH1 ENST00000216489 ENSG00000157212 PAXIP1 ENST00000404141 
ENSG00000189046 ALKBH2 ENST00000429722 ENSG00000132646 PCNA ENST00000379160 
ENSG00000166199 ALKBH3 ENST00000302708 ENSG00000127980 PEX1 ENST00000248633 
ENSG00000125843 AP5S1 ENST00000246041 ENSG00000243251 PGBD3 ENST00000374127 
ENSG00000242802 AP5Z1 ENST00000348624 ENSG00000140451 PIF1 ENST00000268043 
ENSG00000166313 APBB1 ENST00000299402 ENSG00000140464 PML ENST00000268058 
ENSG00000100823 APEX1 ENST00000216714 ENSG00000064933 PMS1 ENST00000441310 
ENSG00000169188 APEX2 ENST00000374987 ENSG00000122512 PMS2 ENST00000265849 
ENSG00000175279 APITD1 ENST00000602787 ENSG00000039650 PNKP ENST00000322344 
ENSG00000169621 APLF ENST00000303795 ENSG00000101868 POLA1 ENST00000379059 
ENSG00000137074 APTX ENST00000379813 ENSG00000070501 POLB ENST00000265421 
ENSG00000112249 ASCC3 ENST00000369162 ENSG00000062822 POLD1 ENST00000440232 
ENSG00000111875 ASF1A ENST00000229595 ENSG00000106628 POLD2 ENST00000406581 
ENSG00000034533 ASTE1 ENST00000264992 ENSG00000077514 POLD3 ENST00000263681 
ENSG00000138138 ATAD1 ENST00000308448 ENSG00000175482 POLD4 ENST00000312419 
ENSG00000215915 ATAD3C ENST00000378785 ENSG00000177084 POLE ENST00000320574 
ENSG00000149311 ATM ENST00000278616 ENSG00000100479 POLE2 ENST00000216367 
ENSG00000175054 ATR ENST00000350721 ENSG00000140521 POLG ENST00000268124 
ENSG00000164053 ATRIP ENST00000320211 ENSG00000256525 POLG2 ENST00000539111 
ENSG00000085224 ATRX ENST00000373344 ENSG00000170734 POLH ENST00000372236 
ENSG00000066427 ATXN3 ENST00000393287 ENSG00000101751 POLI ENST00000579534 
ENSG00000168646 AXIN2 ENST00000307078 ENSG00000122008 POLK ENST00000241436 
ENSG00000105393 BABAM1 ENST00000359435 ENSG00000166169 POLL ENST00000370162 
ENSG00000138376 BARD1 ENST00000260947 ENSG00000122678 POLM ENST00000242248 
ENSG00000009954 BAZ1B ENST00000339594 ENSG00000130997 POLN ENST00000511885 
ENSG00000107949 BCCIP ENST00000368759 ENSG00000051341 POLQ ENST00000264233 
ENSG00000270181 
BIVM-
ERCC5 
ENST00000602836 ENSG00000181222 POLR2A ENST00000322644 
ENSG00000197299 BLM ENST00000355112 ENSG00000047315 POLR2B ENST00000381227 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000102978 POLR2C ENST00000219252 
ENSG00000139618 BRCA2 ENST00000544455 ENSG00000144231 POLR2D ENST00000272645 
ENSG00000185515 BRCC3 ENST00000369462 ENSG00000099817 POLR2E ENST00000215587 
ENSG00000158019 BRE ENST00000344773 ENSG00000100142 POLR2F ENST00000442738 
ENSG00000136492 BRIP1 ENST00000259008 ENSG00000168002 POLR2G ENST00000301788 
ENSG00000159388 BTG2 ENST00000290551 ENSG00000163882 POLR2H ENST00000456318 
ENSG00000158636 C11orf30 ENST00000529032 ENSG00000105258 POLR2I ENST00000221859 
ENSG00000185504 C17orf70 ENST00000327787 ENSG00000005075 POLR2J ENST00000292614 
ENSG00000131944 C19orf40 ENST00000588258 ENSG00000147669 POLR2K ENST00000353107 
ENSG00000162585 C1orf86 ENST00000378546 ENSG00000177700 POLR2L ENST00000322028 
ENSG00000134480 CCNH ENST00000256897 ENSG00000149923 PPP4C ENST00000279387 
ENSG00000152669 CCNO ENST00000282572 ENSG00000163605 PPP4R2 ENST00000356692 
ENSG00000081377 CDC14B ENST00000375241 ENSG00000011485 PPP5C ENST00000012443 
ENSG00000146670 CDCA5 ENST00000275517 ENSG00000164306 PRIMPOL ENST00000314970 
ENSG00000170312 CDK1 ENST00000395284 ENSG00000126583 PRKCG ENST00000263431 
ENSG00000123374 CDK2 ENST00000266970 ENSG00000253729 PRKDC ENST00000314191 
ENSG00000134058 CDK7 ENST00000256443 ENSG00000198890 PRMT6 ENST00000370078 
ENSG00000136807 CDK9 ENST00000373264 ENSG00000110107 PRPF19 ENST00000227524 
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ENSG00000129355 CDKN2D ENST00000393599 ENSG00000100764 PSMC1 ENST00000261303 
ENSG00000153879 CEBPG ENST00000284000 ENSG00000165916 PSMC3 ENST00000298852 
ENSG00000110274 CEP164 ENST00000278935 ENSG00000013275 PSMC4 ENST00000157812 
ENSG00000147400 CETN2 ENST00000370277 ENSG00000087191 PSMC5 ENST00000310144 
ENSG00000167670 CHAF1A ENST00000301280 ENSG00000100519 PSMC6 ENST00000445930 
ENSG00000159259 CHAF1B ENST00000314103 ENSG00000115233 PSMD14 ENST00000409682 
ENSG00000131778 CHD1L ENST00000369258 ENSG00000068878 PSME4 ENST00000404125 
ENSG00000149554 CHEK1 ENST00000534070 ENSG00000164611 PTTG1 ENST00000393964 
ENSG00000183765 CHEK2 ENST00000382580 ENSG00000113456 RAD1 ENST00000382038 
ENSG00000101204 CHRNA4 ENST00000370263 ENSG00000152942 RAD17 ENST00000509734 
ENSG00000127586 CHTF18 ENST00000262315 ENSG00000070950 RAD18 ENST00000264926 
ENSG00000185043 CIB1 ENST00000328649 ENSG00000164754 RAD21 ENST00000297338 
ENSG00000100865 CINP ENST00000536961 ENSG00000244588 RAD21L1 ENST00000409241 
ENSG00000092853 CLSPN ENST00000318121 ENSG00000179262 RAD23A ENST00000586534 
ENSG00000008405 CRY1 ENST00000008527 ENSG00000119318 RAD23B ENST00000358015 
ENSG00000121671 CRY2 ENST00000443527 ENSG00000113522 RAD50 ENST00000265335 
ENSG00000141551 CSNK1D ENST00000314028 ENSG00000051180 RAD51 ENST00000382643 
ENSG00000213923 CSNK1E ENST00000396832 ENSG00000111247 RAD51AP1 ENST00000228843 
ENSG00000269307 
CTD-
2278I10.6 
ENST00000596542 ENSG00000182185 RAD51B ENST00000487270 
ENSG00000139842 CUL4A ENST00000375440 ENSG00000108384 RAD51C ENST00000337432 
ENSG00000158290 CUL4B ENST00000404115 ENSG00000185379 RAD51D ENST00000590016 
ENSG00000198924 DCLRE1A ENST00000361384 ENSG00000002016 RAD52 ENST00000358495 
ENSG00000118655 DCLRE1B ENST00000369563 ENSG00000197275 RAD54B ENST00000336148 
ENSG00000152457 DCLRE1C ENST00000378278 ENSG00000085999 RAD54L ENST00000371975 
ENSG00000167986 DDB1 ENST00000301764 ENSG00000172613 RAD9A ENST00000307980 
ENSG00000134574 DDB2 ENST00000256996 ENSG00000151164 RAD9B ENST00000392672 
ENSG00000079785 DDX1 ENST00000381341 ENSG00000101773 RBBP8 ENST00000399722 
ENSG00000124795 DEK ENST00000397239 ENSG00000239306 RBM14 ENST00000310137 
ENSG00000178028 DMAP1 ENST00000372289 ENSG00000100387 RBX1 ENST00000216225 
ENSG00000100206 DMC1 ENST00000216024 ENSG00000187456 RDM1 ENST00000293273 
ENSG00000138346 DNA2 ENST00000399180 ENSG00000100918 REC8 ENST00000311457 
ENSG00000143476 DTL ENST00000366991 ENSG00000004700 RECQL ENST00000444129 
ENSG00000163840 DTX3L ENST00000296161 ENSG00000108469 RECQL5 ENST00000317905 
ENSG00000122547 EEPD1 ENST00000242108 ENSG00000135945 REV1 ENST00000258428 
ENSG00000146648 EGFR ENST00000275493 ENSG00000009413 REV3L ENST00000358835 
ENSG00000255150 EID3 ENST00000527879 ENSG00000035928 RFC1 ENST00000381897 
ENSG00000154920 EME1 ENST00000393271 ENSG00000049541 RFC2 ENST00000055077 
ENSG00000197774 EME2 ENST00000568449 ENSG00000133119 RFC3 ENST00000380071 
ENSG00000173818 ENDOV ENST00000518137 ENSG00000163918 RFC4 ENST00000392481 
ENSG00000135999 EPC2 ENST00000258484 ENSG00000111445 RFC5 ENST00000454402 
ENSG00000012061 ERCC1 ENST00000013807 ENSG00000168411 RFWD3 ENST00000361070 
ENSG00000104884 ERCC2 ENST00000391945 ENSG00000171792 RHNO1 ENST00000489288 
ENSG00000163161 ERCC3 ENST00000285398 ENSG00000163961 RNF168 ENST00000318037 
ENSG00000175595 ERCC4 ENST00000311895 ENSG00000166439 RNF169 ENST00000299563 
ENSG00000134899 ERCC5 ENST00000355739 ENSG00000112130 RNF8 ENST00000373479 
ENSG00000225830 ERCC6 ENST00000355832 ENSG00000260914 
RP11-
343C2.11 
ENST00000570054 
ENSG00000182150 ERCC6L2 ENST00000288985 ENSG00000254469 
RP11-
849H4.2 
ENST00000528511 
ENSG00000258838 
ERCC6-
PGBD3 
ENST00000515869 ENSG00000132383 RPA1 ENST00000254719 
ENSG00000049167 ERCC8 ENST00000265038 ENSG00000117748 RPA2 ENST00000373912 
ENSG00000174371 EXO1 ENST00000366548 ENSG00000106399 RPA3 ENST00000223129 
ENSG00000164002 EXO5 ENST00000372703 ENSG00000204086 RPA4 ENST00000373040 
ENSG00000104313 EYA1 ENST00000340726 ENSG00000129197 RPAIN ENST00000405578 
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ENSG00000064655 EYA2 ENST00000327619 ENSG00000143947 RPS27A ENST00000272317 
ENSG00000158161 EYA3 ENST00000373871 ENSG00000185088 RPS27L ENST00000330964 
ENSG00000112319 EYA4 ENST00000367895 ENSG00000149273 RPS3 ENST00000278572 
ENSG00000163322 FAM175A ENST00000321945 ENSG00000048392 RRM2B ENST00000251810 
ENSG00000198690 FAN1 ENST00000362065 ENSG00000258366 RTEL1 ENST00000508582 
ENSG00000187741 FANCA ENST00000389301 ENSG00000175792 RUVBL1 ENST00000322623 
ENSG00000181544 FANCB ENST00000398334 ENSG00000183207 RUVBL2 ENST00000595090 
ENSG00000158169 FANCC ENST00000289081 ENSG00000181555 SETD2 ENST00000409792 
ENSG00000144554 FANCD2 ENST00000287647 ENSG00000170364 SETMAR ENST00000358065 
ENSG00000112039 FANCE ENST00000229769 ENSG00000107290 SETX ENST00000224140 
ENSG00000183161 FANCF ENST00000327470 ENSG00000116560 SFPQ ENST00000357214 
ENSG00000221829 FANCG ENST00000378643 ENSG00000156384 SFR1 ENST00000369727 
ENSG00000140525 FANCI ENST00000310775 ENSG00000127922 SHFM1 ENST00000248566 
ENSG00000115392 FANCL ENST00000402135 ENSG00000146414 SHPRH ENST00000367505 
ENSG00000187790 FANCM ENST00000267430 ENSG00000096717 SIRT1 ENST00000212015 
ENSG00000116663 FBXO6 ENST00000376753 ENSG00000077463 SIRT6 ENST00000337491 
ENSG00000168496 FEN1 ENST00000305885 ENSG00000014824 SLC30A9 ENST00000264451 
ENSG00000070193 FGF10 ENST00000264664 ENSG00000132207 SLX1A ENST00000251303 
ENSG00000132436 FIGNL1 ENST00000419119 ENSG00000181625 SLX1B ENST00000330181 
ENSG00000111206 FOXM1 ENST00000342628 ENSG00000188827 SLX4 ENST00000294008 
ENSG00000140718 FTO ENST00000471389 ENSG00000153147 SMARCA5 ENST00000283131 
ENSG00000105325 FZR1 ENST00000395095 ENSG00000163104 SMARCAD1 ENST00000359052 
ENSG00000116717 GADD45A ENST00000370986 ENSG00000099956 SMARCB1 ENST00000263121 
ENSG00000178295 GEN1 ENST00000381254 ENSG00000072501 SMC1A ENST00000322213 
ENSG00000110768 GTF2H1 ENST00000265963 ENSG00000077935 SMC1B ENST00000357450 
ENSG00000145736 GTF2H2 ENST00000330280 ENSG00000136824 SMC2 ENST00000286398 
ENSG00000183474 GTF2H2C ENST00000510979 ENSG00000108055 SMC3 ENST00000361804 
ENSG00000262261 GTF2H2D ENST00000577126 ENSG00000113810 SMC4 ENST00000357388 
ENSG00000111358 GTF2H3 ENST00000543341 ENSG00000198887 SMC5 ENST00000361138 
ENSG00000213780 GTF2H4 ENST00000259895 ENSG00000163029 SMC6 ENST00000448223 
ENSG00000272047 GTF2H5 ENST00000607778 ENSG00000157106 SMG1 ENST00000446231 
ENSG00000188486 H2AFX ENST00000530167 ENSG00000123415 SMUG1 ENST00000508394 
ENSG00000128731 HERC2 ENST00000261609 ENSG00000142168 SOD1 ENST00000270142 
ENSG00000172273 HINFP ENST00000350777 ENSG00000021574 SPAST ENST00000315285 
ENSG00000137309 HMGA1 ENST00000447654 ENSG00000141255 SPATA22 ENST00000573128 
ENSG00000149948 HMGA2 ENST00000403681 ENSG00000145375 SPATA5 ENST00000274008 
ENSG00000189403 HMGB1 ENST00000405805 ENSG00000171763 SPATA5L1 ENST00000305560 
ENSG00000164104 HMGB2 ENST00000296503 ENSG00000164808 SPIDR ENST00000297423 
ENSG00000205581 HMGN1 ENST00000380749 ENSG00000010072 SPRTN ENST00000295050 
ENSG00000136273 HUS1 ENST00000258774 ENSG00000149136 SSRP1 ENST00000278412 
ENSG00000188996 HUS1B ENST00000380907 ENSG00000169689 STRA13 ENST00000392359 
ENSG00000086758 HUWE1 ENST00000342160 ENSG00000103266 STUB1 ENST00000219548 
ENSG00000137331 IER3 ENST00000259874 ENSG00000116030 SUMO1 ENST00000392246 
ENSG00000132740 IGHMBP2 ENST00000255078 ENSG00000092201 SUPT16H ENST00000216297 
ENSG00000148153 INIP ENST00000374242 ENSG00000175854 SWI5 ENST00000320188 
ENSG00000128908 INO80 ENST00000361937 ENSG00000173928 SWSAP1 ENST00000312423 
ENSG00000115274 INO80B ENST00000233331 ENSG00000160551 TAOK1 ENST00000261716 
ENSG00000153391 INO80C ENST00000441607 ENSG00000135090 TAOK3 ENST00000392533 
ENSG00000114933 INO80D ENST00000403263 ENSG00000187735 TCEA1 ENST00000521604 
ENSG00000169592 INO80E ENST00000563197 ENSG00000139372 TDG ENST00000392872 
ENSG00000143624 INTS3 ENST00000318967 ENSG00000042088 TDP1 ENST00000335725 
ENSG00000152409 JMY ENST00000396137 ENSG00000111802 TDP2 ENST00000378198 
ENSG00000172977 KAT5 ENST00000341318 ENSG00000166848 TERF2IP ENST00000300086 
ENSG00000186625 KATNA1 ENST00000367411 ENSG00000133863 TEX15 ENST00000256246 
ENSG00000102781 KATNAL1 ENST00000380615 ENSG00000105619 TFPT ENST00000391759 
ENSG00000167216 KATNAL2 ENST00000245121 ENSG00000140534 TICRR ENST00000268138 
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ENSG00000166803 KIAA0101 ENST00000300035 ENSG00000064545 TMEM161A ENST00000162044 
ENSG00000166783 KIAA0430 ENST00000396368 ENSG00000118245 TNP1 ENST00000236979 
ENSG00000050030 KIAA2022 ENST00000055682 ENSG00000260716 TONSL ENST00000409379 
ENSG00000079616 KIF22 ENST00000160827 ENSG00000131747 TOP2A ENST00000423485 
ENSG00000151657 KIN ENST00000379562 ENSG00000163781 TOPBP1 ENST00000260810 
ENSG00000268361 L34079.2 ENST00000594374 ENSG00000141510 TP53 ENST00000269305 
ENSG00000105486 LIG1 ENST00000263274 ENSG00000067369 TP53BP1 ENST00000382044 
ENSG00000005156 LIG3 ENST00000378526 ENSG00000078900 TP73 ENST00000378295 
ENSG00000174405 LIG4 ENST00000356922 ENSG00000213689 TREX1 ENST00000422277 
ENSG00000196365 LONP1 ENST00000360614 ENSG00000183479 TREX2 ENST00000330912 
ENSG00000116670 MAD2L2 ENST00000235310 ENSG00000130726 TRIM28 ENST00000253024 
ENSG00000129071 MBD4 ENST00000249910 ENSG00000153827 TRIP12 ENST00000283943 
ENSG00000258839 MC1R ENST00000555147 ENSG00000071539 TRIP13 ENST00000166345 
ENSG00000125885 MCM8 ENST00000378896 ENSG00000136319 TTC5 ENST00000258821 
ENSG00000111877 MCM9 ENST00000316316 ENSG00000122691 TWIST1 ENST00000242261 
ENSG00000187778 MCRS1 ENST00000357123 ENSG00000176890 TYMS ENST00000323274 
ENSG00000137337 MDC1 ENST00000376406 ENSG00000221983 UBA52 ENST00000442744 
ENSG00000162039 MEIOB ENST00000412554 ENSG00000170315 UBB ENST00000302182 
ENSG00000133895 MEN1 ENST00000337652 ENSG00000150991 UBC ENST00000536769 
ENSG00000125871 MGME1 ENST00000377710 ENSG00000077721 UBE2A ENST00000371558 
ENSG00000170430 MGMT ENST00000306010 ENSG00000119048 UBE2B ENST00000265339 
ENSG00000076242 MLH1 ENST00000231790 ENSG00000109332 UBE2D3 ENST00000357194 
ENSG00000119684 MLH3 ENST00000355774 ENSG00000177889 UBE2N ENST00000318066 
ENSG00000155229 MMS19 ENST00000438925 ENSG00000077152 UBE2T ENST00000367274 
ENSG00000146263 MMS22L ENST00000275053 ENSG00000244687 UBE2V1 ENST00000340309 
ENSG00000020426 MNAT1 ENST00000261245 ENSG00000169139 UBE2V2 ENST00000523111 
ENSG00000185787 MORF4L1 ENST00000331268 ENSG00000104343 UBE2W ENST00000419880 
ENSG00000123562 MORF4L2 ENST00000423833 ENSG00000135018 UBQLN1 ENST00000376395 
ENSG00000103152 MPG ENST00000219431 ENSG00000188021 UBQLN2 ENST00000338222 
ENSG00000020922 MRE11A ENST00000323929 ENSG00000160803 UBQLN4 ENST00000368309 
ENSG00000095002 MSH2 ENST00000233146 ENSG00000104517 UBR5 ENST00000520539 
ENSG00000113318 MSH3 ENST00000265081 ENSG00000116750 UCHL5 ENST00000367455 
ENSG00000057468 MSH4 ENST00000263187 ENSG00000087206 UIMC1 ENST00000377227 
ENSG00000204410 MSH5 ENST00000375703 ENSG00000076248 UNG ENST00000242576 
ENSG00000255152 
MSH5-
SAPCD1 
ENST00000493662 ENSG00000005007 UPF1 ENST00000262803 
ENSG00000116062 MSH6 ENST00000234420 ENSG00000162607 USP1 ENST00000339950 
ENSG00000160953 MUM1 ENST00000344663 ENSG00000103194 USP10 ENST00000219473 
ENSG00000172732 MUS81 ENST00000308110 ENSG00000048028 USP28 ENST00000003302 
ENSG00000132781 MUTYH ENST00000372098 ENSG00000140455 USP3 ENST00000380324 
ENSG00000173559 NABP1 ENST00000425611 ENSG00000170242 USP47 ENST00000339865 
ENSG00000139579 NABP2 ENST00000380198 ENSG00000187555 USP7 ENST00000344836 
ENSG00000104320 NBN ENST00000265433 ENSG00000198382 UVRAG ENST00000356136 
ENSG00000198646 NCOA6 ENST00000374796 ENSG00000163945 UVSSA ENST00000389851 
ENSG00000185115 NDNL2 ENST00000332303 ENSG00000165280 VCP ENST00000358901 
ENSG00000140398 NEIL1 ENST00000564784 ENSG00000132612 VPS4A ENST00000254950 
ENSG00000154328 NEIL2 ENST00000284503 ENSG00000119541 VPS4B ENST00000238497 
ENSG00000109674 NEIL3 ENST00000264596 ENSG00000136709 WDR33 ENST00000322313 
ENSG00000170322 NFRKB ENST00000524794 ENSG00000165392 WRN ENST00000298139 
ENSG00000151092 NGLY1 ENST00000280700 ENSG00000124535 WRNIP1 ENST00000380773 
ENSG00000187736 NHEJ1 ENST00000356853 ENSG00000076924 XAB2 ENST00000358368 
ENSG00000147140 NONO ENST00000276079 ENSG00000136936 XPA ENST00000375128 
ENSG00000181163 NPM1 ENST00000296930 ENSG00000154767 XPC ENST00000285021 
ENSG00000169189 NSMCE1 ENST00000361439 ENSG00000073050 XRCC1 ENST00000262887 
ENSG00000156831 NSMCE2 ENST00000287437 ENSG00000196584 XRCC2 ENST00000359321 
ENSG00000107672 NSMCE4A ENST00000369023 ENSG00000126215 XRCC3 ENST00000553264 
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ENSG00000065057 NTHL1 ENST00000219066 ENSG00000152422 XRCC4 ENST00000511817 
ENSG00000106268 NUDT1 ENST00000397049 ENSG00000079246 XRCC5 ENST00000392133 
ENSG00000198585 NUDT16 ENST00000502852 ENSG00000196419 XRCC6 ENST00000359308 
ENSG00000143748 NVL ENST00000281701 ENSG00000166896 XRCC6BP1 ENST00000300145 
ENSG00000114026 OGG1 ENST00000302036 ENSG00000100811 YY1 ENST00000262238 
ENSG00000167770 OTUB1 ENST00000538426 ENSG00000011590 ZBTB32 ENST00000392197 
ENSG00000083093 PALB2 ENST00000261584 ENSG00000072121 ZFYVE26 ENST00000347230 
ENSG00000112941 PAPD7 ENST00000230859 ENSG00000121988 ZRANB3 ENST00000264159 
ENSG00000143799 PARP1 ENST00000366794 ENSG00000214941 ZSWIM7 ENST00000399277 
ENSG00000129484 PARP2 ENST00000250416    
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Table A8 - Gene list used for analysis of truncating variants based on interactions with known CPGs 
in GeneMania 
 
Gene identifier 
Gene 
name 
Canonical 
transcript 
Gene identifier 
Gene 
name 
Canonical 
transcript 
ENSG00000073734 ABCB11 ENST00000263817 ENSG00000133895 MEN1 ENST00000337652 
ENSG00000106546 AHR ENST00000242057 ENSG00000076242 MLH1 ENST00000231790 
ENSG00000110711 AIP ENST00000279146 ENSG00000119684 MLH3 ENST00000355774 
ENSG00000134982 APC ENST00000457016 ENSG00000251349 
MSANTD3-
TMEFF1 
ENST00000502978 
ENSG00000100823 APEX1 ENST00000216714 ENSG00000095002 MSH2 ENST00000233146 
ENSG00000149311 ATM ENST00000278616 ENSG00000116062 MSH6 ENST00000234420 
ENSG00000168646 AXIN2 ENST00000307078 ENSG00000099810 MTAP ENST00000380172 
ENSG00000163930 BAP1 ENST00000460680 ENSG00000132781 MUTYH ENST00000372098 
ENSG00000138376 BARD1 ENST00000260947 ENSG00000104320 NBN ENST00000265433 
ENSG00000197299 BLM ENST00000355112 ENSG00000196712 NF1 ENST00000358273 
ENSG00000107779 BMPR1A ENST00000372037 ENSG00000186575 NF2 ENST00000338641 
ENSG00000012048 BRCA1 ENST00000471181 ENSG00000239672 NME1 ENST00000336097 
ENSG00000139618 BRCA2 ENST00000544455 ENSG00000165671 NSD1 ENST00000439151 
ENSG00000136492 BRIP1 ENST00000259008 ENSG00000065057 NTHL1 ENST00000219066 
ENSG00000156970 BUB1B ENST00000287598 ENSG00000083093 PALB2 ENST00000261584 
ENSG00000185504 C17orf70 ENST00000327787 ENSG00000109132 PHOX2B ENST00000226382 
ENSG00000131944 C19orf40 ENST00000588258 ENSG00000064933 PMS1 ENST00000441310 
ENSG00000110395 CBL ENST00000264033 ENSG00000122512 PMS2 ENST00000265849 
ENSG00000110092 CCND1 ENST00000227507 ENSG00000062822 POLD1 ENST00000440232 
ENSG00000134371 CDC73 ENST00000367435 ENSG00000106628 POLD2 ENST00000406581 
ENSG00000039068 CDH1 ENST00000261769 ENSG00000177084 POLE ENST00000320574 
ENSG00000105810 CDK6 ENST00000265734 ENSG00000170734 POLH ENST00000372236 
ENSG00000111276 CDKN1B ENST00000228872 ENSG00000180644 PRF1 ENST00000441259 
ENSG00000129757 CDKN1C ENST00000414822 ENSG00000108946 PRKAR1A ENST00000589228 
ENSG00000147889 CDKN2A ENST00000498124 ENSG00000204983 PRSS1 ENST00000311737 
ENSG00000147883 CDKN2B ENST00000276925 ENSG00000185920 PTCH1 ENST00000331920 
ENSG00000245848 CEBPA ENST00000498907 ENSG00000171862 PTEN ENST00000371953 
ENSG00000166037 CEP57 ENST00000325542 ENSG00000051180 RAD51 ENST00000382643 
ENSG00000183765 CHEK2 ENST00000382580 ENSG00000182185 RAD51B ENST00000487270 
ENSG00000114270 COL7A1 ENST00000328333 ENSG00000108384 RAD51C ENST00000337432 
ENSG00000083799 CYLD ENST00000427738 ENSG00000185379 RAD51D ENST00000590016 
ENSG00000167986 DDB1 ENST00000301764 ENSG00000139687 RB1 ENST00000267163 
ENSG00000134574 DDB2 ENST00000256996 ENSG00000160957 RECQL4 ENST00000428558 
ENSG00000100697 DICER1 ENST00000526495 ENSG00000132383 RPA1 ENST00000254719 
ENSG00000144535 DIS3L2 ENST00000325385 ENSG00000159216 RUNX1 ENST00000300305 
ENSG00000130826 DKC1 ENST00000369550 ENSG00000126524 SBDS ENST00000246868 
ENSG00000107099 DOCK8 ENST00000453981 ENSG00000073578 SDHA ENST00000264932 
ENSG00000197561 ELANE ENST00000590230 ENSG00000167985 SDHAF2 ENST00000301761 
ENSG00000119888 EPCAM ENST00000263735 ENSG00000117118 SDHB ENST00000375499 
ENSG00000012061 ERCC1 ENST00000013807 ENSG00000143252 SDHC ENST00000367975 
ENSG00000104884 ERCC2 ENST00000391945 ENSG00000204370 SDHD ENST00000375549 
ENSG00000163161 ERCC3 ENST00000285398 ENSG00000197249 SERPINA1 ENST00000448921 
ENSG00000175595 ERCC4 ENST00000311895 ENSG00000183918 SH2D1A ENST00000371139 
ENSG00000134899 ERCC5 ENST00000355739 ENSG00000004864 SLC25A13 ENST00000416240 
ENSG00000182197 EXT1 ENST00000378204 ENSG00000188827 SLX4 ENST00000294008 
ENSG00000151348 EXT2 ENST00000395673 ENSG00000141646 SMAD4 ENST00000342988 
ENSG00000106462 EZH2 ENST00000320356 ENSG00000127616 SMARCA4 ENST00000429416 
ENSG00000103876 FAH ENST00000407106 ENSG00000099956 SMARCB1 ENST00000263121 
ENSG00000187741 FANCA ENST00000389301 ENSG00000073584 SMARCE1 ENST00000348513 
ENSG00000181544 FANCB ENST00000398334 ENSG00000184895 SRY ENST00000383070 
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ENSG00000158169 FANCC ENST00000289081 ENSG00000168610 STAT3 ENST00000264657 
ENSG00000144554 FANCD2 ENST00000287647 ENSG00000118046 STK11 ENST00000326873 
ENSG00000112039 FANCE ENST00000229769 ENSG00000107882 SUFU ENST00000369902 
ENSG00000183161 FANCF ENST00000327470 ENSG00000139546 TARBP2 ENST00000266987 
ENSG00000221829 FANCG ENST00000378643 ENSG00000132604 TERF2 ENST00000603068 
ENSG00000140525 FANCI ENST00000310775 ENSG00000164362 TERT ENST00000310581 
ENSG00000115392 FANCL ENST00000402135 ENSG00000106799 TGFBR1 ENST00000374994 
ENSG00000187790 FANCM ENST00000267430 ENSG00000135956 TMEM127 ENST00000258439 
ENSG00000026103 FAS ENST00000355740 ENSG00000177302 TOP3A ENST00000321105 
ENSG00000091483 FH ENST00000366560 ENSG00000141510 TP53 ENST00000269305 
ENSG00000154803 FLCN ENST00000285071 ENSG00000108395 TRIM37 ENST00000262294 
ENSG00000179348 GATA2 ENST00000341105 ENSG00000165699 TSC1 ENST00000298552 
ENSG00000177628 GBA ENST00000327247 ENSG00000103197 TSC2 ENST00000219476 
ENSG00000169562 GJB1 ENST00000374022 ENSG00000126088 UROD ENST00000246337 
ENSG00000165474 GJB2 ENST00000382844 ENSG00000134086 VHL ENST00000256474 
ENSG00000147257 GPC3 ENST00000394299 ENSG00000015285 WAS ENST00000376701 
ENSG00000010704 HFE ENST00000357618 ENSG00000165392 WRN ENST00000298139 
ENSG00000256269 HMBS ENST00000278715 ENSG00000184937 WT1 ENST00000332351 
ENSG00000135100 HNF1A ENST00000257555 ENSG00000136936 XPA ENST00000375128 
ENSG00000113263 ITK ENST00000422843 ENSG00000154767 XPC ENST00000285021 
ENSG00000125952 MAX ENST00000358664 ENSG00000126215 XRCC3 ENST00000553264 
 
282 
 
Table A9 - Known and possible proto-oncogene cancer predisposition genes used for analysis  
 
Gene identifier Gene name 
Canonical 
transcript 
Gene identifier 
Gene 
name 
Canonical 
transcript 
ENSG00000181409 AATK ENST00000326724 ENSG00000198399 ITSN2 ENST00000355123 
ENSG00000159842 ABR ENST00000302538 ENSG00000160145 KALRN ENST00000240874 
ENSG00000170776 AKAP13 ENST00000361243 ENSG00000128052 KDR ENST00000263923 
ENSG00000171094 ALK ENST00000389048 ENSG00000157404 KIT ENST00000288135 
ENSG00000003393 ALS2 ENST00000264276 ENSG00000133703 KRAS ENST00000256078 
ENSG00000076928 ARHGEF1 ENST00000337665 ENSG00000164715 LMTK2 ENST00000297293 
ENSG00000104728 ARHGEF10 ENST00000349830 ENSG00000142235 LMTK3 ENST00000270238 
ENSG00000074964 ARHGEF10L ENST00000361221 ENSG00000062524 LTK ENST00000263800 
ENSG00000132694 ARHGEF11 ENST00000368194 ENSG00000101977 MCF2 ENST00000519895 
ENSG00000196914 ARHGEF12 ENST00000397843 ENSG00000126217 MCF2L ENST00000535094 
ENSG00000198844 ARHGEF15 ENST00000361926 ENSG00000053524 MCF2L2 ENST00000328913 
ENSG00000130762 ARHGEF16 ENST00000378378 ENSG00000153208 MERTK ENST00000295408 
ENSG00000110237 ARHGEF17 ENST00000263674 ENSG00000105976 MET ENST00000318493 
ENSG00000104880 ARHGEF18 ENST00000359920 ENSG00000158186 MRAS ENST00000289104 
ENSG00000142632 ARHGEF19 ENST00000270747 ENSG00000164078 MST1R ENST00000296474 
ENSG00000116584 ARHGEF2 ENST00000361247 ENSG00000030304 MUSK ENST00000374448 
ENSG00000240771 ARHGEF25 ENST00000333972 ENSG00000173848 NET1 ENST00000355029 
ENSG00000114790 ARHGEF26 ENST00000356448 ENSG00000066248 NGEF ENST00000264051 
ENSG00000163947 ARHGEF3 ENST00000338458 ENSG00000197885 NKIRAS1 ENST00000443659 
ENSG00000214694 ARHGEF33 ENST00000409978 ENSG00000168256 NKIRAS2 ENST00000307641 
ENSG00000204959 ARHGEF34P ENST00000378112 ENSG00000213281 NRAS ENST00000369535 
ENSG00000213214 ARHGEF35 ENST00000378115 ENSG00000198400 NTRK1 ENST00000524377 
ENSG00000183111 ARHGEF37 ENST00000333677 ENSG00000148053 NTRK2 ENST00000376214 
ENSG00000236699 ARHGEF38 ENST00000420470 ENSG00000140538 NTRK3 ENST00000360948 
ENSG00000136002 ARHGEF4 ENST00000326016 ENSG00000154358 OBSCN ENST00000570156 
ENSG00000165801 ARHGEF40 ENST00000298694 ENSG00000134853 PDGFRA ENST00000257290 
ENSG00000050327 ARHGEF5 ENST00000056217 ENSG00000113721 PDGFRB ENST00000261799 
ENSG00000129675 ARHGEF6 ENST00000250617 ENSG00000120278 PLEKHG1 ENST00000367328 
ENSG00000102606 ARHGEF7 ENST00000375741 ENSG00000090924 PLEKHG2 ENST00000409794 
ENSG00000131089 ARHGEF9 ENST00000253401 ENSG00000126822 PLEKHG3 ENST00000247226 
ENSG00000167601 AXL ENST00000301178 ENSG00000196155 PLEKHG4 ENST00000360461 
ENSG00000186716 BCR ENST00000305877 ENSG00000124126 PREX1 ENST00000371941 
ENSG00000170312 CDK1 ENST00000395284 ENSG00000046889 PREX2 ENST00000288368 
ENSG00000185324 CDK10 ENST00000353379 ENSG00000112655 PTK7 ENST00000481273 
ENSG00000008128 CDK11A ENST00000404249 ENSG00000196396 PTPN1 ENST00000371621 
ENSG00000248333 CDK11B ENST00000407249 ENSG00000179295 PTPN11 ENST00000351677 
ENSG00000167258 CDK12 ENST00000447079 ENSG00000127947 PTPN12 ENST00000248594 
ENSG00000065883 CDK13 ENST00000181839 ENSG00000163629 PTPN13 ENST00000436978 
ENSG00000058091 CDK14 ENST00000265741 ENSG00000152104 PTPN14 ENST00000366956 
ENSG00000138395 CDK15 ENST00000450471 ENSG00000072135 PTPN18 ENST00000175756 
ENSG00000102225 CDK16 ENST00000276052 ENSG00000175354 PTPN2 ENST00000309660 
ENSG00000059758 CDK17 ENST00000261211 ENSG00000126542 PTPN20CP ENST00000506185 
ENSG00000117266 CDK18 ENST00000506784 ENSG00000070778 PTPN21 ENST00000556564 
ENSG00000155111 CDK19 ENST00000368911 ENSG00000134242 PTPN22 ENST00000359785 
ENSG00000123374 CDK2 ENST00000266970 ENSG00000076201 PTPN23 ENST00000265562 
ENSG00000156345 CDK20 ENST00000325303 ENSG00000070159 PTPN3 ENST00000374541 
ENSG00000250506 CDK3 ENST00000425876 ENSG00000088179 PTPN4 ENST00000263708 
ENSG00000135446 CDK4 ENST00000257904 ENSG00000110786 PTPN5 ENST00000358540 
ENSG00000164885 CDK5 ENST00000485972 ENSG00000111679 PTPN6 ENST00000456013 
ENSG00000105810 CDK6 ENST00000265734 ENSG00000143851 PTPN7 ENST00000309017 
ENSG00000134058 CDK7 ENST00000256443 ENSG00000169410 PTPN9 ENST00000306726 
ENSG00000132964 CDK8 ENST00000381527 ENSG00000006451 RALA ENST00000005257 
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ENSG00000136807 CDK9 ENST00000373264 ENSG00000144118 RALB ENST00000272519 
ENSG00000100490 CDKL1 ENST00000395834 ENSG00000116473 RAP1A ENST00000369709 
ENSG00000138769 CDKL2 ENST00000429927 ENSG00000127314 RAP1B ENST00000250559 
ENSG00000006837 CDKL3 ENST00000265334 ENSG00000125249 RAP2A ENST00000245304 
ENSG00000205111 CDKL4 ENST00000378803 ENSG00000181467 RAP2B ENST00000323534 
ENSG00000008086 CDKL5 ENST00000379989 ENSG00000123728 RAP2C ENST00000342983 
ENSG00000182578 CSF1R ENST00000286301 ENSG00000100302 RASD2 ENST00000216127 
ENSG00000204580 DDR1 ENST00000376575 ENSG00000058335 RASGRF1 ENST00000419573 
ENSG00000162733 DDR2 ENST00000367922 ENSG00000113319 RASGRF2 ENST00000265080 
ENSG00000176490 DIRAS1 ENST00000323469 ENSG00000100276 RASL10A ENST00000216101 
ENSG00000165023 DIRAS2 ENST00000375765 ENSG00000141150 RASL10B ENST00000268864 
ENSG00000162595 DIRAS3 ENST00000370981 ENSG00000122035 RASL11A ENST00000241463 
ENSG00000107554 DNMBP ENST00000324109 ENSG00000128045 RASL11B ENST00000248706 
ENSG00000114346 ECT2 ENST00000392692 ENSG00000103710 RASL12 ENST00000220062 
ENSG00000203734 ECT2L ENST00000423192 ENSG00000134533 RERG ENST00000256953 
ENSG00000146648 EGFR ENST00000275493 ENSG00000111404 RERGL ENST00000229002 
ENSG00000187682 ERAS ENST00000338270 ENSG00000165731 RET ENST00000355710 
ENSG00000141736 ERBB2 ENST00000269571 ENSG00000106615 RHEB ENST00000262187 
ENSG00000065361 ERBB3 ENST00000267101 ENSG00000167550 RHEBL1 ENST00000301068 
ENSG00000178568 ERBB4 ENST00000342788 ENSG00000143622 RIT1 ENST00000368322 
ENSG00000152767 FARP1 ENST00000319562 ENSG00000152214 RIT2 ENST00000326695 
ENSG00000006607 FARP2 ENST00000264042 ENSG00000185483 ROR1 ENST00000371079 
ENSG00000102302 FGD1 ENST00000375135 ENSG00000169071 ROR2 ENST00000375708 
ENSG00000146192 FGD2 ENST00000274963 ENSG00000047936 ROS1 ENST00000368508 
ENSG00000127084 FGD3 ENST00000375482 ENSG00000126458 RRAS ENST00000246792 
ENSG00000139132 FGD4 ENST00000427716 ENSG00000133818 RRAS2 ENST00000256196 
ENSG00000154783 FGD5 ENST00000285046 ENSG00000163785 RYK ENST00000296084 
ENSG00000180263 FGD6 ENST00000343958 ENSG00000115904 SOS1 ENST00000426016 
ENSG00000077782 FGFR1 ENST00000425967 ENSG00000100485 SOS2 ENST00000216373 
ENSG00000066468 FGFR2 ENST00000457416 ENSG00000182957 SPATA13 ENST00000424834 
ENSG00000068078 FGFR3 ENST00000340107 ENSG00000060140 STYK1 ENST00000075503 
ENSG00000160867 FGFR4 ENST00000292408 ENSG00000120156 TEK ENST00000380036 
ENSG00000102755 FLT1 ENST00000282397 ENSG00000156299 TIAM1 ENST00000286827 
ENSG00000122025 FLT3 ENST00000241453 ENSG00000146426 TIAM2 ENST00000461783 
ENSG00000037280 FLT4 ENST00000261937 ENSG00000066056 TIE1 ENST00000372476 
ENSG00000174775 HRAS ENST00000451590 ENSG00000038382 TRIO ENST00000344204 
ENSG00000140443 IGF1R ENST00000268035 ENSG00000092445 TYRO3 ENST00000263798 
ENSG00000171105 INSR ENST00000302850 ENSG00000141968 VAV1 ENST00000602142 
ENSG00000027644 INSRR ENST00000368195 ENSG00000160293 VAV2 ENST00000371850 
ENSG00000205726 ITSN1 ENST00000381318 ENSG00000134215 VAV3 ENST00000370056 
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Table A10 - Genes with Gene Ontology terms indicating role in telomere function used in analysis 
 
Gene identifier Gene name 
Canonical 
transcript 
Gene identifier 
Gene 
name 
Canonical 
transcript 
ENSG00000102977 ACD ENST00000393919 ENSG00000039650 PNKP ENST00000322344 
ENSG00000100823 APEX1 ENST00000216714 ENSG00000014138 POLA2 ENST00000265465 
ENSG00000149311 ATM ENST00000278616 ENSG00000062822 POLD1 ENST00000440232 
ENSG00000175054 ATR ENST00000350721 ENSG00000106628 POLD2 ENST00000406581 
ENSG00000178999 AURKB ENST00000585124 ENSG00000077514 POLD3 ENST00000263681 
ENSG00000105173 CCNE1 ENST00000262643 ENSG00000175482 POLD4 ENST00000312419 
ENSG00000175305 CCNE2 ENST00000520509 ENSG00000177084 POLE ENST00000320574 
ENSG00000166226 CCT2 ENST00000299300 ENSG00000100479 POLE2 ENST00000216367 
ENSG00000163468 CCT3 ENST00000295688 ENSG00000148229 POLE3 ENST00000374171 
ENSG00000115484 CCT4 ENST00000394440 ENSG00000115350 POLE4 ENST00000483063 
ENSG00000150753 CCT5 ENST00000280326 ENSG00000128513 POT1 ENST00000357628 
ENSG00000146731 CCT6A ENST00000275603 ENSG00000204569 PPP1R10 ENST00000376511 
ENSG00000135624 CCT7 ENST00000258091 ENSG00000198056 PRIM1 ENST00000338193 
ENSG00000156261 CCT8 ENST00000286788 ENSG00000146143 PRIM2 ENST00000607273 
ENSG00000178971 CTC1 ENST00000315684 ENSG00000065675 PRKCQ ENST00000263125 
ENSG00000168036 CTNNB1 ENST00000349496 ENSG00000110958 PTGES3 ENST00000262033 
ENSG00000118655 DCLRE1B ENST00000369563 ENSG00000113522 RAD50 ENST00000265335 
ENSG00000172795 DCP2 ENST00000389063 ENSG00000051180 RAD51 ENST00000382643 
ENSG00000174953 DHX36 ENST00000496811 ENSG00000185379 RAD51D ENST00000590016 
ENSG00000138346 DNA2 ENST00000399180 ENSG00000160957 RECQL4 ENST00000428558 
ENSG00000012061 ERCC1 ENST00000013807 ENSG00000035928 RFC1 ENST00000381897 
ENSG00000175595 ERCC4 ENST00000311895 ENSG00000049541 RFC2 ENST00000055077 
ENSG00000171824 EXOSC10 ENST00000376936 ENSG00000133119 RFC3 ENST00000380071 
ENSG00000151876 FBXO4 ENST00000281623 ENSG00000163918 RFC4 ENST00000392481 
ENSG00000168496 FEN1 ENST00000305885 ENSG00000111445 RFC5 ENST00000454402 
ENSG00000109534 GAR1 ENST00000226796 ENSG00000080345 RIF1 ENST00000243326 
ENSG00000163938 GNL3 ENST00000418458 ENSG00000132383 RPA1 ENST00000254719 
ENSG00000166923 GREM1 ENST00000300177 ENSG00000117748 RPA2 ENST00000373912 
ENSG00000083307 GRHL2 ENST00000251808 ENSG00000106399 RPA3 ENST00000223129 
ENSG00000147421 HMBOX1 ENST00000397358 ENSG00000258366 RTEL1 ENST00000508582 
ENSG00000135486 HNRNPA1 ENST00000340913 ENSG00000026036 
RTEL1-
TNFRSF6B 
ENST00000482936 
ENSG00000122566 HNRNPA2B1 ENST00000354667 ENSG00000077463 SIRT6 ENST00000337491 
ENSG00000092199 HNRNPC ENST00000320084 ENSG00000132207 SLX1A ENST00000251303 
ENSG00000138668 HNRNPD ENST00000313899 ENSG00000188827 SLX4 ENST00000294008 
ENSG00000153187 HNRNPU ENST00000283179 ENSG00000157106 SMG1 ENST00000446231 
ENSG00000080824 HSP90AA1 ENST00000334701 ENSG00000198952 SMG5 ENST00000361813 
ENSG00000096384 HSP90AB1 ENST00000371554 ENSG00000070366 SMG6 ENST00000263073 
ENSG00000004487 KDM1A ENST00000400181 ENSG00000116698 SMG7 ENST00000507469 
ENSG00000136826 KLF4 ENST00000374672 ENSG00000060688 SNRNP40 ENST00000263694 
ENSG00000155858 LSM11 ENST00000286307 ENSG00000125835 SNRPB ENST00000438552 
ENSG00000076984 MAP2K7 ENST00000397979 ENSG00000100028 SNRPD3 ENST00000215829 
ENSG00000085511 MAP3K4 ENST00000392142 ENSG00000182004 SNRPE ENST00000414487 
ENSG00000100030 MAPK1 ENST00000215832 ENSG00000067066 SP100 ENST00000340126 
ENSG00000181085 MAPK15 ENST00000338033 ENSG00000197122 SRC ENST00000373578 
ENSG00000102882 MAPK3 ENST00000263025 ENSG00000120438 TCP1 ENST00000321394 
ENSG00000089022 MAPKAPK5 ENST00000551404 ENSG00000100726 TELO2 ENST00000262319 
ENSG00000020922 MRE11A ENST00000323929 ENSG00000257949 TEN1 ENST00000397640 
ENSG00000136997 MYC ENST00000377970 ENSG00000129566 TEP1 ENST00000262715 
ENSG00000139579 NABP2 ENST00000380198 ENSG00000147601 TERF1 ENST00000276603 
ENSG00000145414 NAF1 ENST00000274054 ENSG00000132604 TERF2 ENST00000603068 
ENSG00000135372 NAT10 ENST00000257829 ENSG00000166848 TERF2IP ENST00000300086 
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ENSG00000104320 NBN ENST00000265433 ENSG00000164362 TERT ENST00000310581 
ENSG00000115053 NCL ENST00000322723 ENSG00000092330 TINF2 ENST00000267415 
ENSG00000117650 NEK2 ENST00000366999 ENSG00000173273 TNKS ENST00000310430 
ENSG00000151414 NEK7 ENST00000367385 ENSG00000149115 TNKS1BP1 ENST00000532437 
ENSG00000145912 NHP2 ENST00000274606 ENSG00000107854 TNKS2 ENST00000371627 
ENSG00000182117 NOP10 ENST00000328848 ENSG00000067369 TP53BP1 ENST00000382044 
ENSG00000143748 NVL ENST00000281701 ENSG00000005007 UPF1 ENST00000262803 
ENSG00000121274 PAPD5 ENST00000436909 ENSG00000151461 UPF2 ENST00000356352 
ENSG00000169116 PARM1 ENST00000307428 ENSG00000169062 UPF3A ENST00000375299 
ENSG00000140694 PARN ENST00000437198 ENSG00000141499 WRAP53 ENST00000316024 
ENSG00000143799 PARP1 ENST00000366794 ENSG00000165392 WRN ENST00000298139 
ENSG00000041880 PARP3 ENST00000398755 ENSG00000079246 XRCC5 ENST00000392133 
ENSG00000102699 PARP4 ENST00000381989 ENSG00000196419 XRCC6 ENST00000359308 
ENSG00000132646 PCNA ENST00000379160 ENSG00000114127 XRN1 ENST00000264951 
ENSG00000140451 PIF1 ENST00000268043 ENSG00000204859 ZBTB48 ENST00000377674 
ENSG00000254093 PINX1 ENST00000314787 ENSG00000138311 ZNF365 ENST00000410046 
ENSG00000135549 PKIB ENST00000258014 ENSG00000180532 ZSCAN4 ENST00000318203 
ENSG00000140464 PML ENST00000268058    
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Appendix 4 - Tumour type labels designated as arising from GTEx tissues 
 
Table A11 – Tumour type labels designated as arising from GTEx tissues 
 
GTEx tisue GTEx tissue filename 
Single word 
equivalent 1 
Single word 
equivalent 2 
Single word 
equivalent 3 
Single word 
equivalent 4 
Adipose_Subcutaneous Adipose_Subcutaneous.v7.signif_variant_gene_pairs.txt Lipoma    
Adipose_Visceral_Omentum Adipose_Visceral_Omentum.v7.signif_variant_gene_pairs.txt No occurences    
Adrenal_Gland Adrenal_Gland.v7.signif_variant_gene_pairs.txt Phaeochromoctoma ACC   
Artery_Aorta Artery_Aorta.v7.signif_variant_gene_pairs.txt No occurences    
Artery_Coronary Artery_Coronary.v7.signif_variant_gene_pairs.txt No occurences    
Artery_Tibial Artery_Tibial.v7.signif_variant_gene_pairs.txt No occurences    
Brain_Amygdala Brain_Amygdala.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Anterior_cingulate_cortex_BA24 Brain_Anterior_cingulate_cortex_BA24.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Caudate_basal_ganglia Brain_Caudate_basal_ganglia.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Cerebellar_Hemisphere Brain_Cerebellar_Hemisphere.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Cerebellum Brain_Cerebellum.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Cortex Brain_Cortex.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Frontal_Cortex_BA9 Brain_Frontal_Cortex_BA9.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Hippocampus Brain_Hippocampus.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Hypothalamus Brain_Hypothalamus.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Nucleus_accumbens_basal_ganglia Brain_Nucleus_accumbens_basal_ganglia.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Putamen_basal_ganglia Brain_Putamen_basal_ganglia.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Spinal_cord_cervical_c-1 Brain_Spinal_cord_cervical_c-1.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Brain_Substantia_nigra Brain_Substantia_nigra.v7.signif_variant_gene_pairs.txt CNS CNS nerve sheath   
Breast_Mammary_Tissue Breast_Mammary_Tissue.v7.signif_variant_gene_pairs.txt Breast    
Cells_EBV-transformed_lymphocytes Cells_EBV-transformed_lymphocytes.v7.signif_variant_gene_pairs.txt Haem. lymphoid    
Cells_Transformed_fibroblasts Cells_Transformed_fibroblasts.v7.signif_variant_gene_pairs.txt N/A    
Colon_Sigmoid Colon_Sigmoid.v7.signif_variant_gene_pairs.txt Colorectal    
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Colon_Transverse Colon_Transverse.v7.signif_variant_gene_pairs.txt Colorectal    
Esophagus_Gastroesophageal_Junction Esophagus_Gastroesophageal_Junction.v7.signif_variant_gene_pairs.txt Oesophagus    
Esophagus_Mucosa Esophagus_Mucosa.v7.signif_variant_gene_pairs.txt Oesophagus    
Esophagus_Muscularis Esophagus_Muscularis.v7.signif_variant_gene_pairs.txt Oesophagus    
Heart_Atrial_Appendage Heart_Atrial_Appendage.v7.signif_variant_gene_pairs.txt Cardiac myxoma    
Heart_Left_Ventricle Heart_Left_Ventricle.v7.signif_variant_gene_pairs.txt No occurences    
Liver Liver.v7.signif_variant_gene_pairs.txt No occurences    
Lung Lung.v7.signif_variant_gene_pairs.txt Lung    
Minor_Salivary_Gland Minor_Salivary_Gland.v7.signif_variant_gene_pairs.txt Salivary gland    
Muscle_Skeletal Muscle_Skeletal.v7.signif_variant_gene_pairs.txt Soft tissue sarcoma    
Nerve_Tibial Nerve_Tibial.v7.signif_variant_gene_pairs.txt 
PNS nerve sheath 
benign 
PNS nerve sheath 
Nerve sheath 
benign 
 
Ovary Ovary.v7.signif_variant_gene_pairs.txt Ovary    
Pancreas Pancreas.v7.signif_variant_gene_pairs.txt Pancreas    
Pituitary Pituitary.v7.signif_variant_gene_pairs.txt Pituitary    
Prostate Prostate.v7.signif_variant_gene_pairs.txt Prostate    
Skin_Not_Sun_Exposed_Suprapubic Skin_Not_Sun_Exposed_Suprapubic.v7.signif_variant_gene_pairs.txt NMSC Melanoma Skin benign  
Skin_Sun_Exposed_Lower_leg Skin_Sun_Exposed_Lower_leg.v7.signif_variant_gene_pairs.txt NMSC Melanoma Skin benign  
Small_Intestine_Terminal_Ileum Small_Intestine_Terminal_Ileum.v7.signif_variant_gene_pairs.txt Small bowel GINET   
Spleen Spleen.v7.signif_variant_gene_pairs.txt No occurences    
Stomach Stomach.v7.signif_variant_gene_pairs.txt Gastric    
Testis Testis.v7.signif_variant_gene_pairs.txt Testicular    
Thyroid Thyroid.v7.signif_variant_gene_pairs.txt Thyroid    
Uterus Uterus.v7.signif_variant_gene_pairs.txt Endometrial Uterine leiomyoma 
Uterine 
sarcoma 
 
Vagina Vagina.v7.signif_variant_gene_pairs.txt No occurences    
Whole_Blood Whole_Blood.v7.signif_variant_gene_pairs.txt Haem. lymphoid Haem. myeloid 
Haem. 
polycythaemia 
Haem. 
thrombocythaemia 
 
ACC - Adrenocortical carcinoma, CNS – Central nervous system, Haem. – Haematological, PNS – Peripheral nervous system 
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Appendix 5 - Detail and validation of structural variants called from whole genome 
sequencing data and described in Chapter 3 and Chapter 6 
 
Variant 1 – Chromosome 17 deletion involving FLCN 
 
Coordinates – 17:17134310-17136696 (Manta), 17:17134474-17137867 (Canvas) 
Description – Deletion of exon 2 
Phenotype - Breast cancer, 46y; Pulmonary lymphangioleiomyomatosis, 47y   
Sanger sequencing validation comment - Long Range PCR with primers to amplify across  
17:17134310-17137867 shows wild type and deleted allele as two bands (wild type allele at ~5,700bp 
and deleted allele at ~3,500bp). Deletion confirmed though no sequence data from across breakpoints. 
   
Figure A1 – IGV plot pertaining to chromosome 17 deletion involving FLCN 
 
 
Reads viewed as pairs and grouped by insert size. Read pairs corresponding to deletion shown by large insert 
size (highlighted in red). 
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Variant 2 – Chromosome 10 inversion involving PTEN 
 
Coordinates – 2:89713996-89719837 (Manta) 
Description – Inversion of exon 7 
Phenotype – Breast cancer, 45y 
Sanger sequencing validation comment - PCR primers across breakpoint 10:89719837 produce unique 
fragment. Sanger sequence data shows inversion is present.  
 
Figure A2 - IGV plot pertaining to chromosome 10 inversion involving PTEN 
 
 
 
Reads viewed as pairs and grouped by pair orientation. Read pairs corresponding to inversion shown by right-
right (RR) or left-left (LL) orientation (highlighted in red). 
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Variant 3 – Chromosome 18:9 translocation involving SMAD4 
 
Coordinates – 18:48556624-9:127732713 (Manta) 
Description – Translocation with breakpoint within untranslated part of exon 1 
Phenotype - Central nervous system tumour, 45y 
Sanger sequencing validation comment - ~700bp unique fragment with primers MP007R-MP008R 
across SMAD4 Translocation Breakpoint. Sanger sequencing of the unique fragments showed 
fragment maps to chromosome 9 at translocation breakpoint 9:127732713 and fusion of chr18 
transcript into chr9. Translocation confirmed. 
 
Figure A3.1 - IGV plot pertaining to chromosome 18:9 translocation involving SMAD4 – 
Breakpoint at SMAD4 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 5 (highlighted in green). 
 
Figure A3.2 - IGV plot pertaining to chromosome 18:9 translocation involving SMAD4 – 
Breakpoint at SCAI 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 18 (highlighted in pale green). 
291 
 
Variant 4 – Chromosome 9 tandem duplication involving TSC1 
 
Coordinates – 9:135803187-135807261 (Manta) 
Description – Duplication involving exon 3 
Phenotype – Testicular cancer, 47y; Prostate cancer, 64y; Lung cancer, 70y     
Sanger sequencing validation comment - Obtained unique fragment in that would only be amplified if 
tandem duplication present. Sanger sequencing of the fragment across breakpoint successful. Tandem 
duplication confirmed. 
 
Figure A4 - IGV plot pertaining to chromosome 9 tandem duplication involving TSC1 
 
 
Reads viewed as pairs and grouped by pair orientation. Read pairs corresponding to inversion shown by right-
left (RL) orientation (highlighted in red). 
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Variant 5 – Chromosome 16 inversion involving TSC2 
 
Coordinates – 16:1566500-2119769 (Manta) 
Description – Inversion with breakpoint in intron 16-17 
Phenotype - Small bowel cancer, 42y; Colorectal cancer, 43y 
Sanger sequencing validation comment - PCR primers across breakpoint 16:1566500 gave two bands, 
the wild-type sized band and a slightly larger band. Gel purification and Sanger sequencing of the 
unique larger band demonstrates that the inversion is present. Unable to sequence to confirm at 
breakpoint 16:2119769. Inversion confirmed. 
 
Figure A5.1 - IGV plot pertaining to chromosome 16 inversion involving TSC2 – Breakpoint at 
TSC2 
 
 
Reads grouped by pair orientation. Read pairs corresponding to inversion shown by right-right (RR) and left-left 
(LL) orientation (highlighted in red). Breakpoints of inversion too distant for viewing as read pairs. 
 
Figure A5.2 - IGV plot pertaining to chromosome 16 inversion involving TSC2 – Breakpoint at 
IFT140 
 
 
Reads grouped by pair orientation. Read pairs corresponding to inversion shown by right-right (RR) and left-left 
(LL) orientation (highlighted in red). Breakpoints of inversion too distant for viewing as read pairs. 
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Variant 6 – Chromosome 1 deletion involving FH 
 
Coordinates – 1: 237244834-242310908 (Canvas) 
Description – Full gene deletion 
Phenotype - Multiple cutaneous leiomyomata, <55y 
Sanger sequencing validation comment - Long range PCR with primers to amplify across 
1:237244834-242310908 gives unique ~7500bp fragment. Gel purification and attempt at Sanger 
sequencing. No data obtained for exact breakpoints. Deletion probably confirmed. 
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Variant 7 – Chromosome 17:10 translocation involving FLCN 
 
Coordinates – 17:17121531-10:43731507 (Manta) 
Description – Translocation with breakpoint in intron 9-10 
Phenotype - Multiple fibrofolliculomas, 18y; Renal cell carcinoma, 53y  
Sanger sequencing validation comment – Amplification demonstrated specific bands to confirm the 
translocation. Sanger sequencing data obtained from those amplicons putting breakpoints at 
~17:17121526 and ~10:43731498. 
 
Figure A6.1 - IGV plot pertaining to chromosome 17:10 translocation involving FLCN – 
Breakpoint at FLCN 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 10 (highlighted in pink). 
 
Figure A6.2 - IGV plot pertaining to chromosome 17:10 translocation involving FLCN – 
Breakpoint at RASGEF1A 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 17 (highlighted in purple). 
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Variant 8 – Chromosome 10:6 translocation affecting HABP2 
Coordinates – 10:115318616-6:7227789 (Manta) 
Description – Translocation with breakpoint between exons 1 and 2 (both coding) 
Phenotype - Breast cancer (bilateral), 46y; Colorectal cancer, 51y; Pancreatic cancer, 52y 
Sanger sequencing validation comment – Validation by Sanger sequencing not performed. 
 
Figure A7.1 - IGV plot pertaining to chromosome 10:6 translocation affecting HABP2 – 
Breakpoint at HABP2 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 6 (highlighted in orange). 
 
Figure A7.2 - IGV plot pertaining to chromosome 10:6 translocation affecting HABP2 – 
Breakpoint at RREB1 
 
 
Reads grouped by alignment chromosome of mate pair. No read pairs corresponding to translocation evident. 
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Variant 9 – Chromosome 10:5 deletion affecting BMPR1A 
 
Coordinates – 10: 88559247-5:107163219 (Manta) 
Description – Translocation with breakpoint between exons 1 and 2 (both non-coding) 
Phenotype – Breast cancer, 52y; Central nervous system meningioma, 56y; Breast cancer, 58y; 
Aerodigestive tract cancer, 63y 
Sanger sequencing validation comment – Validation by Sanger sequencing not performed 
 
Figure A8.1 - IGV plot pertaining to chromosome 10:5 translocation affecting BMPR1A – 
Breakpoint at BMPR1A 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 5 (highlighted in blue). 
 
Figure A8.2 - IGV plot pertaining to chromosome 10:5 translocation affecting BMPR1A – 
Breakpoint at 5q21.3 
 
 
Reads grouped by alignment chromosome of mate pair. Read pairs corresponding to translocation shown by 
alignment to chromosome 10 (highlighted in pink).
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Variant 10 – Chromosome 19 deletion affecting eQTL where variants reported to reduce 
ZNF284 expression 
 
Coordinates – 19: 43765327-43848192 (Canvas) 
Description – Deletion of entire eQTL region 
Phenotype – Prostate cancer, 54y; Colorectal cancer, 54y 
Sanger sequencing validation comment – Validation by Sanger sequencing not performed 
 
